EP1425302A2 - Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer - Google Patents

Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Info

Publication number
EP1425302A2
EP1425302A2 EP20020713469 EP02713469A EP1425302A2 EP 1425302 A2 EP1425302 A2 EP 1425302A2 EP 20020713469 EP20020713469 EP 20020713469 EP 02713469 A EP02713469 A EP 02713469A EP 1425302 A2 EP1425302 A2 EP 1425302A2
Authority
EP
European Patent Office
Prior art keywords
hs
ests
protein
homo sapiens
ss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20020713469
Other languages
German (de)
French (fr)
Inventor
Daniel Afar
Kurt C. Gish
David H. Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Design Labs Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US26396501P priority Critical
Priority to US263965P priority
Priority to US26592801P priority
Priority to US265928P priority
Priority to US282698P priority
Priority to US28269801P priority
Priority to US09/829,472 priority patent/US20040146862A1/en
Priority to US829472 priority
Priority to US28859001P priority
Priority to US288590P priority
Priority to US294443P priority
Priority to US29444301P priority
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to PCT/US2002/002242 priority patent/WO2002059377A2/en
Publication of EP1425302A2 publication Critical patent/EP1425302A2/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.

Description

METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST

CANCER

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one- in-eight, with a l-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%-90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti- hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11 : 647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-ceU antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al, 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUCl). MUCl is a transmembrane protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al, 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547): 1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al, 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al, 2000, Cancer Treat. Rev. 26:269-286), none are currently approved for breast cancer therapy in the US.

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO- 97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. SUMMARY OF THE INVENTION The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25. In one embodiment, the biological sample is a tissue sample. In another erhbodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface. In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA. In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment. Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid. In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25. In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized. In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect. In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody. In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer. In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein. In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a prefereed embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease. Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer. In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer. Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

Definitions

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymoφhic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of

Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1 -25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms. A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another puφose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.mh.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymoφhic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat 'I. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al, eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al, J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nhn.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive- valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat 'I. Acad. Sci. USA 90:5873- 5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc. An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org). The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure. The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ- carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the conesponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymoφhic variants, interspecies homologs, and alleles of the invention.typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5)

Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al, Molecular Biology of the Cell (3rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure fonned, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui &

Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10): 1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al, J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111 :2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incoφorated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al, Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs are described in Rawls, C & E News June 2, 1997 page 35. AU of these references are hereby expressly incoφorated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (Tm) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in Tm for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non- naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes {e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incoφorating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incoφorated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature. 144:945 (1962); David et al., Biochemistry. 13:1014 (1974); Pain et al., J. Immunol. Meth.. 40:219 (1981); and Nygren, 1 Histochem. and Cvtochem.. 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin. As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression. The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the pmposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the pmposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology— Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in IX SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al. The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include in vitro, in vivo, and ex vivo activities.

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in moφhological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1- 25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher. The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell moφhology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed. 1994).

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor. "Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incoφoration of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmoφhological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3T ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well- characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2> a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)' may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al, Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al, Immunology Today 4:72 (1983); Cole et al, pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al, Nature 348:552-554 (1990); Marks et al, Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity. Identification of breast cancer-associated sequences

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingeφrint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic puφoses or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy puφoses, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs. Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a prefened embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a prefened embodiment, breast cancer sequences are those that are up- regulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being prefened. AU unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incoφorated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al, Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g.,

European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and freatment of breast cancer is hereby expressly incoφorated by reference. In another prefened embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 1,2, 3, 15, 16 etc.). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being prefened. Informatics

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drag development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity conelation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (.see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using anay analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be conelated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of conelates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a prefened embodiment, prior data processing using highspeed computers is utilized. An anay of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al, Bioinformatics (2001); Biological Sequence Analysis : Probabilistic Models of Proteins and Nucleic Acids (Durbin et al, eds., 1999); Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et al, eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995). The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained. In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders, hi a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an anay of magnetic domains on a magnetizable medium or as an anay of charge states or transistor gate states, such as an anay of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingeφrint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source. When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an LBM- compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format

(e.g., Linux, SunOS, Solaris, ATX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method. The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an anay of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention. In a prefened embodiment, the invention provides a computer system for comparing a query target to a database containing an anay of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transfened to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of conespondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of breast cancer-associated proteins Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); abenant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al, Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al, Proteins 28:405-420 (1997); Bateman et al, Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al, Nuc. Acids Res. 26:320-322- (1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intraceUular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted {see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell- associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly prefened in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly prefened in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

Use of breast cancer nucleic acids

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generaUy determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule. The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al, supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences conesponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening pmposes or for administration to a patient.

In a prefened embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being prefened, and from about 30 to about 50 bases being particularly prefened. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases. In a prefened embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being prefened, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity. As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non- covalent binding" and grammatical equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions. In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica- based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A prefened substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incoφorated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a prefened embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to,' amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly prefened. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a prefened embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incoφorated by reference; these methods of attachment form the basis of the Affimetrix GeneChip™ technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al, PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3 ' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Ehner, e.g., www2.perkin-elmer.com). Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) {see Wu & Wallace, Genomics 4:560 (1989), Landegren et al, Science 241:1077 (1988), and Barringer et al, Gene 89:117 (1990)), transcription amplification (Kwoh et al, Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (GuateUi et al, Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

Expression of breast cancer proteins from nucleic acids

In a prefened embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in. the art {see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating exfrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a prefened embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention. In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, supra). In addition, in a prefened embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVΕC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines. In a prefened embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incoφorated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, heφes simplex virus promoter, and the CMV promoter {see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a prefened embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the tip and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e.g., Fernandez & Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, breast cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a prefened embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression puφoses.

In a prefened embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse- phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, Protein Purification (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary. Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Variants of breast cancer proteins In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly prefened. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., Ml 3 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generaUy made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine. Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1- bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N- maleimido-l,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate. , Other modifications include deamidation of glutaminyl and asparaginyl residues to the conesponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, Proteins: Structure and Molecular Properties, pp. 79-86 (1983)), acetylation of the N- terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for puφoses herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns. Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al, Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al, Anal Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al, Meth. Enzymol, 138:350 (1987). Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al, Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al, Molecular and Cellular Biology 5:3610-3616 (1985)); and the Heφes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al, Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al, BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al, Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al, J. Biol. Chem.

266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al, Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, prefened PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being prefened, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, supra).

Antibodies to breast cancer proteins

In a prefened embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a prefened embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., CoUgan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation. The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1- 25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a prefened embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is prefened, with at least about 50% being particularly prefened and about a 95- 100% decrease being especially prefened. In a prefened embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by conesponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions conespond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al, Nature 321 :522-525 (1986); Riechmann et al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al, Nature 321:522-525 (1986); Riechmann et al, Nature 332:323-327 (1988); Verhoeyen et al, Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the conesponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the conesponding sequence from a non- human species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al, J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al,

Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al, J. Immunol. 147(l):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene reanangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks βt al, Bio/Technology 10:779- 783 (1992); Lonberg et al, Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al, Nature Biotechnology 14:845-51 (1996); Neuberger, Nature

Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a prefened embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another prefened embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non- competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, LNF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells. In another prefened embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a prefened embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their conesponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety. In another prefened embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a Kd of at least about 0.1 mM, more usually at least about 1 μM, preferably at least about 0.1 μM or better, and most preferably, 0.01 μM or better. Selectivity of binding is also important.

Detection of breast cancer sequence for diagnostic and therapeutic applications In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fmgeφrint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount oftranscri.pt, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression anays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incoφorated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%), more preferably at least about 100%, more preferably at least about 150%), more preferably at least about 200%, with from 300 to at least 1000% being especially prefened.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g. , with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins conesponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test. In a prefened embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

In a prefened embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3- indoyl phosphate. In a prefened embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or conesponding polypeptide level. In a prefened embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or conesponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer. Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A prefened method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another prefened method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove nonspecific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another prefened embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a prefened embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another prefened embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins. Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein. In a prefened embodiment, in situ hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, anays of tissue samples, including breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingeφrints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a prefened embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that conelate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being prefened. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

In a prefened embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a prefened embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al, Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996). In a prefened embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a prefened embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra. Having identified the differentially expressed genes herein, a variety of assays may be executed. In a prefened embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The prefened amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., tlirough the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a prefened embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.. In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well. Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out inTable 17. Generally, in a prefened embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner. The term "test compound" or "drag candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In prefened embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fmgeφrint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are ran in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Prefened small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly prefened are peptides. In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity.

Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

In one prefened embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et al, J. Med. Chem. 37(9): 1233-1251 (1994)). Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al, Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al, Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al, J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al, J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al, J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al, Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell etal, J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al, J. Med. Chem. 37:1385 (1994), nucleic acid libraries {see, e.g., Strategene, Coφ.), peptide nucleic acid libraries ( ee, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al, Nature Biotechnology 14(3):309-314 (1996), and PCT US96/10287), carbohydrate libraries {see, e.g., Liang et al, Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pynolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; moφholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like). Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). • A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Coφoration, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available {see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Prefened assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Coφ., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Coφ. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly prefened in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being prefened, and human proteins being especially prefened. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a prefened embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being prefened, and from about 7 to about 15 being particularly prefened. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incoφorate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a prefened embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a prefened embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a prefened embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature. After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

In a prefened embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730,

5.594.117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352,

5.594.118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incoφorated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with prefened embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce nonspecific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile. Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a prefened embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes refened to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a prefened embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a prefened embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA. Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

Assays to identify compounds with modulating activity can be performed in vitro. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are prefened. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art. In a prefened embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes refened to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a prefened embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

Thus, in a prefened embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Prefened embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a prefened embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and anays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Prefened methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a prefened embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this pmpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a prefened embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., 125I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a prefened embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein. h a prefened embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drag design to synthesize agents that interact with that site. Drug candidates that affect the activity of a breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound. A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a prefened embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Prefened cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a prefened embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process. In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound. In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stined suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stined suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed., 1994), herein incoφorated by reference. See also, the methods section of Garkavtsev et al. (1996), supra, herein incoφorated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected moφhologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal sunounding cells. Alternatively, labeling index with (3H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (3H)-thymidine at saturation density is a prefened method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (3H)- thymidine is determined autoradiographically. See, Freshney (1994), supra.

Growth factor or serum dependence

Transformed cells have a lower serum dependence than their normal counteφarts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al, J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their nonnal counteφarts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counteφarts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al. , J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251 :5694-5702 (1976); Whur et al, Br. J. Cancer 42:305- 312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth, in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer- associated sequences. Tumor cells exhibit a good conelation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), supra, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with 125I and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra.

Tumor growth in vivo Effects of breast cancer- associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al, Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al, Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A . Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse {see, e.g., Giovanella et al, J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an inadiated mouse {see, e.g., Bradley et al, Br. J. Cancer 38:263 (1978); Selby et al, Br. J. Cancer 41 :52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of breast cancer Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single- stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A prefened antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen {Cancer Res. 48:2659 (1988 and van der Krol et al (BioTechniques 6:958 (1988)).

Ribozymes

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, haiφin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al, Adv. in

Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of haiφin ribozymes are described, e.g., in Hampel et al, Nucl Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., WO 94/26877; Ojwang et al, Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al, Human Gene Therapy 1:39-45 (1994); Leavitt et al, Proc. Natl. Acad. Sci. USA 92:699- 703 (1995); Leavitt et al, Human Gene Therapy 5:1151-120 (1994); and Yamada et al, Virology 205: 121-126 (1994)). Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its conesponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a prefened embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a prefened embodiment, the gene therapy techniques include the incoφoration of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incoφorated by reference in its entirety. Alternatively, e.g. when the breast cancer sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of abreast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic pmposes. In a prefened embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

Methods of identifying variant breast cancer-associated sequences Without being bound by theory, expression of various breast cancer sequences is conelated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a prefened embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a prefened embodiment, the presence of a difference in the sequence between the breast cancer gene of the patient and the known breast cancer gene conelates with a disease state or a propensity for a disease state, as outlined herein.

In a prefened embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another prefened embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the pmpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incoφorated by reference.

A "patient" for the pmposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the prefened embodiment the patient is a mammal, preferably a primate, and in the most prefened embodiment the patient is human. The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, infranasally, fransdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the prefened embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "PharmaceuticaUy acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyravic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly prefened are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral adminisfration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art. The compositions for adminisfration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington 's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et α/.,eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous adminisfration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally adminisfrable compositions will be known or apparent to those skilled in the art, e.g., Remington 's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra . The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially anest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is refened to as a "prophylactically effective dose." The particular dose required for a prophylactic freatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, adminisfration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recunence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell {see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al, eds., Current Protocols (supplemented through 1999), and Sambrook et al, Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

In a prefened embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incoφoration into the genome) or as antisense compositions, as will be appreciated by those in the art.

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g-.,Vitiello, A. et al, J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres {see, e.g., Eldridge, et al, Molec. Immunol. 28:287-294, (1991); Alonso et al, Vaccine 12:299-306 (1994); Jones et al, Vaccine .13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) {see, e.g., Takahashi et al, Nature 344:873-875 (1990); Hu et al, Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) {see, e.g., Tarn, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tarn, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al, In: Concepts in vaccine development (Kauffriann, ed., p. 379, 1996); Chakrabarti, et al, Nature 320:535 (1986); Hu et al, Nature 320:537 (1986); Kieny, et al, AIDS Bio/Technology 4:790 (1986); Top et al, J. Infect. Dis. 124:148 (1971); Chanda et al, Virology 175:535 (1990)), particles of viral or synthetic origin {see, e.g., Kofler et al, J. Immunol. Methods. 192:25 (1996); Eldridge etal, Sem. Hematol 30:16 (1993); Falo et al, Nature Med. 7:649 (1995)), adjuvants (Wanen et al, Annu. Rev. Immunol. 4:369 (1986); Gupta et al, Vaccine 11:293 (1993)), liposomes (Reddy et al, J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al, Science 259:1745 (1993); Robinson et al, Vaccine 11:957 (1993); Shiver et al, In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al, Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants. Vaccines can be administered as nucleic acid compositions wherein DNA or

RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al, Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization pmposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia viras expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al, Nature 351 :456-460 (1991). A wide variety of other vectors useful for therapeutic adminisfration or immunization e.g. adeno and adeno-associated viras vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al, Mol Med Today 6:66-71 (2000); Shedlock et al, JLeukoc Biol 68:793-806 (2000); Hipp et al.Jn Vivo 14:571-85 (2000)).

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the confrol of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of abreast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a prefened embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another prefened embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, fransgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the fransgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instractional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instractional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the foUowing materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on conelations with important parameters in disease which may be identified in historical or outcome data.

EXAMPLES

Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

Purifying total RNA from tissue sample using TRIzol Reagent The sample weight is first estimated. The tissue samples are homogenized in

1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polyfron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a SorvaU superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared homogenate is then fransfened to a new tube(s). Samples may be frozen and stored at -60 to

-70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogemzation mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp, for 2-3 minutes and next centrifuged at 6500 φm in a SorvaU superspeed for 30 min. at 4oC.

The next process is RNA Precipitation. The aqueous phase is fransfened to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp, for 10 minutes an centrifuged at 6500 φm in SorvaU for 20 min. at 4°C.

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing . They are next centrifuged at <8000 φm (<7500 x g) for 5 minutes at 4°C.

The RNA wash is decanted. The pellet is carefully fransfened to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H20. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen' s RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA. The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-freated water, 2 x Binding Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A+ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is fransfened to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

Then, the spin column is fransfened to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low. The absorbance is next read to determine the yield, using diluted Elution

Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H20 at lug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g.. Oiagen's RNeasv kit). No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 φm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 φm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 φm. The flowthrough is discarded, and the column membrane dried by centrifuging for 2 min at maximum speed. The column is fransfened to a new 1.5-ml collection tube. 30-50 ul of

RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 φm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

First Strand cDNA Synthesis

The first strand can be make using using Gibco 's "Superscript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of poly A+ mRNAl. For total RNA, 2 ul of Superscript RT is used; for polyA mRNA, 1 ul of Superscript RT is used. The final volume offirst strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol

T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Sfrand Buffer, 2 ul of 0.1M DTT, and 1 ul of lOmM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the Superscript RT followed by incubation at 37°C for 1 hour.

Second Strand Synthesis

For the second sfrand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H20; 30 ul 5X 2nd Strand Buffer; 3 ul lOmM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2 hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

Cleaning up cDNA The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25 :24: 1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then fransfened to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is fransfened to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100%> ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80%) ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

In vitro Transcription ("IVT") and labeling with biotin

In vitro Transcription (INT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDΝA into a thin-wall PCR tube. Make ΝTP labeling mix by combining 2 ul T7 lOxATP (75 mM) (Ambion); 2 ul T7 lOxGTP (75 mM) (Ambion); 1.5 ul T7 lOxCTP (75 mM) (Ambion); 1.5 ul T7 1 OxUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio- 11 -UTP

(Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul lOx T7 transcription buffer (Ambion); and 2 ul lOx T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RΝA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen 's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and elecfrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final cone); 50 pM 948-b confrol oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with lxMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to INT): The following mixture is prepared: IVT antisense RΝA; 4 μg: μl

Random Hexamers (1 μg/μl): 4 μl H2O: μl , _

14 μl

Incubate the above 14 μl mixture at 70°C for 10 min.; then put on ice. The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl

50X dΝTP mix: 0.6 μl

H2O: 2.4 μl

Cy3 or Cy5 dUTP (lmM): 3 μl

SS RT II (BRL): l μl

16 μl

The above solution is added to the hybridization reaction and incubated for 30 min., 42°C.

Then, 1 μl SSII is added and incubated for another hour before being placed on ice. The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, lOmM of dTTP and is made by adding 25 μl each of lOOmM dATP, dCTP, and dGTP; 10 μl of lOOmM dTTP to 15 μl H2O. ]

RNA degradation is performed as follows. Add 86 μl H2O, 1.5 μl IM NaOH/ 2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 μl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 μl buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

Sample preparation

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H20. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp, for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0J5ml 10% SDS in 250ml H2O; IX SSC: 5 min., 12.5 ml 20X SSC in 250ml H2O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H2O. Dry slides and scan at appropiate PMT's and channels.

TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incoφorated in their entirety here and throughout the application where primekeys are provided), dowmegulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of normal breast tissue to tumor

Pkey ExAccn UnigenelD UnigeneTitle R1

100472 D90084 Hs.1023 pyruvate dehydrogenase (lipoa ide) alpha 5

100499 T51986 Hs.283108 hemoglobin, gamma G 10

100545 M55405 gb:Homo sapiens mucin (MUC-3) mRNA, part 5

100549 BE142019 Hs.222056 Homo sapiens cDNA FLJ11572 fis, clone HE 10

100613 X52078 Hs.101047 transcription factor3 (E2A immunoglobul 5

100635 BE259039 Hs.129953 Ewing sarcoma breakpoint region 1 5

100645 X16841 Hs.167988 neural cell adhesion molecule 1 5

100654 A03758 NM_000477*:Homo sapiens albumin (ALB), m 10

100702 L27065 gb:Human neurofibromatosis 2 (NF2) mRNA, 5

100915 M60832 Hs.249239 collagen, type VIII, alpha 2 5

100971 BE379727 Hs.83213 fatty acid binding protein 4, adipocyte 10

101125 AJ250562 Hs.82749 transmembrane 4 superfamily member 2 5

101166 M90424 Hs.2099 lipocalin 1 (protein migrating faster th 5

101184 NM 001674 Hs.460 activating transcription factor 3 10

101336 NM 006732 Hs.75678 FBJ murine osteosarcoma viral oncogene h 10

101367 X03350 Hs.4 alcohol dehydrogenase 1 B (class I), beta 10

101447 M21305 gb:Human alpha satellite and satellite 3 10

101461 N98569 Hs76422 phospholipase A2, group HA (platelets, 10

101511 M27826 Hs.267319 endogenous retroviral protease 10

101634 AV650262 Hs.75765 GR02 oncogene 5

101736 M74447 Hs.502 transporter 2, ATP-binding cassette, sub 10

102208 U22961 gb:Human mRNA clone with similarity to L 10

102297 NM 001504 Hs.198252 G protein-coupled receptor 9 5

102450 U48251 Hs75871 protein kinase C binding protein 1 10

102515 U89337 Hs.169886 tenascin XB 10

102571 U60115 Hs.239069 four and a half LIM domains 1 5

102800 AA313538 gb:EST185419 Colon carcinoma (HCC) cell 10

102857 NM 006744 Hs.76461 retinol-binding protein 4, interstitial 10

102990 AA829286 Hs.332053 serum amyloid A1 10

103434 X98085 Hs.54433 tenascin R (restrictin, janusin) 5

103747 AA081995 gb:zn26d06.r1 Stratagene neuroepithelium 10

103750 AA126129 gb:zm78c07.r1 Stratagene neuroepithelium 5

103812 AA137107 Hs.326391 Homo sapiens, clone MGC:16638, mRNA, com 10

103851 AA326216 Hs.8719 hypothetical protein MGC1136 5

104080 AB041036 Hs.57771 kallikrein 11 (KLK11 ; TLSP; PRSS20; hipp 5

104093 R50727 Hs.336970 ESTs 10

104106 AA422123 gb:zv26h12.r1 Soares_NhHMPu_S1 Homo sapi 5

104109 AL353957 Hs.284181 hypothetical protein DKFZp434P0531 10

104250 F06638 Hs.12440 Homo sapiens clone 24734 mRNA sequence 10

104340 AA426189 gb:zw11e09.r1 Soares_NhHMPu S1 Homo sapi 5

104492 N73185 Hs.94285 EST 10

104506 N91071 Hs.109650 ESTs 10

104511 N99542 Hs.572 orosomucoid 1 5

104532 AI498763 Hs.203013 hypothetical protein FU12748 10 104536 R24024 Hs.158101 Homo sapiens cDNA FLJ14673 fis, clone NT 5

104572 Y11312 Hs.132463 phosphoinositide-3-kinase, class 2, beta 5

104659 AW969769 Hs.105201 ESTs 5

104677 AA009764 Hs.190380 ESTs 10

104711 AA017245 Hs.32794 ESTs 10

104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10

104764 AI039243 Hs.278585 ESTs 5

105005 AI298208 Hs.28805 ESTs 10

105036 AA130390 Hs.25549 hypothetical protein FLJ20898 10

105105 R61532 Hs.87016 hypothetical protein FU22938 5

105231 AW970043 Hs.238039 hypothetical protein FLJ11090 5

105239 AA221036 gb:zr03f12.M Stratagene NT2 neuronal pr 10

105921 AA421973 Hs.169119 ESTs, Weakly similar to T25731 hypotheti 5

105957 BE242857 Hs.27021 hypothetical protein FLJ1 59 5

106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10

106119 AL359624 Hs.11387 KIAA1453 protein 5

106181 AI803651 Hs.191608 ESTs 10

106194 AW976171 Hs.286194 hypothetical protein FLJ22233 5

106233 AI085846 Hs.25522 IAA1808 protein 10

106379 AL042069 Hs.119021 DKFZP434N061 protein 10

106451 AW235928 Hs.313182 ESTs 10

106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10

106700 AA906434 Hs.3776 zinc finger protein 216 5

106782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10

106851 AI458623 gb:tk04g09.x1 NCI_CGAP_Lu24 Homo sapiens 5

106870 AI983730 Hs.26530 serum deprivation response (phosphatidyl 5

106892 AI347578 Hs.124015 hypothetical protein MGC2605 5

106954 AF128847 Hs.204038 indolethylamine N-methyltransferase 5

106991 AJ223811 Hs.30127 hypothetical protein 5

107103 AI446183 Hs.9572 ESTs, Highly similar to CYA5_HUMAN ADENY 5

107124 AB006532 Hs.31442 RecQ protein-like 4 10

107148 AI005036 Hs.334305 GS1999full 10

107214 AF127026 Hs.5394 myosin IA 10

107242 AB020672 Hs.175411 K1AA0865 protein 10

107331 AI905985 Hs.111805 ESTs 10

107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 5

107423 W26652 Hs.6163 PTEN induced putative kinase 1 5

107447 W28516 Hs.19210 hypothetical protein MGC11308 10

107451 AL042425 Hs.283976 hypthetical protein PR02389 10

107453 AI092790 Hs.334703 hypothetical protein FLJ14529 5

107459 W38002 Empirically selected from AFFX single pr 10

107683 N53167 Hs.47623 ESTs 10

107711 W96141 Hs.220687 ESTs 10

107754 AA017462 Hs.269244 ESTs 10

107757 BE621721 Hs.280792 hypothetical protein FLJ12387 similar to 10

107864 AA025060 Hs.61246 ESTs 10

107872 BE271 08 Hs.95110 ESTs, Weakly similar to A55943 1 -phospha 10

107888 AA025836 Hs.191637 ESTs 5

107997 AL049176 Hs.82223 chordin-like 10

108056 AA043675 Hs.62633 ESTs 10

108081 AA093668 Hs.28578 muscleblind (Drasophila)-like 5

108113 AA012881 Hs.72531 hypothetical protein FLJ11838 10

108238 AA059473 Hs.66783 EST 10

108257 AA677927 Hs.144269 ESTs 5

108335 AA07Q500 gb:zm70h03.s1 Stratagene neuroepithelium 5

108351 AA071193 gb:zf79b12.s1 Soares_pineal_gland_N3HPG 10

108382 NM 06770 Hs.67726 macrophage receptor with collagenous str 5

108392 AA075124 gb:zm86a01.s1 Stratagene ovarian cancer 10

108441 AA079079 gb:zm97c09.s1 Stratagene colon HT29 (937 10

108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 10

108497 AA074897 gb:zm85a05.r1 Stratagene ovarian cancer 10

108604 AA934589 Hs.49696 ESTs 5

108662 AF117646 Hs.156637 Cas-Br-M (murine) ectropic retroviral tr 5

108706 AA121820 Hs.74569 KIAA0842 protein 10

108738 AA126583 Hs.158725 ESTs 10

108827 AI273692 Hs.110470 ESTs 10

109123 AI028376 Hs.73232 ESTs 10 109389 AA101325 Hs.86154 hypothetical protein FLJ 12457 10

109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 5

109919 R40604 Hs.129539 ESTs, Weakly similar to MCAT_HUMAN MITOC 10

110006 AI094674 Hs.30524 ring finger protein 24 10

110141 H46749 Hs.31540 ESTs 10

110354 W22165 Hs.22586 ESTs 5

110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine:polyp 10

110448 H51276 Hs.13526 hypothetical protein FLJ12688 • 10

110455 H52576 gb:yt85e08.r1 Soares_pineal_gland_N3HPG 5

110540 H72639 Hs.167608 ESTs 5

110553 H60593 Hs.124990 ESTs 10

110976 AL044174 Hs.159526 patched (Drosophila) homolog 10

110987 AI753316 Hs.26034 ESTs 5

111158 N66616 Hs.138629 H.sapiens mRNA for subtelomeric repeat s 5

111168 AI798376 gb:tr34b07.x1 NCI_CGAP_θv23 Homo sapiens 10

111187 AJ224864 Hs.9688 leukocyte membrane antigen 5

111307 AA641636 Hs.37477 ESTs, Weakly similar to T46908 hypotheti 5

111400 R00144 Hs.189771 ESTs 10

111498 AI168511 gb:ow90h09.s1 Soares_fetal_liver_spleen_ 10

111651 R16733 Hs.20499 ESTs 10

111738 R26065 gb:yh39d03.s1 Soares placenta Nb2HP Homo 5

111803 AA593731 Hs.325823 ESTs, Moderately similar to ALU5_HUMAN A 10

111995 R42333 Hs.302292 ESTs 10

112071 AL117490 Hs.47225 Ras-associated protein Rap1 10

112204 NM 006668 Hs.25121 cytochrome P450, subfamily 46 (cholester 10

112258 R51889 Hs.24990 ESTs 5

112490 R31094 Hs.24378 ESTs 10

112588 R77302 gb:yi75h08.s1 Soares placenta Nb2HP Homo 10

112654 BE618629 Hs.268809 ESTs 5

112784 T98628 Hs.191290 ESTs 5

112817 AI057205 Hs.14584 ESTs 5

112885 AA581428 Hs.5021 EST 10

112913 T16837 Hs.4241 ESTs 5

113149 T51588 gb:yb27e06.s1 Stratagene fetal spleen (9 10

113174 T54659 Hs.301755 Homo sapiens cDNA FLJ11465 fis, clone HE 5

113203 AA743563 Hs.10305 ESTs 5

113299 AW207424 Hs.332594 ESTs 10

113367 N92359 Hs.14518 ESTs, Moderately similar to A48752 B-cel 10

113457 R16763 Hs.268679 ESTs 5

113563 AA913635 Hs.326413 Homo sapiens cDNA FLJ20812 fis, clone AD 10

113574 R06874 Hs.268628 ESTs, Moderately similar to ALU1_HUMAN A 5

113776 AI791905 Hs.95549 hypothetical protein 10

113790 AI244311 Hs.26912 ESTs 10

113807 W07586 Hs.8045 ESTs 3

113958 W86195 gb:zh54e05.s1 Soares_fetal_liver_spleen_ 10

114211 Z39319 Hs.27347 EST 10

114254 AB018263 Hs.180338 tumor necrosis factor receptor superfami 5

114349 AA745978 Hs.28273 ESTs 5

114449 AA020736 gb:ze63b11.s1 Soares retina N2b4HR Homo 5

114484 AA034378 Hs.267319 endogenous retroviral protease 5

114576 AA065096 gb:zm50a02.s1 Stratagene fibroblast (937 5

114624 AA081507 gb:zn05b10.r1 Stratagene hNT neuron (937 5

114844 AA234826 Hs.87386 EST 5

114906 AA234462 Hs.87350 ESTs 5

115624 AK000725 Hs.50579 hypothetical protein FLJ20718 3

115666 AF173081 Hs.178215 Vertebrate LIN7 homolog 1 , Tax interacti 5

115712 AB020649 Hs.74569 KIAA0842 protein 5

115889 AA398841 Hs.39850 hypothetical protein FLJ20517 10

115949 AI478427 Hs.43125 esophageal cancer related gene 4 protein 10

116107 AL133916 Hs.172572 hypothetical protein FLJ20093 10

116180 AA463902 Hs.13522 ESTs, Weakly similar to I38022 hypotheti 5

116267 AW968703 Hs.30085 hypothetical protein FU23186 5

116291 AW410377 Hs.41502 hypothetical protein FLJ21276 5

116527 AW194253 Hs.68607 ESTs 10

116659 BE314852 Hs.168694 Homo sapiens clone 23763 unknown mRNA, p 5

116708 F10528 Hs.70001 ESTs, Moderately similar to JC6169 nude 5

117058 AW801806 gb:IL5-UM0070-110400-062-g07 UM0070 Homo 5 117151 AI803656 Hs.42373 ESTs 5

117226 N20468 gb:yx39b10.s1 Soares melanocyte 2NbHM Ho 10

117323 AI472863 Hs.43387 ESTs 5

117571 N34417 Hs.44584 ESTs 3

117624 N26627 Hs.82364 ESTs, Weakly similar to JC4124 pregnancy 5

117673 N40551 Hs.184043 Homo sapiens Ets-1 binding protein (E1B) 10

117847 N49285 Hs.182391 ESTs 10

117877 AW263476 Hs.44268 myelin gene expression factor 2 10

117919 BE222341 Hs.279472 ESTs 5

118049 N53145 gb:yv55f09.s1 Soares fetal liver spleen 3

118413 AW955696 Hs.90960 ESTs 10

118613 AI078236 Hs.49688 ESTs 5

118664 N70907 Hs.230619 EST 10

118858 AL122040 Hs.102981 Homo sapiens mRNA; cDNA DKFZp434G1972 (f 3

118902 AA993527 Hs.293907 hypothetical protein FU23403 5

119039 AI160570 Hs.252097 pregnancy specific beta-1 -glycoprotein 6 3

119159 AF142419 Hs.15020 homolog of mouse quaking OKI (KH domain 5

119216 AA514422 Hs.221849 ESTs 5

119317 AK002001 Hs.51305 v-maf musculoaponeurotic fibrosarcoma (a 10

119366 T77892 gb:yd20f04.s1 Soares fetal liver spleen 5

119378 T81824 Hs.90949 EST 5

119528 W38051 Empirically selected from AFFX single pr 10

119792 AL049798 Hs.80552 dermatopontin 3

119800 AF086332 Ha58314 ESTs 10

119817 AF088061 Hs.159690 ESTs 5

119835 AF086429 Hs.58429 ESTs 5

119923 AW803308 Hs.62954 fem'tin, heavy'polypeptide 1 5

119961 U34249 Hs.337461 Human putative zinc finger protein (ZNFB 5

120379 AL042725 gb:DKFZp434B1822_r1 434 (synonym: htes3) 10

120931 AW136934 Hs.97162 ESTs 5

121037 AA907743 Hs.142373 ESTs 5

121282 AA401695 Hs.97334 ESTs 5

121382 AA405763 Hs.111939 Homo sapiens cDNA FLJ20470 fis, clone KA 5

121764 AA421452 Hs.164851 ESTs, Weakly similar to KIAA0926 protein 5

122034 AK000229 Hs.98017 Homo sapiens cDNA FU20222 fis, clone CO 10

122441 AA447555 Hs.99116 EST 10

122756 AA458945 Hs.95898 ESTs 10

122771 AW135093 Hs.97282 ESTs, Highly similar to G100 HUMAN 110 K 5

123601 AA609122 Hs.112645 Homo sapiens mRNA; cDNA DKFZp434D2472 (f 5

123623 AI024595 Hs.97508 a disintegrin and metalloproteinase doma 5

123941 AA621529 gb:af47a02.s1 Soares_tota|_fetus_Nb2HF8_ 10

124215 H62570 gb:yr44a01.r1 Soares fetal liver spleen 5

124276 H83465 gb:ys91a11.s1 Soares retina N2b5HR Homo 5

124680 AK001527 Hs.163953 hypothetical protein FU10665 5

125099 NM 014312 Hs.112377 cortic al thymocyte receptor (X. laevis 10

125121 T98199 Hs.48403 hypothetical protein FLJ10847 10

125188 BE299567 Hs.271749 ESTs, Moderately similar to ALU8_HUMAN A 5

125284 NM 002666 Hs.103253 perilipin 10

125906 BE256206 Hs.17775 p75NTR-associated cell death executor; o 5

128484 AA485421 Hs.270503 ESTs, Weakly similar to ALU7_HUMAN ALU S 10

128511 NM_002250 Hs.10082 potassium intermediate/small conductance 10

128538 R44214 Hs.101189 ESTs 5

128606 C16161 Hs.283040 hypothetical protein PR02543 5

128850 AA193106 Hs.180817 chromosome 11 open reading frame 23 10

128870 H39537 Hs.75309 eukaryotic translation elongation factor 10

128903 AW150717 Hs.296176 STAT induced STAT inhibitor 3 10

128931 N62889 Hs.107242 Homo sapiens cDNA FLJ12965 fis, clone NT 10

129001 AA443323 Hs.107812 BPOZ protein 5

129091 AA056483 Hs.301463 Human Chromosome 16 BAC clone CIT987SK-A 5

129101 NMJ13403 Hs.108665 zinedin 10

129146 AL117472 Hs.108924 SH3-domain protein 5 (ponsin) 5

129213 A1146494 Hs.109525 ESTs, Weakly similar to IRX2.HUMAN IROQU 3

129228 U40714 Hs.239307 tyrosyl-tRNA synthetase 5

129265 AA530892 Hs.171695 dual specificity phosphatase 1 5

129285 BE617015 Hs.11006 ESTs, Moderately similar to T17372 plasm 10

129346 AF110141 Hs.288908 WAS protein family, member 2 10

129368 NM 003877 Hs.110776 STAT induced STAT inhibitor-2 5 129371 X06828 Hs.110802 von Willebrand factor 5

129381 AW245805 Hs.110903 claudin 5 (transmembrane protein deleted 10

129440 W37944 Hs.4007 Sarcolemmal-associated protein 5

129441 BE061069 Hs.301943 KIAA0467 protein 10

129516 AF020038 Hs.11223 isocitrate dehydrogenase 1 (NADP+), solu 10

129554 BE222078 Hs.113069 ESTs 10

129684 BE622468 Hs.11924 ESTs, Weakly similar to I38022 hypotheti 5

129702 AI304966 Hs.12035 ESTs, Weakly similar to I38022 hypotheti 5

129778 AK001676 Hs. 2457 hypothetical protein FU10814 10

129893 AK000956 Hs.13209 hypothetical protein FLJ10094 5

129928 AI338993 Hs.134535 ESTs 5

129973 AJ251760 Hs.273385 guanine nucleotide binding protein (G pr 5

129977 NM 000399 Hs.1395 early growth response 2 (Krox-20 (Drosop 5

130014 NM 001158 Hs.143102 amine oxidase, copper containing 2 (reti 5

130085 M62402 Hs.274313 insulin-like growth factor binding prate 10

130089 AA452006 Hs.333199 ESTs 5

130162 W80711 Hs.319946 Homo sapiens mRNA for KIAA1727 protein, 5

130243 D88435 Hs.153227 cyclin G associated kinase 10

130315 AI241084 Hs.154353 nonselective sodium potassium/proton exc 5

130339 AA435746 gb:zt79e03.s1 Soares_testis_NHT Homo sap 5

130400 V00517 Hs.283108 hemoglobin, gamma G 10

130436 NM 01928 Hs.155597 D component of complement (adipsin) 10

130478 X72308 Hs.251526 small inducible cytokine A7 (monocyte ch 5

130480 BE222978 Hs.15760 MYG1 protein 10

130494 AW390834 Hs.75874 pregnancy-associated plasma protein A 5

130563 BE270472 Hs.279900 HSPC015 protein 10

130589 AL110226 Hs.16441 DKFZP434H204 protein 10

130606 AI652143 Hs.288382 hypothetical protein FLJ13111 5

130634 AI769067 Hs.127824 ESTs, Weakly similarto T28770 hypotheti 3

130683 AA993269 Hs.17872 Homo sapiens, clone IMAGE:3875012, mRNA 10

130689 NM 006691 Hs.17917 extracellular link domain-containing 1 10

130716 AA232075 Hs.18259 XPA binding protein 1; putative ATP(GTP) 5

130718 AF263462 Hs.18376 KIAA1319 protein 10

130722 N41322 Hs.18441 ESTs 5

130798 M81349 Hs.1955 serum amyloid A4, constitutive 10

130840 BE048821 Hs.20144 small inducible cytokine subfamily A (Cy 10

131184 AB040935 Hs.23954 cerebral cell adhesion molecule 10

131261 AA360419 Hs.171776 inositol(myo)-1(or4)-monophosphatase 1 10

131282 X03350 Hs.4 alcohol dehydrogenase 1 B (class 1), beta 10

131328 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco 10

131340 AK000393 Hs.25817 BTB (POZ) domain containing 2 5

131341 AF110908 Hs.297660 TNF receptor-associated factor 3 5

131406 H83294 Hs.284122 Wnt inhibitory factor-1 5

131489 BE394648 Hs.27414 hypothetical protein 5

131543 AW966881 Hs.41639 programmed cell death 2 10

131692 BE559681 Hs.30736 KIAA0124 protein 5

131753 AA829286 Hs.332053 serum amyloid A1 10

131756 AA443966 Hs.31595 ESTs 10

131785 H69342 Hs.26320 TRABID protein 10

131815 AA021258 Hs.32753 ESTs 5

131819 BE244961 Hs.173103 FE65-LIKE 2 5

131828 AJ000263 Hs.278658 keratin, hair, basic, 6 (monilethrix) 10

131888 AW294659 Hs.34054 Homo sapiens cDNA: FLJ22488 fis, clone H 5

131927 AJ003112 Hs.34780 doublecortex; lissencephaly, X-linked (d 5

131949 AK000010 Hs.258798 hypothetical protein FLJ20003 10

132115 H81604 Hs.178471 KIAA0798 gene product 5

132177 X80818 Hs.178078 glutamate receptor, metabotropic 4 5

132296 AA467752 Hs.195161 ESTs 5

132426 AW118072 Hs.89981 diacylglycerol kinase, zeta (104kD) 10

132477 S68874 Hs.170917 prostaglandin E receptor 3 (subtype EP3) 5

132675 AI291496 Hs.5476 Homo sapiens, clone IMAGE:3530123, mRNA, 10

132796 NM_006283 Hs.173159 transforming, acidic coiled-coil contain 10

132898 W28548 Hs.224829 ESTs 10

132905 NM_004235 Hs.7934 Kruppel-like factor 4 (gut) 10

132953 BE175645 Hs.321264 LBP protein 32 5

133116 BE563966 Hs.6529 ESTs, Weakly similar to I78885 serine/th 5

133120 NMJ303278 Hs.65424 tetranectin (plasminogen-binding protein 10 133139 AF052138 Hs.6580 Homo sapiens cDNA: FLJ23227 fis, clone C 5

133163 AA668224 Hs.6634 Homo sapiens cDNA: FLJ22547 fis, clone H 5

133268 AW956781 Hs.293937 ESTs, Weakly similar to FXD2JHUMAN FORKH 5

133272 NM 002776 Hs.69423 kallikrein 10 (KLK10) (PRSSL1) (nesl) 5

133379 AA207059 gb:zq80h09.s1 Stratagene hNT neuron (937 5

133407 AF017987 Hs.7306 secreted frizzled-related protein 1 5

133552 H21497 Hs.7471 BBP-like protein 1 5

133702 L02321 Hs.75652 glutathione S-transferase M5 5

133719 H26904 Hs.75736 apolipoproteiπ D 5

133731 N71725 Hs.272572 hemoglobin, alpha 2 10

133789 T85626 Hs.76239 hypothetical protein FLJ20608 5

134007 AF072441 Hs.7840 calcineurin binding protein 1 10

134055 D86062 Hs.182423 ES1 (zebrafish) protein, human homolog o 10

134111 AI372588 Hs.8022 TU3A protein 10

134117 AA081846 Hs.7921 Homo sapiens mRNA; cDNA DKFZp566E183 (fr 10

134177 BE243319 Hs.79672 KIAA0652 gene product 5

134308 AW905827 Hs.81454 ketohexokinase (fructokinase) 10

134361 BE549343 Hs.82208 acyl-Coenzyme A dehydrogenase, very long 5

134369 AF207664 Hs.8230 a disintegrin-like and metalloprotease ( 5

134449 L34155 Hs.83450 laminin, alpha 3 (nicein (150kD), kalini 5

134467 AI190413 Hs.8373 ESTs 10

134496 M64936 gb:Homo sapiens retinoic acid-inducible 10

134510 NM_002757 Hs.250870 mitogen-activated protein kinase kinase 10

134550 M26315 Hs.85258 CD8 antigen, alpha polypeptide (p32) 10

134577 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor 5

134591 U73394 Hs.166085 killer cell immunoglobulin-like receptor 5

134678 AL008583 Hs.182595 dynein, axonemal, light polypeptide 4 5

134728 D10216 Hs.89394 POU domain, class 1, transcription facto 5

134758 NM_000078 Hs.89538 cholesteryl ester transfer protein, plas 10

134786 T29618 Hs.89640 TEK tyrosine kinase, endothelial (venous 10

134912 T87521 Hs.261457 ESTs 5

134963 NM_003394 Hs.91985 wingless-type MMTV integration site fami 10

134969 H22570 Hs.172572 hypothetical protein FLJ20093 5

135001 AA302517 Hs.92732 KIAA1444 protein 5

135066 X04430 Hs.93913 interleukin 6 (interferon, beta 2) 10

135173 AL036557 Hs.95910 putative lymphocyte G0/G1 switch gene 10

135197 U76456 Hs.190787 tissue inhibitor of metalloproteinase 4 5

135219 AB002361 Hs.96633 KIAA0363 protein 5

135250 U83171 Hs.97203 small inducible cytokine subfamily A (Cy 5

135304 AA416829 Hs.191597 ESTs 5

135337 AA905406 Hs.9905 ESTs, Weakly similar to unnamed protein 3

135417 X55019 Hs.99975 cholinergic receptor, nicotinic, delta p 10

101367 X03350 Hs.4 alcohol dehydrogenase 1B (class I), beta 5

128870 H39537 Hs.75309 eukaryotic translation elongation factor 5

129381 AW245805 Hs.110903 claudin 5 (transmembrane protein deleted 5

130085 M62402 Hs.274313 insulin-like growth factor binding prate 5

130689 NM.006691 Hs.17917 extracellular link domain-containing 1 10

133120 NM 003278 Hs.65424 tetranectin (plasminogen-binding protein 3

133407 AF017987 Hs.7306 secreted frizzled-related protein 1 5

133731 N71725 Hs.272572 hemoglobin, alpha 2 5

134369 AF207664 Hs.8230 a disintegrin-like and metalloprotease ( 5

135066 X04430 Hs.93913 interleukin 6 (interferon, beta 2) ■ 10

135173 AL036557 Hs.95910 putative lymphocyte G0/G1 switch gene 5

322580 AK001852 Hs.274151 ligatin 5

408790 AW580227 Hs.47860 neurotrophic tyrosine kinase, receptor, type 2 10

418043 AW377752 Hs.83341 AXL receptor tyrosine kinase 5

427458 BE208364 Hs.29283 ESTs, Weakly similar to LKHU proteoglycan link 5

446674 AA563892 Hs.306000 solute carrier family 4 (anion exchanger), memb 10

449826 U85642 Hs.138506 ESTs 5

RC_H15814 .s Human apM1 mRNA for GS3109 (novel adipose specific collagen 10

YEL024w/RIP1 EST -YEL024W/RIP1 3 TABLE IA

Table 1 A shows the accession numbers for those pkeys lacking unigenelD's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT Number Accessions

108446 112224J AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 108497 110079_2 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041 AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053 AA131489 AA071308 AA063317 AA070156 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895 AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929

124215 1597154J H62570 H59063

117058 1219924J AW801806 H90434 BE086530

110455 46874 H52576 AF085971 H52172

111168 38585 A1798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570

111498 411008J AI168511 AI022712 AA700366 R07371 R07324 104340 46289J0 AA426189 F15201 103747 117944 AA081995 AA101099 134496 46501J M64936 AI025512 AI382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 AI269283 T40311

AI6845693 A AAA225577001111

AI079277 AI241318 BE327710 AW975215 AW896268 AA884990 BE327514

103750 118365 AA126129 AA126033 AA082561 105239 34624J AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627

AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241

AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904

C16859

120379 34624_3 AL042725 BE063316 AW975610 AA457591 BE062092 AI655202 AA714296 AI267264 AI075321 AA223286 AA071122

AA227849 AA216700 AI696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868

AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045

114624 111686_1 AA081507 AA070071 AA070840 AA084362 106851 322947 AI458623 AA639708 AA485409 R22065 AA485570 108392 113549 AA075124 AA075208 100545 22955J1 M55405 AW752552 100654 tigr_HT2969 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365

100702 tigr_HT3413 L27065 102208 6735_9 U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195

AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 A1042512 AI383957 AA156873 AI333101 N70806 AI141254 AI383191 AI401237 A1080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 AI133272 V00494 M12523 M12523 AI207526 AI133120 AI064802 AI174993 AH 14729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AM 10799 D17107 NMJ00477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 A1174710 Al 133290 Al 133304 Al 174948 AI207484 Al 110717 AF074624 AI114515 AF063516 AI110642 AI114559AI114498 AI114759 AI207568 AI064960 AI174753 Ah 14666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189174936 AI207490 A1132925 AI064701 AI174748 AM 14663 AI133104 AI132999 AI133100 AI064925 AI064979 AI133063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 N56507 T87485 AH 33622 AA343370 T40075 T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 AH 14589 R06691 AH 10629 AF063503 AI140543 AA334661 AA332720 AA343262 T73513 T86549 AI114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AI174786 AI132926 R09237 AI064838 AI133660 T60398 T88753 T55930 T92126 AI444602 T60996 AH 14792 H93911 AI133106 R10779 AI065020 T90925 T50889 D17029 AH33703 AA333805 AI133040 AI133017 AI064857 AH 10730 AF074637 AI207567 H71080 T73217 AA343950 AH74743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AH14676 AI064778 AA035710 W52763 AH14786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AH 10809 R28984 A1174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 AH 14590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 AI203974 AI189471 AA005147 AI478102 AI207662 AI192792 AI768421 AI064737 AW051713 AA936693 A1133117 AI766232 A1913646 T83962 AI065112 AI207689 AH74684 AI207702 T81475 AI133325 AI032512 AA701169 AI936354 AH 14720 AI433289 AA046980 AI823482 AH14536 AA860651 AW242644 R07469 AW300438 AH33416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AH50977 T62890 T71374 T68294 AH74774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AH 14860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 AH87111 T64308 T62071 T69427 AI114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 AI207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 AI312890 T67751 AH74983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

123941 genbank_AA621529 AA621529 118049 genbank_N53145 N53145 102800 14782_20 AA313538 U88895 U88902 104106 AA422123J_atAA422123_i 111738 genbank_R26065 R26065 113149 genbank_T51588 T51588 113958 genbank_W86195 W86195 108335 genbank_AA070500 AA070500 108351 genbank_AA071193 AA071193 108441 genbank_AA079079 AA079079 124276 genbank_H83465 H83465 101447 entrez_M21305 M21305 117226 genbank_N20468 N20468 133379 genbank_AA207059 AA207059.AA207241 119366 genbank_T77892 T77892 119528 NOT_FOUND_entrez_W38051 W38051 112588 genbank_R77302 R77302 114449 genbank_AA020736 AA020736 114576 genbank_AA065096 AA065096 107459 W38002_s_at W38002 s 130339 genbank_AA435746 AA435746 TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes dowmegulated in tumor tissue compared to normal breast tissue.

Pkey: Unic iue Eos probes et identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of normal breast tissue to tumor

Pkey ExAccn UnigenelD Unigene Tittle R1

100499 T51986 Hs.283108 hemoglobin, gamma G 10

100549 BE142019 Hs.222056 Homo sapiens cDNA FLJ11572 fis, clone HE 10

100654 A03758 NM_000477*:Homo sapiens albumin (ALB), m 10

100971 BE379727 Hs.83213 fatty acid binding protein 4, adipocyte 10

101184 NM 001674 Hs.460 activating transcription factor 3 10

101336 NM 006732 Hs.75678 FBJ murine osteosarcoma viral oncogene h 10

101367 X03350 Hs.4 alcohol dehydrogenase 1B (class I), beta 10

101447 M21305 gb:Human alpha satellite and satellite 3 10

101461 N98569 Hs.76422 phospholipase A2, group HA (platelets, 10

101511 M27826 Hs.267319 endogenous retroviral protease 10

101736 M74447 Hs.502 transporter 2, ATP-binding cassette, sub-famil 10

102208 U22961 gb:Human mRNA clone with similarity to L 10

102450 U48251 Hs.75871 protein kinase C binding protein 1 10

102800 AA313538 gb:EST185419 Colon carcinoma (HCC) cell 10

102857 NM 006744 Hs.76461 retinol-binding protein 4, interstitial 10

102990 AA829286 Hs.332053 serum amyloid A1 10

103747 AA081995 gb:zn26d06.M Stratagene neuroepithelium 10

103812 AA137107 Hs.326391 Homo sapiens, clone MGC:16638, mRNA, com 10

104093 R50727 Hs.336970 ESTs 10

104109 AL353957 Hs.284181 hypothetical protein DKFZp434P0531 10

104250 F06638 Hs.12440 Homo sapiens clone 24734 mRNA sequence 10

104492 N73185 Hs.94285 EST 10

104506 N91071 Hs.109650 ESTs 10

104532 AI498763 Hs.203013 hypothetical protein FLJ 12748 10

104677 AA009764 Hs.190380 ESTs 10

104711 AA017245 Hs.32794 ESTs 10

104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10

105005 AI298208 Hs.28805 ESTs 10

105036 AA130390 Hs.25549 hypothetical protein FLJ20898 10

105239 AA221036 gb:zr03f12.M Stratagene NT2 neuronal pr 10

106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10

106181 AI803651 Hs.191608 ESTs 10

106283 AI085846 Hs.25522 KIAA1808 protein 10

106379 AL042069 Hs.119021 DKFZP434N061 protein 10

106451 AW235928 Hs.313182 ESTs 10

106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10

106782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10

107124 AB006532 Hs.31442 RecQ protein-like 4 10

107148 AI005036 Hs.334305 GS1999full 10

107214 AF127026 Hs.5394 myosin IA 10

107242 AB020672 Hs.175411 KIAA0865 protein 10

107331 AI905985 Hs.111805 ESTs 10

107447 W28516 Hs.19210 hypothetical protein MGC11308 10

107451 AL042425 Hs.283976 hypthetical protein PR02389 10

107872 BE271708 Hs.95110 ESTs, Weakly similar to A55943 1 -phospha 10

108351 AA071193 gb:zf79b12.s1 Soares pineaLgland N3HPG 10

109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10

110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine:polyp 10

110976 AL044174 Hs.159526 patched (Drosophila) homolog 5 111168 AI798376 gb:tr34b07.x1 NCI CGAP 0v23 Homo sapiens 10

111651 R16733 Hs.20499 ESTs 10

111803 AA593731 Hs.325823 ESTs, Moderately similar to ALU5_HUMAN A 10

114484 AA034378 Hs.267319 endogenous retroviral protease 10

125284 NM_002666 Hs.103253 perilipin 10

128850 AA193106 Hs.180817 chromosome 11 open reading frame 23 5

128903 AW150717 Hs.296176 STAT induced STAT inhibitor 3 10

129346 AF110141 Hs.288908 WAS protein family, member 2 10

129381 AW245805 Hs.110903 claudin 5 (transmembrane protein deleted 10

129516 AF020038 Hs.11223 isocitrate dehydrogenase 1 (NADP+), solu 10

129554 BE222078 Hs.113069 ESTs 10

130085 M62402 Hs.274313 insulin-like growth factor binding prate 10

130243 D88435 Hs.153227 cyclin G associated kinase 10

130400 V00517 Hs.283108 hemoglobin, gamma G 10

130436 NM 001928 Hs.155597 D component of complement (adipsin) 10

130563 BE270472 Hs.279900 HSPC015 protein 10

130589 AL110226 Hs.16441 DKFZP434H204 protein 10

130683 AA993269 Hs.17872 Homo sapiens, clone IMAGE:3875012, mRNA 10

130689 NM 006691 Hs.17917 extracellular link domain-containing 1 10

130689 AA046747 Hs.17917 extracellular link domain-containing 1 10

130718 N70196 Hs.18376 KIAA1319 protein 10

130798 M81349 Hs.1955 serum amyloid A4, constitutive 10

130840 BE048821 Hs.20144 small inducible cytokine subfamily A (Cy 10

131184 AB040935 Hs.23954 cerebral cell adhesion molecule 10

131282 X03350 Hs.4 alcohol dehydrogenase 1B (class I), beta 10

131328 AW939251 Hs.25647 v-fos FBJ murine osteosarcoma viral onco 10

131543 AW966881 Hs.41639 programmed cell death 2 10

131753 AA829286 Hs.332053 serum amyloid A1 10

131785 H69342 Hs.26320 TRABID protein 10

131828 AJ000263 Hs.278658 keratin, hair, basic, 6 (monilethrix) 10

132426 AW118072 Hs.89981 diacylglycerol kinase, zeta (104kD) 10

132675 AI291496 Hs.5476 Homo sapiens, clone IMAGE:3530123, mRNA, 10

132898 W28548 Hs.224829 ESTs 10

132905 NM.004235 Hs.7934 Kruppel-like factor 4 (gut) 10

133120 NM 003278 Hs.65424 tetranectin (pTasminogen-binding protein 10

133407 AF017987 Hs.7306 secreted frizzled-related protein 1 10

133719 H26904 Hs.75736 apolipoprotein D 10

134007 AF072441 Hs.7840 calcineurin binding protein 1 10

134055 D86062 Hs.182423 ES1 (zebrafish) protein, human homolog o 10

134111 AI372588 Hs.8022 TU3A protein 5

134117 AA081846 Hs.7921 Homo sapiens mRNA; cDNA DKFZp566E183 (fr 5

134177 BE243319 Hs.79672 KIAA0652 gene product 10

134369 AF207664 Hs.8230 a disintegrin-like and metalloprotease ( 10

134496 M64936 gb:Homo sapiens retinoic acid-inducible 10

134510 NMJ02757 Hs.250870 mitogen-activated protein kinase kinase 10

134550 M26315 Hs.85258 CD8 antigen, alpha polypeptide (p32) 5

134758 NM 000078 Hs.89538 cholesteryl ester transfer protein, plas 5

134963 NMJ03394 Hs.91985 wingless-type MMTV integration site fami 10

135066 X04430 Hs.93913 interleukin 6 (interferon, beta 2) 10

408790 AW580227 Hs.47860 neurotrophic tyrosine kinase, receptor, type 2 10

446674 AA563892 Hs.306000 solute carrier family 4 (anion exchanger), memb 10 TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigenelD's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

111168 38585J AI798376 S46400AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718

AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570 103747 117944 1 AA081995 AA101099

134496 46501J M64936 AI025512 AI382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 AI269283 T40311

AI684569 AA257011 AI079277 AI241318 BE327710 AW975215 AW896268 AA884990 BE327514 105239 34624 AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904

C16859 100654 tigr_HT2969 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495

X51363 X51364 X51365 102208 6735_9 U22961 AA203623 AA503337 AH74733 AI192802 C06092 AA035357 AH90619 AI199244 AI828450 AA602296 AI378195 AI209170 AI186653 AH27795 AH83846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 A1745413

AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AH41254 AI383191 A1401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 A1378348 AI559265 AA877103 W84464 AA625146 R68379 AH33207 AH32980 AI133214 AI064826 AI061615 AI133473 AH74852 AH33404 AH33272 V00494 M12523 M12523 AI207526 AH33120 AI064802 AH74993 AH 14729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AH 10799 D17107 NM_000477 AF190168 R50724 A1248416 AI207432 AH33684 AI133345 AH74710

AI133290 AI133304 A1174948 AI207484 AH 10717 AF074624 A1114515 AF063516 AI110642 AH14559 AI114498 AI114759 AI207568 AI064960 AH74753 AH 14666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 AI207490 AH 32925 AI064701 AH74748 AH 14663 AH33104 AH32999 AH33100 AI064925 AI064979 AI133063 AA343347 T69091 AA233989 T39772 A1444620 T52290 D16931 T40012 T48403 T58926 T69195 A1133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979

N56507 T87485 AH 33622 AA343370 T40075 T69671 T53849 T74820 AF075316 AH 10818 T40121 T57381 AI114468 AA332728 T51362 AH 14589 R06691 AH 10629 AF063503 AH40543 AA334661 AA332720 AA343262 T73513 T86549 AI114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 AH32926 R09237 AI064838 AH33660 T60398 T88753 T55930 T92126 AI444602 T60996 AH14792 H93911 AI133106 R10779 AI065020 T90925 T50889 D17029 AI133703 AA333805 AI133040 AH33017 AI064857 AI110730 AF074637 AI207567

H71080 T73217 AA343950 AI174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T6036 T69176 T73356 T58795 T61233 T39955 T60612 AH14676 A1064778 AA035710 W52763 AH14786 T83564 AA341859 T81684 T55769 AH 14710 T51776 AA343213 AH14714 T58102 AH 10809 R28984 AH74854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269

H54053 T73211 AH 14590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 AI203974 AH89471 AA005147 AI478102 AI207662 AH92792 AI768421 AI064737 AW051713 AA936693 AI133117 AI766232 AI913646 T83962 AI065112 AI207689 AH74684 AI207702 T81475 AH33325 AI032512 AA701169 AI936354 AI114720 AI433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363 T78943 A1823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AH74774 T67411 T68318

AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AH 14860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 AH87111 T64308 T62071 T69427 AI114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 AI207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 AI312890 T67751 AI174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

102800 14782_20 AA313538 U88895 U88902

108351 genbank_AA071193 AA071193

101447 entrez_M21305 M21305

TABLE 3: Figure 3 from BRCA 001 US Table 3 shows genes dowmegulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of normal breast tissue to tumor

Pkey ExAccn UnigenelD UnigeneTitle R1

101336 NM 006732 Hs.75678 FBJ murine osteosarcoma viral oncogene h 10.0

102208 U22961 gb:Human mRNA clone with similarity to L 10.0

102990 AA829286 Hs.332053 serum amyloid A1 10.0

111168 AI798376 gb:tr34b07.x1 NCI_CGAP_θv23 Homo sapiens 10.0

111803 AA593731 Hs.325823 ESTs, Moderately similarto ALU5_HUMAN A 10.0

130085 M62402 Hs.274313 insulin-like growth factor binding prate 10.0

130840 BE048821 Hs.20144 small inducible cytokine subfamily A (Cy 10.0

131543 AW966881 Hs.41639 programmed cell death 2 10.0

133120 NM 003278 Hs.65424 tetranectin (plas inogen-binding protein 10.0

134758 NM 000078 Hs.89538 cholesteryl ester transfer protein, plas 10.0

TABLE 3A

Table 3 A shows the accession numbers for those pkeys lacking unigenelD's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

111168 38585J AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567

AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254

AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570 1022086735_9 U22961 AA203623 AA503337 AH 74733 AH92802 C06092 AA035357 AI190619 AH99244 AI828450 AA602296 AI378195 AI209170 AI186653 Al 127795 AM 83846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092

AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AH41254 AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 AI133207 AH32980 AH33214 AI064826 AI061615 Al 133473 Al 174852 AI133404 AH 33272 V00494 M12523 M12523 AI207526 AH33120 AI064802 AH74993 AH 14729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AH 10799 D17107 NM 000477 AF190168 R50724 AI248416 AI207432 AI133684 AH 33345 AI174710 AH 33290 AH33304 AI174948

AI207484 AH 10717 AF074624 AH 14515 AF063516 AH 10642 AH 14559 AH 14498 AH 14759 AI207568 AI064960 AH74753 AH14666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 A1207490 AM32925 AI064701 A1174748 AI114663 A1133104 AH 32999 AH33100 AI064925 AI064979 AH33063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 N56507 T87485 Al 133622 AA343370 T40075

T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AH14468 AA332728 T51362 AH 14589 R06691 AH 10629 AF063503 Al 140543 AA334661 AA332720 AA343262 T73513 T86549 AM 14840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 AM 32926 R09237 A1064838 AI133660 T60398 T88753 T55930 T92126 AI444602 T60996 AH 14792 H93911 AI133106 R10779 AI065020 T90925 T50889 D17029 AH33703 AA333805 AM33040 AH33017 AI064857 AM 10730 AF074637 AI207567 H71080 T73217 AA343950 AH74743 AA334224 AA334281

R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AH 14676 AI064778 AA035710 W52763 AH 14786 T83564 AA341859 T81684 T55769 AH14710 T51776 AA343213 AH 14714 T58102 AI110809 R28984 AH74854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 AI114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976

R02576 T95666 AI203974 AM89471 AA005147 AI478102 A1207662 AI192792 AI768421 AI064737 AW051713 AA936693 AH33117 AI766232 AI913646 T83962 AI065112 AI207689 AI174684 AI207702 T81475 AI133325 AI032512 AA701169 AI936354 AI114720 AI433289 AA046980 AI823482 AM14536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AH50977 T62890 T71374 T68294 AI174774 , T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 A1064819 AI205880 T62895 T69430 T95111

AA025050 T73330 W52657 T71984 T69118 W92684 AH 14860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 AI187111 T64308 T62071 T69427 AH 14750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 AI207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 AI312890 T67751 Al 174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412

T64300 T28321 T55864 TABLE 4: Figure 4 from BRCA 001 US Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number

Unigene Title: Unigene gene title R1 : Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD Unigene Title R1

100113 NM_001269Hs.84746 chromosome condensation 1 2.3

100114 X02308 Hs.82962 thymidylate synthetase 2.9 100131 D12485 Hs.11951 ectonucleotide pyrophosphatase/phosphodiesterase 1 1.9 100146 BE185499 Hs.2471 KIAA0020 gene product 1.9

100147 D13666 Hs.136348 osteoblast specific factor 2 (fascidin l-like) (periostin) 7.5

100154 H60720 Hs.81892 KIAA0101 gene product 9.2

100163 W44671 Hs.124 gene predicted from cDNA with a complete coding sequence 1.6

100220 AW015534 Hs.217493 annexin A2 2.0 100265 D38521 Hs.112396 KIAA0077 protein 1.5

100271 BE160081 Hs.256290 S100 calcium-binding protein A11 (calgizzarin) 13.5

100275 BE242802 Hs.154797 KIAA0090 protein 5.1

100323 D50920 Hs.23106 KIAA0130 gene product 1.9

100335 AW247529 Hs.6793 platelet-activating factor acetylhydralase, isoform lb, gamma subunit (29kD) 2.7 100364 NM_004341Hs.154868 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 2.0

100372 NM_014791Hs.184339 KIAA0175 gene product 2.6

100393 D84145 Hs.39913 novel RGD-containing protein 3.2

100400 AW954324 Hs.75790 phosphatidylinositol glycan, class C 1.5

100418 D86978 Hs.84790 KIAA0225 protein 2.0 100482 M65028 Hs.81361 heterogeneous nuclear ribonucleoprotein A/B 2.9

100518 NM_004415Hs.74316 desmoplakin (DPI, DPH) 1.9

100666 L05424 Hs.169610 CD44 antigen (homing function and Indian blood group system) 5.7

100667 L05424 Hs.169610 CD44 antigen (homing function and Indian blood group system) 9.0

100668 L05424 Hs.169610 CD44 antigen (homing function and Indian blood group system) 7.6 100678 AW502935 Hs.740 PTK2 protein tyrosine kinase 2 53.2

100685 AA328229 Hs.184582 ribosomal protein L24 1.8

100690 AA383256 Hs.1657 estrogen receptor 1 1.6

100783 AF078847 Hs.191356 general transcription factor IIH, polypeptide 2 (44kD subunit) 5.9

100850 AA836472 Hs.297939 cathepsin B 1.7 100892 BE245294 Hs.180789 S164 protein 1.7

100945 AF002225 Hs.180686 ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome) 1.5

100969 AA157634 Hs.79172 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 6.3

100988 AK000405 Hs.76480 ubiquitin-like 4 11.4

100999 H38765 Hs.80706 diaphorase (NADH/NADPH) (cytochrome b-5 reductase) 1.6 101031 J05070 Hs.151738 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type I collagenase) 8.2

101045 J05614 gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region. 5.0

101077 N99692 Hs.75227 Empirically selected from AFFX single probeset 2.6

101093 L06419 Hs.75093 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type Vl)1.4

101161 NM_006262Hs.37044 peripherin 16.9 101186 AA020956 Hs.179881 core-binding factor, beta subunit 2.0

101216 AA284166 Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) 1.8

101228 AA333387 Hs.82916 chaperonin containing TCP1, subunit 6A (zeta 1) 1.7

101247 AA132666 Hs.78802 glycogen synthase kinase 3 beta 1.9

101249 L18964 Hs.1904 protein kinase C, iota 1.5 101332 J04088 Hs.156346 topoiso erase (DNA) II alpha (170kD) 5.2

101332 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 3.4

101352 AI494299 Hs.16297 COX17 (yeast) homolog, cytochrome c oxidase assembly protein 6.3

101396 BE267931 Hs.78996 proliferating cell nuclear antigen 4.2

101445 M21259 gb:Human Alu repeats in the region 5' to the small nuclear rib 1.9 101470 NM_000546Hs.1846 tumor protein p53 (Li-Fraumeni syndrome) 1.6 101478 NM_002890Hs.758 RAS p21 protein activator (GTPase activating protein) 1 2.5 101483 M24486 Hs.76768 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxyiase), alpha polypeptide I 5.5 101540 J04977 Hs.84981 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining 2.1 101573 AW248421 Hs.250758 proteasome (prosome, macropain) 26S subunit, ATPase, 3 1.6 101580 NM_012151Hs.83363 coagulation factor Vlll-associated (intronic transcript) 5.7 101592 AF064853 Hs.91299 guanine nucleotide binding protein (G protein), beta polypeptide 2 1.8 101592 AF064853 Hs.91299 guanine nucleotide binding protein (G pr 5.6 101621 BE391804 Hs.62661 guanylate binding protein 1 , interferon-inducible, 67kD 2.4 101702 AW504089 Hs.179574 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform 1.3 101734 M74099 Hs.147049 cut (Drosophila)-like 1 (CCAAT displacement protein) 2.1 101759 M80244 Hs.184601 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 5.0 101767 M81057 Hs.180884 carboxypeptidase B1 (tissue) 14.4 101782 AA306495 Hs.1869 phosphoglucomutase 1 5.2 101805 AW409747 Hs.75612 stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) 8.6 101806 AA586894 Hs.112408 S100 calcium-binding protein A7 (psoriasin 1) 8.9 101810 NM_000318Hs.180612 peraxisomal membrane protein 3 (35kD, Zellweger syndrome) 3.2 101879 AA176374 Hs.243886 nuclear autoantigenic sperm protein (histone-binding) 1.6 101911 AA441787 Hs.119689 glycoprotein hormones, alpha polypeptide 31.3 101920 AF182645 Hs.8024 IK cytokine, down-regulator of HLA II 1.8 101973 U41514 Hs.80120 UDP-N-acetyl-alpha-D<jalactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 2.4 101983 AI904232 Hs.75323 prohibitin 8.4 102009 BE245149 Hs.82643 protein tyrosine kinase 9 1.3 102036 BE250127 Hs.82906 CDC20 (cell division cycle 20, S. cerevisiae, homolog) 2.0 102083 T35901 Hs.75117 interleukin enhancer binding factor 2, 45kD 1.6 102083 T35901 Hs.75117 interleukin enhancer binding factor 2, 4 1.3 102107 BE258602 Hs.182366 heat shock protein 75 1.4 102123 NM_001809Hs.1594 centromere protein A (17kD) 1.8 102165 BE313280 Hs.159627 death associated protein 3 4.6 102198 AW950852 Hs.74598 polymerase (DNA directed), delta 2, regulatory subunit (50kD) 4.3 102217 AA829978 Hs.301613 JTV1 gene 6.7 102220 U24389 Hs.65436 lysosomal 4.3 102234 AW163390 Hs.278554 heterochromatin-like protein 1 1.9 102260 AL039104 Hs.159557 karyopherin alpha 2 (RAG cohort 1 , importin alpha 1 ) 4.4 102302 AA306342 Hs.69171 protein kinase C-like 2 2.7 102330 BE298063 Hs.77254 chromobox homolog 1 (Drosophila HP1 beta) 1.5 102339 BE378432 Hs.95577 cyclin-dependent kinase 4 2.3 102348 U37519 Hs.87539 aldehyde dehydrogenase 3 family, member B2 2.0 102349 AU077055 Hs.289107 baculoviral IAP repeat-containing 2 3.2 102369 U39840 Hs.299867 hepatocyte nuclear factor 3, alpha 2.0 102374 U33635 Hs.90572 PTK7 protein tyrosine kinase 7 6.2 102391 AA296874 Hs.77494 deoxyguanosine kinase 1.5 102455 U48705 Hs.75562 discoidin domain receptor family, member 1 6.9 102465 NM_001359Hs.81548 2,4-dienoyl CoA reductase 1 , mitochondrial 1.8 102488 U50939 Hs.61828 amyloid beta precursor protein-binding protein 1 , 59kD 1.5 102489 AL080116 Hs.74420 origin recognition complex, subunit 3 (yeast homolog)-like 3.3 102494 AM 88137 Hs.75193 COP9 homolog 2.1 102501 AF217197 Hs.74562 siah binding protein 1; FBP interacting repressor; pyrimidine tract binding splicing 3.2 102522 BE250944 Hs.183556 solute earner family 1 (neutral amino acid transporter), member 5 2.8 102532 AF040253 Hs.70186 suppressor of Ty (S.cerevisiae) 5 homolog 5.7 102564 U59423 Hs.79067 MAD (mothers against decapentaplegic, Drosophila) homolog 1 2.3 102568 W81489 Hs.223025 RAB31 , member RAS oncogene family 5.3 102580 U60808 Hs.152981 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 2.1 102581 AU077228 Hs.77256 enhancer of zeste (Drosophila) homolog 2 1.6 102582 U61232 Hs.32675 tubulin-specific chaperone e 2.1 102617 AW161453 Hs.198767 COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 1.8 102618 AL037672 Hs.81071 extracellular matrix protein 1 5.8 102627 AL021918 Hs.158174 zinc finger protein 184 (Kruppel-like) 1.3 102663 NM_002270Hs.168075 karyopherin (importin) beta 2 1.8 102676 BE262989 Hs.12045 putative protein 2.3 102687 NM_007019Hs.93002 ubiquitin carrier protein E2-C 4.3 102689 U96132 Hs.171280 hydroxyacyl-Coenzyme A dehydrogenase, type II 6.0 102696 BE540274 Hs.239 forkhead box M1 4.2 102704 AU077058 Hs.54089 BRCA1 associated RING domain 1 1.9 102705 T97490 Hs.50002 small inducible cytokine subfamily A (Cys-Cys), member 19 2.3 102750 AB014460 Hs.66196 nth (E.coli endonuclease lll)-like 1 1.2 102801 BE252241 Hs.38041 pyridoxal (pyridoxine, vitamin B6) kinase 6.4 102812 U90549 Hs.236774 high-mobility group (nonhistone chromosomal) protein 17-like 3 1.6 102827 BE244588 Hs.6456 chaperonin containing TCP1, subunit 2 (beta) 5.6 102831 AA262170 Hs.80917 adaptor-related protein complex 3, sigma 1 subunit 2.0 102844 AV653790 Hs.324275 WW domain-containing protein 1 1.3 102868 X02419 Hs.77274 plasminogen activator, urokinase 4.4 102925 BE440142 Hs.2943 signal recognition particle 19kD 1.9 102935 BE561850 Hs.80506 small nuclear ribonucleoprotein polypeptide A' 2.4 102968 AU076611 Hs.154672 methylene tetrahydrafolate dehydragenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase2.7 102983 BE387202 Hs.118638 non-metastatic cells 1, protein (NM23A) expressed in 3.1 102985 U95742 Hs.2707 G1 to S phase transition 1 5.2 103023 AW500470 Hs.117950 multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase 1.6 103038 AA926960 Hs.334883 CDC28 protein kinase 1 2.5 103060 NM_005940Hs.155324 matrix metalloproteinase 11 (MMP11; stromelysin 3) 4.5 103080 AU077231 Hs.82932 cyclin DI (PRAD1: parathyroid adenomatosis 1) 3.1 103089 D31152 Hs.179729 collagen, type X, alpha 1 (Schmid metaphyseal chondradysplasia) 2.4 103177 BE244377 Hs.48876 famesyl-diphosphate farnesyltransferase 1 3.5 103178 AA205475 Hs.275865 ribosomal protein S18 9.9 103179 NM_001777Hs.82685 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 1.3 103181 X69636 Hs.334731 Homo sapiens, clone IMAGE:3448306, mRNA, partial eds 2.0 103185 NM_006825Hs.74368 transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment 1.6 103191 AA401039 Hs.2903 protein phosphatase 4 (formerly X), catalytic subunit 2.5 103193 NM_004766Hs.75724 coatomer protein complex, subunit beta 2 (beta prime) 2.2 103194 NM_004939Hs.78580 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 6.3 103206 X72755 Hs.77367 monokine induced by gamma interferon 8.8 103223 BE275607 Hs.1708 chaperonin containing TCP1, subunit 3 (gamma) 3.0 103232 X75962 Hs.129780 tumor necrosis factor receptor superfamily, member 4 1.8 103238 AI369285 Hs.75189 death-associated protein 5.6 103297 NM_001545Hs.9078 immature colon carcinoma transcript 1 1.9 103330 AI803447 Hs.77496 small nuclear ribonucleoprotein polypeptide G 2.5 103349 X89059 gb:H.sapiens mRNA for unknown protein expressed in macrophage 1.6 103376 AL036166 Hs.323378 coated vesicle membrane protein 1.8 103391 X94453 Hs.114366 pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase) 2.3 103392 X94563 gb:H.sapiens dbi/acbp gene exon 1 & 2. 4.0 103430 BE564090 Hs.20716 translocase of inner mitochondrial membrane 17 (yeast) homolog A 1.3 103491 AF264750 Hs.288971 myeloid/lymphoid or mixed-lineage leukemia 3 5.6 103505 AL031224 Hs.33102 transcription factor AP-2 beta (activating enhancer-binding protein 2 beta) 5.1 103547 AI376722 Hs.180062 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7) 9.7 103588 NM_006218Hs.85701 phosphoinositide-3-kinase, catalytic, alpha polypeptide 2,0 103613 NM_000346Hs.2316 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) 1.3 103621 BE379766 Hs.150675 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD) 2.0 103622 AA609685 Hs.278672 membrane component, chromosome 11, surface marker 1 2.3 103727 AI878883 Hs.296381 growth factor receptor-bound protein 2 1.3 103749 AL135301 Hs.8768 hypothetical protein FLJ 10849 1.8 103754 AI015709 Hs.172089 Homo sapiens mRNA; cDNA DKFZp586l2022 (from clone DKFZp586l2022) 1.3 103780 AA094752 Hs.169992 hypothetical 43.2 Kd protein 7.5 103795 H26531 Hs.7367 Homo sapiens BTB domain protein (BDPL) mRNA, partial eds 1.2 103797 AA080912 gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar 1.5 103813 AI042582 Hs.181271 CGI-120 protein 1.5 103855 W02363 Hs.302267 hypothetical protein FLJ 10330 1.5 103886 AK001278 Hs.105737 hypothetical protein FLJ 10416 similar to constitutive photomorphogenic protein 1 6.5 104052 NM_002407Hs.97644 mammaglobin 2 2.9 104079 AA251242 Hs.103238 ESTs 1.4 104174 AA478984 Hs.6451 PRO0659 protein 5.6 104227 AB002343 Hs.98938 protocadherin alpha 9 1.6 104275 AI751970 Hs.101067 GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2 5.4 104325 BE379766 Hs.150675 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD) 6.3 104370 AA324597 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 1.6 104423 R83113 Hs.1432 protein kinase C substrate 80K-H 5.2 104482 AB037762 Hs.44268 myelin gene expression factor 2 1.2 104532 A1498763 Hs.203013 hypothetical protein FLJ 12748 2.1 104563 AL117403 Hs.306189 DKFZP434F1735 protein 1.2 104667 AI239923 Hs.30098 ESTs 1.3 104757 AI694413 Hs.332649 olfactory receptor, family 2, subfamily I, member 6 2.3 104804 AI858702 Hs.31803 ESTs, Weakly similarto N-WASP [H.sapiens] 1.3 104806 AB023175 Hs.22982 KIAA0958 protein 2.3 104827 AW052006 Hs.8551 PRP4/STK/WD splicing factor 10.9 104846 AI250789 Hs.32478 ESTs 5.6 104854 AA041276 Hs.154729 3-phosphoinositide dependent protein kinase-1 12.3 104867 AA278898 Hs.225979 hypothetical protein similar to small G proteins, especially RAP-2A 2.0

104871 T78044 Hs.28893 Homo sapiens mRNA; cDNA DKFZp56402364 (from clone DKFZp56402364) 1.3

104896 AW015318 Hs.23165 ESTs 17.7

104909 AW408164 Hs.249184 transcription factor 19 (SC1) 5.0 104916 AW958157 Hs.155489 NS1 -associated protein 1 1.7

104919 AA026880 Hs.25252 pralactin receptor 1.4

104930 AF043467 Hs.32893 neurexophilin 2 2.2

104973 NMJM5310HS.6763 KIAA0942 protein 5.0

104974 Y12059 Hs.278675 bromodomain-containing 4 1.4 104975 AL136877 Hs.50758 SMC4 (structural maintenance of chromosomes 4, yeast)-like 1 2.4

104975 AL136877 Hs.50758 SMC4 (structural maintenance of chramoso 2.3

104978 AH99268 Hs.19322 Homo sapiens, Similarto RIKEN cDNA 2010317E24 gene, clone IMAGE:3502019, mRNA, partial cds7.2

104979 AA937934 Hs.321062 ESTs 1.3 104994 AI499930 Hs.334885 mitochondrial GTP binding protein 3.5 105009 BE379584 Hs.34789 dolichyl-diphosphooligosaccharide-protein glycosyltransferase 5.5

105012 AF098158 Hs.9329 chromosome 20 open reading frame 1 3.3

105028 AI050715 Hs.2331 E2F transcription factor 5, p130-binding 2.2 105032 AA127818 gb:zl12a02.s1 Soares_pregnantuterus_NbHPU Homo sapiens cDNA clone IMAGE:5016743' 6.8

105039 AA907305 Hs.36475 ESTs 2.5 105041 AB037716 Hs.26204 KIAA1295 protein 2.2

105045 BE242899 Hs.129951 speckle-type POZ protein 3.8

105079 AA151342 Hs.12677 CGI-147 protein 9.5

105087 AA147884 Hs.9812 Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716 5.6

105088 H58589 Hs.35156 Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114 2.2 105095 Z78407 Hs.27023 vesicle transport-related protein 2.2

105110 BE387350 Hs.33122 KIAA1160 protein 1.6

105126 AW975433 Hs.36288 ESTs 6.3

105127 AA045648 Hs.301957 nudix (nucleoside diphosphate linked moiety X)-type motif 5 2.1 105141 AA164687 Hs.177576 mannosyi (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A 2.7 105158 AW976357 Hs.234545 hypothetical protein NUF2R 1.9

105169 BE245294 Hs.180789 S164 protein 1.7

105186 AA191512 Hs.28005 Homo sapiens cDNA FLM 1309 fis, clone PLACE1010076 4.8

105254 AA071276 Hs.19469 KIAA0859 protein 1.9

105281 AA263143 Hs.24596 RAD51-interacting protein 2.8 105288 N99673 Hs.3585 ESTs, Weakly similarto AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens] 1.9

105302 AA700122 Hs.3355 sentrin-specific protease 8.0

105331 AW270037 Hs.179507 KIAA0779 protein 1.8

105359 NM_016015Hs.8054 CGl-68 protein 8.2

105366 BE264645 Hs.282093 hypothetical protein FLJ21918 5.0 105373 AW887701 Hs.32356 hypothetical protein FLJ20628 2.5

105374 BE242803 Hs.262823 hypothetical protein FLJ10326 2.2

105387 AW592146 Hs.108636 membrane protein CH1 2.3

105393 AF167570 Hs.256583 interleukin enhancer binding factor 3, 90kD 5.4

105399 BE386877 Hs.334811 Npw38-binding protein NpwBP 1.6 105400 AF198620 Hs.65648 RNA binding motif protein 8A 1.6 105445 AA252395 gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:6850263', mRNA sequence. 5.0

105507 BE268348 Hs.226318 CCR4-NOT transcription complex, subunit 7 1.6

105529 AA113449 Hs.32471 hypothetical protein FLJ20364 1.3

105530 AB023179 Hs.9059 KIAA0962 protein 3.4 105547 AA262640 Hs.27445 unknown 9.3

105564 BE616694 Hs.288042 hypothetical protein FLJ14299 1.4

105596 AA579535 Hs.18490 hypothetical protein FLJ20452 10.9

105597 AF054284 Hs.334826 splicing factor3b, subunit 1, 155kD 2.9 105608 AI808201 Hs.287863 hypothetical protein FLJ 12475 1.7 105610 AA280072 Hs.99872 fetal Alzheimer antigen - 1.4

105617 AK000892 Hs.4069 glucocorticoid modulatoiy element binding protein 1 1.7

105620 AW302245 Hs.181390 casein kinase 1, gamma 2 5.5

105658 AA985190 Hs.246875 hypothetical protein FLJ20059 9.4

105697 AW499988 Hs.27801 zinc finger protein 278 2.0 105708 R26944 Hs.180777 Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264) 1.7

105743 BE246502 Hs.9598 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short 2.6

105746 AW151952 Hs.46679 hypothetical protein FLJ20739 1.5

105759 AH23118 Hs.15159 chemokine-like factor, alternatively spliced 1.3

105771 AI267720 Hs.153221 synovial sarcoma, translocated to X chromosome 1.6 105820 AA741336 Hs.152108 transcriptional unit N143 2.2

105826 AA478756 Hs.194477 E3 ubiquitin ligase SMURF2 1.3

105856 AI262106 Hs.12653 ESTs 2.4 105858 AF151066 Hs.281428 hypothetical protein 2.9 105875 AK001708 Hs.32271 hypothetical protein FLJ10846 1.4 105930 AF016371 Hs.9880 peptidyl prolyl isomerase H (cyclophilin H) 5.2 106000 AW194426 Hs.20726 ESTs 1.7 106011 AW081202 Hs.12284 Homo sapiens, clone IMAGE:2989556, mRNA, partial eds 2.8 106017 AA477956 Hs.26268 ESTs 1.4 106073 AL157441 Hs.17834 downstream neighbor of SON 1.4 106078 AA130158 Hs.19977 ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION 1.6 106094 AA533491 Hs.23317 hypothetical protein FLJ14681 6.8 106140 AB006624 Hs.14912 KIAA0286 protein 1.6 106271 AA251393 Hs.289052 Homo sapiens, Similarto RIKEN cDNA 5430429M05 gene, clone MGC:13155, mRNA, complete eds 10.S 106288 AB037742 Hs.24336 KIAA1321 protein 1.3 106300 Y10043 Hs.9114 high-mobility group (nonhistone chromosomal) protein 4 3.6 106333 AL043114 Hs.22410 ESTs, Weakly similar to A54849 collagen alpha 1 (VII) chain precursor [H.sapiens] 5.4 106350 AK001404 Hs.194698 cyclin B2 5.7 106359 AW390282 Hs.31130 transmembrane 7 superfamily member 2 6.3 106381 AB040916 Hs.24106 KIAA1483 protein 6.5 106389 AW748420 Hs.6236 Homo sapiens cDNA: FLJ21487 fis, clone COL05419 2.2 106457 AF119256 Hs.27801 zinc finger protein 278 2.7 106470 D63078 Hs.186180 Homo sapiens cDNA: FLJ23038 fis, clone LNG02039 2.3 106531 AA454036 Hs.8832 ESTs 1.6 106586 AA243837 Hs.57787 ESTs 1.6 106589 AK000933 Hs.28661 Homo sapiens cDNA FLJ10071 fis, clone HEMBA1001702 2.4 106610 AA458882 Hs.79732 fibulin 1 7.9 106624 NM_003595Hs.26350 tyrosylprotein sulfotransferase 2 7.7 106650 AL049951 Hs.22370 Homo sapiens mRNA; cDNA DKFZp564O0122 (from clone DKFZp564O0 22) 1.8 106669 AV657117 Hs.184164 ESTs, Moderately similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens] 1.3 106713 BE614802 Hs.184352 hypothetical protein FLJ12549 4.5 106717 AA600357 Hs.239489 TIA1 cytotoxic granule-associated RNA-binding protein 1.3 106723 BE388094 Hs.21857 ESTs 1.6 106795 AF174487 Hs.293753 Bcl-2-related ovarian killer protein-like 5.7 106829 AW959893 Hs.27099 hypothetical protein FLJ23293 similar to ARL-6 interacting protein-2 16.2 106831 BE564871 Hs.29463 centrin, EF-hand protein, 3 (CDC31 yeast homolog) 1.5 106846 AB037744 Hs.34892 KIAA1323 protein 2.2 106852 AF151031 Hs.300631 hypothetical protein 1.3 106873 N49809 Hs.11197 Homo sapiens, clone IMAGE:3343149, mRNA, partial eds 16.8 106886 W79171 Hs.9567 GL002 protein 1.5 106906 AA861271 Hs.222024 transcription factor BMAL2 2.2 106920 AK001838 Hs.296323 serum/glucocorticoid regulated kinase 3.3 106945 AK000511 Hs.6294 hypothetical protein DKFZp434L1435 similar to valyl tRNA synthetase 6.8 106973 BE156256 Hs.11923 hypothetical protein 6.6 106977 AL043152 Hs.50421 KIAA0203 gene product 4.8 106978 AW631480 Hs.8688 ESTs 6.0 107004 AA146872 Hs.300700 hypothetical protein FLJ20727 1.3 107029 AF264750 Hs.288971 myeloid/lymphoid or mixed-lineage leukemia 3 1.8 107071 AW385224 Hs.35198 ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function) 1.7 107113 AK000733 Hs.23900 GTPase activating protein 2.5 107125 AK000512 Hs.69388 hypothetical protein FLJ20505 1.7 107136 AV661958 Hs.8207 GK001 protein 4.6 107136 AV661958 Hs.8207 GK001 protein 3.3 107146 AK001455 Hs.5198 Down syndrome critical region gene 2 2.0 107151 AW378065 Hs.8687 ESTs 6.3 107155 AW391927 Hs.7946 KIAA1288 protein 33.5 107174 BE122762 Hs.25338 ESTs 5.2 107197 W15477 Hs.64639 glioma pathogenesis-related protein 6.1 107221 AW888411 Hs.81915 leukemia-associated phosphoprotein p18 (stathmin) 17.4 107243 BE219716 Hs.34727 ESTs, Moderately similar to I38759 zinc finger/leucine zipper protein [H.sapiens] 7.4 107248 AW263124 Hs.31511 nuclear receptor co-repressor/HDAC3 complex subunit 1.8 107263 D60341 Hs.21198 translocase of outer mitochondrial membrane 70 (yeast) homolog A 6.6 107265 BE379594 Hs.49136 ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION 2.5 107298 N95657 Hs.6820 ESTs, Moderately similar to YOJ1_CAEEL HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN 2.5 107298 N95657 Hs.6820 ESTs, Moderately similar to YOJ1_CAEEL H 1.7 107299 BE277457 Hs.30661 hypothetical protein MGC4606 3.2 107316 T63174 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324) 2.0 107354 NM_006299Hs.96448 zinc finger protein 193 5.0 107392 AW299900 Hs.267632 TATA element modulatory factor 1 1,2 107481 AA307703 Hs.279766 kinesin family member 4A 1.6 107529 BE515065 Hs.296585 nucleolar protein (KKE/D repeat) 3.0 107554 AA001386 Hs.59844 ESTs 1.3 107681 BE379594 Hs.49136 ESTs, Moderately similarto ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION 2.2 107772 AA018587 Hs.303055 ESTs, Weakly similarto ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION 2.1 107859 AW732573 Hs.47584 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 8.4 107901 L42612 Hs.335952 keratin 6B 2.5 107901 L42612 Hs.335952 keratin 6B 1.6 107922 BE153855 Hs.61460 Ig superfamily receptor LNIR 2.2 107974 AW956103 Hs.61712 pyruvate dehydrogenase kinase, isoenzyme 1 6.7 108040 AL121031 Hs.159971 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 1.5 108230 AA054224 Hs.59847 ESTs 1.3 108274 AF129535 Hs.272027 F-box only protein 5 7.1 108296 N31256 Hs.161623 ESTs 2.5 108496 AA083069 Hs.339659 ESTs 3.5 108607 BE300380 Hs.69476 Homo sapiens cDNA FLJ 12758 fis, clone NT2RP2001328 3.4 108621 AA101809 Hs.182685 ESTs 1.6 108634 AW022410 Hs.69507 ESTs 1.7 108647 BE546947 Hs.44276 homeo box C10 108695 AB029000 Hs.70823 KIAA1077 protein 7.2 108717 AA122393 Hs.70811 hypothetical protein FLJ20516 1.3 108740 AI089575 Hs.9071 progesterone membrane binding protein 2.7 108828 AK001693 Hs.273344 DKFZP564O0463 protein 1.8 108859 AL121500 Hs.178904 ESTs 1.5 108872 H06720 Hs.111680 endosulfine alpha 2.1 108891 AI801235 Hs.48480 ESTs 5.3 108894 AK001431 Hs.5105 hypothetical protein FLJ10569 4.0 108955 AA149754 Hs.195155 Homo sapiens amino acid transport system N2 (SN2) mRNA, complete eds 5.6 108982 AA151708 Hs.171980 homeo box (expressed in ES cells) 1 1.6 108987 AA152178 Hs.23467 hypothetical protein FLJ10633 6.2 109002 AB028987 Hs.72134 KIAA1064 protein 1.7 109011 AA156542 Hs.72127 ESTs 1.4 109026 AA157811 gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu repetitive 5.3 109068 AA164293 Hs.72545 ESTs 2.9 109101 AW608930 Hs.52184 hypothetical protein FLJ20618 1.6 109112 AW419196 Hs.257924 hypothetical protein FLJ13782 3.2 109124 AK000684 Hs.183887 hypothetical protein FLJ22104 1.7 109139 AJ 132592 Hs.59757 zinc finger protein 281 2.6 109166 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkinesin 6) 2.9 109198 BE566742 Hs.58169 highly expressed in cancer, rich in leucine heptad repeats 2.0 109213 NM_016603Hs.82035 potential nuclear protein C50RF5; GAP-like protein 5.3 109220 AW958181 Hs.189998 ESTs 5.7 109233 AU077281 Hs.170285 nucleoporin 214kD (CAIN) 5.3 109270 N99673 Hs.3585 ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens] 1.4 109273 AA375752 Hs.82719 Homo sapiens mRNA; cDNA DKFZp586F1822 (from clone DKFZp586F1822) 2.9 109313 AF153201 Hs.86276 C2H2 (Kruppel-type) zinc finger protein 1.3 109341 AA213506 Hs.115099 EST 2.9 109391 AL096858 Hs.184245 KIAA0929 protein Msx2 interacting nuclear target (MINT) homolog 1.5 109420 H83603 Hs.40408 homeo box C9 2.2 109426 N30531 Hs.42215 protein phosphatase 1 , regulatory subunit 6 3.0 109429 AH60029 Hs.61438 ESTs 1.9 109445 AA232103 Hs.189915 ESTs 1.8 109450 AB032969 Hs.173042 K1AA1143 protein 3.7 109468 NM_015310Hs.6763 KIAA0942 protein 3.2 109478 AW074143 Hs.87134 ESTs 2.0 109570 L40027 Hs.118890 glycogen synthase kinase 3 alpha 2.1 109662 F02614 Hs.27319 ESTs 1.4 109825 R71264 Hs.16798 ESTs 1.3 110039 H11938 Hs.21907 histone acetyltransferase 2.0 110056 AA503041 Hs.279009 matrix Gla protein 2.5 110085 AA603840 Hs.29956 KIAA0460 protein 1.7 110110 T07353 Hs.7948 ESTs 29 110129 R51853 Hs.226429 ESTs, Weakly similarto ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION 1 110154 NM_014521Hs.17667 SH3-domain binding protein 4 4.2 110240 AI668594 Hs.176588 ESTs, Weakly similar to CP4Y_HUMAN CYTOCHROME P4504A11 PRECURSOR [H.sapiens] 4.2 110242 N41744 Hs.19978 CGI-30 protein 1.3 110259 H28428 Hs.32406 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] 2.2 110312 BE256986 Hs.11896 hypothetical protein FLJ 12089 2.1 110330 AI288666 Hs.16621 DKFZP434H 16 protein 6.2

110501 H55748 gb:yq94a01 ,s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:2034003' 6.1

110504 H55915 Hs.210859 hypothetical protein FLJ11016 6.1

110525 H57330 Hs.37430 EST 6.3

110568 AK001160 Hs.5999 hypothetical protein FLJ 10298 1.3

110699 T97586 Hs.18090 ESTs 1.8

110705 AB007902 Hs.32168 KIAA0442 protein 1.6

110742 AW190338 Hs.28029 hypothetical protein MGC11256 7.6

110761 AL138077 Hs.16157 hypothetical protein FLJ12707 2.5

110762 BE044245 Hs.30011 hypothetical protein MGC2963 9.3

110765 AK000322 Hs.18457 hypothetical protein FLJ20315 5.5

110769 BE000831 Hs.23837 Homo sapiens cDNA FLJ11812 fis, clone HEMBA1006364 2.1

110799 AI089660 Hs.323401 dpy-30-like protein 1.5

110805 T25829 Hs.24048 FK506 binding protein precursor 6.6

110813 AA767373 Hs.35669 ESTs, Moderately similar to ALU1JHUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION 5.7

110820 R33261 Hs.6614 ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens] 3.4

110840 N31598 Hs.12727 hypothetical protein FLJ21610 1.7

110844 AI740792 Hs.167531 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 1.7

110854 BE612992 Hs.27931 hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase 4.7

110856 AA992380 gb:ot37g06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3' similar to contains element 2.3

110885 BE384447 Hs.16034 hypothetical protein MGC13186 3.5

110897 AL117430 Hs.6880 DKFZP434D156 protein 2.2

110915 BE092285 Hs.29724 hypothetical protein FLJ13187 2.6

110918 H04360 Hs.24283 ESTs, Moderately similar to reduced expression in cancer [H.sapiens] 1.9

110958 NM 005864HS.24587 signal transduction protein (SH3 containing) 6.7

110963 AK002180 Hs.11449 DKFZP5640123 protein 2.0

110981 AK001980 Hs.24284 ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2 1.3

110984 AW613287 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) 1.1

111125 N63823 Hs.269115 ESTs, Moderately similarto Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens] 3.6

111132 AB037807 Hs.83293 hypothetical protein 2.1

111164 N46180 Hs.122489 Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170 2.3

111172 R67419 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 3.7

111174 AL050166 Hs.26295 Homo sapiens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122) 7.5

111179 AK000136 Hs.10760 asporin (LRR class 1) 7.1

111184 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HEP08257 6.7

111184 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE 3.3

111189 N67603 Hs.272130 ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens] 3.6

111216 AW139408 Hs.152940 ESTs 1.5

111221 AB037782 Hs.15119 KIAA1361 protein 2.6

111223 AA852773 Hs.334838 KIAA1866 protein 4.6

111239 N90956 Hs.17230 hypothetical protein FLJ22087 7.9

111285 AA778711 Hs.4310 eukaryotic translation initiation factor 1 A 6.9

111299 AB033091 Hs.74313 KIAA1265 protein 5.0

111312 AI523913 Hs.34504 ESTs 3.8

111318 T99755 Hs.334728 ESTs 1.2

111337 AA837396 Hs.263925 LIS1 -interacting protein NUDE1, rat homolog 5.1

111352 H58589 Hs.35156 Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114 2.2

111370 AI478658 Hs.94631 brefeldin A-inhibited guanine nucleotide-exchange protein 1 2.8

111384 N94606 Hs.288969 HSCARG protein 2.2

111389 AK000987 Hs.169111 oxidation resistance 1 2.1

111391 NM_003896Hs.225939 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase) 5.1

111392 W46342 Hs.325081 Homo sapiens, clone IMAGE:3659680, mRNA, partial eds 8.4

111452 R02354 Hs.15999 ESTs 2.7

111486 AI051194 Hs.227978 EST 6.5

111549 W90638 Hs.20321 ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE 1.4

111585 R10720 Hs.20670 EST 1.6

111627 R52656 Hs.21691 ESTs 1.6

111870 AB037834 Hs.18685 Homo sapiens mRNA for KIAA1413 protein, partial eds 2.4

111937 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016) 10.6

111944 AW083791 Hs.21263 suppressor of potassium transport defect 3 6.6

111987 NM_015310Hs.6763 KIAA0942 protein 5.1

112134 R41823 Hs.7413 ESTs; calsyntenin-2 2.8

112244 AB029000 Hs.70823 KIAA1077 protein 14.6

112388 R46071 Hs.301693 Homo sapiens, clone IMAGE:3638994, mRNA, partial eds 9.0

112456 NM_016248Hs.232076 A kinase (PRKA) anchor protein 11 1.4

112464 AW007287 Hs.28538 Homo sapiens cDNA: FLJ21086 fis, clone CAS03272 1.4

112506 AI742756 Hs.26079 ESTs 3.2 112513 R68425 Hs.13809 hypothetical protein FU10648 2.0

112752 AK001635 Hs.14838 hypothetical protein FLJ10773 1.8

112884 AK000004 Hs.5013 Homo sapiens mRNA for FLJ00004 protein, partial eds 6.6

112923 T10258 Hs.5037 EST 1.5

112936 AW970826 Hs.6185 KIAA1557 protein 3.2

112958 R61388 Hs.6724 ESTs 6.0

112966 Z44718 Hs.102548 glucocorticoid receptor DNA binding factor 1 6.4

112978 AK000272 Hs.7099 hypothetical protein FLJ20265 1.2

112995 AA737033 Hs.7155 ESTs, Moderately similar to 2115357A TYKi protein [M. usculus] 5.6

112996 BE276112 Hs.7165 zinc finger protein 259 2.0

113047 AI571940 Hs.7549 ESTs 1.9

113049 AW965190 Hs.7560 Homo sapiens mRNA for KIAA1729 protein, partial eds 2.4

113089 T40707 Hs.270862 ESTs 1.3

113196 T57317 gb:yb51a03.s1 Stratagene fetal spleen (937205) Homo sapiens cDNA clone IMAGE.746683', 1.7

113248 T63857 gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence 2.8

113254 AK002180 Hs.11449 DKFZP5640123 protein 1.3

113277 AW971049 Hs.11774 protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 3.2

113429 AA688021 Hs.179808 ESTs 1.2

113499 AI467908 Hs.8882 ESTs 5.9

113547 H59588 Hs.15233 ESTs 2.0

113554 AW503990 Hs.142442 HP1-BP74 3.6

113647 AA813887 Hs.188173 Homo sapiens cDNA FLJ12187 fis, clone MAMMA1000831 1.3

113702 T97307 gb:ye53h05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGEH214973', 4.4

113722 AV653556 Hs.184411 albumin 1.3

113759 AW499665 Hs.9456 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 1.2

113777 BE266947 Hs.10590 zinc finger protein 313 13.4

113783 AL359588 Hs.7041 hypothetical protein DKFZp762B226 1.7

113791 AI269096 Hs.135578 chitobiase, di-N-acetyl- 1.3

113808 W44735 Hs.9286 Homo sapiens cDNA: FLJ21278 fis, clone COL01832 3.3

113811 BE207480 Hs.6994 Homo sapiens cDNA: FLJ22044 fis, clone HEP09141 3.1

113817 H13325 Hs.332795 hypothetical protein DKFZp761017121 3.2

113826 AW378212 Hs.24809 hypothetical protein FLJ10826 2.3

113834 T26483 Hs.6059 EGF-containing fibulin-like extracellular matrix protein 2 11.3

113868 W57902 Hs.90744 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 2.7

113870 AL079314 Hs.16537 hypothetical protein, similar to (U06944) PRAJA1 6.1

113885 AW959486 Hs.21732 ESTs 6.6

113923 AW953484 Hs.3849 hypothetical protein FLJ22041 similar to FK506 binding proteins 1.9

113989 W87544 Hs.268828 ESTs 1.2

114022 AI539519 Hs.120969 Homo sapiens cDNA FLJ11562 fis, clone HEMBA1003197 5.4

114030 AI825386 Hs.164478 hypothetical protein FLJ21939 similar to 5-azacytidine induced gene 2 9.4

114060 AB029551 Hs.7910 RING1 and YY1 binding protein 1.8

114196 AF017445 Hs.150926 fucose-1 -phosphate guanylyltransferase 1.5

114226 AB028968 Hs.7989 KIAA1045 protein 1.8

114253 BE149866 Hs.14831 Homo sapiens, Similar to zinc finger protein 136 (clone pHZ-20), clone MGC:10647, mRNA, complete eds 2.3

114262 AL117518 Hs.3686 KIAA0978 protein 1.4

114275 AW515443 Hs.306117 KIAA0306 protein 15.8

114292 AI815395 Hs.184641 fatty acid desaturase 2 1.9

114309 AA332453 Hs.20824 CGI-85 protein 2.4

114392 AA249590 Hs.100748 ESTs, Weakly similar to A28996 proline-rich protein M14 precursor - mouse [M.musculus] 1.8

114407 BE539976 Hs.103305 Homo sapiens mRNA; cDNA DKFZp434B0425 (from clone DKFZp434B0425) 1.2

114455 H37908 Hs.271616 ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE 5.5

114463 AL120247 Hs.40109 KIAA0872 protein 5.2

114464 AI091713 Hs.106597 Homo sapiens, Similarto RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial cds1.2

114471 AA028074 Hs.104613 RP42 homolog 1.8

114480 BE066778 Hs.151678 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) 13.4

114671 AA766268 Hs.266273 hypothetical protein FLJ 13346 1.9

114698 AA476966 Hs.110857 polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa) 3.5

114730 AI373544 Hs.331328 intermediate filament protein syncoilin 3.8

114767 AI859865 Hs.154443 minichromosome maintenance deficient (S. cerevisiae) 4 1.6

114774 AV656017 Hs.184325 CGI-76 protein 3.1

114798 AA159181 Hs.54900 serologically defined colon cancer antigen 1 3.5

114860 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 4.3

114895 AA236177 Hs.76591 KIAA0887 protein 7.1

114896 BE539101 Hs.5324 hypothetical protein 1.3

114911 AA236672 gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE 23771 3', mRNA sequence. 1.5

114930 AA237022 Hs.188717 ESTs 2.0

114938 AA242834 Hs.58384 ESTs 2.9 114965 AI733881 Hs.72472 BMP-R1B 2.3

115023 AF102546 Hs.63931 dachshund (Drosophila) homolog 1.3

115038 AA252360 Hs.87968 toll-like receptor 9 1.6

115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076 11.8

115062 AA253314 Hs.154103 UM protein (similar to rat protein kina 1.5

115117 AI670847 Hs.5324 hypothetical protein 1.5

115121 AI634549 Hs.88155 ESTs 2.8

115206 AW183695 Hs.186572 ESTs 2.5

115221 AW365434 Hs.79741 hypothetical protein FLJ10116 1.5

115239 BE251328 Hs.73291 hypothetical protein FLJ 10881 1.3

115242 AI368236 Hs.283732 ESTs, Moderately similar to ALU1 HUMAN ALU SUBFAMILY J SEQUENCE 1.4

115278 AK002163 Hs.301724 hypothetical protein FLJ11301 1.5

115285 AW972872 Hs.293736 ESTs 2.4

115291 BE545072 Hs.122579 hypothetical protein FLJ10461 6.2

115400 AI215069 Hs.89113 ESTs 6.6

115468 AA314349 Hs.48499 tumor antigen SLP-8p 7.4

115471 AK001376 Hs.59346 hypothetical protein FLJ10514 1.4

115479 AW301608 Hs.278188 ESTs, Moderately similar to I54374 gene NF2 protein [H.sapiens] 4.0

115496 AW247593 Hs.71819 eukaryotic translation initiation factor 4E binding protein 1 16.3

115500 Y14443 Hs.88219 zinc finger protein 200 5.0

115553 AJ275986 Hs.71414 transcription factor (SMIF gene) 2.5

115581 AI540842 Hs.61082 ESTs 6.1

115587 BE081342 Hs.283037 HSPC039 protein 2.9

115590 AA399477 Hs.67896 7-60 protein 5.3

115646 N36110 Hs.305971 solute carrier family 2 (facilitated glucose transporter), member 10 4.7

115652 BE093589 Hs.38178 hypothetical protein FLJ23468 10.6

115655 AL048269 Hs.288544 Homo sapiens, clone MGC:16063, mRNA, complete eds 12.7

115663 AH38785 Hs.40507 ESTs 2.0

115676 AA953006 Hs.88143 ESTs 3.0

115690 AA625132 Hs.44159 hypothetical protein FLJ2 615 1.7

115693 AF231023 Hs.55173 cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog 6.8

115715 BE395161 Hs.1390 proteasome (prosome, macropain) subunit, beta type, 2 1.7

115734 AI950339 Hs.40782 ESTs 2.6

115811 NM_015434Hs.48604 DKFZP434B168 protein 2.1

115823 AI732742 Hs.87440 ESTs 2.1

115837 AI675217 Hs.42761 ESTs 1.3

115844 AI373062 Hs.332938 hypothetical protein MGC5370 4.4

115866 AW062629 Hs.52081 KIAA0867 protein 7.2

115875 N55669 Hs.333823 mitochondrial ribosomal protein L13 1.2

115941 AI867451 Hs.46679 hypothetical protein FLJ20739 5.5

115968 AB037753 Hs.62767 KIAA1332 protein 9.8

116003 BE275469 Hs.66493 Down syndrome critical region gene 5 1.4

116011 AL359053 Hs.57664 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735 2.4

116108 AA770688 Hs.28777 H2A histone family, member L 1.8

116134 BE243834 Hs.50441 CGI-04 protein 1.4

116189 N35719 Hs.44749 ESTs, Moderately similar to T00358 hypothetical protein KIAA0684 [H.sapiens] 1.2

116195 AW821113 Hs.72402 ESTs 2.1

116238 AV660717 Hs.47144 DKFZP586N0819 protein 1.7

116246 AF265555 Hs.250646 baculoviral IAP repeat-containing 6 1.7

116262 AI936442 Hs.59838 hypothetical protein FLJ10808 1.7

116298 AI955411 Hs.94109 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 1.9

116318 AF097645 Hs.58570 deleted in cancer 1 ; RNA helicase HDB/DICE1 4.9

116325 AI472106 Hs.49303 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 1.4

116336 AL133033 Hs.4084 KIAA1025 protein 1.9

116339 AK000290 Hs.44033 dipeptidyl peptidase 8 1.5

116350 AA497129 Hs.184771 nuclear factor l/C (CCAAT-binding transcription factor) 1.9

116358 AI149586 Hs.38125 interferon-induced protein 75, 52kD 1.9

116365 N50174 Hs.46765 ESTs 6.1

116368 N90466 Hs.71109 KIAA1229 protein 1.6

116417 AW499664 Hs.12484 Human clone 23826 mRNA sequence 7.4

116436 AA161411 Hs.58668 chromosome 21 open reading frame 57 2.1

116462 AF218313 Hs.236828 putative helicase RUVBL 1.5

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 2.1

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 1.2

116575 AA312572 Hs.6241 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 1.5

116637 AK001043 Hs.92033 integrin-linked kinase-associated serine/threonine phosphatase 2C 2.7

116640 X89984 Hs.211563 B-cell CLL/lymphoma7A 2.3 116700 AI800202 Hs.317589 hypothetical protein MGC10765 1.4

116705 AW074819 Hs.12313 hypothetical protein FLJ 14566 3.4

116732 AW152225 Hs.165909 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 2.9

116921 AW068115 Hs.821 biglycan 8.3

116926 H73608 Hs.290830 ESTs 1.7

117034 U72209 Hs.180324 YY1 -associated factor 2 3.4

117132 AI393666 Hs.42315 p10-binding protein 5.2

117247 N21032 gb:yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:2648033', mRNA sequence. 5.5

117276 N71183 Hs.121806 Homo sapiens cDNA FLJ11971 fis, clone HEMBB1001208 1.5

117284 AK001701 Hs.183779 Homo sapiens cDNA FLJ10590 fis, clone NT2RP2004392, weakly similar to MNN4 PROTEIN 2.0

117367 AI041793 Hs.42502 ESTs 2.0

117368 AI878942 Hs.90336 ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J 2.1

117382 AF150275 Hs.40173 ESTs 2.7

117412 N32536 Hs.42645 solute earner family 16 (monocarboxylic acid transporters), member 6 1.4

117557 AF123050 Hs.44532 diubiquitin 3.4

117588 N34895 Hs.44648 ESTs 3.4

117745 BE294925 Hs.46680 CGI-12 protein 3.0

117754 AA121673 Hs.59757 zinc finger protein 281 1.9

117879 N54706 Hs.303025 chromosome 11 open reading frame 24 1.8

117881 AF161470 Hs.260622 butyrate-induced transcript 1 5.7

117904 BE540675 Hs.332938 hypothetical protein MGC5370 ' 5.9

117911 AL137379 Hs.47125 hypothetical protein FLJ13912 1.7

117933 Y10518 Hs.116470 hypothetical protein FLJ20048 1.7

117983 AL110246 Hs.47367 KIAA1785 protein 5.4

118078 N54321 Hs.47790 EST 5.2

118301 AA453902 Hs.293264 ESTs 2.6

118429 AA243332 Hs.74649 cytochrome c oxidase subunit Vic 2.5

118472 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 4.1

118488 AJ277275 Hs.50102 rapa-2 (rapa gene) 1.2

118509 N22617 Hs.43228 Homo sapiens cDNA FLJ11835 fis, clone HEMBA1006595 1.5

118528 AI949952 Hs.49397 ESTs 7.4

118656 A1458020 Hs.293287 ESTs 2.5

118670 AA332845 Hs.152618 ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiensl 1.2

118698 AB033113 Hs.50187 KIAA1287 protein 2.1

118737 AA199686 gb:zq75g09. Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:6474885' 5.2

118925 N92293 Hs.206832 ESTs, Moderately similarto ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION 1.4

118984 AI668709 Hs.240722 ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION 3.6

118986 AF148713 Hs.125830 bladder cancer overexpressed protein 4.8

119206 W24781 Hs.293798 KIAA1710 protein 1.7

119235 AW453069 Hs.3657 activity-dependent neuroprotective protein 2.2

119235 AW453069 Hs.3657 activity-dependent neuroprotective prote 1.6

119265 BE539706 Hs.285363 ESTs ' 1.4

119279 N57568 Hs.48028 EST 25.1

119298 NM 001241HS.155478 cycϋn T2 1.6

119338 AI417240 Hs.320836 ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens] 1.3

119349 T65004 Hs.163561 ESTs 8.4

119403 AL117554 Hs.119908 nucleolar protein NOP5/NOP58 6.7

119478 AI624342 Hs.170042 ESTs 2.4

119486 AI796730 Hs.55513 ESTs 2.1

119513 W37933 Empirically selected from AFFX single probeset 1.9

119601 AK000155 Hs.91684 Homo sapiens mRNA; cDNA DKFZp667H03 (from clone DKFZp667H03) 3.7

119602 AW675298 Hs.233694 hypothetical protein FLJ11350 3.0

119676 AA243837 Hs.57787 ESTs 1.4

119682 W61019 Hs.57811 ESTs 1.2

119774 AB032977 Hs.6298 KIAA1151 protein 1.8

119780 NM 016625HS.191381 hypothetical protein 3.1

119789 BE393948 Hs.50915 kallikrein 5 (KLK5; KLK-L2; stratum corneum tryptic enzyme) 9.2

119805 AJ223810 Hs.43213 ESTs, Weakly similar to IEFSJHUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP 3.6

119818 AA130970 Hs.58382 hypothetical protein FLJ11101 2.5

119863 AA081218 Hs.58608 Homo sapiens cDNA FLJ 14206 fis, clone NT2RP3003157 2.7

119905 AW449064 Hs.119571 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 2.6

119966 AA703129 Hs.58963 ESTs 2.7

120132 W57554 Hs.125019 lymphoid nuclear protein (LAF-4) mRNA 1.2

120206 H26735 Hs.91668 Homo sapiens clone PP1498 unknown mRNA 45.7

120248 AI924294 Hs.173259 uncharacterized bone marrow protein BM033 1.2

120253 AA131376 Hs.326401 fibroblast growth factor 12B 38.9

120269 AW131940 Hs.104030 ESTs 9.6 120274 AA177051 gb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens cDNA clone IMAGEH94 similar to contains Alu 4.6

120280 AA190577 gb:zp52g02.s1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 3', mRNA sequence 2.0

120296 AW995911 Hs.299883' hypothetical protein FLJ23399 1.8

120297 AA191384 Hs.104072 ESTs, Weakly similarto Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens] 15.2 120324 AA195517 Hs.191643 ESTs 5.5

120325 AA195651 Hs.104106 ESTs 6.4

120327 AK000292 Hs.278732 hypothetical protein FLJ20285 16.1

120336 N85785 Hs.181165 eukaryotic translation elongation factor 1 alpha 1 2.9

120342 AW450669 Hs.45068 hypothetical protein DKFZp434H 43 5.7 120345 AA210722 Hs.104158 ESTs 4.5

120349 AW969481 Hs.55189 hypothetical protein 16.8

120352 R06859 Hs.193172 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 5.0

120356 AF000545 Hs.296433 putative purinergic receptor 28.1

120371 AA219305 Hs.104196 EST 12.4 120382 AA228026 Hs.38774 ESTs 4.0

120383 AL109963 Hs.123122 FSH primary response (LRPR1, rat) homolog 1 9.7

120386 AW969665 Hs.154848 hypothetical protein DKFZp434D0127 32.6

120388 AA232874 Hs.104245 ESTs 3.1

120389 AW967985 Hs.325572 ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION 21.7 120396 AA134006 Hs.79306 eukaryotic translation initiation factor 4E 12.5

120404 AB023230 Hs.96427 KIAA1013 protein 7.2

120418 AW966893 Hs.26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F1323) 11.4

120423 AA236453 Hs.18978 Homo sapiens cDNA: FLJ22822 fis, clone KA1A3968 1.9

120472 AI950087 gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence 19.4 120473 AA251973 Hs.269988 ESTs 5.4

120484 AA253170 Hs.96473 EST 10.4

120504 AA256837 gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:6823873', mRNA sequence. 3.9

120509 BE047718 Hs.96545 ESTs 9.4

120520 AA258601 Hs.161731 EST 2.4 120535 BE350244 Hs.96547 ESTs 2.5

120551 AA279160 Hs.111407 Homo sapiens, clone IMAGE:3613029, mRNA, partial eds 5.2

120570 AA280679 Hs.271445 ESTs, Weakly similar to ALU1JHUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION 14.4

120582 BE244830 Hs.284228 ZNF135-like protein 10.2

120590 AW372799 Hs.125790 leucine-rich repeat-containing 2 2.1 120596 AA282074 Hs.237323 N-acetylglucosamine-phosphate mutase 7.5

120619 AW965339 Hs.111471 ESTs 2.5

120624 AW407987 Hs.173518 M-phase phosphoprotein homolog 52.0

120639 AA286942 gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:7015053' similarto contains Alu2.4

120648 AA287095 Hs.140309 Homo sapiens, clone IMAGE:3677194, mRNA, partial eds 5.0 120653 AW063659 Hs.191649 ESTs 2.2

120668 AW969638 Hs.112318 6.2 kd protein 2.2

120669 BE536739 Hs.109909 ESTs 1.9

120695 AA976503 gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.H PTR7 46.8

120696 AI821539 Hs.97249 ESTs 2.5 120713 AW449855 Hs.96557 Homo sapiens CDNA FLJ12727 fis, clone NT2RP2000027 5.9

120718 AA292747 Hs.97296 ESTs 2.9

120750 AH91410 Hs.96693 ESTs, Moderately similar to 2109260A B cell growth factor [H.sapiens] 7.0

120774 AI608909 Hs.193985 ESTs 7.8

120807 AA346385 Hs.30002 SH3-confaining protein SH3GLB2; KIAA1848 protein 6.8 120809 AA346495 gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing 0 family repeat, 4.4

120938 AA386260 Hs.104632 EST 4.4

120977 AA398155 Hs.97600 ESTs 4.4

120984 BE262951 Hs.99052 ESTs 5.6

120985 AI219896 Hs.97592 ESTs 1.2 121011 AA398360 Hs.97608 EST 3.1

121026 AI439713 Hs.165295 ESTs 3.5

121081 AA398721 Hs.186749 ESTs. Highly similarto I37550 mismatch repair protein MSH2 [H.sapiens] 5.4

121133 AA363307 Hs.97032 ESTs 3.7

121176 AL121523 Hs.97774 ESTs 1.7 121223 AI002110 Hs.97169 ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens] 2.9

121320 AA403008 Hs.301927 cδ.1A 1.9

121340 AW956981 Hs.97910 Homo sapiens CDNA FLJ13383 fis, clone PLACE1001024 3.5

121408 AA406137 Hs.98019 EST 6.0

121439 AA410190 Hs.98076 ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens] 7.4 121450 AA406430 Hs.105362 Homo sapiens, clone MGC:18257, mRNA, complete eds 6.9

121452 AW971063 Hs.292882 ESTs 1.8

121455 H58306 Hs.15165 retinoic acid induced 14 10.5 121457 W07404 Hs.144502 hypothetical protein FLJ22055 3.4

121496 AA442224 Hs.97900 ESTs 14.4

121505 AA494172 Hs.194417 ESTs 13.1

121508 AA402515 Hs.97887 ESTs 28.0 121513 AA416653 Hs.181510 ESTs 6.2

121514 AA412112 gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE 275633', mRNA sequence. 2.6

121549 AA412477 Hs.98142 EST 7.4

121558 AA412497 gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:7301503' similarto contains2.8

121577 AA411970 Hs.98096 EST 3.5 ' 121581 AA416568 gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence 6.1

121589 AD001528 Hs.89718 spermine synthase 3.9

121594 AA626010 Hs.98247 ESTs 2.2

121622 AA416931 Hs.126065 ESTs 4.2

121655 AA421537 Hs.178072 Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023) 7.8 121682 AA418160 Hs.86043 Homo sapiens CDNA FLJ13558 fis, clone PLACE1007743 2.0

121690 AV660305 Hs.110286 ESTs 4.7

121706 U55184 Hs.154145 hypothetical protein FLJ 11585 12.7

121714 AA419225 Hs.98269 Homo sapiens cDNA FLJ 11953 fis, clone HEMBB 1000883 8.1

121729 AI949597 Hs.98325 ESTs 1.8 121731 AA421041 Hs.180744 ESTs 4.0

121744 AA398784 Hs.97514 ESTs 7.1

121748 BE536911 Hs.234545 hypothetical protein NUF2R 19.5

121773 AB033022 Hs.158654 KIAA1196 protein 7.9

121775 AA421773 Hs.161008 ESTs 1.7 121776 AA292579 Hs.125133 hypothetical protein FLJ22501 6.6

121786 AI810774 Hs.98376 ESTs 10.5

121832 AW340797 Hs.98434 ESTs 5.8

121836 AA328348 Hs.218289 ESTs 3.8

121839 AA425691 Hs.191606 ESTs, Highly similar to KIAA1048 protein [H.sapiens] 5.0 121842 AF027406 Hs.104865 serine/threonine kinase 23 2.7

121847 AA446628 Hs.2799 cartilage linking protein 1 2.3

121871 AW972668 Hs.293044 ESTs 2.9

121882 AA426376 Hs.98459 ESTs 5.0

121911 AA427950 gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE7734993' 7.2 121915 AA428179 Hs.223405 ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens] 2.5

121935 AA428647 Hs.98611 EST 2.3

121983 AA298760 Hs.180191 hypothetical protein FLJ 14904 3.4

121985 AI862570 Hs.299214 Homo sapiens, clone 1MAGE:2822295, mRNA, partial eds 11.4

121995 AA210863 Hs.3532 nemo-like kinase 3.8 121999 AA430211 Hs.98668 EST 6.4

122009 AW292763 Hs.160822 Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804 2.2

122013 AA431085 Hs.98706 ESTs 6.5

122036 W92142 Hs.271963 ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION 13.1

122050 AI453076 Hs.166109 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 9.1 122060 AA431738 Hs.98750 EST 13.1

122114 AW161023 Hs.104921 ESTs 1.5

122188 AA398838 gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence 3.3

122204 AA435936 Hs.98842 EST 5.6

122246 AA329550 Hs.29417 HCF-binding transcription factor Zhangfei 5.1 122257 AA436819 Hs.98899 ESTs 5.6

122302 AA441801 Hs.104947 ESTs 5.8

122341 AW601969 Hs.99010 hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1 2.0

122356 AA443794 Hs.98390 ESTs 7.3

122369 AA443985 Hs.303222 ESTs 12.2 122371 AA868555 Hs.178222 ESTs 5.0

122372 AA446008 Hs.336677 EST 7.6

122378 AB032948 Hs.21356 hypothetical protein DKFZp762K20 5 2.5

122405 AA446572 Hs.303223 EST 2.8

122412 AA446869 Hs.119316 ESTs 7.3 122415 AA446918 Hs.99088 EST 1.9

122418 AA446966 Hs.99090 ESTs, Moderately similar to similar to KIAA0766 [H.sapiens] 6.8

122440 AW505139 Hs.9460 Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244) 2.6

122446 AA447603 Hs.99123 EST 1.8

122448 AA447626 Hs.99127 EST 3.5 122458 AI266159 Hs.104980 ESTs 1.5

122460 AW418788 Hs.99148 ESTs, Weakly similarto S43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans] 9.7

122464 AA448158 Hs.99152 EST 4.8 122490 AA448349 Hs.238151 EST 6.1 122492 AA448417 Hs.104990 ESTs 5.4 122502 AA204969 Hs.234863 Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492 1 1..33 122510 AA449232 Hs.99195 ESTs 1 111..22 122530 AW959741 Hs.40368 adaptor-related protein complex 1, sig a 2 subunit 1 100..11 122547 AA779725 Hs.164589 ESTs 2 2..55 122555 AA194055 Hs.293858 ESTs 1 1..99 122570 AA452578 Hs.262907 ESTs 9 9..55 122572 AA452601 Hs.99287 EST 1 111..00 122586 AK001910 Hs.99303 Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516 3 3..44 122587 AB040893 Hs.6968 KIAA1460 protein 2 2..00 122598 AI028173 Hs.99329 ESTs 1 1..77 122599 AL355841 Hs.99330 hypothetical protein FLJ23588 4 4..44 122602 AA411925 Hs.301960 ESTs 4.6 122607 AA453518 Hs.98023 ESTs 61.5 122614 AA453630 Hs.99339 EST 10.7 122616 AA453638 Hs.161873 ESTs 107.3 122617 AI681535 Hs.148135 serine/threonine kinase 33 121.4 122618 AA453641 gb:zx48e06.s1 Soares testis NHT Homo sapiens cDNA clone 3', mRNA sequence 31.1 122622 AA453987 Hs.144802 ESTs 5.6 122717 AA456859 Hs.178358 ESTs 8.5 122762 AI376875 Hs.105119 ESTs 10.4 122829 AW204530 Hs.99500 ESTs 81.8 122834 AA461492 Hs.99545 Homo sapiens cDNA FLJ10658 fis, clone NT2RP2006052 3.6 122836 AA460581 Hs.290996 ESTs 4.5 122837 AA461509 Hs.293565 ESTs, Weakly similarto putative p150 [H.sapiens] 2.7 122838 AA460584 Hs.334386 ESTs 75.3 122854 AA600235 Hs.9625 NIMA (never in mitosis gene a)-related kinase 6 7.7 122856 AI929374 Hs.75367 Src-like-adapter 5.8 122861 AA335721 Hs.119394 ESTs 1.3 122866 BE539656 Hs.283705 ESTs 4.1 122868 AF005216 Hs.115541 Janus kinase 2 (a protein tyrosine kinase) 5.3 122870 AW576312 Hs.318722 Homo sapiens cDNA: FLJ21766 fis, clone C0LF7179 9.9 122872 AW081394 Hs.97103 ESTs 5.3 122879 AA769410 Hs.128654 ESTs 13.9 122907 AA470074 Hs.169896 ESTs 11.5 122916 AA470140 Hs.229170 EST 1.7 122981 AA478951 Hs.105629 ESTs 5.0 123013 AW968324 Hs.1 384 ESTs 15.4 123016 AW338067 Hs.323231 Homo sapiens cDNA FLJ11946 fis, clone HEMBB1000709 2.8 123034 AL359571 Hs.44054 ninein (GSK3B interacting protein) 8.7 123072 AI382600 Hs.104308 ESTs, Weakly similarto KIAA1395 protein [H.sapiens] 8.8 123082 AA485360 Hs.105661 ESTs 3.9 123088 AI343652 Hs.105667 ESTs 3.8 123110 AA486256 Hs.193510 EST 7.4 123114 BE304942 Hs.265848 myomegalin 2.8 123131 T52027 Hs.271795 ESTs, Weakly similarto I38022 hypothetical protein [H.sapiens] 2.4 123132 AI061582 Hs.324179 Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434 15.6 123136 AW451999 Hs.194024 ESTs 5.1 123149 AI734179 Hs.105676 ESTs 23.8 123152 AW601773 Hs.270259 ESTs 5.2 123258 AA490929 Hs.105274 ESTs, Weakly similar to RMS1_HUMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 [H.sapiens] 9.3 123315 AA496369 gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755827 3' similar to4.1 123369 AA504757 Hs.105738 ESTs 6.9 123394 AA731404 Hs.105510 ESTs 3.6 123433 AW450922 Hs.112478 ESTs 3.7 123466 AA599042 Hs.112503 EST 7.4 123470 AW303285 Hs.303632 Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene similar to 3.5 123471 AB021644 Hs.197219 zinc finger protein 14 (KOX 6) 5.2 123475 BE439553 Hs.250528 Homo sapiens, clone IMAGE:4098694, mRNA, partial eds 1.7 123482 N95059 Hs.55098 ESTs 1.6 123486 BE019072 Hs.334802 Homo sapiens cDNA FLJ14680 fis, clone NT2RP2004242, weakly similar to 2.4 123508 AW380388 Hs.155546 KIAA1080 protein; Goigi-associated, gamma-adaptin ear containing, ARF-binding protein 2 2.2 123615 AA609170 gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence 7.8 123619 AA602964 gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens cDNA clone, mRNA sequence 2.8 123658 AA609364 gb:zu71d09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similarto contains Alu. 1.7 123674 AI269609 Hs.105187 kinesin protein 9 gene 5.7 123735 NM_013241Hs.95231 FH1/FH2 domain-containing protein 10.0 123738 AA609891 Hs.112777 EST 5.2 123753 AA609955 Hs.234961 Huntingtin interacting protein E 30.6 123804 AA620464 Hs.261915 EST, Weakly similar to S65657 alpha-1 C-adrenergic receptor splice form 2 [H.sapiens] 2.1 123811 AA620586 gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:9513203' 2.7 123951 AB012922 Hs.173043 metastasis-associated 1-like 1 6.2 123983 AJ272267 Hs.146178 choline dehydrogenase . 4.4 124001 L42542 Hs.75447 ralA binding protein 1 7.0 124006 AI147155 Hs.270016 ESTs 8.1 124070 AI950314 Hs.154762 HIV-1 rev binding protein 2 3.7 124074 H05635 Hs.294030 topoisomerase-related function protein 4-2 1.2 124178 BE463721 Hs.97101 putative G protein-coupled receptor 3.1 124203 AA372796 Hs.269339 ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens] 5.7 124352 AA640891 Hs.102406 ESTs 3.1 124375 D87454 Hs.192966 KIAA0265 protein 3.5 124385 AI267847 gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains 57.1 124390 AA317338 Hs.7535 COBW-like protein 2.8 124391 AF155099 Hs.279780 NY-REN-18 antigen 7.1 124417 N34059 gb:yv28h09.s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone 3' similar to contains Alu 3.3 124428 H13540 Hs.82202 ribosomal protein L17 2.9 124440 AA532519 Hs.129043 Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a 7.8 124466 R10084 Hs.113319 kinesin heavy chain member 2 2.6 124482 N53935 gb:yv59d09.s1 Soares fetal liver spleen 1 NFLS Homo sapiens cDNA clone 3', mRNA sequence 7.9 124498 H79433 Hs.268997 ESTs 7.8 124515 AA669097 Hs.109370 ESTs 3.3 124608 N71076 Hs.102800 ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens] 4.5 124631 NM_014053Hs.270594 FLVCR protein 3.2 124634 AI765123 Hs.143671 Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371 5.8 124637 AA160474 Hs.75798 hypothetical protein 9.3 124642 AW968856 Hs.278569 sorting nexin 17 3.5 124649 N92593 Hs.313054 ESTs 6.1 124656 AW297702 Hs.102915 ESTs 8.3 124661 R48170 Hs.78436 EphB1 5.6 124683 AA381661 Hs.119878 ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7.9 124712 R09166 Hs.191148 ESTs 5.7 124735 R22952 Hs.268685 ESTs 11.3 124761 AA374756 Hs.93560 Homo sapiens mRNA for KIAA1771 protein, partial eds 9.0 124768 AW368528 Hs.100855 ESTs 8.1 124775 R41772 Hs.100878 ESTs 4.9 124777 R41933 Hs.140237 ESTs, Weakly similar to ALU1JHUMAN ALU SUBFAMILY J SEQUENCE 2.8 124788 R43543 Hs.100912 Homo sapiens cDNA: FLJ22726 fis, clone HSH5005 5.1 124809 AL355722 Hs.106875 Homo sapiens EST from clone 35214, full insert 4.2 124811 R46068 Hs.288912 hypothetical protein FLJ22604 14.2 124812 R47948 Hs.188732 ESTs 7.9 124822 AA418160 Hs.86043 Homo sapiens cDNA FU13558 fis, clone PLACE1007743 6.6 124825 AA501669 Hs.336693 ESTs 2.3 124833 AW975868 Hs.294100 ESTs 2.7 124857 R63652 Hs.137190 ESTs 2.3 124860 R65763 Hs.101477 EST 23.9 124863 AI382555 Hs.127950 bromodomain-containing 1 2.0 124876 AF135422 Hs.27059 GDP-mannose pyrophosphorylase A 4.4 124878 BE397530 Hs.288057 hypothetical protein FLJ22242 2.7 124902 H37941 Hs.101883 ESTs 5.7 124903 AW296713 Hs.221441 ESTs 32.4 124930 AI076343 Hs.173939 ESTs, Weakly similar to ALUB_HUMAN 111! ALU CLASS B WARNING ENTRY 111 [H.sapiens] 22.8 124942 R99978 Hs.268892 ESTs, Moderately similar to B34087 hypothetical protein [H.sapiens] 6.1 124958 AI078645 Hs.431 murine leukemia viral (bmi-1 ) oncogene homolog 1.9 124980 T40841 Hs.98681 ESTs 4.5 125002 T59338 Hs.269463 ESTs, Weakly similar to ALU1.HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION 4.9 125047 T79815 Hs.279793 ESTs 5.0 125051 T79956 Hs.100588 EST 135.3 ' 125056 T81310 Hs.100592 ESTs 5.4 125101 AI472068 Hs.286236 KIAA1856 protein 5.6 125113 T96595 Hs.302270 ESTs, Weakly similar to ALUFJHUMAN 111! ALU CLASS F WARNING ENTRY 111 [H.sapiens] 1.8 125115 T97341 gb:ye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGEH21856 3' similarto 9.6 125125 AI222382 Hs.240767 Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end of the gene 1.5 125147 W38150 Empirically selected from AFFX single probeset 1.7 125161 W44657 Hs.144232 EST 10.7 125249 AA630863 Hs.131375 ESTs, Moderately similar to ALUB_HUMAN III! ALU CLASS B WARNING ENTRY !!! [H.sapiens] 1.3 125255 AF098162 Hs.118631 timeless (Drosophila) homolog 9.4 125279 AW401809 Hs.4779 KIAA1150 protein 1.5 125280 AH23705 Hs.106932 ESTs 8.0 125298 AW972542 Hs.289008 Homo sapiens cDNA: FLJ21814 fis, clone HEP01068 1.5 125660 AW292171 Hs.23978 scaffold attachment factor B 5.9 125827 NM_003403Hs.97496 YY1 transcription factor 1.2 125891 U29589 Hs.7138 cholinergic receptor, muscarinic 3 6.4 126005 AW409701 Hs.1578 baculoviral IAP repeat-containing 5 (survivin) 14.3 126202 AA157632 Hs.272630 vacuolar proton pump delta polypeptide 2.4 126695 AA643322 Hs.172028 a disintegrin and metalloproteinase domain 10 9.1 127050 AW411066 Hs.274351 CGl-89 protein 17.0 127274 AW966158 Hs.58582 Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947 12.8 128355 AW293012 Hs.161623 ESTs 7.3 128493 D87466 Hs.240112 KIAA0276 protein 3.1 128493 D87466 Hs.240112 KIAA0276 protein 1.3 128522 BE173977 Hs.10098 putative nucleolar RNA helicase 9.4 128527 AA504583 Hs.101047 transcription factor3 (E2A immunoglobulin enhancer binding factors E12/E47) 1.5 128528 R39234 Hs.251699 ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens] 2.8 128595 U31875 Hs.272499 short-chain alcohol dehydrogenase family member 12.1 128599 NM_015366Hs.102336 Rho GTPase activating protein 8 2.3 128604 AI879099 Hs.102397 GIOT-3 forgonadofropin inducible transcription repressor-3 • 1.3 128608 BE267994 Hs.102419 zinc finger protein 7.1 128625 AB037841 Hs.102652 hypothetical protein ASH1 1.3 128629 AL096748 Hs.102708 DKFZP434A043 protein 3.2 128639 AW582962 Hs.102897 CGI-47 protein 2.0 128656 AA458542 Hs.10326 coatomer protein complex, subunit epsilon 1.4 128656 AA458542 Hs.10326 coatomer protein complex, subunit epsilo 1.3 128658 BE397354 Hs.324830 diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 2.4 128670 AA975486 Hs.103441 Homo sapiens, Similarto RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete eds 7.1 128691 W27939 Hs.103834 hypothetical protein MGC5576 7.7 128696 BE081143 Hs.225977 nuclear receptor coactivator 3 3.8 128700 Y15221 Hs.103982 small inducible cytokine subfamily B (Cys-X-Cys), member 11 1.6 128714 T85231 Hs.179661 tubulin, beta 5 7.6 128717 AK001564 Hs.104222 hypothetical protein FLJ10702 5.5 128733 BE147740 Hs.104558 ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens] 2.7 128737 AF292100 Hs.104613 RP42 homolog 2.8 128742 AA307211 Hs.251531 proteasome (prosome, macropain) subunit, alpha type, 4 4.4 128746 AI470163 Hs.323342 actin related protein 2/3 complex, subunit 4 (20 kD) 2.2 128747 AB027249 Hs.104741 PDZ-binding kinase; T-cell originated protein kinase 2.8 128772 BE302796 Hs.105097 thymidine kinase 1, soluble 5.3 128781 N71826 Hs.105465 small nuclear ribonucleoprotein polypeptide F 53.9 128797 NMJ02975HS.105927 stem cell growth factor; lymphocyte secreted C-type lectin 13.3 128806 AW630942 Hs.106061 RD RNA-binding protein 2.6 128814 AW248431 Hs.256526 nuclear prelamin A recognition factor 2.2 128830 BE281170 Hs.106357 valosin-containing protein 5.9 128835 AK001731 Hs.106390 Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924) 1.6 128854 BE159181 Hs.168232 hypothetical protein FLJ 13855 2.2 128854 BE159181 Hs.168232 hypothetical protein FLJ13855 1.9 128868 AA419008 Hs.106730 chromosome 22 open reading frame 3 3.0 128868 AA419008 Hs.106730 chromosome 22 open reading frame 3 2.2 128871 AF189723 Hs.106778 ATPase, Ca++ transporting, type 2C, member 1 1.5 128891 F34856 Hs.292457 Homo sapiens, clone MGCH6362, mRNA, complete eds 13.3 128906 R57988 Hs.10706 epithelial protein lost in neoplasm beta 4.7 128920 AA622037 Hs.166468 programmed cell death 5 1.4 128925 R67419 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 1.9 128946 Y13153 Hs.107318 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 7.2 128949 AA009647 Hs.8850 a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12) 2.4 128958 AW139032 Hs.107376 hypothetical protein DKFZp434N035 1.3 128959 AI580127 Hs.107381 hypothetical protein FLJ 11200 10.9 128965 AW150697 Hs.107418 ESTs 1.4 128970 AI375672 Hs.165028 ESTs 1.3 128975 BE560779 Hs.284233 NlCE-5 protein 14.0 128979 AW271217 Hs.281434 Homo sapiens cDNA FLJ14028 fis, clone HEMBA1003838 1.6 128995 AI816224 Hs.107747 DKFZP566C243 protein 1.9 129019 AI950087 gb:wq05c02.x1 NCLCGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence 2.9 129021 AL044675 Hs.173081 KIAA0530 protein 3.8

129021 AL044675 Hs.173081 KIAA0530 protein 2.5

129032 R80088 Hs.108104 ubiquitin-conjugating enzyme E2L 3 3.4

129076 AW296806 Hs.326234 ESTs, Highly similarto T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens] 5.0

129078 AI351010 Hs.102267 lysosomal 2.1

129088 AA744610 Hs.194431 palladin 17.1

129095 L12350 Hs.108623 thro bospondin 2 2.7

129096 AA463189 Hs.288906 WW Domain-Containing Gene 20.9

129097 BE243933 Hs.108642 zinc finger protein 22 (KOX 15) 3.0

129099 AF146074 Hs.108660 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 5.8

129136 W93048 Hs.250723 hypothetical protein MGC2747 5.9

129149 AA356620 Hs.108947 KIAA0050 gene product 6.3

129172 AW162916 Hs.241576 hypothetical protein PR02577 1.8

129192 AA286914 Hs.183299 ESTs 2.1

129194 AA150797 Hs.109276 latexin protein 3.2

129198 N57532 Hs.109315 KIAA1415 protein 5.8

129207 AI934365 Hs.109439 osteoglycin (osteoinductive factor, mimecan) 8.0

129228 U40714 Hs.239307 tyrosyl-tRNA synthetase 2.9

129229 AF013758 Hs.109643 polyadenylate binding protein-interacting protein 1 3.2

129254 AA252468 Hs.1098 DKFZp434J1813 protein 2.6

129255 AI961727 Hs.109804 H1 histone family, member X 7.3

129288 W26392 Hs.110080 ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens] 9.6

129296 AI051967 Hs.110122 ESTs 1.2

129323 AA287239 Hs.5518 Homo sapiens cDNA FLJ 11311 fis, clone PLACE1010102 5.1

129340 H75334 Hs.11050 F-box only protein 9 4.6

129347 BE614192 Hs.279869 melanoma-associated antigen recognised by cytotoxic T lymphocytes 7.6

129362 U30246 Hs.110736 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 6.7

129366 BE220806 Hs.184697 Homo sapiens clone 23785 mRNA sequence 8.6

129370 AI686379 Hs.110796 SAR1 protein 1.4

129372 NM 016039HS.110803 CGl-99 protein 2.0

129403 AF149785 Hs.111126 pituitary tumor-transforming 1 interacting protein 7.4

129404 AI267700 Hs.317584 ESTs 5.0

129404 AI267700 Hs.317584 ESTs 2.5

129423 AA204686 Hs.234149 hypothetical protein FLJ20647 10.2

129449 AI096988 Hs.111554 ADP-ribosylation factor-like 7 8.0

129453 AW974265 Hs.111632 Lsm3 protein 3.2

129482 AA188185 Hs.289043 spindlin 6.7

129482 AA188185 Hs.289043 spindlin 3.6

129513 AW843633 Hs.306163 hypothetical protein AL110115 7.1

129515 AF255303 Hs.112227 membrane-associated nucleic acid binding protein 2.5

129527 AA769221 Hs.270847 delta-tubulin 3.2

129559 W01296 Hs.11360 hypothetical protein FLJ14784 7.5

129560 AA317841 Hs.7845 hypothetical protein MGC2752 6.8

129570 AI923097 Hs.11441 chromosome 1 open reading frame 8 2.0

129575 F08282 Hs.278428 progestin induced protein 1.6

129587 H14718 Hs.11506 Human clone 23589 mRNA sequence 6.8

129588 BE408300 Hs.301862 postmeiotic segregation increased 2-like 9 1.4

129591 N57423 Hs.179898 HSPC055 protein 7.3

129594 AW403724 Hs.36989 coagulation factor VII (serum profhrombin conversion accelerator) 9.0

129596 AF035537 Hs.115521 REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta 1.6

129628 U38945 Hs.1174 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 2.2

129628 U38945 Hs.1174 cyclin-dependent kinase inhibitor 2A (me 1.4

129629 AK000398 Hs.11747 hypothetical protein FLJ20391 3.8

129649 AD000092 Hs.16488 calreticulin 3.3

129675 NM_015556Hs.172180 KIAA0440 protein 13.4

129680 U03749 gb:Human chromogranin A (CHGA) gene, promoter an 14.1

129689 AW748482 Hs.77873 B7 homolog 3 2.6

129702 AI304966 Hs.12035 ESTs, Weakly similarto 138022 hypothetical protein [H.sapiens] 7.4

129720 AA156214 Hs.12152 APMCF1 protein 2.0

129721 NM_001415Hs.211539 eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD) 1.7

129726 H15474 Hs.132898 fatty acid desaturase 1 8.3

129778 AK001676 Hs.12457 hypothetical protein FLJ10814 1.8

129779 AA394090 Hs.12460 Homo sapiens clone 23870 mRNA sequence 5.4

129800 AF052112 Hs.12540 lysosomal 1.7

129806 AB023148 Hs.173373 KIAA0931 protein 1.2

129815 BE565817 Hs.26498 hypothetical protein FLJ21657 3.1

129840 NM_006590Hs.12820 SnRNP assembly defective 1 homolog 1.8 129861 AL049999 Hs.85963 DKFZP564M182 protein 2.2

129864 AI393237 Hs.129914 runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) 1.7

129869 AI222069 Hs.13015 hypothetical protein similarto mouse DnajH 2.7

129922 AF042379 Hs.13386 gamma-tubulin complex protein 2 4.5 129945 BE514376 Hs.165998 PAI-1 mRNA-binding protein 1.8

129953 AA412195 Hs.13740 ESTs 2.5

129972 AW753185 Hs.180628 dynamin 1-like 1.8

129983 U09848 Hs.132390 zinc finger protein 36 (KOX 18) 1.3

129989 AB015856 Hs.247433 activating transcription factor 6 4.0 130010 AA301116 Hs.142838 nucleolar phosphoprotein Nopp34 1.6

130081 AA287325 Hs.14713 ESTs 4.0

130082 S73265 Hs.1473 gastrin-releasing peptide 1.8 130097 AL046962 Hs.14845 forkhead box 03A 2.8 130100 AL135561 Hs.14891 hypothetical protein FLJ21047 2.3 130111 X53002 Hs.149846 integrin, beta 5 2.3

130112 AA916785 Hs.180610 splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated) 3.0

130112 AA916785 Hs.180610 splicing factor proline/glutamine rich ( 2.1

130128 L76937 Hs.150477 Wemersyndrome 1.8

130135 AA311426 Hs.21635 tubulin, gamma 1 6.1 130211 NM_003358Hs.23703 ESTs, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.sapiens] 1.6

130212 D80001 Hs.152629 KIAA0179 protein 1.3

130236 R85367 Hs.51957 splicing factor, arginine/serine-rich 2, interacting protein 2.0

130241 AL035588 Hs.153203 MyoD family inhibitor 3.2

130242 X79201 Hs.153221 synovial sarcoma, translocated to X chromosome 5.4 130249 D81983 Hs.322852 GAS2-related on chromosome 22 4.8

130263 NM_002497Hs.153704 NIMA (never in mitosis gene a)-related kinase 2 1.4

130287 AA479005 Hs.154036 tumor suppressing subtransferable candidate 3 2.6

130310 AB011121 Hs.154248 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 6.3

130353 Z19084 Hs.172210 MUF1 protein 6.2 130356 AF127577 Hs.155017 nuclear receptor interacting protein 1 2.4

130357 AJ224442 Hs.155020 putative methyltransferase 3.4

130359 NM_013449Hs.277401 bromodomain adjacent to zinc finger domain, 2A 8.5

130367 AL135301 Hs.8768 hypothetical protein FLJ10849 1.4

130372 AI077464 Hs.5011 RNA binding motif protein 9 3.3 130393 N89487 Hs.155291 KIAA0005 gene product 1.8

130399 AW374106 Hs.155356 hypothetical protein MGC2840 similar to a putative glucosyltransferase 3.4

130407 BE385099 Hs.334727 hypothetical protein MGC3017 2.3

130409 NM_001197Hs.155419 BCL2-interacting killer (apoptosis-inducing) 2.7

130419 AF037448 Hs.155489 NS1-associated protein 1 1.8 130441 U63630 Hs.155637 protein kinase, DNA-activated, catalytic polypeptide 2.3

130448 BE513202 Hs.15589 PPAR binding protein 3.9

130455 D90041 Hs.155956 N-acetyltransferase 1 (arylamine N-acetyltransferase) 33.6

130455 D90041 Hs.155956 N-acetyltransferase 1 (arylamine N-acety 4.6

130471 AL121438 Hs.183706 adducin 1 (alpha) 2.7 130485 BE245851 Hs.180779 H2B histone family, member B 5.0

130487 U49844 Hs.77613 ataxia telangiectasia and Rad3 related 4.3

130498 L38951 Hs.180446 karyopherin (importin) beta 1 1.6

130503 BE208491 Hs.295112 KIAA0618 gene product 16.1

130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pseudoaehondroplasia, epiphyseal dysplasia 1, multiple) 6.1 130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pse 5.3

130526 AW876523 Hs.15929 hypothetical protein FLJ12910 2.1

130542 U64675 Hs.179825 RAN binding protein 2-like 1 7.8

130544 AA321238 Hs.4310 eukaryotic translation initiation factor 1 A 1.5

130553 AF062649 Hs.252587 pituitary tumor-transforming 1 14.4 130556 AI907018 Hs.15977 Empirically selected from AFFX single probeset 4.7

130567 AA383092 Hs.1608 replication protein A3 (14kD) 7.9

130568 AA232119 Hs.16085 putative G-protein coupled receptor 3.3 130574 AF083208 Hs.16178 apoptosis antagonizing transcription factor 1.2 130586 AB007891 Hs.16349 KIAA0431 protein 5.6 130598 AL042210 Hs.16493 hypothetical protein DKFZp762N2316; KIAA1803 protein 1.4

130601 AA609738 Hs.16525 ESTs 1.5

130614 AI354355 Hs.16697 down-regulator of transcription 1 , TBP-binding (negative cofactor 2) 1.3

130617 M90516 Hs.1674 glutamine-fructose-6-phosphate transaminase 1 12.1

130617 M90516 Hs.1674 glutamine-fructose-6-phosphatetransamin 2.4 130618 AA383439 Hs.16758 Spir-1 protein 15.9

130667 BE246961 Hs.17639 Homo sapiens ubiquitin protein ligase (UBE3B) mRNA, partial eds 13.9

130674 AL048842 Hs.194019 attractin 1.5 130675 AA442233 Hs.17731 hypothetical protein FLJ12892 5.4 130692 AA652501 Hs.13561 hypothetical protein MGC4692 5.0 130693 R68537 Hs.17962 ESTs 2.0 130712 AJ271881 Hs.279762 bromodomain-containing 7 1.8 130714 AI348274 Hs.18212 DNA segment on chromosome X (unique) 9879 expressed sequence 2.0 130730 AB007920 Hs.18586 KIAA0451 gene product 3.7 130744 H59696 Hs.18747 POP7 (processing of precursor, S. cerevisiae) homolog 3.1 130751 AF052105 Hs.18879 chromosome 12 open reading frame 1.4 130757 AL036067 Hs.18925 protein x 0001 5.7 130768 AF258627 Hs.211562 ATP-binding cassette, sub-family A (ABC1), member 1 5.1 130789 AK000355 Hs.8899 sirtuin (silent mating type information regulation 2, S.cerevlsiae, homolog) 5 5.2 130815 AB018298 Hs.19822 SEC24 (S. cerevisiae) related gene family, member D 1.5 130836 J05068 Hs.2012 transcobalamin I (vitamin B12 binding protein, R binder family) 15.7 130841 AL157468 Hs.325825 Homo sapiens cDNA FLJ20848 fis, clone ADKA01732 2.8 130843 AA447492 Hs.20183 ESTs, Weakly similar to AF164793 1 protein x 013 [H.sapiens] 1.5 130844 U76248 Hs.20191 seven in absentia (Drosophila) homolog 2 3.4 130855 AJ243706 Hs.143323 putative DNA/chromatin binding motif 1.7 130861 NM_016578Hs.20509 HBV pX associated protein-8 1.9 130879 NM_003416Hs.2076 zinc finger protein 7 (KOX 4, clone HF.16) 1.4 130880 BE514434 Hs.20830 kinesin-like 2 2.1 130892 AL120837 Hs.20993 high-glucose-regulated protein 8 2.4 130898 AB033078 Hs.186613 sphingosine-1 -phosphate lyase 1 1.7 130911 BE409769 Hs.21189 DnaJ (Hsp40) homolog, subfamily A, member 2 1.8 130919 N79110 Hs.21276 collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 2.3 130944 BE382657 Hs.21486 signal transducer and activator of transcription 1 , 91 kD 5.4 130971 N39842 Hs.301444 KIAA1673 2.2 130992 BE398091 Hs.74316 desmoplakin (DPI, DPII) 1.8 130993 T97401 Hs.21929 ESTs 1.6 131005 AV658308 Hs.2210 thyroid hormone receptor interactor 3 1.6 131028 AI879165 Hs.2227 CCAAT/enhancer binding protein (C/EBP), gamma 1.2 131042 AI826288 Hs.171637 hypothetical protein MGC2628 1.6 131046 AA321649 Hs.2248 small inducible cytokine subfamily B (Cys-X-Cys), member 10 7.4 131046 AA321649 Hs.2248 small inducible cytokine subfamily B (Cy 3.0 131047 H23230 Hs.22481 ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens] 1.7 131060 AA194422 Hs.22564 myosin VI 5.1 131060 AA194422 Hs.22564 myosin VI 2.5 131070 N53344 Hs.22607 ESTs 7.1 131076 AA749230 Hs.26433 doliehyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 ( 2.0 131076 AA749230 Hs.26433 doliehyl-phosphate (UDP-N-acetylglucosam 1.9 131099 AL133353 Hs.226581 COX15 (yeast) homolog, cytochrome c oxidase assembly protein 7.0 131174 NM_006540Hs.29131 nuclear receptor coactivator 2 1.9 131185 BE280074 Hs.23960 cyclin B1 5.8 131206 AW138839 Hs.24210 ESTs 2.0 131213 AA885699 Hs.24332 CGI-26 protein 7.0 131225 H62087 Hs.31659 thyroid hormone receptor-associated protein, 95-kD subunit 7.5 131231 N47468 Hs.59757 zinc finger protein 281 2.9 131233 D89053 Hs.268012 fatty-acid-Coenzyme A ligase, long-chain 3 3.5 131243 AW383256 Hs.24752 spectrin SH3 domain binding protein 1 2.8 131245 AL080080 Hs.24766 thioredoxin domain-containing 2.8 131247 AL043100 Hs.326190 fatty acid amide hydrolase 5.6 131281 AA251716 Hs.25227 ESTs 5.7 131283 X80038 Hs.339713 Homo sapiens clone F19374 APO E-C2 gene cluster 1.3 131305 AV656017 Hs.184325 CGI-76 protein 5.0 131320 AA505691 Hs.145696 splicing factor (CC1.3) 1.8 131339 AF058696 Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 2.6 131339 AF058696 Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 2.6 131375 AW293165 Hs.143134 ESTs 5.4 131390 BE269388 Hs.182698 mitochondrial ribosomal protein L20 5.3 131410 BE259110 Hs.279836 HSPC166 protein 2.2 131412 NM_012247Hs.124027 SELENOPHOSPHATE SYNTHETASE ; Human selenium donor protein 2.0 131429 AL046302 Hs.26750 hypothetical protein FLJ21908 1.4 131458 BE297567 Hs.27047 hypothetical protein FLJ20392 1.7 131475 AA992841 Hs.27263 KIAA1458 protein 2.0 131501 AV661958 Hs.8207 GK001 protein 2.6 131501 AV661958 Hs.8207 GK001 protein 1.6 131511 AA732153 Hs.27865 Homo sapiens cDNA: FLJ21333 fis, clone COL02535 2.0 131528 AU076408 Hs.28309 UDP-glucose dehydrogenase 1.6 131532 BE268278 Hs.28393 hypothetical protein MGC2592 7.4

131543 AW966881 Hs.41639 programmed cell death 2 2.2

131544 AL355715 Hs.28555 programmed cell death 9 (PDCD9) 2.1

131562 NM 003512HS.28777 H2A histone family, member L 1.7

131564 T93500 Hs.28792 Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405 5.1

131564 T93500 Hs.28792 Homo sapiens cDNA FLJ11041 fis, clone PL 1.8

131569 AL389951 Hs.271623 nucleoporin 50kD 5.0

131618 BE393822 Hs.29645 Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial eds 1.8

131622 R78195 Hs.29692 Homo sapiens cDNA FLJ11436 fis, clone HEMBA1001213 1.3

131623 AB037791 Hs.29716 hypothetical protein FLJ10980 2.2

131623 AB037791 Hs.29716 hypothetical protein FLJ10980 1.9

131643 AW410601 Hs.30026 HSPC182 protein 2.9

131653 AW960597 Hs.30164 ESTs 1.3

131656 AI218918 Hs.30209 KIAA0854 protein 2.8

131669 X52486 Hs.3041 uracil-DNA glycosylase 2 2.8

131692 BE559681 Hs.30736 K1AA0124 protein 5.6

131714 AA642831 Hs.31016 putative DNA binding protein 2.9

131722 D13757 Hs.311 phosphoribosyl pyrophosphate amidotransferase 3.4

131737 AK001641 Hs.31323 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein 3.8

131760 X76732 Hs.3164 nucleobindin 2 2.9

131760 X76732 Hs.3164 nucleobindin 2 2.8

131763 AI878932 Hs.317 topoisomerase (DNA) I 3.4

131772 AA382590 Hs.170980 KIAA0948 protein 25.5

131774 BE267158 Hs.169474 DKFZP586J0119 protein 5.5

131787 D87077 Hs.196275 KIAA0240 protein 2.4

131793 AW966127 Hs.32246 Homo sapiens cDNA FLJ14656 fis, clone NT2RP2002439 7.9

131795 BE501849 Hs.32317 high-mobility group 20B 1.4

131798 X86098 Hs.301449 adenovirus 5 E1A binding protein 4.1

131817 U20536 Hs.3280 caspase 6, apoptosis-related cysteine protease 4.2

131824 U28838 Hs.32935 TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2 3.5

131850 AI251317 Hs.33184 ESTs 5.1

131878 AA083764 Hs.6101 hypothetical protein MGC3178 5.8

131885 BE502341 Hs.3402 ESTs 13.7

131885 BE502341 Hs.3402 ESTs 2.4

131887 W17064 Hs.332848 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 3

131900 AA099014 Hs.231029 Homo sapiens, clone MGC:15961, mRNA, complete eds 8.7

131900 AA099014 Hs.231029 Homo sapiens, clone MGC: 15961, mRNA, com 2.0

131904 AF078866 Hs.284296 Homo sapiens cDNA: FLJ22993 fis, clone KAT11914 5.5

131905 AA179298 Hs.3439 stomatin-like 2 11.3

131913 AW207440 Hs.185973 degenerative spemnatocyte (homolog Drosophila; lipid desaturase) 1.7

131916 AA025976 Hs.34569 ESTs 5.2

131925 AF151048 Hs.183180 anaphase promoting complex subunit 11 (yeast APC11 homolog) 2.7

131929 BE541211 Hs.34804 Homo sapiens cDNA FLJ11472 fis, clone HEMBA1001711 5.3

131941 BE252983 Hs.35086 ubiquitin specific protease 1 2.3

131950 AA355113 Hs.35380 x 001 protein 1.5

131962 AK000046 Hs.267448 hypothetical protein FLJ20039 2.3

131965 W79283 Hs.35962 ESTs 1.4

131971 BE567100 Hs.154938 hypothetical protein MDS025 3.5

131977 U90441 Hs.3622 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II 6.5

131985 AA503020 Hs.36563 hypothetical protein FLJ22418 2.4

131991 AF053306 Hs.36708 budding uninhibited by benzimidazoles 1 (yeast homolog), beta 2.1

132019 H56995 Hs.37372 Homo sapiens DNA binding peptide mRNA, partial eds 3.2

132031 AF193844 Hs.3758 COP9 complex subunit 7a 5.8

132062 BE266155 Hs.3832 clathrin-associated protein AP47 1.5

132084 NM_002267Hs.3886 karyopherin alpha 3 (importin alpha 4) 3.7

132103 BE171921 Hs.3991 ESTs 1.4

132105 AV646076 Hs.39959 ESTs 5.8

132116 AW960474 Hs.40289 ESTs 1.7

132176 AA857025 Hs.8878 kinesin-like 1 3.3

132180 NM_004460Hs.418 fibroblast activation protein, alpha 14.7

132192 AA206153 Hs.4209 mitochondrial ribosomal protein L37 5.5

132194 R42432 Hs.4212 ESTs 4.4

132203 NM_004782Hs.194714 synaptosomal-associated protein, 29kD 2.2

132207 BE206939 Hs.42287 E2F transcription factor 6 2.2

132235 AV658411 Hs.42656 KIAA1681 protein 7.8

132240 AB018324 Hs.42676 KIAA0781 protein 1.5

132252 AI566004 Hs.141269 Homo sapiens cDNA: FLJ21550 fis, clone COL06258 1.3 132266 AA301228 Hs.43299 hypothetical protein FLJ12890 5.7 132273 AA227710 Hs.43658 DKFZP586L151 protein 4.2 132276 AA653507 Hs.285711 hypothetical protein FLJ13089 2.1 132288 N36110 Hs.305971 solute carrier family 2 (facilitated glucose transporter), member 10 1.5 132294 AB023191 Hs.44131 KIAA0974 protein 10.0 132298 NM_015986Hs.7120 cytokine receptor-like molecule 9 1.9 132299 AW405882 Hs.44205 cortistatin 9.2 132325 N37065 Hs.44856 hypothetical protein FLJ12116 2.0 132348 AW067708 Hs.170311 heterogeneous nuclear ribonucleoprotein D-like 6.5 132370 AW572805 Hs.46645 ESTs 3.8 132374 AF155582 Hs.46744 corel UDP-galactose:N-acetylgalactosamine-alpha-R beta 1 ,3-galactosyltransferase 1.5 132376 AI279892 Hs.46801 sorting nexin 14 12.5 132384 AA312135 Hs.46967 HSPC034 protein 28.3 132393 AL135094 Hs.47334 hypothetical protein FLJ 14495 1.9 132450 AA100012 Hs.48827 hypothetical protein FLJ12085 1.9 132452 AW973521 Hs.247324 mitochondrial ribosomal protein S14 6.1 132456 AB011084 Hs.48924 KIAA0512 gene product; ALEX2 1.7 132465 AW169847 Hs.49169 KIAA1634 protein 8.6 132470 AI224456 Hs.4934 H.sapiens polyA site DNA 5.2 132484 X16660 Hs.119007 RAB4, member RAS oncogene family 1.4 132518 AW885606 Hs.5064 ESTs 6.1 132528 T78736 Hs.50758 SMC4 (structural maintenance of chromosomes 4, yeast)-like 1 3.3 132530 AA306105 Hs.50785 SEC22, vesicle trafficking protein (S. cerevisiae)-like 1 2.0 132532 AA454132 Hs.5080 mitochondrial ribosomal protein L16 2.9 132534 BE388673 Hs.5086 hypothetical protein MGC10433 2.2 132543 BE568452 Hs.5101 protein regulator of cytokinesis 1 7.3 132571 AW674699 Hs.5169 suppressor of G2 allele of SKP1, S. cerevisiae, homolog of 1.7 132574 AW631437 Hs.5184 TH1 drosophila homolog 7.1 132596 AK001484 Hs.5298 CGI-45 protein 2.2 132611 AA345547 Hs.53263 hypothetical protein FLJ 13287 2.2 132612 H12751 Hs.5327 PR01914 protein 6.8 132616 BE262677 Hs.283558 hypothetical protein PR01855 14.0 132638 AI796870 Hs.54277 DNA segment on chromosome X (unique) 9928 expressed sequence 11.4 132648 U51127 Hs.54434 hypothetical protein MGC1715 1.9 132668 AB018319 Hs.5460 KIAA0776 protein 2.6 132692 AW191962 Hs.249239 collagen, type VIII, alpha 2 2.0 132715 F11875 Hs.5534 Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645 1.5 132718 NM_004600Hs.554 Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro) 3.0 132724 AI142265 Hs.55498 geranylgeranyl diphosphate synthase 1 2.4 132731 AH89075 Hs.301872 hypothetical protein MGC4840 12.4 132744 AA010233 Hs.55921 glutamyl-prolyl-tRNA synthetase 14.6 132760 AA125985 Hs.56145 thymosin, beta, identified in neuroblastoma cells 2.7 132771 Y10275 Hs.56407 phosphoserine phosphatase 3.0 132773 AA459713 Hs.295901 KIAA0493 protein 2.3 132784 AH42133 Hs.56845 GDP dissociation inhibitor 2 1.8 132798 AI026701 Hs.5716 KIAA0310 gene product 3.7 132807 U07418 Hs.57301 mutt. (E. coli) homolog 1 (colon cancer, nonpolyposis type 2) 1.8 132810 AB007944 Hs.5737 KIAA0475 gene product 5.9 132813 BE313625 Hs.57435 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 8.7 132815 AI815189 Hs.57475 sex comb on midleg homolog 1 6.4 132817 N27852 Hs.57553 tousled-like kinase 2 3.6 132821 AJ251595 Hs.169610 CD44 antigen (homing function and Indian blood group system) 2.8 132833 U78525 Hs.57783 eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD) 14.6 132842 NM_016154Hs.279771 Homo sapiens clone PP1596 unknown mRNA 1.6 132844 F12200 Hs.5811 chromosome 21 open reading frame 59 2.5 132851 U09716 Hs.287912 lectin, mannose-binding, 1 1.4 132863 BE268048 Hs.236494 RAB10, member RAS oncogene family 4.2 132869 AW963217 Hs.203961 ESTs, Moderately similarto AF116721 89 PR02168 [H.sapiens] 2.8 132873 AW007683 Hs.58598 KIAA1266 protein 2.0 132875 NM_004850Hs.58617 Rho-associated, coiled-coil containing protein kinase 2 1.6 132891 BE267143 Hs.59271 U2(RNU2) small nuclear RNA auxiliary factor 1 (non-standard symbol) 1.4 132897 AW503667 Hs.59545 ring finger protein 15 5.4 132902 AI936442 Hs.59838 hypothetical protein FLJ10808 6.1 132912 AW732760 Hs.167578 Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374 7.1 132913 W78714 Hs.60257 Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921 2.8 132940 T79136 Hs.127243 Homo sapiens mRNA for KIAA1724 protein, partial eds 6.1 132941 AI817165 Hs.6120 hypothetical protein FLJ13222 10.3 132942 AA554458 Hs 197751 KIAA0666 protein 1 8 132952 AI658580 Hs 61426 Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial eds 22 132962 AA576635 Hs 6153 CGI-48 protein 49 132972 AA034365 Hs 288924 Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575 27 132973 AA035446 Hs 323277 ESTs 53 132977 AA093322 Hs 301404 RNA binding motif protein 3 32 132980 AA040696 Hs 62016 ESTs 1 3 132994 AA112748 Hs 279905 clone HQ0310 PRO0310p1 30 133012 AA847843 Hs 62711 Homo sapiens, clone IMAGE 3351295, mRNA 103 133015 AJ002744 Hs 246315 UDP-N-acetyl-alpha-D-galactosamine polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7) 2 1 133016 AI439688 Hs 6289 hypothetical protein FLJ20886 1 3 133053 AI065016 Hs 6390 Homo sapiens clone FLB3344 PRO0845 mRNA, complete eds 60 133062 AW500374 Hs 64056 PRO0149 protein 53 133069 BE247441 Hs 6430 protein with polyglutamine repeat, calcium (ca2+) homeostasis endoplasmic reticulum protein 49 133091 AK001628 Hs 64691 KIAA0483 protein 35 133110 AA808177 Hs 65228 ESTs 13 1 133134 AF198620 Hs 65648 RNA binding motif protein 8A 1 3 133145 H94227 Hs 6592 Homo sapiens, clone IMAGE 2961368, mRNA, partial eds 22 133152 Z11695 Hs 324473 mitogen-activated protein kinase 1 1 3 133174 AA431620 Hs 324178 hypothetical protein MGC2745 17 1 133175 AW955632 Hs 66666 ESTs, Weakly similarto S19560 proline-nch protein MP4 - mouse [M musculus] 1 8 133177 X97795 Hs 66718 RAD54 (S cerevisiae) like 49 133197 AI275243 Hs 180201 hypothetical protein FLJ20671 3 1 133208 AI801777 Hs 6774 ESTs 44 133226 AW954569 Hs 296287 Homo sapiens, Similar to bromodomain-containing 4, clone IMAGE 3542455, mRNA, partial eds 1 7 133228 AI492924 Hs 6831 golgi phosphoprotein 1 60 133240 AK001489 Hs 242894 ADP-nbosylation factor-like 1 1 5 133254 AI567421 Hs 273330 Homo sapiens, clone IMAGE 3544662, mRNA, partial eds 1 4 133266 AH60873 Hs 69233 zinc finger protein 56 133268 AW956781 Hs 293937 ESTs, Weakly similar to FXD2JHUMAN FORKHEAD BOX PROTEIN D2 [H sapiens] 1 9 133285 M76477 Hs 289082 GM2 ganglioside activator protein 47 133291 BE297855 Hs 69855 NRAS-related gene 50 133314 AA102670 Hs 70725 gamma-aminobutyπc acid (GABA) A receptor, pi 27 133321 T79526 Hs 179516 integral type I protein 93 133327 AL390127 Hs 7104 Kruppel-like factor 13 44 133347 BE257758 Hs 71475 acid cluster protein 33 1 8 133360 AI016521 Hs 71816 v-akt munne thymoma viral oncogene homolog 1 55 133366 AA292811 Hs 72050 non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) 27 133367 AF231919 Hs 18759 KIAA0539 gene product 1 7 133370 AF245505 Hs 72157 DKFZP564I1922 protein 1 8 133383 BE313555 Hs 7252 K1AA1224 protein 1 7 133390 AI950382 Hs 72660 phosphatidylseπne receptor 1 3 133391 AW103364 Hs 727 inhibin, beta A (activin A, activin AB alpha polypeptide) 16 1 133394 AA305127 Hs 237225 hypothetical protein HT023 122 133437 AL031591 Hs 7370 phosphotidylinositol transfer protein, beta 104 133452 NM_002759Hs 274382 protein kinase, interferon-inducible double stranded RNA dependent 1 2 133453 AI659306 Hs 73826 protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) 1 7 133500 AW964804 Hs 74280 hypothetical protein FLJ22237 11 1 133529 W45623 Hs 74571 ADP-nbosylation factor 1 28 133540 AL037159 Hs 74619 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 29 133543 AU077073 Hs 108327 damage-specific DNA binding protein 1 (127kD) 25 133578 AU077050 Hs 75066 translin 1 5 133579 X75346 Hs 75074 mitogen-activated protein kinase-activated protein kinase 2 2 1 133582 BE391579 Hs 75087 Fas-activated seπne/threonine kinase 1 3 133594 AW160781 Hs 172589 nuclear phosphoprotein similar to S cerevisiae PWP1 22 133595 AA393273 Hs 75133 transcnption factor 6-lιke 1 (mitochondrial transcription factor 1-lιke) 1 5 133599 NM_002885Hs 75151 RAP1, GTPase activating protein 1 57 133621 NM_004893Hs 75258 H2A histone family, member Y 255 133627 NM_002047Hs 75280 glycyl-tRNA synthetase 158 133631 NM_000401Hs 75334 exostoses (multiple) 2 33 133649 U25849 Hs 75393 acid phosphatase 1, soluble 1 6 133690 AV661185 Hs 75574 mitochondπal nbosomal protein L19 4 1 133720 L27841 Hs 75737 peπcentπolar ateπal 1 1 5 133722 AW969976 Hs 279009 matnx Gla protein 63 133751 AW402048 Hs 334787 Homo sapiens, Similar to likely ortholog of yeast ARV1 , clone IMAGE 3506392, mRNA 39 133757 T52946 Hs 196209 RAE1 (RNA export 1 , S pombe) homolog 1 7 133760 BE271766 Hs 181357 laminiπ receptor 1 (67kD, nbosomal protein SA) 1 8 133765 M62194 Hs.75929 cadherin 11, type 2, OB-cadherin (osteoblast) 1.5

133780 AA557660 Hs.76152 decorin 3.5

133784 BE622743 Hs.301064 arfaptin 1 6.8

133791 M34338 Hs.76244 sper idine synthase 2.6 133797 AL133921 Hs.76272 retinoblastoma-binding protein 2 1.4

133822 D50525 Hs.699 peptidylprolyl isomerase B (cyclophilin B) 8.0

133842 AW797468 Hs.285013 putative human HLA class II associated protein I 13.5

133845 AA147026 Hs.76704 ESTs 2.2

133850 W29092 Hs.7678 cellular retinoic acid-binding protein 1 1.8 133859 U86782 Hs.178761 26S proteasome-associated padl homolog 2.0

133865 AB011155 Hs.170290 discs, large (Drosophila) homolog 5 2.8

133867 AW340125 Hs.76989 KIAA0097 gene product 6.7

133868 AB012193 Hs.183874 cullin 4A 2.5 133881 U30872 Hs.77204 centromere protein F (350/400kD, itosin) • 3.0 133922 U30825 Hs.77608 splicing factor, arginine/serine-rich 9 1.4

133924 D86326 Hs.325948 vesicle docking protein p115 5.4

133929 NM_006306Hs.211602 SMC1 (structural maintenance of chromosomes 1, yeast)-like 1 4.9

133936 L17128 Hs.77719 gamma-glutamyl carboxylase 3.7

133941 BE244332 Hs.77770 adaptor-related protein complex 3, mu 2 subunit 12.1 133959 X81 89 Hs.77897 splicing factor 3a, subunit 3, 60kD 9.7

133976 AI908165 Hs.169946 GATA-binding protein 3 (T-cell receptor gene activator) 3.1

133989 AL040328 Hs.78202 SWI/SNF related, matrix associated, actin dependent regulator of chromatin 1.3

133997 AI824113 Hs.78281 regulator of G-protein signalling 12 9.7

134010 AB016092 Hs.197114 RNA binding protein; AT-rich element binding factor 2.4 134015 D31764 Hs.278569 sorting nexin 17 2.5

134070 NM_003590Hs.78946 cullin 3 1.3

134110 U41060 Hs.79136 LIV-1 protein, estrogen regulated 4.2

134129 NM_014742Hs.79305 KIAA0255 gene product 2.2

134134 H86504 Hs.173328 protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 5.0 134200 BE559598 Hs.197803 KIAA0160 protein 3.2

134206 AF107463 Hs.79968 splicing factor 30, survival of motor neuron-related 2.5

134208 NM 00288HS.79993 peroxisomal biogenesis factor 7 2.1

134219 NM_000402Hs.80206 glucose-δ-phosphate dehydrogenase 9.1

134234 BE300078 Hs.80449 Homo sapiens, clone IMAGE:3535294, mRNA, partial eds 2.8 134275 AI878910 Hs.3688 cisplatin resistance-associated overexpressed protein 1.8

134292 AI906291 Hs.81234 immunoglobulin superfamily, member 3 2.0

134301 AW502505 Hs.81360 Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HSU90909 2.5

134305 U61397 Hs.81424 ubiquitin-like 1 (sentrin) 2.8

134324 AB029023 Hs.179946 KIAA1100 protein 10.4 134326 AW903838 Hs.81800 chondroitin sulfate proteoglycan 2 (versican) 1.9

134329 N92036 Hs.81848 RAD21 (S. pombe) homolog 2.6

134337 NM_004922Hs.81964 SEC24 (S. cerevisiae) related gene family, member C 2.3

134348 AW291946 Hs.82065 interleukin 6 signal transducer (gp130, oncostatin M receptor) 13.0

134367 AA339449 Hs.82285 phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, 8.8 134376 X06560 Hs.82396 2,,5'-oligoadenylate synthetase 1 (4046 kD) 1.5

134379 AW362124 Hs.323193 hypothetical protein MGC3222 8.1

134384 AI589941 Hs.8254 Homo sapiens, Similar to tumor differentially expressed 1 , clone IMAGE:3639252, mRNA, partial eds 2.6

134391 AA417383 Hs.82582 integrin, beta-like 1 (with EGF-like repeat domains) 4.1

134395 AA456539 Hs.8262 lysosomal 1.7 134403 AA334551 Hs.82767 sperm specific antigen 2 2.6

134405 AW067903 Hs.82772 collagen, type XI, alpha 1 1.3

134411 BE272095 Hs.167791 reticulocalbin 1, EF-hand calcium binding domain 3.2

134415 AI750762 Hs.82911 protein tyrosine phosphatase type IVA, member 2 1.9

134421 AU077196 Hs.82985 collagen, type V, alpha 2 10.3 134424 Z44190 Hs.83023 peroxisomal biogenesis factor 11B 2.4

134446 AA112036 Hs.83419 KIAA0252 protein 1.2

134447 M58603 Hs.83428 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 1.6 134470 X54942 Hs.83758 CDC28 protein kinase 2 2.1 134480 NM_005000Hs.83916 Empirically selected from AFFX single probeset 5.3 134485 X82153 Hs.83942 cathepsin K (pycnodysostosis) 2.5

134498 AW246273 Hs.84131 threonyl-tRNA synthetase 2.1

134513 AA425473 Hs.84429 KIAA0971 protein 3.8

134516 AK001571 Hs.273357 hypothetical protein FLJ10709 2.4

134520 BE091005 Hs.74861 activated RNA polymerase II transcription cofactor 4 6.7 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.3

134577 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor for tRNAs) 5.5

134582 AA927177 Hs.86041 CGG triplet repeat binding protein 1 5.8 134612 AW068223 Hs 171581 ubiquitin C-terminal hydrolase UCH37 22

134624 AF035119 Hs 8700 deleted in liver cancer 1 20

134632 X78520 Hs 174139 chloπde channel 3 23

134654 AK001741 Hs 8739 hypothetical protein FLJ 10879 1 4

134664 AA256106 Hs 87507 ESTs 729

134666 BE391929 Hs 8752 transmembrane protein 4 85

134687 U62317 Hs 88251 arylsulfatase A 60

134692 NM_003474Hs 8850 a dismtegπn and metalloproteinase domain 12 (meltπn alpha) 43

134705 BE161887 Hs 88799 anaphase-promoting complex subunit 10 23

134714 Y14768 Hs 890 lysosomal 67

134719 AA852985 Hs 89232 chromobox homolog 5 (Drosophila HP1 alpha) 23

134722 AF129536 Hs 284226 F-box only protein 6 29

134724 AF045239 Hs 321576 ring finger protein 22 66

134746 X07871 Hs 89476 CD2 antigen (p50), sheep red blood cell receptor 23

134751 AW630803 Hs 89497 lamin B1 62

134790 BE002798 Hs 287850 integral membrane protein 1 1 9

134806 AD001528 Hs 89718 spermme synthase 1 8

134834 AW451370 Hs 8991 adaptor-related protein complex 1, gamma 2 subunit 1 4

134850 AI701162 Hs 90207 hypothetical protein MGC11138 1 4

134853 BE268326 Hs 90280 5-amιnoιmιdazole-4-carboxamιde nbonucleotide formyltransferase/IMP cyclohydralase 56

134859 D26488 Hs 90315 KIAA0007 protein 28

134880 AI879195 Hs 90606 15 kDaselenoprotein 1 7

134910 AA532963 Hs 9100 Homo sapiens CDNA FLJ13100 fis, clone NT2RP3002255 1 7

134925 AW885909 Hs 6975 PRO1073 protein 2 1

134955 AW401361 Hs 91773 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 1 3

134971 AI097346 Hs 286049 phosphosenne aminotransferase 2 1

134975 R50333 Hs 92186 Leman coiled-coil protein 23

135011 AB037835 Hs 92991 KIAA1414 protein 1 6

135022 NM_000408Hs 93201 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 39

135032 AW301984 Hs 173685 hypothetical protein FLJ12619 62

135077 AW503733 Hs 9414 KIAA1488 protein 20

135083 AB036063 Hs 94262 p53-ιnducιble nbonucleotide reductase small subunit 2 homolog 1 3

135095 AF027219 Hs 9443 zinc finger protein 202 71

135096 AA081258 Hs 132390 zinc finger protein 36 (KOX 18) 32

135153 AI093155 Hs 95420 JM27 protein 25

135181 BE250865 Hs 279529 px19-lιke protein 1 4

135199 AA477514 Hs 96247 translin-associated factor X 50

135207 N26427 Hs 9634 ESTs, Highly similarto C10_HUMAN PUTATIVE C10 PROTEIN [H sapiens] 6 1

135214 T78802 Hs 96560 hypothetical protein FLJ11656 46

135243 BE463721 Hs 97101 putative G protein-coupled receptor 56

135245 AI028767 Hs 262603 ESTs 35

135257 AW291023 Hs 97255 ESTs, Weakly similar to A46010 X-lmked retinopathy protein [H sapiens] 1 2

135263 AI088775 Hs 55498 geranylgeranyl diphosphate synthase 1 26

135274 AA448460 Hs 112017 GE36 gene 53

135294 AA150320 Hs 9800 protein kinase Njmu-R1 9 1

135295 AI090838 Hs 98006 ESTs 24

135307 AI743770 Hs 98368 ESTs, Weakly similar to KIAA0822 protein [H sapiens] 133

135321 AI652069 Hs 98614 nbosome binding protein 1 (dog 180kD homolog) 26

135354 AA456454 Hs 183418 cell division cycle 2-lιke 1 (PITSLRE proteins) 83

135361 AA373452 Hs 167700 Homo sapiens cDNA FLJ10174 fis, clone HEMBA1003959 1 5

135389 U05237 Hs 99872 fetal Alzheimer antigen 49

135400 X78592 Hs 99915 androgen receptor (dihydrotestosterone receptor, testicular feminization, spinal and bulbar 20

134975 R50333 Hs 92186 Leman coiled-coil protein 26

135011 AB037835 Hs 92991 KIAA1414 protein 14

135022 NM_000408Hs 93201 glycerol-3-phosphate dehydrogenase 2 (mi 1 6

135032 AW301984 Hs 173685 hypothetical protein FLJ12619 1 4

135077 AW503733 Hs 9414 KIAA1488 protein 1 8

135083 AB036063 Hs 94262 p53-ιnducιble nbonucleotide reductase s 25

135095 AF027219 Hs 9443 zinc finger protein 202 1 5

135096 AA081258 Hs 132390 zinc finger protein 36 (KOX 18) 2 1

135153 AI093155 Hs 95420 JM27 protein 44

135181 BE250865 Hs 279529 px19-lιke protein 149

135199 AA477514 Hs 96247 translin-associated factor X 1 3

135207 N26427 Hs 9634 ESTs, Highly similar to C10_HUMAN PUTATI 1 7

135214 T78802 Hs 96560 hypothetical protein FLJ11656 6 1

135243 BE463721 Hs 97101 putative G protein-coupled receptor 27

135245 AI028767 Hs 262603 ESTs 122 135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.6

135263 AI088775 Hs.55498 geranylgeranyl diphosphate synthase 1 1.8

135274 AA448460 Hs.112017 GE36 gene 4.1

135294 AA150320 Hs.9800 protein kinase Njmu-R1 1.2 135295 AI090838 Hs.98006 ESTs 4.8

135307 AI743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8

135321 AI652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3

135354 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.7

135361 AA373452 Hs.167700 Homo sapiens cDNA FLJ10174 fis, clone HE 7.9 135389 U05237 Hs.99872 fetal Alzheimer antigen 1.9

135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9

302256 AA857131 Hs.171595 HIV TAT specific factor 1 5.3

302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c-erb-b2, 2.2

303135 AW592789 Hs.279474 HSPC070 protein 1.4 303686 AK000714 Hs.109441 MSTP033 protein 5.2

310085 R43191 Hs.101248 Homo sapiens clone 1MAGE:32553, mRNA seq 2.3

315518 AA808229 Hs.167771 ESTs 2.8

317781 NM_007057Hs.42650 ZW10 interactor 2.0

320836 AI268997 Hs.197289 rab3 GTPase-activating protein, non-cata 5.5 321114 AA902256 Hs.78979 Golgi apparatus protein 1 1.4

322221 N24236 Hs.179662 nucleosome assembly protein 1-like 1 1.3

322474 AF118083 Hs.29494 PR01912 protein 2.9

322556 BE041451 Hs.177507 hypothetical protein 1.6

323541 AF292100 Hs.104613 RP42 homolog 1.8 407827 BE278431 Hs.40323 BUB3 (budding uninhibited by benzimidazo 1.6

408196 AL034548 Hs.43627 SRY (sex determining region Y)-box 22 6.1

408813 AI580090 Hs.48295 RNA helicase family 5.6

409176 R73727 Hs.101617 ESTs, Weakly similar to T32527 hypotheti 2.6

413670 AB000115 Hs.75470 hypothetical protein, expressed in osteo 2.4 414108 AI267592 Hs.75761 SFRS protein kinase 1 1.5

414846 AW304454 Hs.77495 UBX domain-containing 1 4.2

416980 AA381133 Hs.80684 high-mobility group (nonhistone chromoso 23.6

417378 R57256 Hs.82037 TATA box binding protein (TBP)-associate 5.8

418283 S79895 Hs.83942 cathepsin K (pycnodysostosis) 1.3 418467 NM_006910Hs.85273 retinoblastoma-binding protein 6 1.6

420269 U72937 Hs.96264 alpha thalassemia/mental retardation syn 2.3

420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 1.6

421225 AA463798 Hs.102696 MCT-1 protein 3.5

421642 AF172066 Hs.106346 retinoic acid repressible protein 4.9 421828 AW891965 Hs.279789 histone deacetylase 3 3.1

421983 AI252640 Hs.110364 peptidylprolyl isomerase C (cyclophilin 1.9

422052 AA302744 Hs.104518 ESTs 2.4

422055 NM_014320Hs.111029 putative heme-binding protein 4.1

423750 AF165883 Hs.298229 prefoldin 2 7.0 424001 W67883 Hs.137476 paternally expressed 10 (PEG10; KIAA105 4.9

425182 AF041259 Hs.155040 zinc finger protein 217 3.4

425284 AF155568 Hs.155489 NS1 -associated protein 1 2.1

426372 BE304680 Hs.169531 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 7.5

428049 AW183765 Hs.182238 GW128 protein 1.7 428477 AW500533 Hs.11482 splicing factor, arginine/serine-rich 11 2.4

437562 AB001636 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 3.8

438449 AK001333 Hs.6216 Homo sapiens hepatocellular carcinoma-as 5.6

441560 F13386 Hs.7888 Homo sapiens clone 23736 mRNA sequence 2.0

445580 AF167572 Hs.12912 skbl (S. pombe) homolog 7.5 446999 AA151520 Hs.334822 hypothetical protein MGC4485 2.2

447111 AI017574 Hs.17409 cysteine-rich protein 1 (intestinal) 2.8

447778 BE620592 Hs.71190 ESTs, Weakly similar to S16506 hypotheti 1.7

448873 NM_003677Hs.22393 density-regulated protein 5.9

449687 W68520 Hs.331328 intermediate filament protein syncoilin 5.6 450701 H39960 Hs.288467 Homo sapiens cDNA FLJ 12280 fis, clone MA 1.4

450703 AA011202 Hs.184771 nuclear factor l/C (CCAAT-binding transc 4.7

452461 N78223 Hs.108106 transcription factor 2.9

452511 BE408178 Hs.285165 Homo sapiens cDNA FLJ20845 fis, clone AD 12.1

453157 AF077036 Hs.31989 DKFZP586G1722 protein 4.7 453658 BE541906 Hs.87819 Homo sapiens, clone MGC:2492, mRNA, comp 1.3

100833 AF135168 Hs. 08802 N-ethylmaleimide-sensitive factor 3.2

102481 U50360 gb:Human calcium, calmodulin-dependent p 6.2 102827 BE244588 Hs.6456 chaperonin containing TCP1, subunit 2 (b 7.9 103549 BE270465 Hs.78793 protein kinase C, zeta 2.0 104331 AB040450 Hs.279862 cdk inhibitor p21 binding protein 5.3 110018 AW579842 Hs.104557 hypothetical protein FLJ10697 2.0 115008 AK001827 Hs.87889 helicase-moi 5.7 119075 M10905 Hs.287820 fibronectin 1 1.3 119615 AL034423 Hs.75875 ubiquitin-conjugating enzyme E2 variant 2.9 125006 BE065136 Hs.145696 splicing factor (CC1 ,3) 1.7 127609 X80031 Hs.530 collagen, type IV, alpha 3 (Goodpasture 2.4 129209 R62676 Hs.17820 Rho-associated, coiled-coil containing p 5.2 129917 M30773 Hs.278540 protein phosphatase 3 (formerly 2B), reg 4.5 130182 BE267033 Hs.192853 ubiquitin-conjugating enzyme E2G 2 (homo 11.0 130365 W56119 Hs.155103 eukaryotic translation initiation factor 3.3 131135 NM_016569Hs.267182 TBX3-iso protein 1.3 131853 AI681917 Hs.3321 ESTs, Highly similar to IRX1_HUMAN IROQU 3.2 131881 AW361018 Hs.3383 upstream regulatory element binding prot 14.3 132726 N52298 Hs.55608 hypothetical protein MGC955 3.0 135193 X95525 Hs.96103 TATA box binding protein (TBP)-associate 2.7 409487 H19886 gb:yn57a05.r1 Soares adult brain N2b5H 2.3 416040 AW819158 Hs.289044 Homo sapiens cDNA FLJ12048 fis, clone HE 7.4

TABLE 4A

Table 4 A shows the accession numbers for those pkeys lacking unigenelD's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

123615 30686_-15 AA609170 123619 371681J AA602964AA609200 101445 1650_-5 M21259 124385 656394J AI267847 N27351 124417 1642364J N34059 N46979 124482 1657509J N53935 N53950 102481 31281 -28 U50360 103349 11052_-2 X89059 110856 1934614. AA992380 N33063 N21418 H79958 R21911 H79957

103797 109699J AA080912AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA113892 AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305

120280 160212J AA190577 AA181657 113248328626J T63857 AW971220 AA493469 T63699 120472445732 AI950087 N70208 R97040 N36809 AI3081 9 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 A1653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 A1022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005

12901944573_2 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 A/872193 AI763273 AW1 3586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005

1206959683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 A1796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468

122188 275673 AA398838 AA435847 121581 283769 AA416568 AA442889 AA417233 AA442223 122618305217J AA453641 AA454061 109026 1504311 AA157811 AA836869 123658 genbank_AA609364 AA609364 123811 genbank_AA620586 AA620586 125115 genbank_T97341 T97341 125147 NOT_FOUND_entrez_W38150 W38150 118737382979 AA199686 N73861 120274 genbank_AA177051 AA177051 113196 genbank_T57317 T57317 120504 genbank_AA256837 AA256837 120639 genbank_AA286942 AA286942 120809 genbank_AA346495 AA346495

113702 genbank_T97307 T97307

129680 23162J U03749 NM 01275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432

AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214 AA894441 A1803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992 101045 entrez_J05614J05614

117247 genbank N21032

110501 genbank H55748

103392 entrez_X94563X94563

105032 genbank AA127818

119513 NθT_FOUND_eπtrez W37933

105445 genbank AA252395

121514 genbank AA412112

121558 genbank AA412497

121911 genbank AA427950

123315 714071J AA496369AA496646

114911 genbank AA236672

409487 1134778J H19886 AW402806 T10231

TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene numbei r

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD UnigeneTitle R1

100114 X02308 Hs.82962 thymidylate synthetase 2.9

100147 D13666 Hs.136348 osteoblast specific factor 2 (fasciclin 7.5

100154 H60720 Hs.81892 KIAA0101 gene product 9.2

100335 AW247529 Hs.6793 platelet-activating factor acetylhydrola 2.7

100666 L05424 Hs.169610 CD44 antigen (homing function and Indian 5.7

100667 L05424 Hs.169610 CD44 antigen (homing function and Indian 9

100668 L05424 Hs.169610 CD44 antigen (homing function and Indian 7.6

100678 AW502935 Hs.740 PTK2 protein tyrosine kinase 2 53.2

100988 AK000405 Hs.76480 ubiquitin-like 4 11.4

101031 J05070 Hs.151738 matrix metalloproteinase 9 (gelatinase B 8.2

101045 J05614 gb:Human proliferating cell nuclear anti 5

101332 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 3.4

101352 AI494299 Hs.16297 COX17 (yeast) homolog, cytochrome c oxid 6.3

101580 NM 012151HS.83363 coagulation factor Vlll-associated (intr 5.7

101592 AF064853 Hs.91299 guanine nucleotide binding protein ( 5.6

101767 M81057 Hs.180884 carboxypeptidase B1 (tissue) 14.4

101806 AA586894 Hs.112408 S100 calcium-binding protein A7 (psorias 8.9

101810 NM_000318Hs.180612 peroxisomal membrane protein 3 (35kD, Ze 3.2

101983 AI904232 Hs.75323 prohibitin 8.4

102107 BE258602 Hs.182366 heat shock protein 75 1.4

102165 BE313280 Hs.159627 death associated protein 3 4.6

102198 AW950852 Hs.74598 polymerase (DNA directed), delta 2, regu 4.3

102217 AA829978 Hs.301613 JTV1 gene 6.7

102220 U24389 Hs.65436 lysosomal 4.3

102302 AA306342 Hs.69171 protein kinase C-like 2 2.7

102348 U37519 Hs.87539 aldehyde dehydrogenase 3 family, member 2

102374 U33635 Hs.90572 PTK7 protein tyrosine kinase 7 6.2

102455 U48705 Hs.75562 discoidin domain receptor family, member 6.9

102568 W81489 Hs.223025 RAB31, member RAS oncogene family 5.3

102618 AL037672 Hs.81071 extracellular matrix protein 1 5.8

102687 NM_007019Hs.93002 ubiquitin carrier protein E2-C 4.3

102689 U96132 Hs.171280 hydroxyacyl-Coenzyme A dehydrogenase, ty ' 6

102704 AU077058 Hs.54089 BRCA1 associated RING domain 1 1.9

102705 T97490 Hs.50002 small inducible cytokine subfamily A (Cy 2.3

102801 BE252241 Hs.38041 pyridoxal (pyridoxine, vitamin B6) kinas 6.4

102827 BE244588 Hs.6456 chaperonin containing TCP1, subunit 2 (b 5.6

103060 NM 005940HS.155324 matrix metalloproteinase 11 (MMP11; stro 4.5

103080 AU077231 Hs.82932 cyclin D1 (PRAD1: parathyroid adenomatos 3.1

103178 AA205475 Hs.275865 ribosomal protein S18 9.9

103206 X72755 Hs.77367 monokine induced by gamma interferon 8.8

103238 AI369285 Hs.75189 death-associated protein 5.6

103547 AI376722 Hs.180062 proteasome (prosome, macropain) subunit, 9.7

103549 BE270465 Hs.78793 protein kinase C, zeta 7.9

103886 AK001278 Hs.105737 hypothetical protein FLJ10416 similarto 6.5

104325 BE379766 Hs.150675 polymerase (RNA) II (DNA directed) polyp 6.3

104827 AW052006 Hs.8551 PRP4/STK/WD splicing factor 10.9

104846 AI250789 Hs.32478 ESTs 5.6

104854 AA041276 Hs.154729 3-phosphoinositide dependent protein kin 12.3

104867 AA278898 Hs.225979 hypothetical protein similar to small G 2 104896 AW015318 Hs.23165 ESTs 17.7 104909 AW408164 Hs.249184 transcription factor 19 (SC1) 5 104916 AW958157 Hs.155489 NS1-associated protein 1 1.7 104919 AA026880 Hs.25252 prolactin receptor 1.4 104974 Y12059 Hs.278675 bromodomain-containing 4 1.4 104978 AI199268 Hs.19322 Homo sapiens, Similar to RIKEN cDNA 2010 7.2 105012 AF098158 Hs.9329 chromosome 20 open reading frame 1 3.3 105039 AA907305 Hs.36475 ESTs 2.5 105079 AA151342 Hs.12677 CGI-147 protein 9.5 105088 H58589 Hs.35156 Homo sapiens cDNA FLJ 11027 fis, clone PL 2.2 105393 AF167570 Hs.256583 interleukin enhancer binding factor 3, 9 5.4 105547 AA262640 Hs.27445 unknown 9.3 105564 BE616694 Hs.288042 hypothetical protein FLJ14299 1.4 105658 AA985190 Hs.246875 hypothetical protein FLJ20059 9.4 105746 AW151952 Hs.46679 hypothetical protein FLJ20739 1.5 105858 AF151066 Hs.281428 hypothetical protein 2.9 105930 AF016371 Hs.9880 peptidyl prolyl isomerase H (cyclophilin 5.2 106094 AA533491 Hs.23317 hypothetical protein FLJ14681 6.8 106350 AK001404 Hs.194698 cyclin B2 5.7 106359 AW390282 Hs.31130 transmembrane 7 superfamily member 2 6.3 106610 AA458882 Hs.79732 fibulin 1 7.9 106624 NM_003595Hs.26350 tyrosylprotein sulfotransferase 2 7.7 106713 BE614802 Hs.184352 hypothetical protein FLJ12549 4.5 106829 AW959893 Hs.27099 hypothetical protein FLJ23293 similar to 16.2 106846 AB037744 Hs.34892 KIAA1323 protein 2.2 106873 N49809 Hs.11197 Homo sapiens, clone IMAGE:3343149, mRNA, 16.8 106973 BE156256 Hs.11923 hypothetical protein 6.6 107029 AF264750 Hs.288971 myeloid/lymphoid or mixed-lineage leukem 1.8 107197 W15477 Hs.64639 glioma pathogenesis-related protein 6.1 107859 AW732573 Hs.47584 potassium voltage-gated channel, delayed 8.4 107901 L42612 Hs.335952 keratin 6B 2.5 107922 BE153855 Hs.61460 ig superfamily receptor LNIR 2.2 107974 AW956103 Hs.61712 pyruvate dehydrogenase kinase, isoenzyme 6.7 108274 AF129535 Hs.272027 F-box only protein 5 7.1 108647 BE546947 Hs.44276 homeo box C10 9.8 108695 AB029000 Hs.70823 KIAA1077 protein 7.2 108894 AK001431 Hs.5105 hypothetical protein FLJ10569 4 109011 AA156542 Hs.72127 ESTs 1.4 109068 AA164293 Hs.72545 ESTs 2.9 109273 AA375752 Hs.82719 Homo sapiens mRNA; cDNA DKFZp586F1822 (f 2.9 109468 NM_015310Hs.6763 KIAA0942 protein 3.2 110240 AI668594 Hs.176588 ESTs, Weakly similar to CP4YJHUMAN CYTOC 4.2 110330 AI288666 Hs.16621 DKFZP4341116 protein 6.2 110501 H55748 gb:yq94a01.s1 Soares fetal liver spleen 6.1 110742 AW190338 Hs.28029 hypothetical protein MGC11256 7.6 110762 BE044245 Hs.30011 hypothetical protein MGC2963 9.3 110856 AA992380 gb:ot37g06.s1 Soares_testis_NHT Homo sap 2.3 110958 NM_005864Hs.24587 signal transduction protein (SH3 contain 6.7 111125 N63823 Hs.269115 ESTs, Moderately similar to Z195JHUMAN Z 3.6 111179 AK000136 Hs.10760 asporin (LRR class 1) 7.1 111239 N90956 Hs.17230 hypothetical protein FLJ22087 7.9 111285 AA778711 Hs.4310 eukaryotic translation initiation factor 6.9 111392 W46342 Hs.325081 Homo sapiens, clone IMAGE:3659680, mRNA, 8.4 111937 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr 10.6 112244 AB02900Q Hs.70823 KIAA1077 protein 14.6 112995 AA737033 Hs.7155 ESTs, Moderately similar to 2115357A TYK 5.6 113777 BE266947 Hs.10590 zinc finger protein 313 13.4 113791 AI269096 Hs.135578 chitobiase, di-N-acetyl- 1.3 113811 BE207480 Hs.6994 Homo sapiens cDNA: FLJ22044 fis, clone H 3.1 113834 T26483 Hs.6059 EGF-containing fibulin-like extracellula 11.3 113868 W57902 Hs.90744 proteasome (prosome, macropain) 26S subu 2.7 113870 AL079314 Hs.16537 hypothetical protein, similar to (U06944 6.1 113923 AW953484 Hs.3849 hypothetical protein FLJ22041 similar to 1.9 114275 AW515443 Hs.306117 KIAA0306 protein 15.8 114895 AA236177 Hs.76591 KIAA0887 protein 7.1 114965 AI733881 Hs.72472 BMP-R1B 2.3 115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN 11.8 115278 AK002163 Hs.301724 hypothetical protein FLJ11301 1.5

115291 BE545072 Hs.122579 hypothetical protein FLJ10461 6.2

115652 BE093589 Hs.38178 hypothetical protein FLJ23468 10.6

115693 AF231023 Hs.55173 cadherin, EGF LAG seven-pass G-type rece 6.8

115941 AI867451 Hs.46679 hypothetical protein FLJ20739 5.5

115968 AB037753 Hs.62767 KIAA1332 protein 9.8

116011 AL359053 Hs.57664 Homo sapiens mRNA full length insert cDN 2.4

116417 AW499664 Hs.12484 Human clone 23826 mRNA sequence 7.4

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 2.1

116637 AK001043 Hs.92033 integrin-linked kinase-associated serine 2.7

117132 AI393666 Hs.42315 p10-binding protein 5.2

117881 AF161470 Hs.260622 butyrate-induced transcript 1 5.7

118528 AI949952 Hs.49397 ESTs 7.4

119075 M10905 Hs.287820 fibronectin 1 5.7

119265 BE539706 Hs.285363 ESTs 1.4

119349 T65004 Hs.163561 ESTs 8.4

119403 AL117554 Hs.119908 nucleolar protein NOP5/NOP58 6.7

119789 BE393948 Hs.50915 kallikrein 5 (KLK5; KLK-L2; stratum com 9.2

120206 H26735 Hs.91668 Homo sapiens clone PP1498 unknown mRNA 45.7

120253 AA131376 Hs.326401 fibroblast growth factor 12B 38.9

120297 AA191384 Hs.104072 ESTs, Weakly similarto Z195_HUMAN ZINC 15.2

120325 AA195651 Hs.104106 ESTs 6.4

120327 AK000292 Hs.278732 hypothetical protein FLJ20285 16.1

120349 AW969481 Hs.55189 hypothetical protein 16.8

120356 AF000545 Hs.296433 putative purinergic receptor 28.1

120371 AA219305 Hs.104196 EST 12.4

120383 AL109963 Hs.123122 FSH primaiy response (LRPR1, rat) homolo 9.7

120386 AW969665 Hs.154848 hypothetical protein DKFZp434D0127 32.6

120389 AW967985 Hs.325572 ESTs, Moderately similar to ALU7_HUMAN A 21.7

120396 AA134006 Hs.79306 eukaryotic translation initiation factor 12.5

120418 AW966893 Hs.26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (f 11.4

120472 AI950087 gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien 19.4

120484 AA253170 Hs.96473 EST 10.4

120570 AA280679 Hs.271445 ESTs, Weakly similar to ALU1_HUMAN ALU S 14.4

120582 BE244830 Hs.284228 ZNF135-like protein 10.2

120596 AA282074 Hs.237323 N-acetylglucosamine-phosphate mutase 7.5

120624 AW407987 Hs.173518 M-phase phosphoprotein homolog 52

120695 AA976503 gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens 46.8

120713 AW449855 Hs.96557 Homo sapiens CDNA FLJ12727 fis, clone NT 5.9

120750 AI191410 Hs.96693 ESTs, Moderately similar to 2109260A B e 7

120774 AI608909 Hs.193985 ESTs 7.8

120807 AA346385 Hs.30002 SH3-containing protein SH3GLB2; KIAA1848 6.8

120809 AA346495 gb:EST52657 Fetal heart II Homo sapiens 4.4

120984 BE262951 Hs.99052 ESTs 5.6

121081 AA398721 Hs.186749 ESTs, Highly similar to I37550 mismatch 5.4

121408 AA406137 Hs.98019 EST 6

121505 AA494172 Hs.194417 ESTs 13.1

121508 AA402515 Hs.97887 ESTs 28

121513 AA416653 Hs.181510 ESTs 6.2

121549 AA412477 Hs.98142 EST 7.4

121558 AA412497 gb:zt95g12.s1 Soares_testis_NHT Homo sap 2.8

121655 AA421537 Hs.178072 Homo sapiens mRNA; cDNA DKFZp434B1023 (f 7.8

121744 AA398784 Hs.97514 ESTs 7.1

121748 BE536911 Hs.234545 hypothetical protein NUF2R 19.5

121773 AB033022 Hs.158654 KIAA1196 protein 7.9

121832 AW340797 Hs.98434 ESTs 5.8

121839 AA425691 Hs.191606 ESTs, Highly similarto KIAA1048 protein 5

121882 AA426376 Hs.98459 ESTs 5

121911 AA427950 gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_ 7.2

121999 AA430211 Hs.98668 EST 6.4

122013 AA431085 Hs.98706 ESTs 6.5

122036 W92142 Hs.271963 ESTs, Weakly similar to ALU5_HUMAN ALU S 13.1

122356 AA443794 Hs.98390 ESTs 7.3

122371 AA868555 Hs.178222 ESTs 5

122372 AA446008 Hs.336677 EST 7.6 122460 AW418788 Hs.99148 ESTs, Weakly similar to S43569 R01H10.6 9.7 122490 AA448349 Hs.238151 EST 6.1 122492 AA448417 Hs.104990 ESTs 5.4 122510 AA449232 Hs.99195 ESTs 11.2 122530 AW959741 Hs.40368 adaptor-related protein complex 1, sigma 10.1 122572 AA452601 Hs.99287 EST 11 122607 AA453518 Hs.98023 ESTs 61.5 122614 AA453630 Hs.99339 EST 10.7 122616 AA453638 Hs.161873 ESTs 107.3 122618 AA453641 gb:zx48e06.s1 Soares_testis_NHT Homo sap 31.1 122622 AA453987 Hs.144802 ESTs 5.6 122717 AA456859 Hs.178358 ESTs 8.5 122829 AW204530 Hs.99500 ESTs 81.8 122838 AA460584 Hs.334386 ESTs 75.3 122856 AI929374 Hs.75367 Src-like-adapter 5.8 122868 AF005216 Hs.115541 Janus kinase 2 (a protein tyrosine kinas 5.3 122907 AA470074 Hs.169896 ESTs 11.5 123016 AW338067 Hs.323231 Homo sapiens cDNA FLJ11946 fis, clone HE 2.8 123034 AL359571 Hs.44054 ninein (GSK3B interacting protein) 8.7 123136 AW451999 Hs.194024 ESTs 5.1 123152 AW601 73 Hs.270259 ESTs 5.2 123394 AA731404 Hs.105510 ESTs 3.6 123466 AA599042 Hs.112503 EST 7.4 123486 BE019072 Hs.334802 Homo sapiens cDNA FLJ14680 fis, clone NT 2.4 123615 AA609170 gb:af12a12.s1 Soares_testis_NHT Homo sap 7.8 123735 NM_013241Hs.95231 FH1/FH2 domain-containing protein 10 123753 AA609955 Hs.234961 Huntingtin interacting protein E 30.6 124006 AI147155 Hs.270016 ESTs 8.1 124385 AI267847 gb:aq49a10.x1 Stanley Frontal NB pool 2 57.1 124440 AA532519 Hs.129043 Human DNA sequence from clone 989H11 on 7.8 124656 AW297702 Hs.102915 ESTs 8.3 124683 AA381661 Hs.119878 ESTs, Weakly similar to M3K9_HUMAN MITOG 7.9 124735 R22952 Hs.268685 ESTs 11.3 124761 AA374756 Hs.93560 Homo sapiens mRNA for KIAA1771 protein, 9 124768 AW368528 Hs.100855 ESTs 8.1 124788 R43543 Hs.100912 Homo sapiens cDNA: FLJ22726 fis, clone H 5.1 124811 R46068 Hs.288912 hypothetical protein FLJ22604 14.2 124812 R47948 Hs.188732 ESTs 7.9 124822 AA418160 Hs.86043 Homo sapiens cDNA FLJ 13558 fis, clone PL 6.6 124860 R65763 Hs.101477 EST 23.9 124S03 AW296713 Hs.221441 ESTs 32.4 124930 AI076343 Hs.173939 ESTs, Weakly similar to ALUBJHUMAN !!!! 22.8 124942 R99978 Hs.268892 ESTs, Moderately similar to B34087 hypot 6.1 125051 T79956 Hs.100588 EST 135.3 125056 T81310 Hs.100592 ESTs 5.4 125101 AI472068 Hs.286236 KIAA1856 protein 5.6 125115 T97341 gb:ye57e05.s1 Soares fetal liver spleen 9.6 125280 AI123705 Hs.106932 ESTs 8 127274 AW966158 Hs.58582 Homo sapiens cDNA FLJ12789 fis, clone NT 12.8 128528 R39234 Hs.251699 ESTs, Weakly similar to IDN4-GGTR14 (H.s 2.8 128670 AA975486 Hs.103441 Homo sapiens, Similar to RIKEN cDNA 1700 7.1 128691 W27939 Hs.103834 hypothetical protein MGC5576 7.7 128772 BE302796 Hs.105097 thymidine kinase 1 , soluble 5.3 128781 N71826 Hs.105465 small nuclear ribonucleoprotein polypept 53.9 128797 NM_002975Hs.105927 stem cell growth factor; lymphocyte seer 13.3 128868 AA419008 Hs.106730 chromosome 22 open reading frame 3 3 128891 F34856 Hs.292457 Homo sapiens, clone MGC:16362, mRNA, com 13.3 128946 Y13153 Hs.107318 kynurenine 3-monooxygenase (kynurenine 3 7.2 128975 BE560779 Hs.284233 NICE-5 protein 14 128995 AI816224 Hs.107747 DKFZP566C243 protein 1.9 129019 AI950087 gb:wq05c02.x1 NCI_CGAP_Kid12 Homosapien 2.9 129076 AW296806 Hs.326234 ESTs, Highly similar to T46422 hypotheti 5 129088 AA744610 Hs.194431 palladin 17.1 129096 AA463189 Hs.288906 WW Domain-Containing Gene 20.9 129198 N57532 Hs.109315 KIAA1415 protein 5.8 129347 BE614192 Hs.279869 melanoma-associated antigen recognised b 7.6 129362 U30246 Hs.110736 solute carrier family 12 (sodium/potassi 6.7 129372 NM_016039Hs.110803 CGI-99 protein 2 129404 AI267700 Hs.317584 ESTs 5 129482 AA188185 Hs.289043 spindlin 6.7 129559 W01296 Hs.11360 hypothetical protein FLJ14784 7.5 129587 H14718 Hs.11506 Human clone 23589 mRNA sequence 6.8 129629 AK000398 Hs.11747 hypothetical protein FLJ20391 3.8 129649 AD000092 Hs.16488 calreticulin 3.3 129680 U03749 gb:Human chromogranin A (CHGA) gene, pro 14.1 129689 AW748482 Hs.77873 B7 homolog 3 2.6 129702 AI304966 Hs.12035 ESTs, Weakly similar to I38022 hypotheti 7.4 129720 AA156214 Hs.12152 APMCF1 protein 2 130010 AA301116 Hs.142838 nucleolar phosphoprotein Nopp34 1.6 130097 AL046962 Hs.14845 forkhead box 03A 2.8 130135 AA311426 Hs.21635 tubulin, gamma 1 6.1 130211 NM_003358Hs.23703 ESTs, Moderately similar to CEGT.HUMAN C1.6 130242 X79201 Hs.153221 synovial sarcoma, translocated to X chro 5.4 130359 NM_013449Hs.277401 bromodomain adjacent to zinc finger doma 8.5 130365 W56119 Hs.155103 eukaryotic translation initiation factor 11 130448 BE513202 Hs.15589 PPAR binding protein 3.9 130455 D90041 Hs.155956 N-acetyltransferase 1 (arylamine N-acety 33.6 130471 AL121438 Hs.183706 adducin 1 (alpha) 2.7 130503 BE208491 Hs.295112 KIAA0618 gene product 16.1 130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pse 6.1 130542 U64675 Hs.179825 RAN binding protein 2-like 1 7.8 130553 AF062649 Hs.252587 pituitary tumor-transforming 1 14.4 130556 AI907018 Hs.15977 Empirically selected from AFFX single pr 4.7 130567 AA383092 Hs.1608 replication protein A3 (14kD) 7.9 130574 AF083208 Hs.16178 apoptosis antagonizing transcription fac 1.2 130617 M90516 Hs.1674 giutamine-fructose-6-phosphate transamin 12.1 130667 BE246961 Hs.17639 Homo sapiens ubiquitin protein ligase (U 13.9 130693 R68537 Hs.17962 ESTs 2 130744 H59696 Hs.18747 POP7 (processing of precursor, S. cerevi 3.1 130757 AL036067 Hs.18925 protein x 0001 5.7 130880 BE514434 Hs.20830 kinesin-like 2 2.1 130944 BE382657 Hs.21486 signal transducer and activator of trans 5.4 131046 AA321649 Hs.2248 small inducible cytokine subfamily B (Cy 7.4 131060 AA194422 Hs.22564 myosin VI 5.1 131099 AL133353 Hs.226581 COX15 (yeast) homolog, cytochrome c oxid 7 131135 NM_016569Hs.267182 TBX3-iso protein 3.3 131185 BE280074 Hs.23960 cyclin B1 5.8 131225 H62087 Hs.31659 thyroid hormone receptor-associated prat 7.5 131245 AL080080 Hs.24766 thioredoxin domain-containing 2.8 131283 X80038 Hs.339713 Homo sapiens clone F19374 APO E-C2 gene 1.3 131569 AL389951 Hs.271623 nucleoporin 50kD 5 131643 AW410601 Hs.30026 HSPC182 protein 2.9 131714 AA642831 Hs.31016 putative DNA binding protein 2.9 131722 D13757 Hs.311 phosphoribosyl pyrophosphate amidotransf 3.4 131760 X76732 Hs.3164 nucleobindin 2 2.9 131793 AW966127 Hs.32246 Homo sapiens cDNA FLJ14656 fis, clone NT 7.9 131885 BE502341 Hs.3402 ESTs 13.7 131900 AA099014 Hs.231029 Homo sapiens, clone MGC:15961 , mRNA, com 8. 131905 AA179298 Hs.3439 stomatin-like 2 11.3 131941 BE252983 Hs.35086 ubiquitin specific protease 1 2.3 131971 BE567100 Hs.154938 hypothetical protein MDS025 3.5 132180 NM_004460Hs.418 fibroblast activation protein, alpha 14.7 132203 NM_004782Hs.194714 synaptosomal-associated protein, 29kD 7.8 132273 AA227710 Hs.43658 DKFZP586L151 protein 10 132288 N36110 Hs.305971 solute carrier family 2 (facilitated glu 9.2 132294 AB023191 Hs.44131 KIAA0974 protein 2 132348 AW067708 Hs.170311 heterogeneous nuclear ribonucleoprotein 12.5 132370 AW572805 Hs.46645 ESTs 28.3 132384 AA312135 Hs.46967 HSPC034 protein 6.1 132450 AA100012 Hs.48827 hypothetical protein FLJ12085 8.6 132465 AW169847 Hs.49169 KIAA1634 protein 6.1 132532 AA454132 Hs.5080 mitochondrial ribosomal protein L16 7.1 132574 AW631437 Hs.5184 TH1 drosophila homolog 14 132638 AI796870 Hs.54277 DNA segment on chromosome X (unique) 99212.4 132718 NM_004600Hs.554 Sjogren syndrome antigen A2 (60kD, ribon 3.7 132726 N52298 Hs.55608 hypothetical protein MGC955 14.3 132731 AI189075 Hs.301872 hypothetical protein MGC4840 5.9 132744 AA010233 Hs.55921 glutamyl-prolyl-tRNA synthetase 6.4 132773 AA459713 Hs.295901 KIAA0493 protein 14.6 132798 AI026701 Hs.5716 KIAA0310 gene product 2.5 132810 AB007944 Hs.5737 KIAA0475 gene product 4.2 132833 U78525 Hs.57783 eukaryotic translation initiation factor 6.1 132842 NM_016154Hs.279771 Homo sapiens clone PP1596 unknown mRNA7.1 132851 U09716 Hs.287912 lectin, annose-binding, 1 6.1 132891 BE267143 Hs.59271 U2(RNU2) small nuclear RNA auxiliary fac 2.7 132941 AI817165 Hs.6120 hypothetical protein FLJ13222 2.1 132972 AA034365 Hs.288924 Homo sapiens cDNA FLJ11392 fis, clone HE 3.5 132980 AA040696 Hs.62016 ESTs 1.3 132994 AA112748 Hs.279905 clone HQ0310 PRO0310p1 17.1 133016 AI439688 Hs.6289 hypothetical protein FLJ20886 4.4 133177 X97795 Hs.66718 RAD54 (S.cerevisiae)-like 4.4 133208 AI801777 Hs.6774 ESTs 5.5 133254 AI567421 Hs.273330 Homo sapiens, clone IMAGE:3544662, mRNA, 1.3 133266 AI160873 Hs.69233 zinc finger protein 16.1 133268 AW956781 Hs.293937 ESTs, Weakly similar to FXD2_HUMAN FORKH 12.2 133285 M76477 Hs.289082 GM2 ganglioside activator protein 10.4 133390 AI950382 Hs.72660 phosphatidylserine receptor 5.7 133391 AW103364 Hs.727 inhibin, beta A (activin A, activin AB a 25.5 133540 AL037159 Hs.74619 proteasome (prosome, macropain) 26S subu 1.7 133594 AW160781 Hs.172589 nuclear phosphoprotein similarto S. cer 2.6 133621 NM_004893Hs.75258 H2A histone family, member Y 13.5 133720 L27841 Hs.75737 pericentriolar material 1 6.7 133760 BE271766 Hs.181357 iaminin receptor 1 (67kD, ribosomal prat 5.4 133784 BE622743 Hs.301064 arfaptin 1 12.1 133791 M34338 Hs.76244 spermidine synthase 9.7 133797 AL133921 Hs.76272 retinoblastoma-binding protein 2 1.3 133822 D50525 Hs.699 peptidylprolyl isomerase B (cyclophilin 9.7 133850 W29092 Hs.7678 cellular retinoic acid-binding protein 1 4.2 133865 AB011155 Hs.170290 discs, large (Drosophila) homolog 5 5 133881 U30872 Hs.77204 centromere protein F (350/400kD, mitosin 9.1 133924 D86326 Hs.325948 vesicle docking protein p115 1.8 133959 X81789 Hs.77897 splicing factor 3a, subunit 3, 60kD 10.4 133989 AL040328 Hs.78202 SWI/SNF related, matrix associated, acti 2.6 133997 A1824113 Hs.78281 regulator of G-protein signalling 12 13 134234 BE300078 Hs.80449 Homo sapiens, clone IMAGE:3535294, mRNA, 10.3 134348 AW291946 Hs.82065 interleukin 6 signal transducer (gp130, 6.7 134376 X06560 Hs.82396 2',5'-oligoadenylate synthetase 1 (40-46 5.5 134379 AW362124 Hs.323193 hypothetical protein MGC3222 5.8 134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.7 134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 iamin B1 6.1 134790 BE002798 Hs.287850 integral membrane protein 1 1.2 134806 AD001528 Hs.89718 spermine synthase 2.6 134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 AI097346 Hs.286049 phosphoserine aminotransferase 2 135181 BE250865 Hs.279529 px19-like protein 14.9 135207 N26427 Hs.9634 ESTs, Highly similar to C10 HUMAN PUTAT1 1.7 135245 AI028767 Hs.262603 ESTs 12.2 135257 AW291023 Hs.97255 ESTs, Weakly similarto A46010 X-linked 7.6 135307 AI743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135321 AI652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 135354 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.7 135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3 424001 W67883 Hs.137476 paternally expressed 10 (PEG10; KIAA105 7 425182 AF041259 . HS.155040 zinc finger protein 217 2.3

446999 AA151520 Hs.334822 hypothetical protein MGC4485 7.5

450701 H39960 Hs.288467 Homo sapiens cDNA FLJ12280 fis, clone MA 5.6

452461 N78223 Hs.108106 transcription factor 4.7

453157 AF077036 Hs.31989 DKFZP586G1722 protein 12.1

TABLE 5A

Table 5 A shows the accession numbers for those pkeys lacking unigenelD's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column. Pkey: Unique Eos probeset identifier number

CAT number. Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

123615 30686_-15 AA609170

124385 656394J AI267847 N27351

110856 19346 4 AA992380 N33063 N21418 H79958 R21911 H79957

120472 44573_2 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 A1539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 A1564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005

129019 44573_2 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 A1689062 AA282915 AW102898 AI872193 A1763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005

120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468

122618 305217J AA453641 AA454061

125115 genbank_T97341 T97341

120809 genbank_AA346495 AA346495

129680 23162J U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122

AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214 AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992

101045 entrez_J05614J05614

110501 genbank_H55748 H55748

121558 genbank_AA412497 AA412497

121911 genbank_AA427950 AA427950 TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD UnigeneTitle R1

100147 D13666 Hs.136348 osteoblast specific factor 2 (fasciclin 7.5

100678 AW502935 Hs.740 PTK2 protein tyrosine kinase 2 53.2

101806 AA586894 Hs.112408 S 00 calcium-binding protein A7 (psorias 8.9

102455 U48705 Hs.75562 discoidin domain receptor family, member 6.9

103206 X72755 Hs.77367 monokine induced by gamma interferon 8.8

105743 BE246502 Hs.9598 sema domain, immunoglobulin domain (Ig), 2.6

105746 AW151952 Hs.46679 hypothetical protein FLJ20739 1.5

106373 AW503807 Hs.21907 histone acetyltransferase 1.8

110240 AI668594 Hs.176588 ESTs, Weakly similar to CP4Y_HUMAN CYTOC 4.2

119260 AK001724 Hs.102950 coat protein gamma-cop 3.2

120206 H26735 Hs.91668 Homo sapiens clone PP1498 unknown mRNA 45.7

120253 AA131376 Hs.326401 fibroblast growth factor 12B 38.9

120297 AA191384 Hs.104072 ESTs, Weakly similarto Z195_HUMAN ZINC 15.2

120624 AW407987 Hs.173518 M-phase phosphoprotein homolog 52

120695 AA976503 gb:oq30a04.s1 NCLCGAP GC4 Homo sapiens 46.8

120807 AA346385 Hs.30002 SH3-containing protein SH3GLB2; KIAA1848 6.8

121508 AA402515 Hs.97887 ESTs 28

122607 AA453518 Hs.98023 ESTs 61.5

122616 AA453638 Hs.161873 ESTs 107.3

122618 AA453641 gb:zx48e06.s1 Soares testis NHT Homo sap 31.1

122829 AW204530 Hs.99500 ESTs 81.8

122838 AA460584 Hs.334386 ESTs 75.3

123753 AA609955 Hs.234961 Huntingtin interacting protein E 30.6

124385 AI267847 gb:aq49a10.x1 Stanley Frontal NB pool 2 57.1

124860 R65763 Hs.101477 EST 23.9

124930 AI076343 Hs.173939 ESTs, Weakly similarto ALUB HUMAN !!!! 22.8

125051 T79956 Hs.100588 EST 135.3

128781 N71826 Hs.105465 small nuclear ribonucleoprotein polypept 53.9

129096 AA463189 Hs.288906 WW Domain-Containing Gene 20.9

129347 BE614192 Hs.279869 melanoma-associated antigen recognised b 7.6

129689 AW748482 Hs.77873 B7 homolog 3 2.6

130503 BE208491 Hs.295112 KIAA0618 gene product 16.1

130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pse 6.1

131046 AA321649 Hs.2248 small inducible cytokine subfamily B (Cy 7.4

131643 AW410601 Hs.30026 HSPC182 protein 2.9

131925 AF151048 Hs.183180 anaphase promoting complex subunit 11 (y 2.7

132180 NM 004460Hs.418 fibroblast activation protein, alpha 14.7

132370 AW572805 Hs.46645 ESTs 28.3

132994 AA112748 Hs.279905 clone HQ0310 PRO0310p1 17.1

133016 AI439688 Hs.6289 hypothetical protein FLJ20886 4.4

133266 AI160873 Hs.69233 zinc finger protein 16.1

133391 AW103364 Hs.727 inhibin, beta A (activin A, activin AB a 25.5

134169 AI690916 Hs.178137 transducer of ERBB2, 1 1.2

134219 NM_000402Hs.8O206 glucose-6-phosphate dehydrogenase 1.9

134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9

134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8

134975 R50333 Hs.92186 Leman coiled-coil protein 2.6

135181 BE250865 Hs.279529 px19-like protein 14.9

322556 BE041451 Hs.177507 hypothetical protein 2.9 TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigenelD's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

124385 656394J AI267847 N27351

120695 9683 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 A1241295 AA402816 AA291468

122618 305217J AA453641 AA454061

TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal breast tissue

ORF struct info: Structural characterization of open reading frame for the sequence of the gene

Pkey ExAccn UnigenelD UnigeneTitle R1 ORF struct info

100113 NM 001269 Hs.84746 chromosome condensation 1 2.3 TM

100114 X02308 Hs.82962 thymidylate synthetase 2.9 other

100131 D12485 Hs.11951 ectonucleotide pyrophosphatase/phosphodi 1.9 other

100146 BE185499 Hs.2471 KIAA0020 gene product 1.9 TM

100147 D13666 Hs.136348 osteoblast specific factor 2 (fasciclin 7.6 other

100154 H60720 Hs.81892 KIAA0101 gene product 9.2 other

100163 W44671 Hs.124 gene predicted from cDNA with a complete 1.6 other

100220 AW015534 Hs.217493 annexin A2 2 other

100265 D38521 Hs.112396 KIAA0077 protein 1.5 other

100271 BE160081 Hs.256290 S100 calcium-binding protein A11 (calgiz 13.5 other

100275 BE242802 Hs.154797 KIAA0090 protein 5.1 other

100323 D50920 Hs.23106 KIAA0130 gene product 1.9 TM

100335 AW247529 Hs.6793 platelet-activating factor acetylhydrola 2.7 other

100364 NM 004341 Hs.154868 carbamoyl-phosphate synthetase 2, aspart 2 other

100372 NM 014791 Hs.184339 KIAA0175 gene product 2.6 other

100393 D84145 Hs.39913 novel RGD-containing protein 3.2 other

100400 AW954324 Hs.75790 phosphatidylinositol glycan, class C 1.5 other

100418 D86978 Hs.84790 KIAA0225 protein 2 other

100482 M65028 Hs.81361 heterogeneous nuclear ribonucleoprotein 2.9 other

100518 NM 004415 Hs.74316 desmoplakin (DPI, DPII) 1.9 other

100666 L05424 Hs.169610 CD44 antigen (homing function and Indian 5.7 other

100667 L05424 Hs.169610 CD44 antigen (homing function and Indian 9 ?

100668 L05424 Hs.169610 CD44 antigen (homing function and Indian 7.7 other

100678 AW502935 Hs.740 PTK2 protein tyrosine kinase 2 53.2 other

100783 AF078847 Hs.191356 general transcription factor IIH, polype 6 other

100892 BE245294 Hs.180789 S164 protein 1.7 ?

100945 AF002225 Hs.180686 ubiquitin protein ligase E3A (human papi 1.5 other

100969 AA157634 Hs.79172 solute carrier family 25 (mitochondrial 6.3 other

100988 AK000405 Hs.76480 ubiquitin-like 4 11.4 ?

100999 H38765 Hs.80706 diaphorase (NADH/NADPH) (cytochrome b-5 1.6 other

101031 J05070 Hs.151738 matrix metalloproteinase 9 (gelatinase B 8.4 other

101045 J05614 gb:Human proliferating cell nuclear anti 5 ?

101077 N99692 Hs.75227 Empirically selected from AFFX single pr 2.6 other

101093 L06419 Hs.75093 procollagen-lysine, 2-oxoglutarate 5-dio 1.4 ?

101186 AA020956 Hs.179881 core-binding factor, beta subunit 2 TM

101216 AA284166 Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK 1.8 other

101228 AA333387 Hs.82916 chaperonin containing TCP1, subunit 6A ( 1.7 TM

101247 AA132666 Hs.78802 glycogen synthase kinase 3 beta 1.9 other

101249 L18964 Hs.1904 protein kinase C, iota 1.5 other

101332 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 5.3 other

101352 AI494299 Hs.16297 COX17 (yeast) homolog, cytochrome c oxid 4.2 other

101396 BE267931 Hs.78996 proliferating cell nuclear antigen 1.9 TM

101445 M21259 gb:Human Alu repeats in the region 5' to 1.6 TM

101470 NM_000546 Hs.1846 tumor protein p53 (Li-Fraumeni syndrome) 2.5 other

101478 NM_002890 Hs.758 RAS p21 protein activator (GTPase activa 5.5 other 101483 M24486 Hs.76768 procollagen-proline, 2-oxoglutarate 4-di 2.1 other

101540 J04977 Hs.84981 X-ray repair complementing defective rep 1.6 other

101573 AW248421 Hs.250758 proteasome (prosome, macropain) 26S subu 5.7 other

101580 NM 012151 Hs.83363 coagulation factor Vlll-associated (intr 1.8 other

101592 AF064853 Hs.91299 guanine nucleotide binding protein (G pr 5.6 ?

101621 BE391804 Hs.62661 guanylate binding protein 1, interferon- 2.4 other

101702 AW504089 Hs.179574 protein phosphatase 2 (formerly 2A), reg 1.3 other

101734 M74099 Hs.147049 cut (Drosophila)-like 1 (CCAAT displacem 2.1 ?

101759 M80244 Hs.184601 solute carrier family 7 (cationic amino 5 TM

101767 M81057 Hs.180884 earboxypeptidase B1 (tissue) 14.4 SS,

101782 AA306495 Hs.1869 phosphoglucomutase 1 5.2 other

101805 AW409747 Hs.75612 stress-indueed-phosphoprotein 1 (Hsp70/H 8.6 other

101806 AA586894 Hs.112408 S100 calcium-binding protein A7 (psorias 8.9 SS.TM

101810 NM 000318 Hs.180612 peroxisomal membrane protein 3 (35kD, Ze 3.2 TM

101879 AA176374 Hs.243886 nuclear autoantigenic sperm protein (his 1.6 other

101911 AA441787 Hs.119689 glycoprotein hormones, alpha polypeptide 31.3 ?

101920 AF182645 Hs.8024 IK cytokine, down-regulator of HLA II 1.8 other

101973 U41514 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp 2.4 other

102009 BE245149 Hs.82643 protein tyrosine kinase 9 1.3 other

102036 BE250127 Hs.82906 CDC20 (cell division cycle 20, S. cerevi 2 ?

102083 T35901 Hs.75117 interleukin enhancer binding factor 2, 4 1.6 other

102107 BE258602 Hs.182366 heat shock protein 75 1.4 other

102123 NM_001809 Hs.1594 centromere protein A (17kD) 1.8 other

102165 BE313280 Hs.159627 death associated protein 3 4.6 ?

102198 AW950852 Hs.74598 polymerase (DNA directed), delta 2, regu 4.4 ?

102217 AA829978 Hs.301613 JTV1 gene 6.7 other

102220 U24389 Hs.65436 lysosomal 4.4 TM

102234 AW163390 Hs.278554 heterochromatin-like protein 1 1.9 TM

102260 AL039104 Hs.159557 karyopherin alpha 2 (RAG cohort 1, impor 4.4 other

102302 AA306342 Hs.691 1 protein kinase C-like 2 2.7 ?

102330 BE298063 Hs.77254 chromobox homolog 1 (Drosophila HP1 beta 1.5 other

102339 BE378432 Hs.95577 cyclin-dependent kinase 4 2.3 TM

102348 U37519 Hs.87539 aldehyde dehydrogenase 3 family, member 2 TM

102349 AU077055 Hs.289107 baculoviral IAP repeat-containing 2 3.2 other

102369 U39840 Hs.299867 hepatocyte nuclear factor 3, alpha 2 other

102374 U33635 Hs.90572 PTK7 protein tyrosine kinase 7 6.2 other

102391 AA296874 Hs.77494 deoxyguanosine kinase 1.5 TM

102455 U48705 Hs.75562 discoidin domain receptor family, member 7 other

102465 NM 001359 Hs.81548 2,4-dienoyl CoA reductase 1, mitochondri 1.8 SS,

102488 U50939 Hs.61828 amyloid beta precursor protein-binding p 1.5 ?

102489 AL080116 Hs.74420 origin recognition complex, subunit 3 (y 3.3 other

102494 AI188137 Hs.75193 COP9 homolog 2.1 other

102501 AF217197 Hs.74562 siah binding protein 1; FBP interacting 3.2 other

102522 BE250944 Hs.183556 solute carrier family 1 (neutral amino a 2.8 ?

102532 AF040253 Hs.70186 suppressor of Ty (S.cerevisiae) 5 homolo 5.7 ?

102564 U59423 Hs.79067 MAD (mothers against decapentaplegic, Dr 2.3 other

102568 W81489 Hs.223025 RAB31, member RAS oncogene family 5.3 ' other

102580 U60808 Hs.152981 CDP-diacylglycerol synthase (phosphatida 2.1 other

102581 AU077228 Hs.77256 enhancer of zeste (Drosophila) homolog 2 1.6 ?

102582 U61232 Hs.32675 tubulin-specific chaperone e 2.1 other

102617 AW161453 Hs.198767 COP9 (constitutive photomoφhogenic, Ara 1.8 other

102618 AL037672 Hs.81071 extracellular matrix protein 1 5.8 other

102627 AL021918 Hs.158174 zinc finger protein 184 (Kruppel-like) 1.3 other

102663 NM 002270 Hs.168075 karyopherin (importin) beta 2 1.8 TM

102676 BE262989 Hs.12045 putative protein 2.3 other

102687 NM 07019 Hs.93002 ubiquitin earner protein E2-C 4.4 ?

102689 U96132 Hs.171280 hydroxyacyl-Coenzyme A dehydrogenase, ty 6 ?

102696 BE540274 Hs.239 forkhead box M1 4.2 other

102704 AU077058 Hs.54089 BRCA1 associated RING domain 1 1.9 other

102705 T97490 Hs.50002 small inducible cytokine subfamily A (Cy 2.3 SS.TM

102750 AB014460 Hs.66196 nth (E.coli endonuclease lll)-like 1 1.2 TM

102801 BE252241 Hs.38041 pyridoxal (pyridoxine, vitamin B6) kinas 6.5 other

102812 U90549 Hs.236774 high-mobility group (nonhistone chromoso 1.6 other

102827 BE244588 Hs.6456 chaperonin containing TCP1 , subunit 2 (b 5.6 TM

102844 AV653790 Hs.324275 WW domain-containing protein 1 1.3 TM

102868 X02419 Hs.77274 plasminogen activator, urokinase 4.4 other

102925 BE440142 Hs.2943 signal recognition particle 19kD 1.9 other 102935 BE561850 Hs 80506 small nuclear ribonucleoprotein polypept 24 ?

102968 AU076611 Hs 154672 methylene tetrahydrofolate dehydrogenase 27 other

102983 BE387202 Hs 118638 non-metastatio cells 1, protein (NM23A) 3 1 other

102985 U95742 Hs 2707 G1 to S phase transition 1 52 ?

103023 AW500470 Hs 117950 multifunctional polypeptide similar to S 1 6 other

103038 AA926960 Hs 334883 CDC28 protein kinase 1 25 TM

103060 NMJ05940 Hs 155324 matπx metalloproteinase 11 (MMP11 , stro 45 other

103080 AU077231 Hs 82932 cyclin D1 (PRAD1 parathyroid adenomatos 3 1 other

103089 D31152 Hs 179729 collagen, type X, alpha 1 (Schmid metaph 24 other

103177 BE244377 Hs 48876 farnesyl-diphosphate farnesyltransferase 35 other

103178 AA205475 Hs 275865 nbosomal protein S18 99 ?

103179 NM 001777 Hs 82685 CD47 antigen (Rh-related antigen, integr 1 3 other

103181 X69636 Hs 334731 Homo sapiens, clone IMAGE 3448306, mRNA, 2 other

103185 NM_006825 Hs 74368 transmembrane protein (63kD), endoplasmi 1 6 other

103191 AA401039 Hs 2903 protein phosphatase 4 (formerly X), cata 25 other

103193 NMJ04766 Hs 75724 coatomer protein complex, subunit beta 2 22 TM

103194 NM 004939 Hs 78580 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 63 TM

103206 X72755 Hs 77367 monokine induced by gamma interferon 88 TM

103223 BE275607 Hs 1708 chaperonin containing TCP1, subunit 3 (g 3 other

103232 X75962 Hs 129780 tumor necrosis factor receptor superfami 1 8 other

103238 AI369285 Hs 75189 death-associated protein 56 TM

103297 NM 001545 Hs 9078 immature colon carcinoma transcript 1 1 9 9

103330 AI803447 Hs 77496 small nuclear ribonucleoprotein polypept 25 other

103349 X89059 gb H sapiens mRNA for unknown protein ex 1 6 other

103376 AL036166 Hs 323378 coated vesicle membrane protein 1 8 other

103391 X94453 Hs 114366 pyrrolιne-5-carboxylate synthetase (glut 23 other

103392 X94563 gb H sapiens dbi/acbp gene exon 1 & 2 4 TM

103430 BE564090 Hs 20716 translocase of inner mitochondπal membr 1 3 other

103491 AF264750 Hs 288971 myeloid/lymphoid or mixed-lineage leukem 57 ?

103505 AL031224 Hs 33102 transcπption factor AP-2 beta (activati 5 1 other

103547 AI376722 Hs 180062 proteasome (prosome, macropain) subunit, 97 ?

103588 NM 006218 Hs 85701 phosphoιnosιtιde-3-kιnase, catalytic, al 2 other

103613 NM 000346 Hs 2316 SRY (sex determining region Y)-box 9 (ca 1 3 ?

103621 BE379766 Hs 150675 polymerase (RNA) II (DNA directed) polyp 2 other

103622 AA609685 Hs 278672 membrane component, chromosome 11, surfa 23 TM

103727 AI878883 Hs 296381 growth factor receptor-bound protein 2 1 3 other

103754 AI015709 Hs 172089 Homo sapiens mRNA, cDNA DKFZp586l2022 (f 1 3 other

103780 AA094752 Hs 169992 hypothetical 432 Kd protein 76 ?

103795 H26531 Hs7367 Homo sapiens BTB domain protein (BDPL) m 1 3 SS M

103797 AA080912 gb zn04d03 Stratagene hNT neuron (937 1 6 other

103813 AI042582 Hs 181271 CGI-120 protein 1 6 other

103855 W02363 Hs 302267 hypothetical protein FLJ10330 1 6 other

103886 AK001278 Hs 105737 hypothetical protein FLJ10416 similarto 66 TM

104052 NM 002407 Hs 97644 mammaglobm 2 29 other

104079 AA251242 Hs 103238 ESTs 1 4 other

104174 AA478984 Hs 6451 PRO0659 protein 56 TM

104227 AB002343 Hs 98938 protocadheπn alpha 9 1 6 other

104275 AI751970 Hs 101067 GCN5 (general control of ammo-acid synt 54 other

104325 BE379766 Hs 150675 polymerase (RNA) II (DNA directed) polyp 64 other

104370 AA324597 Hs 21851 Homo sapiens cDNA FLJ 12900 fis, clone NT 1 6 other

104423 R83113 Hs 1432 protein kinase C substrate 80K-H 52 other

104482 AB037762 Hs 44268 myelin gene expression factor 2 1 2 other

104667 AI239923 Hs 30098 ESTs 1 4 other

104757 AI694413 Hs 332649 olfactory receptor, family 2, subfamily 24 other

104804 AI858702 Hs 31803 ESTs, Weakly similar to N-WASP [H sapien 1 4 other

104806 AB023175 Hs 22982 KIAA0958 protein 24 other

104827 AW052006 Hs 8551 PRP4/STK/WD splicing factor 109 other

104846 AI250789 Hs 32478 ESTs 57 other

104854 AA041276 Hs 154729 3-phosphoιnosιtιde dependent protein kin 123 ?

104867 AA278898 Hs 225979 hypothetical protein similarto small G 21 other

104871 T78044 Hs 28893 Homo sapiens mRNA, cDNA DKFZp56402364 (f 1 4 other

104896 AW015318 Hs 23165 ESTs 177 other

104909 AW408164 Hs 249184 transcπption factor 19 (SC1) 5 1 TM

104916 AW958157 Hs 155489 NS1 -associated protein 1 1 8 other

104919 AA026880 Hs 25252 prolactin receptor 1 5 other

104930 AF043467 Hs 32893 neurexophilin 2 23 other

104973 NM 015310 Hs 6763 KIAA0942 protein 5 1 other 104974 Y12059 Hs.278675 bromodomain-containing 4 1.5 other

104975 AL136877 Hs.50758 SMC4 (structural maintenance of chromoso 2.4 other

104978 AI199268 Hs.19322 Homo sapiens, Similarto RIKEN cDNA 2010 7.3 other

104979 AA937934 Hs.321062 ESTs 1.3 other

104994 AI499930 Hs.334885 mitochondrial GTP binding protein 3.6 ?

105009 BE379584 Hs.34789 dolichyl-diphosphooligosaccharide-protei 5.6 other

105012 AF098158 Hs.9329 chromosome 20 open reading frame 1 3.4 other

105028 AI050715 Hs.2331 E2F transcription factor 5, p130-binding 2.2 other

105041 AB037716 Hs.26204 KIAA1295 protein 2.2 other

105045 BE242899 Hs.129951 speckle-type POZ protein 3.9 ?

105079 AA151342 Hs.12677 CGI-147 protein 9.5 TM

105087 AA147884 Hs.9812 Homo sapiens cDNA FLJ14388 fis, clone HE 5.7 other

105088 H58589 Hs.35156 Homo sapiens cDNA FLJ 11027 fis, clone PL 2.2 other

105095 Z78407 Hs.27023 vesicle transport-related protein 2.2 other

105110 BE387350 Hs.33122 KIAA1160 protein 1.6 other

105126 AW975433 Hs.36288 ESTs 6.4 ?

105127 AA045648 Hs.301957 nudix (nucleoside diphosphate linked moi 2.2 other

105141 AA164687 Hs.177576 mannosyi (alpha-1 ,3-)-glycoprotein beta- 2.8 other

105158 AW976357 Hs.234545 hypothetical protein NUF2R 2 other

105169 BE245294 Hs.180789 S164 protein 1.7 other

105186 AA191512 Hs.28005 Homo sapiens cDNA FLJ11309 fis, clone PL 4.9 SS.TM

105254 AA071276 Hs.19469 KIAA0859 protein 2 TM

105281 AA263143 Hs.24596 RAD51 -interacting protein 2.9 ?

105288 N99673 Hs.3585 ESTs, Weakly similarto AF1267431 DNAJ 1.9 TM

105302 AA700122 Hs.3355 sentrin-specific protease 8.2 ?

105331 AW270037 Hs.179507 KIAA0779 protein 1.8 SS,

105359 NM_016015 Hs.8054 CGI-68 protein 8.4 other

105366 BE264645 Hs.282093 hypothetical protein FLJ21918 5.1 other

105373 AW887701 Hs.32356 hypothetical protein FLJ20628 2.6 other

105374 BE242803 Hs.262823 hypothetical protein FLJ10326 2.2 TM

105387 AW592146 Hs.108636 membrane protein CH1 2.3 SS.TM

105393 AF167570 Hs.256583 interleukin enhancer binding factor 3, 9 5.5 SS,

105399 BE386877 Hs.334811 Npw38-binding protein NpwBP 1.6 other

105400 AF198620 Hs.65648 RNA binding motif protein 8A 1.6 other

105445 AA252395 gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens 5.1 ?

105507 BE268348 Hs.226318 CCR4-NOT transcription complex, subunit 1.6 other

105529 AA113449 Hs.32471 hypothetical protein FLJ20364 1.3 other

105530 AB023179 Hs.9059 KIAA0962 protein 3.5 other

105547 AA262640 Hs.27445 unknown 9.3 other

105564 BE616694 Hs.288042 hypothetical protein FLJ14299 1.4 other

105596 AA579535 Hs.18490 hypothetical protein FLJ20452 10.9 TM

105597 AF054284 Hs.334826 splicing factor 3b, subunit 1, 155kD 2.9 TM

105608 AI808201 Hs.287863 hypothetical protein FLJ 12475 1.7 ?

105610 AA280072 Hs.99872 fetal Alzheimer antigen 1.4 other

105617 AK000892 Hs.4069 glucocorticoid modulatory element bindin 1.7 TM

105620 AW302245 Hs.181390 casein kinase 1, gamma 2 5.6 other

105658 AA985190 Hs.246875 hypothetical protein FLJ20059 9.4 other

105697 AW499988 Hs.27801 zinc finger protein 278 2 TM

105708 R26944 Hs.180777 Homo sapiens mRNA; cDNA DKFZp564M0264 (f 1.7 other

105743 BE246502 Hs.9598 sema domain, immunoglobulin domain (Ig), 2.7 other

105746 AW151952 Hs.46679 hypothetical protein FLJ20739 1.5 ?

105759 AI123118 Hs.15159 chemokine-like factor, alternatively spl 1.3 other

105771 AI267720 Hs.153221 synovial sarcoma, translocated to X chro 1.6 other

105820 AA741336 Hs.152108 transcriptional unit N143 2.2 other

105826 AA478756 Hs.194477 E3 ubiquitin ligase SMURF2 1.3 other

105856 AI262106 Hs.12653 ESTs 2.4 other

105858 AF151066 Hs.281428 hypothetical protein 2.9 other

105875 AK001708 Hs.32271 hypothetical protein FLJ10846 1.4 other

105930 AF016371 Hs.9880 peptidyl prolyl isomerase H (cyclophilin 5.3 other

106000 AW194426 Hs.20726 ESTs 1.7 other

106011 AW081202 Hs.12284 Homo sapiens, clone IMAGE:2989556, mRNA, 2.8 other

106017 AA477956 Hs.26268 ESTs 1.4 other

106073 AL157441 Hs.17834 downstream neighbor of SON 1.4 other

106078 AA130158 Hs.19977 ESTs, Moderately similar to ALU8_HUMAN A 1.6 ?

106094 AA533491 Hs.23317 hypothetical protein FLJ14681 6.9 other

106140 AB006624 Hs.14912 KIAA0286 protein 1.6 other

106271 AA251393 Hs.289052 Homo sapiens, Similarto RIKEN cDNA 5430 10.8 ? 106288 AB037742 Hs.24336 KIAA1321 protein 1.3 other

106300 Y10043 Hs.19114 high-mobility group (nonhistone chromoso 3.7 other

106333 AL043114 Hs.22410 ESTs, Weakly similarto A54849 collagen 5.5 SS,

106350 AK001404 Hs.194698 cyclin B2 5.8 other

106359 AW390282 Hs.31130 transmembrane 7 superfamily member 2 6.4 other

106381 AB040916 Hs.24106 KIAA1483 protein 6.6 other

106389 AW748420 Hs.6236 Homo sapiens cDNA: FLJ21487 fis, clone C 2.2 TM

106457 AF119256 Hs.27801 zinc finger protein 278 2.7 other

106470 D63078 Hs.186180 Homo sapiens cDNA: FLJ23038 fis, clone L 2.3 other

106586 AA243837 Hs.57787 ESTs 1.6 other

106589 AK000933 Hs.28661 Homo sapiens cDNA FLJ 10071 fis, clone HE 2.4 ?

106610 AA458882 Hs.79732 fibulin 1 8 SS,

106624 NM 003595 Hs.26350 tyrosylprotein sulfotransferase 2 7.8 other

106650 AL049951 Hs.22370 Homo sapiens mRNA; cDNA DKFZp564O0122 (f 1.8 other

106669 AV657117 Hs.184164 ESTs, Moderately similarto S65657 alpha 1.3 TM

106713 BE614802 Hs.184352 hypothetical protein FLJ12549 ' 4.6 other

106717 AA600357 Hs.239489 TIA1 cytotoxic granule-associated RNA-bi 1.3 other

106723 BE388094 Hs.21857 ESTs 1.6 SS,

106795 AF174487 Hs.293753 Bcl-2-related ovarian killer protein-lik 5.7 other

106829 AW959893 Hs.27099 hypothetical protein FLJ23293 similarto 16.2 TM

106831 BE564871 Hs.29463 centrin, EF-hand protein, 3 (CDC31 yeast 1.5 other

106846 AB037744 Hs.34892 KIAA1323 protein 2.2 other

106852 AF151031 Hs.300631 hypothetical protein 1.3 other

106873 N49809 Hs.11197 Homo sapiens, done IMAGE:3343149, mRNA, 16.8 other

106886 W79171 Hs.9567 GL002 protein 1.5 TM

106906 AA861271 Hs.222024 transcription factor BMAL2 2.2 other

106920 AK001838 Hs.296323 serum/glucocorticoid regulated kinase 3.4 other

106945 AK000511 Hs.6294 hypothetical protein DKFZp434L1435 simil 6.8 ?

106973 BE156256 Hs.11923 hypothetical protein 6.7 other

106978 AW631480 Hs.8688 ESTs 6.1 SS,

107004 AA146872 Hs.300700 hypothetical protein FLJ20727 1.3 other

107029 AF264750 Hs.288971 myeloid/lymphoid or mixed-lineage leukem 1.8 other

107071 AW385224 Hs.35198 ectonucleotide pyrophosphatase/phosphodi 1.7 other

107113 ' AK000733 Hs.23900 GTPase activating protein 2.5 other

107125 AK000512 Hs.69388 hypothetical protein FLJ20505 1.7 other

107136 AV661958 Hs.8207 GK001 protein 4.7 other

107146 AK001455 Hs.5198 Down syndrome critical region gene 2 2 other

107151 AW378065 Hs.8687 ESTs 6.4 TM

107155 AW391927 Hs.7946 KIAA1288 protein 33.5 other

107174 BE122762 Hs.25338 ESTs 5.2 ?

107197 W15477 Hs.64639 glioma pathogenesis-related protein 6.1 other

107221 AW888411 Hs.81915 leukemia-associated phosphoprotein p18 ( 17.4 other

107243 BE219716 Hs.34727 ESTs, Moderately similar to I38759 zinc 7.4 ?

107248 AW263124 Hs.315111 nuclear receptor co-repressor/HDAC3 comp 1.8 other

107263 D60341 Hs.21198 translocase of outer mitochondrial membr 6.7 other

107265 BE379594 Hs.49136 ESTs, Moderately similar to ALU7JHUMAN A 2,5 other

107299 BE277457 Hs.30661 hypothetical protein MGC4606 3.2 TM

107316 T63174 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f 2 TM

107354 NM 06299 Hs.96448 zinc finger protein 193 5 ?

107392 AW299900 Hs.267632 TATA element modulatory factor 1 1.2 other

107481 AA307703 Hs.279766 kinesin family member 4A 1.6 other

107529 BE515065 Hs.296585 nucleolar protein (KKE/D repeat) 3 TM

107554 AA001386 Hs.59844 ESTs 1.4 other

107681 BE379594 Hs.49136 ESTs, Moderately similarto ALU7 HUMAN A 2.3 SS.TM

107772 AA018587 Hs.303055 ESTs, Weakly similarto ALU1_HUMAN ALU S 2.2 ?

107859 AW732573 Hs.47584 potassium voltage-gated channel, delayed 8.4 TM

107901 L42612 Hs.335952 keratin 6B 2.5 other

107922 BE153855 Hs.61460 Ig superfamily receptor LNIR 2.3 other

107974 AW956103 Hs.61712 pyruvate dehydrogenase kinase, isoenzyme 6.8 other

108040 AL121031 Hs.159971 SWI/SNF related, matrix associated, acti 1.6 other

108230 AA054224 Hs.59847 ESTs 1.3 other

108274 AF129535 Hs.272027 F-box only protein 5 7.2 ?

108296 N31256 Hs.161623 ESTs 2.6 other

108496 AA083069 Hs.339659 ESTs 3.6 other

108607 BE300380 Hs.69476 Homo sapiens cDNA FLJ12758 fis, clone NT 3.5 other

108621 AA101809 Hs.182685 ESTs 1.7 other

108634 AW022410 Hs.69507 ESTs 1.8 SS.TM 108647 BE546947 Hs.44276 homeo box C10 9.8 other

108695 AB029000 Hs.70823 KIAA1077 protein 7.3 other

108740 AI089575 Hs.9071 progesterone membrane binding protein 2.8 ?

108828 AK001693 Hs.273344 DKFZP564O0463 protein 1.9 other

108859 AL121500 Hs.178904 ESTs 1.6 TM

108872 H06720 Hs.111680 endosulfine alpha 2.2 other

108891 AI801235 Hs.48480 ESTs 5.4 other

108894 AK001431 Hs.5105 hypothetical protein FLJ10569 4.1 TM

108955 AA149754 Hs.195155 Homo sapiens amino acid transport system 5.7 ?

108982 AA151708 Hs.171980 homeo box (expressed in ES cells) 1 1.7 other

108987 AA152178 Hs.23467 hypothetical protein FLJ 10633 6.3 other

109002 AB028987 Hs.72134 KIAA1064 protein 1.7 other

109011 AA156542 Hs.72127 ESTs 1.5 other

109026 AA157811 gb:zo35d07.s1 Stratagene colon (937204) 5.4 other

109068 AA164293 Hs.72545 ESTs 3 other

109101 AW608930 Hs.52184 hypothetical protein FLJ20618 1.6 SS,

109112 AW419196 Hs.257924 hypothetical protein FLJ13782 3.3 TM

109124 AK000684 Hs.183887 hypothetical protein FLJ22104 1.7 other

109139 AJ132592 Hs.59757 zinc finger protein 281 2.7 other

109166 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkines 3 TM

109198 BE566742 Hs.58169 highly expressed in cancer, rich in leuc 2.1 other

109213 NM 016603 Hs.82035 potential nuclear protein C50RF5; GAP-li 5.4 other

109220 AW958181 Hs.189998 ESTs 5.8 other

109233 AU077281 Hs.170285 nucleoporin 214kD (CAIN) 5.3 other

109270 N99673 Hs.3585 ESTs, Weakly similar to AF126743 1 DNAJ 1.4 other

109273 AA375752 Hs.82719 Homo sapiens mRNA; cDNA DKFZp586F1822 (f 3 other

109313 AF153201 Hs.86276 C2H2 (Kπ ppel-type) zinc finger protein 1.3 other

109341 AA213506 Hs.115099 EST 3 ?

109391 AL096858 Hs.184245 KIAA0929 protein Msx2 interacting nudea 1.5 other

109420 H83603 Hs.40408 homeo box C9 2.2 SS,

109426 N30531 Hs.42215 protein phosphatase 1, regulatory subuni 3.1 TM

109429 A1160029 Hs.61438 ESTs 2 ?

109445 AA232103 Hs.189915 ESTs 1.8 other

109450 AB032969 Hs.173042 KIAA1143 protein 3.8 other

109468 NM_015310 Hs.6763 KIAA0942 protein 3.3 other

109478 AW074143 Hs.87134 ESTs 2 TM

109570 L40027 Hs.118890 glycogen synthase kinase 3 alpha 2.1 other

109662 F02614 Hs.27319 ESTs 1.4 other

109825 R71264 Hs.16798 ESTs 1.3 other

110039 H11938 Hs.21907 histone acetyltransferase 2 other

110056 AA503041 Hs.279009 matrix Gla protein 2.5 other

110085 AA603840 Hs.29956 KIAA0460 protein 1.7 other

110110 T07353 Hs.7948 ESTs 2.9 other

110129 R51853 Hs.226429 ESTs, Weakly similarto ALU1_HUMAN ALU S 1.7 SS,

110154 NM 014521 Hs.1 667 SH3-domain binding protein 4 4.3 other

110240 AI668594 Hs.176588 ESTs, Weakly similar to CP4Y_HUMAN CYTOC 4.3 ?

110242 N41744 Hs.19978 CGI-30 protein 1.3 other

110259 H28428 Hs.32406 ESTs, Weakly similar to I38022 hypotheti 2.2 other

110312 BE256986 Hs.11896 hypothetical protein FLJ12089 2.1 other

110501 H55748 gb:yq94a01.s1 Soares fetal liver spleen 6.1 ?

110504 H55915 Hs.210859 hypothetical protein FLJ11016 6.1 TM

110525 H57330 Hs.37430 EST 6.4 other

110568 AK001160 Hs.5999 hypothetical protein FLJ10298 1.3 ?

110699 T97586 Hs.18090 ESTs 1.8 other

110705 AB007902 Hs.32168 KIAA0442 protein 1.6 TM

110742 AW190338 Hs.28029 hypothetical protein MGC11256 7.8 other

110761 AL138077 Hs.16157 hypothetical protein FLJ12707 2.5 other

110762 BE044245 Hs.30011 hypothetical protein MGC2963 9.3 ?

110765 AK000322 Hs.18457 hypothetical protein FLJ20315 ' 5.5 SS,

110769 BE000831 Hs.23837 Homo sapiens cDNA FLJ11812 fis, clone HE 2.1 TM

110799 AI089660 Hs.323401 dpy-30-like protein 1.5 TM

110805 T25829 Hs.24048 FK506 binding protein precursor 6.7 TM

110813 AA767373 Hs.35669 ESTs, Moderately similar to ALU1JHUMAN A 5.7 other

110820 R33261 Hs.6614 ESTs, Weakly similar to A43932 mucin 2 p 3.4 other

110840 N31598 Hs.12727 hypothetical protein FLJ21610 1.7 TM

110844 AI740792 Hs.167531 methylcrotonoyl-Coenzyme A carboxylase 2 1.7 other

110854 BE612992 Hs.27931 hypothetical protein FLJ 10607 similarto 4.7 other 110856 AA992380 gb:ot37g06.s1 Soares_testis_NHT Homo sap 2.3 other

110885 BE384447 Hs.16034 hypothetical protein MGC13186 3.5 ?

110897 AL117430 Hs.6880 DKFZP434D156 protein 2.2 ?

110915 BE092285 Hs.29724 hypothetical protein FLJ13187 2.6 SS,

110918 H04360 Hs.24283 ESTs, Moderately similarto reduced expr 1.9 TM

110958 NM 005864 Hs.24587 signal transduction protein (SH3 contain 6.7 other

110963 AK002180 Hs.11449 DKFZP5640123 protein 2 other

110981 AK001980 Hs.24284 ADP-ribosyltransferase (NAD+; poly(ADP-r 1.3 other

110984 AW613287 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp 1.8 ?

111125 N63823 Hs.269115 ESTs, Moderately similarto Z195_HUMAN Z 3.7 other

111132 AB037807 Hs.83293 hypothetical protein 2.1 TM

111164 N46180 Hs.122489 Homo sapiens cDNA FLJ 13289 fis, clone OV 2.3 other

111172 R67419 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 3.7 other

111174 AL050166 Hs.26295 Homo sapiens mRNA; cDNA DKFZp586D1122 (f 7.5 other

111179 AK000136 Hs.10760 asporin (LRR class 1) 7.1 other

111184 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE 6.8 other

111189 N67603 Hs.272130 ESTs, Weakly similar to S65824 reverse t 3.6 SS,

111216 AW139408 Hs.152940 ESTs 1.5 other

111221 AB037782 Hs.15119 KIAA1361 protein 2.6 other

111223 AA852773 Hs.334838 KIAA1866 protein 4.7 other

111239 N90956 Hs.17230 hypothetical protein FLJ22087 7.9 ?

111285 AA778711 Hs.4310 eukaryotic translation initiation factor 7 other

111299 AB033091 Hs.74313 KIAA1265 protein 5 other

111312 AI523913 Hs.34504 ESTs 3.8 other

111318 T99755 Hs.334728 ESTs 1.2 TM

111337 AA837396 Hs.263925 LIS1 -interacting protein NUDE1, rat homo 5.1 other

111352 H58589 Hs.35156 Homo sapiens cDNA FLJ11027 fis, clone PL 2.2 other

111370 AI478658 Hs.94631 brefeldin A-inhibited guanine nucleotide 2.8 ?

111384 N94606 Hs.288969 HSCARG protein 2.2 other

111389 AK000987 Hs.169111 oxidation resistance 1 2.1 other

111452 R02354 Hs.15999 ESTs 2.7 TM

111486 AI051194 Hs.227978 EST 6.6 other

111549 W90638 Hs.20321 ESTs, Moderately similar to ZRF1 HUMAN Z 1.4 other

111585 R10720 Hs.20670 EST 1.6 ?

111627 R52656 Hs.21691 ESTs 1.6 other

111870 AB037834 Hs.18685 Homo sapiens mRNA for KIAA1413 protein, 2.4 other

111937 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr 10.6 other

111944 AW083791 Hs.21263 suppressor of potassium transport defect 6.6 TM

111987 NM 015310 Hs.6763 KIAA0942 protein 5,1 other

112134 R41823 Hs.7413 ESTs; calsyntenin-2 2.8 other

112244 AB029000 Hs.70823 KIAA1077 protein 14.6 other

112388 R46071 Hs.301693 Homo sapiens, clone IMAGE:3638994, mRNA, 9 other

112456 NM 016248 Hs.232076 A kinase (PRKA) anchor protein 11 1.4 other

112464 AW007287 Hs.28538 Homo sapiens cDNA: FLJ21086 fis, clone C 1.4 TM

112506 AI742756 Hs.26079 ESTs 3.2 other

112513 R68425 Hs.13809 hypothetical protein FLJ10648 2 TM

112752 AK001635 Hs.14838 hypothetical protein FLJ10773 1.8 other

112884 AK000004 Hs.5013 Homo sapiens mRNA for FLJ00004 protein, 6.6 other

112923 T10258 Hs.5037 EST 1.5 ?

112936 AW970826 Hs.6185 KIAA1557 protein 3.2 other

112958 R61388 Hs.6724 ESTs 6.1 other

112966 Z44718 Hs.102548 glucocorticoid receptor DNA binding fact 6.5 other

112978 AK000272 Hs.7099 hypothetical protein FLJ20265 1.2 other

112995 AA737033 Hs.7155 ESTs, Moderately similar to 2115357A TYK 5.6 other

112996 BE276112 Hs.7165 zinc finger protein 259 2 other

113047 AI571940 Hs.7549 ESTs 1.9 other

113049 AW965190 Hs.7560 Homo sapiens mRNA for KIAA1729 protein, 2.4 TM

113089 T40707 Hs.270862 ESTs 1.3 SS,

113196 T57317 gb:yb51a03.s1 Stratagene fetal spleen (9 1.7 other

113248 T63857 gb:yc16e01.s1 Stratagene lung (937210) H 2.8 other

113254 AK002180 Hs.11449 DKFZP5640123 protein 1.3 other

113277 AW971049 Hs.11774 protein (peptidyl-prolyl cis/trans isome 3.2 other

113429 AA688021 Hs.179808 ESTs 1.2 other

113499 AI467908 Hs.8882 ESTs 6 other

113547 H59588 Hs.15233 ESTs 2 SS,

113647 AA813887 Hs.188173 Homo sapiens cDNA FLJ12187 fis, clone MA 1.3 SS,

113702 T97307 gb:ye53h05.s1 Soares fetal liver spleen 4.4 other 113759 AW499665 Hs.9456 SWI/SNF related, matrix associated, acti 1.2 other

113777 BE266947 Hs.10590 zinc finger protein 313 13.4 other

113783 AL359588 Hs.7041 hypothetical protein DKFZp762B226 1.7 other

113791 AI269096 Hs.135578 chitobiase, di-N-acetyl- 1.3 other

113808 W44735 Hs.9286 Homo sapiens cDNA: FLJ21278 fis, clone C 3.3 other

113811 BE207480 Hs.6994 Homo sapiens cDNA: FLJ22044 fis, clone H 3.1 other

113817 H13325 Hs.332795 hypothetical protein DKFZp761017121 3.2 other

113826 AW378212 Hs.24809 hypothetical protein FLJ10826 2.3 ?

113834 T26483 Hs.6059 EGF-containing fibulin-like extracellula 11.3 TM

113868 W57902 Hs.90744 proteasome (prosome, macropain) 26S subu 2.7 other

113870 AL079314 Hs.16537 hypothetical protein, similarto (U06944 6.1 other

113885 AW959486 Hs.21732 ESTs 6.6 other

113923 AW953484 Hs.3849 hypothetical protein FLJ22041 similarto 1.9 ?

113989 W87544 Hs.268828 ESTs 1.2 other

114022 AI539519 Hs.120969 Homo sapiens cDNA FLJ11562 fis, clone HE 5.4 other

114030 AI825386 Hs.164478 hypothetical protein FLJ21939 similarto 9.4 other

114060 AB029551 Hs.7910 RING1 and YY1 binding protein 1.8 other

114196 AF017445 Hs.150926 fucose-1-phosphate guanylyltransferase 1.5 other

114226 AB028968 Hs.7989 KIAA1045 protein 1.8 other

114253 BE149866 Hs.14831 Homo sapiens, Similarto zinc finger pro 2.3 other

114262 AL117518 Hs.3686 KIAA0978 protein 1.4 TM

114275 AW515443.comp Hs.306117 KIAA0306 protein 15. other

114292 AI815395 Hs.184641 fatty acid desaturase 2 1.9 TM

114309 AA332453 Hs.20824 CGI-85 protein 2.4 other

114392 AA249590 Hs.100748 ESTs, Weakly similar to A28996 proline-r 1.9 other

114407 BE539976 Hs.103305 Homo sapiens mRNA; cDNA DKFZp434B0425 (f 1.3 TM

114455 H37908 Hs.271616 ESTs, Weakly similarto ALU8_HUMAN ALU S 5.6 other

114463 AL120247 Hs.40109 KIAA0872 protein 5.3 TM

114464 AI091713 Hs.106597 Homo sapiens, Similarto RIKEN cDNA 1110 1.3 other

114471 AA028074 Hs.104613 RP42 homolog 1.9 ?

114480 BE066778 Hs.151678 UDP-N-acetyl-alpha-D-gaIactosamine:polyp 13.4 other

114671 AA766268 Hs.266273 hypothetical protein FLJ 13346 2 other

114698 AA476966 Hs.110857 polymerase (RNA) III (DNA directed) poly 3.6 other

114730 AI373544 Hs.331328 intermediate filament protein syncoilin 3.9 other

114767 AI859865 Hs.154443 minichromosome maintenance deficient (S. 1.7 other

114774 AV656017 Hs.184325 CGI-76 protein 3.2 other

114798 AA159181 Hs.54900 serologically defined colon cancer antig 3.6 other

114860 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 4.4 other

114895 AA236177 Hs.76591 KIAA0887 protein 7.2 other

114896 BE539101 Hs.5324 hypothetical protein 1.3 other

114911 AA236672 gb:zt29f02.s1 Soares ovary tumor NbHOT H 1.5 other

114930 AA237022 Hs.188717 ESTs 2 SS,

114938 AA242834 Hs.58384 ESTs 2.9 other

114965 AI733881 Hs.72472 BMP-R1B 2.3 ?

115023 AF102546 Hs.63931 dachshund (Drosophila) homolog 1.3 other

115038 AA252360 Hs.87968 toll-like receptor 9 1.6 other

115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN 11.8 other

115117 AI670847 Hs.5324 hypothetical protein 1.5 other

115206 AW183695 Hs.186572 ESTs 2.5 other

115221 AW365434 Hs.79741 hypothetical protein FLJ10116 1.5 other

115239 BE251328 Hs.73291 hypothetical protein FLJ10881 1.3 TM

115242 AI368236 Hs.283732 ESTs, Moderately similar to ALU1JHUMAN A 1.4 other

115278 AK002163 Hs.30 724 hypothetical protein FLJ11301 1.5 other

115285 AW972872 Hs.293736 ESTs 2.4 other

115291 BE545072 Hs.122579 hypothetical protein FLJ 10461 6.3 SS,

115400 AI215069 Hs.89113 ESTs 6.7 ?

115468 AA314349 Hs.48499 tumor antigen SLP-8p 7.5 ?

115471 AK001376 Hs.59346 hypothetical protein FLJ10514 1.4 TM

115479 AW301608 Hs.278188 ESTs, Moderately similarto I54374 gene 4.1 TM

115496 AW247593 Hs.71819 eukaryotic translation initiation factor 16.3 other

115500 Y14443 Hs.88219 zinc finger protein 200 5 other

115553 AJ275986 Hs.71414 transcription factor (SMIF gene) 2.5 other

115581 AI540842 Hs.61082 ESTs 6.2 other

115587 BE081342 Hs.283037 HSPC039 protein 2.9 other

115590 AA399477 Hs.67896 7-60 protein 5.3 TM

115646 N36110 Hs.305971 solute carrier family 2 (facilitated glu 4.8 ?

115652 BE093589 Hs.38178 hypothetical protein FLJ23468 10.6 other 115655 AL048269 Hs.288544 Homo sapiens, clone MGC:16063, mRNA, com 12.7 TM

115663 AI138785 Hs.40507 ESTs 2 other

115676 AA953006 Hs.88143 ESTs 3.1 other

115690 AA625132 Hs.44159 hypothetical protein FLJ21615 1.7 TM

115693 AF231023 Hs.55173 cadherin, EGF LAG seven-pass G-type rece 6.9 other

115715 BE395161 Hs.1390 proteasome (prosome, macropain) subunit, 1.7 other

115734 AI950339 Hs.40782 ESTs 2.7 TM

115811 NM 015434 Hs.48604 DKFZP434B168 protein 2.1 other

115823 AI732742 Hs.87440 ESTs 2.1 other

115837 AI675217 Hs.42761 ESTs 1.3 other

115844 AI373062 Hs.332938 hypothetical protein MGC5370 4.4 other

115866 AW062629 Hs.52081 KIAA0867 protein 7.3 other

115875 N55669 Hs.333823 mitochondrial ribosomal protein L13 1.2 other

115941 AI867451 Hs.46679 hypothetical protein FLJ20739 5.5 other

115968 AB037753 Hs.62767 KIAA1332 protein 9.8 other

116003 BE275469 Hs.66493 Down syndrome critical region gene 5 1.4 other

116011 AL359053 Hs.57664 Homo sapiens mRNA full length insert cDN 2.4 other

116108 AA770688 Hs.28777 H2A histone family, member L 1.8 other

116134 BE243834 Hs.50441 CGI-04 protein 1.4 other

116189 N35719 Hs.44749 ESTs, Moderately similar to T00358 hypot 1.2 other

116195 AW821113 Hs.72402 ESTs 2.1 other

116238 AV660717 Hs.47144 DKFZP586N0819 protein 1.7 other

116246 AF265555 Hs.250646 baculoviral IAP repeat-containing 6 1.7 other

116262 AI936442 Hs.59838 hypothetical protein FLJ10808 1.8 ?

116298 AI955411 Hs.94109 Homo sapiens cDNA FLJ13634 fis, clone PL 1.9 other

116318 AF097645 Hs.58570 deleted in cancer 1; RNA helicase HDB/DI 5 SS,

116325 AI472106 Hs.49303 Homo sapiens cDNA FLJ11663 fis, clone HE 1.4 SS,

116336 AL133033 Hs.4084 KIAA1025 protein 1.9 ?

116339 AK000290 Hs.44033 dipeptidyl peptidase 8 1.5 other

116350 AA497129 Hs.18477 nuclear factor l/C (CCAAT-biπdiπg transc 1.9 ?

116358 AI149586 Hs.38125 interferon-induced protein 75, 52kD 1.9 ?

116365 N50174 Hs.46765 ESTs 6.1 other

116368 N90466 Hs.71109 KIAA1229 protein 1.6 ?

116417 AW499664 Hs.12484 Human clone 23826 mRNA sequence 7.4 other

116436 AA161411 Hs.58668 chromosome 21 open reading frame 57 2.1 other

116462 AF218313 Hs.236828 putative helicase RUVBL 1.5 TM

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 2.1 TM

116575 AA312572 Hs.6241 phosphoinositide-3-kinase, regulatory su 1.5 other

116637 AK001043 Hs.92033 integrin-linked kinase-associated serine 2.7 other

116640 X89984 Hs.211563 B-cell CLL/lymphoma 7A 2.3 other

116700 AI800202 Hs.317589 hypothetical protein MGC10765 1.4 other

116705 AW074819 Hs.12313 hypothetical protein FLJ 14566 3.4 other

116732 AW152225 Hs.165909 ESTs, Weakly similar to 138022 hypotheti 2.9 other

116926 H73608 Hs.290830 ESTs 1.7 TM

117034 U72209 Hs.180324 YY1-associated factor 2 3.4 TM

117132 AI393666 Hs.42315 p10-binding protein 5.2 ?

117247 N21032 gb:yx46f06.s1 Soares melanocyte 2NbHM Ho 5.5 TM

117276 N71183 Hs.121806 Homo sapiens cDNA FLJ11971 fis, clone HE 1.5 TM

117284 AK001701 Hs.183779 Homo sapiens cDNA FLJ10590 fis, clone NT 2 other

117367 AI041793 Hs.42502 ESTs 2 other

117368 AI878942 Hs.90336 ATPase, H+ transporting, lysosomal (vacu 2.1 ?

117382 AF150275 Hs.40173 ESTs 2.7 TM

117412 N32536 Hs.42645 solute carrier family 16 (monocarboxylic 1.4 other

117557 AF123050 Hs.44532 diubiquitln 3.4 TM

117588 N34895 Hs.44648 ESTs 3.4 ?

117745 BE294925 Hs.46680 CGI-12 protein 3 SS,

117754 AA121673 Hs.59757 zinc finger protein 281 1.9 other

117879 N54706 Hs.303025 chromosome 11 open reading frame 24 1.8 other

117904 BE540675 Hs.332938 hypothetical protein MGC5370 6 ?

117911 AL137379 Hs.47125 hypothetical protein FLJ13912 1.7 other

117933 Y10518 Hs.116470 hypothetical protein FLJ20048 17 other

117983 AL110246 Hs.47367 KIAA1785 protein 5.4 other

118078 N54321 Hs.47790 EST 5.2 other

118301 AA453902 Hs.293264 ESTs 2.6 other

118429 AA243332 Hs.74649 cytochrome c oxidase subunit Vic 2.5 TM

118472 AL157545 Hs.421 9 bromodomain and PHD finger containing, 3 4.1 other

118488 AJ277275 Hs.50102 rapa-2 (rapa gene) 1.2 other 118509 N22617 Hs.43228 Homo sapiens cDNA FLJ11835 fis, clone HE 1.5 other

118528 AI949952 Hs.49397 ESTs 7.4 ?

118656 AI458020 Hs.293287 ESTs 2.5 other

118670 AA332845 Hs.152618 ESTs, Moderately similar to ZN91_HUMAN Z 1.2 TM

118698 AB033113 Hs.50187 KIAA1287 protein 2.1 TM

118737 AA199686 gb:zq75g09.r1 Stratagene hNT neuron (937 5.2 other

118925 N92293 Hs.206832 ESTs, Moderately similar to ALU8_HUMAN A 1.4 other

118984 AI668709 Hs.240722 ESTs, Moderately similar to ALU8_HUMAN A 3.6 other

118986 AF148713 Hs.125830 bladder cancer overexpressed protein 4.9 9

119206 W24781 Hs.293798 KIAA1710 protein 1.7 TM

119235 AW453069 Hs.3657 activity-dependent neuroprotective prate 2.2 other

119265 BE539706 Hs.285363 ESTs 1.4 ?

119279 N57568 Hs.48028 EST 25.1 other

119298 NM 001241 Hs.155478 cyclin T2 1.6 ?

119338 AI417240 Hs.320836 ESTs, Weakly similar to A47582 B-cell gr 1.3 other

119403 AL117554 Hs.119908 nucleolar protein NOP5/NOP58 6.7 TM

119478 AI624342 Hs.170042 ESTs 2.4 other

119486 AI796730 Hs.55513 ESTs 2.1 other

119513 W37933 Empirically selected from AFFX single pr 1.9 other

119601 AK000155 Hs.91684 Homo sapiens mRNA; cDNA DKFZp667l103 (fr 3.7 TM

119602 AW675298 Hs.233694 hypothetical protein FLJ 11350 3 other

119676 AA243837 Hs.57787 ESTs 1.4 other

119682 W61019 Hs.57811 ESTs 1.2 ?

119774 AB032977 Hs.6298 KIAA1151 protein 1.8 TM

119780 NM 016625 Hs.191381 hypothetical protein 3.1 other

119789 BE393948 Hs.50915 kallikrein 5 (KLK5; KLK-L2; stratum com 9.2 other

119805 AJ223810 Hs.43213 ESTs, Weakly similarto IEFSJHUMAN TRANS 3.6 TM

119818 AA130970 Hs.58382 hypothetical protein FLJ11101 2.5 ?

119863 AA081218 Hs.58608 Homo sapiens cDNA FLJ14206 fis, clone NT 2.7 TM

119905 AW449064 Hs.119571 collagen, type III, alpha 1 (Ehlers-Danl 2.6 other

119966 AA703129 Hs.58963 ESTs 2.7 other

120132 W57554 Hs.125019 lymphoid nuclear protein (LAF-4) mRNA 1.2 other

120206 H26735 Hs.91668 Homo sapiens clone PP1498 unknown mRNA 45.7 other

120248 AI924294 Hs.173259 uncharacterized bone marrow protein BM03 1.2 other

120269 AW131940 Hs.104030 ESTs 9.6 other

120274 AA177051 gb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens 4.7 other

120280 AA190577 gb:zp52g02.s1 Stratagene HeLa cell s3 93 2.1 other

120296 AW995911 Hs.299883 hypothetical protein FLJ23399 1.9 TM

120297 AA191384 Hs.104072 ESTs, Weakly similar to Z195 HUMAN ZINC 15.2 other

120324 AA195517 Hs.191643 ESTs 5.6 ?

120325 AA195651 Hs.104106 ESTs 6.5 other

120327 AK000292 Hs.278732 hypothetical protein FLJ20285 16.1 other

120336 N85785 Hs.181165 eukaryotic translation elongation factor 3 other

120342 AW450669 Hs.45068 hypothetical protein DKFZp434l143 5.8 other

120345 AA210722 Hs.104158 ESTs 4.6 SS M

120349 AW969481 Hs.55189 hypothetical protein 16.8 other

120352 R06859 Hs.193172 ESTs, Weakly similar to I38022 hypotheti 5.1 other

120356 AF000545 Hs.296433 putative purinergic receptor 28.1 TM

120371 AA219305 Hs.104196 EST 12.4 ?

120382 AA228026 Hs.38774 ESTs 4.1 TM

120383 AL109963 Hs.123122 FSH primary response (LRPR1, rat) homolo 9.7 TM

120386 AW969665 Hs.154848 hypothetical protein DKFZp434D0127 32.6 other

120388 AA232874 Hs.104245 ESTs 3.2 other

120389 AW967985 Hs.325572 ESTs, Moderately similarto ALU7_HUMAN A 21.7 other

120396 AA134006 Hs.79306 eukaryotic translation initiation factor 12.5 other

120404 AB023230 Hs.96427 KIAA1013 protein 7.3 other

120418 AW966893 Hs.26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (f 11.4 other

120423 AA236453 Hs.18978 Homo sapiens cDNA: FLJ22822 fis, clone K 1.9 other

120472 AI950087 gb:wq05c02.x1 NCI CGAP Kid12 Homo sapien 19.4 other

120473 AA251973 Hs.269988 ESTs 5.5 9

120484 AA253170 Hs.96473 EST 10.4 9

120504 AA256837 gb:zr84d10.s1 Soares_NhHMPu S1 Homo sapi 4 ?

120509 BE047718 Hs.96545 ESTs 9.4 other

120520 AA258601 Hs.161731 EST 2.4 other

120535 BE350244 Hs.96547 ESTs 2.5 ?

120551 AA279160 Hs.111407 Homo sapiens, clone IMAGE.-3613029, mRNA, 5.3 other

120570 AA280679 Hs.271445 ESTs, Weakly similar to ALU1_HUMAN ALU S 14.4 9 120582 BE244830 Hs.284228 ZNF135-like protein 10.2 ?

120590 AW372799 Hs.125790 leucine-rich repeat-containing 2 2.2 ?

120596 AA282074 Hs.237323 N-acetylglucosamine-phosphate mutase 7.6 other

120619 AW965339 Hs.111471 ESTs 2.5 other

120624 AW407987 Hs.173518 M-phase phosphoprotein homolog 52 other

120639 AA286942 gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens 2.4 other

120648 AA287095 Hs.140309 Homo sapiens, clone IMAGE:3677194, mRNA, 5 other

120653 AW063659 Hs.191649 ESTs 2.2 other

120668 AW969638 Hs.112318 6.2 kd protein 2.2 TM

120669 BE536739 Hs.109909 ESTs 1.9 TM

120695 AA976503 gb:oq30a04.s1 NCI CGAP GC4 Homo sapiens 46.8 TM

120696 AI821539 Hs.97249 ESTs 2.5 other

120713 AW449855 Hs.96557 Homo sapiens cDNA FLJ 12727 fis, clone NT 6 other

120718 AA292747 Hs.97296 ESTs 2.9 other

120750 AI191410 Hs.96693 ESTs, Moderately similar to 2109260A B c 7.1 SS,

120774 AI608909 Hs.193985 ESTs 7.9 other

120807 AA346385 Hs.30002 SH3-containing protein SH3GLB2; KIAA1848 7 TM

120809 AA346495 gb:EST52657 Fetal heart II Homo sapiens 4.5 other

120938 AA386260 Hs.104632 EST 4.5 ?

120977 AA398155 Hs.97600 ESTs 4.5 other

120984 BE262951 Hs.99052 ESTs 5.6 other

120985 AI219896 Hs.97592 ESTs 1.3 other

121011 AA398360 Hs.97608 EST 3.2 other

121026 A1439713 Hs.165295 ESTs 3.6 other

121081 AA398721 Hs.186749 ESTs, Highly similarto I37550 mismatch 5.5 other

121133 AA363307 Hs.97032 ESTs 3.8 other

121176 AL121523 Hs.97774 ESTs 1.7 TM

121223 AI002110 Hs.97169 ESTs, Weakly similarto dJ667H12.2.1 [H. 2.9 other

121320 AA403008 Hs.301927 C6.1A 1.9 other

121340 AW956981 Hs.97910 Homo sapiens cDNA FLJ13383 fis, clone PL 3.5 other

121408 AA406137 Hs.98019 EST 6.1 ?

121439 AA410190 Hs.98076 ESTs, Weakly similarto A47582 B-cell gr 7.5 other

121450 AA406430 Hs.105362 Homo sapiens, clone MGC:18257, mRNA, com 7.1 other

121452 AW971063 Hs.292882 ESTs 1.8 other

121455 H58306 Hs.15165 retinoic acid induced 14 10.5 other

121457 W07404 Hs.144502 hypothetical protein FLJ22055 3.5 TM

121496 AA442224 Hs.97900 ESTs 14.4 other

121505 AA494172 Hs.194417 ESTs 13.1 other

121508 AA402515 Hs.97887 ESTs 28 other

121513 AA416653 Hs.181510 ESTs 6.3 other

121514 AA412112 gb:zt69b02.s1 Soares testis NHT Homo sap 2.7 SS,

121549 AA412477 Hs.98142 EST 7.5 ?

121558 AA412497 gb:zt95g12.s1 Soares testis NHT Homo sap 2.8 other

121577 AA411970 Hs.98096 EST 3.5 ?

121581 AA416568 gb:zu05c10.s1 Soares_testis_NHT Homo sap 6.2 TM

121589 AD001528 Hs.89718 spermine synthase 4 other

121594 AA626010 Hs.98247 ESTs 2.2 other

121622 AA416931 Hs.126065 ESTs 4.3 TM

121655 AA421537 Hs.178072 Homo sapiens mRNA; cDNA DKFZp434B1023 (f 7.9 other

121682 AA418160 Hs.86043 Homo sapiens cDNA FLJ13558 fis, clone PL 2 other

121690 AV660305 Hs.110286 ESTs 4.7 ?

121706 U55184 Hs.154145 hypothetical protein FLJ11585 12.7 other

121714 AA419225 Hs.98269 Homo sapiens cDNA FLJ11953 fis, clone HE 8.3 ?

121729 AI949597 Hs.98325 ESTs 1.8 TM

121731 AA421041 Hs.180744 ESTs 4.1 TM

121744 AA398784 Hs.97514 ESTs 7.1 SS,

121748 BE536911 Hs.234545 hypothetical protein NUF2R 19.5 other

121773 AB033022 Hs.158654 KIAA1196 protein 8 other

121775 AA421773 Hs.161008 ESTs 1.7 other

121776 AA292579 Hs.125133 hypothetical protein FLJ22501 6.7 other

121786 AI810774 Hs.98376 ESTs 10.5 other

121832 AW340797 Hs.98434 ESTs 5.9 other

121836 AA328348 Hs.218289 ESTs 3.9 other

121839 AA425691 Hs.191606 ESTs, Highly similar to KIAA1048 protein 5 other

121842 AF027406 Hs.104865 serine/threonine kinase 23 2.7 ?

121847 AA446628 Hs.2799 cartilage linking protein 1 2.3 other

121871 AW972668 Hs.293044 ESTs 2.9 TM 121882 AA426376 Hs.98459 ESTs 5 other

121911 AA427950 gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_ 7.3 TM

121915 AA428179 Hs.223405 ESTs, Moderately similar to A46010 X-lin 2.5 other

121935 AA428647 Hs.98611 EST 2.3 other

121983 AA298760 Hs.180 91 hypothetical protein FLJ14904 3.4 other

121985 AI862570 Hs.299214 Homo sapiens, clone IMAGE:2822295, mRNA, 11.4 other

121995 AA210863 Hs.3532 nemo-like kinase 3.8 9

121999 AA430211 Hs.98668 EST 6.5 other

122009 AW292763 Hs.160822 Homo sapiens cDNA: FLJ20863 fis, clone A 2.2 other

122013 AA431085 Hs.98706 ESTs 6.6 other

122036 W92142 Hs.271963 ESTs, Weakly similarto ALU5_HUMAN ALU S 13.1 other

122050 AI453076 Hs.166109 ELAV (embryonic lethal, abnormal vision, 9.1 other

122060 AA431738 Hs.98750 EST 13.1 9

122114 AW161023 Hs.104921 ESTs 1.5 other

122188 AA398838 gb:zt80d01.r1 Soares testis NHT Homo sap 3.4 other

122204 AA435936 Hs.98842 EST 5.6 other

122246 AA329550 Hs.29417 HCF-binding transcription factor Zhangfe 5.2 other

122257 AA436819 Hs.98899 ESTs 5.6 other

122302 AA441801 Hs.104947 ESTs 5.8 other

122341 AW601969 Hs.99010 hypothetical protein FLJ22263 similarto 2 other

122356 AA443794 Hs.98390 ESTs 7.4 SS.TM

122369 AA443985 Hs.303222 ESTs 12.2 9

122371 AA868555 Hs.178222 ESTs 5 9

122372 AA446008 Hs.336677 EST 7.8 ?

122378 AB032948 Hs.21356 hypothetical protein DKFZp762K2015 2.5 ?

122405 AA446572 Hs.303223 EST 2.8 TM

122412 AA446869 Hs.119316 ESTs 7.4 other

122415 AA446918 Hs.99088 EST 1.9 other

122418 AA446966 Hs.99090 ESTs, Moderately similarto similarto K 6.9 ?

122440 AW505139 Hs.9460 Homo sapiens mRNA; cDNA DKFZp547C244 (fr 2.6 other

122446 AA447603 Hs.99123 EST 1.8 TM

122448 AA447626 Hs.99127 EST 3.5 other

122458 AI266159 Hs.104980 ESTs 1.5 other

122460 AW418788 Hs.99148 ESTs, Weakly similarto S43569 R01H10.6 9.7 other

122464 AA448158 Hs.99152 EST 4.9 other

122490 AA448349 Hs.238151 EST 6.2 9

122492 AA448417 Hs.104990 ESTs 5.5 other

122502 AA204969 Hs.234863 Homo sapiens cDNA FLJ12082 fis, clone HE 1.3 other

122510 AA449232 Hs.99195 ESTs 11.2 9

122530 AW959741 Hs.40368 adaptor-related protein complex 1, sigma 10.1 other

122547 AA779725 Hs.164589 ESTs 2.5 SS,

122555 AA194055 Hs.293858 ESTs 1.9 other

122570 AA452578 Hs.262907 ESTs 9.5 other

122572 AA452601 Hs.99287 EST 11 9

122586 AK001910 Hs.99303 Homo sapiens cDNA FLJ11048 fis, one PL 3.4 other

122587 AB040893 Hs.6968 KIAA1460 protein 2 other

122598 AI028173 Hs.99329 ESTs 1.7 ?

122599 AL355841 Hs.99330 hypothetical protein FLJ23588 4.4 ?

122602 AA411925 Hs.301960 ESTs 4.7 other

122607 AA453518 Hs.98023 ESTs 61.5 other

122614 AA453630 Hs.99339 EST 10.7 ?

122616 AA453638 Hs.161873 ESTs 107.3 ?

122617 AI681535 Hs.148135 serine/threonine kinase 33 121.4 other

122618 AA453641 gb:zx48e06.s1 Soares testis NHT Homo sap 31.1 SS,

122622 AA453987 Hs.144802 ESTs 5.6 other

122717 AA456859 Hs.178358 ESTs 8.5 SS,

122762 AI376875 Hs.105119 ESTs 10.4 other

122829 AW204530 Hs.99500 ESTs 81.8 ?

122834 AA461492 Hs.99545 Homo sapiens cDNA FLJ 10658 fis, clone NT 3.7 9

122836 AA460581 Hs.290996 ESTs 4.6 other

122837 AA461509 Hs.293565 ESTs, Weakly similarto putative p150 [H 2.7 TM

122838 AA460584 Hs.334386 ESTs 75.3 other

122854 AA600235 Hs.9625 NIMA (never in mitosis gene a)-related k 7.8 other

122856 AI929374 Hs.75367 Src-like-adapter 5.8 other

122861 AA335721 Hs.119394 ESTs 1.3 other

122866 BE539656 Hs.283705 ESTs 4.2 other

122868 AF005216 Hs.115541 Janus kinase 2 (a protein tyrosine kinas 5.3 other 122870 AW576312 Hs.318722 Homo sapiens cDNA: FLJ21766 fis, clone C 9.9 ?

122872 AW081394 Hs.97103 ESTs 5.3 other

122879 AA769410 Hs.128654 ESTs 13.9 other

122907 AA470074 Hs.169896 ESTs 11.5 other

122916 AA470140 Hs.229170 EST 1.7 TM

122981 AA478951 Hs.105629 ESTs 5 other

123013 AW968324 Hs.17384 ESTs 15.4 other

123016 AW338067 Hs.323231 Homo sapiens cDNA FLJ11946 fis, clone HE 2.8 other

123034 AL359571 Hs.44054 nineiπ (GSK3B interacting protein) 8.7 other

123072 AI382600 Hs.104308 ESTs, Weakly similarto KIAA1395 protein 8.8 other

123082 AA485360 Hs.105661 ESTs 4 9

123088 AI343652 Hs.105667 ESTs 3.8 other

123110 AA486256 Hs.193510 EST 7.4 other

123114 BE304942 Hs.265848 myomegalin 2.8 9

123131 T52027 Hs.271795 ESTs, Weakly similarto I38022 hypotheti 2.4 other

123132 AI061582 Hs.324179 Homo sapiens cDNA FLJ12371 fis, clone MA 15.6 TM

123136 AW451999 Hs.194024 ESTs 5.2 other

123149 AI734179 Hs.105676 ESTs 23.8 TM

123152 AW601773 Hs.270259 ESTs 5.2 other

123258 AA490929 Hs.105274 ESTs, Weakly similarto RMS1_HUMAN REGUL 9.3 9

123315 AA496369 gb:zv37d10.s1 Soares ovary tumor NbHOT H 4.2 TM

123369 AA504757 Hs.105738 ESTs 7 other

123394 AA731404 Hs.105510 ESTs 3.7 other

123433 AW450922 Hs.112478 ESTs 3.8 other

123466 AA599042 Hs.112503 EST 7.4 other

123470 AW303285 Hs.303632 Human DNA sequence from clone RP11 -110H4 3.5 other

123471 AB021644 Hs.197219 zinc finger protein 14 (KOX 6) 5.2 ?

123475 BE439553 Hs.250528 Homo sapiens, clone IMAGE:4098694, mRNA, 1.7 other

123482 N95059 Hs.55098 ESTs 1.6 other

123486 BE019072 Hs.334802 Homo sapiens cDNA FLJ14680 fis, clone NT 2.4 other

123508 AW380388 Hs.155546 KIAA1080 protein; Goigi-associated, gamm 2.2 TM

123615 AA609170 gb:af12a12.s1 Soares_testis_NHT Homo sap 7.9 other

123619 AA602964 gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens 2.8 other

123658 AA609364 gb:zu71d09.s1 Soares_testis_NHT Homo sap 1.7 9

123674 A1269609 Hs.105187 kinesin protein 9 gene 5.7 9

123735 NM_013241 Hs.95231 FH1/FH2 domain-containing protein 10 other

123738 AA609891 Hs.112777 EST 5.2 other

123753 AA609955 Hs.234961 Huntingtin interacting protein E 30.6 TM

123804 AA620464 Hs.261915 EST, Weakly similar to S65657 alpha-1 C-a 2.1 other

123811 AA620586 gb:ae60g05.s1 Stratagene lung carcinoma 2.7 other

123951 AB012922 Hs.173043 metastasis-associated 1-like 1 6.3 ?

123983 AJ272267 Hs.146178 choline dehydrogenase 4.4 other

124001 L42542 Hs.75447 ralA binding protein 1 7.1 9

124006 AI147155 Hs.270016 ESTs 8.3 SS,

124070 AI950314 Hs.154762 HIV-1 rev binding protein 2 3.8 other

124074 H05635 Hs.294030 topoiso erase-related function protein 4 1.2 SS,

124178 BE463721 Hs.97101 putative G protein-coupled receptor 3.2 9

124203 AA372796 Hs.269339 ESTs, Weakly similar to AF161356 1 HSPC0 5.7 other

124352 AA640891 Hs.102406 ESTs 3.1 TM

124375 D87454 Hs.192966 KIAA0265 protein 3.5 other

124385 AI267847 gb:aq49a10.x1 Stanley Frontal NB pool 2 57.1 9

124390 AA317338 Hs.7535 COBW-like protein 2.8 other

124391 AF155099 Hs.279780 NY-REN-18 antigen 7.1 other

124417 N34059 gb:yv28h09.s1 Soares fetal liver spleen 3.3 other

124428 H13540 Hs.82202 ribosomal protein L1 2.9 other

124440 AA532519 Hs.129043 Human DNA sequence from clone 989H11 on 7.9 other

124466 R10084 Hs.113319 kinesin heavy chain member 2 2.6 TM

124482 N53935 gb:yv59d09.s1 Soares fetal liver spleen 7.9 TM

124498 H79433 Hs.268997 ESTs 7.8 other

124515 AA669097 Hs.109370 ESTs 3.3 other

124608 N71076 Hs.102800 ESTs, Weakly similarto neuronal thread 4.6 9

124631 NM_014053 Hs.270594 FLVCR protein 3.2 other

124634 A1765123 Hs.143671 Homo sapiens cDNA FLJ13533 fis, clone PL 5.8 other

124637 AA160474 Hs.75798 hypothetical protein 9.3 other

124642 AW968856 Hs.278569 sorting nexin 17 3.5 other

124649 N92593 Hs.313054 ESTs 6.1 TM

124661 R48170 Hs.78436 EphB1 5.6 other 124683 AA381661 Hs.119878 ESTs, Weakly similar to M3K9JHUMAN MITOG 7.9 TM

124712 R09166 Hs.191148 ESTs 5.7 other

124735 R22952 Hs.268685 ESTs 11.3 ?

124761 AA374756 Hs.93560 Homo sapiens mRNA for KIAA1771 protein, 9 other

124768 AW368528 Hs.100855 ESTs 8.3 other

124775 R41 72 Hs.100878 ESTs 4.9 other

124777 R41933 Hs.140237 ESTs, Weakly similar to ALU1JHUMAN ALU S 2.8 other

124788 R43543 Hs.100912 Homo sapiens cDNA: FLJ22726 fis, clone H 5.1 other

124809 AL355722 Hs.106875 Homo sapiens EST from clone 35214, full 4.2 other

124811 R46068 Hs.288912 hypothetical protein FLJ22604 14.2 other

124812 R47948 Hs.188732 ESTs 7.9 other

124822 AA418160 Hs.86043 Homo sapiens cDNA FLJ13558 fis, clone PL 6.6 other

124825 AA501669 Hs.336693 ESTs 2.3 SS.TM

124833 AW975868 Hs.294100 ESTs 2.7 SS.TM

124857 R63652 Hs.137190 ESTs 2.3 other

124860 R65763 Hs.101477 EST 23.9 9

124863 AI382555 Hs.127950 bromodomain-containing 1 2 other

124876 AF135422 Hs.27059 GDP-mannose pyrophosphorylase A 4.4 SS,

124878 BE397530 Hs.288057 hypothetical protein FLJ22242 2.7 other

124902 H37941 Hs.101883 ESTs 5.7 other

124903 AW296713 Hs.221441 ESTs 32.4 other

124930 AI076343 Hs.173939 ESTs, Weakly similar to ALUB_HUMAN 111! 22.8 other

124942 R99978 Hs.268892 ESTs, Moderately similarto B34087 hypot 6.1 other

124958 AI078645 Hs.431 murine leukemia viral (bmi-1) oncogene h 1.9 other

124980 T40841 Hs.98681 ESTs 4.5 9

125002 T59338 Hs.269463 ESTs, Weakly similarto ALU1_HUMAN ALU S 4.9 other

125047 T79815 Hs.279793 ESTs 5 9

125051 T79956 Hs.100588 EST 135.3 9

125056 T81310 Hs.100592 ESTs 5.4 other

125101 AI472068 Hs.286236 KIAA1856 protein 5.6 other

125113 T96595 Hs.302270 ESTs, Weakly similarto ALUFJHUMAN IN! 1.8 other

125115 T97341 gb:ye57e05.s1 Soares fetal liver spleen 9.6 9

125125 AI222382 Hs.240767 Human DNA sequence from clone RP1-12G14 1.5 TM

125147 W38150 Empirically selected from AFFX single pr 1.7 ?

125161 W44657 Hs.144232 EST 10.7 9

125249 AA630863 Hs.131375 ESTs, Moderately similar to ALUB_HUMAN ! 1.3 other

125255 AF098162 Hs.118631 timeless (Drosophila) homolog 9.4 other

125279 AW401809 Hs.4779 KIAA1150 protein 1.5 9

125280 AI123705 Hs.106932 ESTs 8.1 9

125298 AW972542 Hs.289008 Homo sapiens cDNA: FLJ21814 fis, clone H 1.5 other

125660 AW292171 Hs.23978 scaffold attachment factor B 5.9 other

125827 NM 003403 Hs.97496 YY1 transcription factor 1.2 ?

125891 U29589 Hs.7138 cholinergic receptor, muscarinic 3 6.5 ?

126005 AW409701 Hs.1578 baculoviral IAP repeat-containing 5 (sur 14.3 ?

126202 AA157632 Hs.272630 vacuolar proton pump delta polypeptide 2.5 SS,

126695 AA643322 Hs.172028 a disintegrin and metalloproteinase doma 9.1 SS.TM

127050 AW411066 Hs.274351 CGI-89 protein 17 other

127274 AW966158 Hs.58582 Homo sapiens cDNA FLJ12789 fis, clone NT 12.8 other

128355 AW293012 Hs.161623 ESTs 7.4 SS,

128493 D87466 Hs.240112 KIAA0276 protein 3.1 TM

128522 BE173977 Hs.10098 putative nucleolar RNA helicase 9.4 other

128527 AA504583 Hs.101047 transcription factor 3 (E2A immunoglobul 1.5 other

128528 R39234 Hs.251699 ESTs, Weakly similar to IDN4-GGTR14 [H.s 2.8 other

128595 U31875 Hs.272499 short-chain alcohol dehydrogenase family 12.1 TM

128599 NM_015366 Hs.102336 Rho GTPase activating protein 8 2.4 ?

128604 AI879099 Hs.102397 GIOT-3 for gonadotrapin inducible transc 1.3 other

128608 BE267994 Hs.102419 zinc finger protein 7.2 other

128625 AB037841 Hs.102652 hypothetical protein ASH1 1.3 other

128629 AL096748 Hs.102708 DKFZP434A043 protein 3.2 other

128639 AW582962 Hs.102897 CGI-47 protein 2 TM

128656 AA458542 Hs.10326 coatomer protein complex, subunit epsilo 1.4 other

128658 BE397354 Hs.324830 diptheria toxin resistance protein requi 2.5 other

128670 AA975486 Hs.103441 Homo sapiens, Similarto RIKEN cDNA 1700 7.1 ?

128691 W27939 Hs.103834 hypothetical protein MGC5576 7.8 9

128696 BE081143 Hs.225977 nuclear receptor coactivator 3 3.8 other

128700 Y15221 Hs.103982 small inducible cytokine subfamily B (Cy 1.6 other

128714 T85231 Hs.179661 tubulin, beta 5 7.8 other 128717 AK001564 Hs.104222 hypothetical protein FLJ10702 5.5 other

128733 BE147740 Hs.104558 ESTs, Moderately similarto I38022 hypot 2.7 TM

128737 AF292100 Hs.104613 RP42 homolog 2.8 TM

128742 AA307211 Hs.251531 proteasome (prosome, macropain) subunit, 4.5 ?

128746 AI470163 Hs.323342 actin related protein 2/3 complex, subun 2.2 other

128747 AB027249 Hs.104741 PDZ-binding kinase; T-cell originated pr 2.8 other

128772 BE302796 Hs.105097 thymidine kinase 1, soluble 5.4 other

128781 N71826 Hs.105465 small nuclear ribonucleoprotein polypept 53.9 TM

128797 NM 002975 Hs.105927 stem cell growth factor; lymphocyte seer 13.3 other

128806 AW630942 Hs.106061 RD RNA-binding protein 2.6 other

128814 AW248431 Hs.256526 nuclear prelamin A recognition factor 2.2 other

128830 BE281170 Hs.106357 valosin-containing protein 6 other

128835 AK001731 Hs.106390 Homo sapiens mRNA; cDNA DKFZp586H0924 (f 1.6 SS,

128854 BE159181 Hs.168232 hypothetical protein FLJ13855 2.3 other

128871 AF189723 Hs.106778 ATPase, Ca++ transporting, type 2C, memb 1.5 9

128906 R57988 Hs.10706 epithelial protein lost in neoplasm beta 4.8 other

128920 AA622037 Hs.166468 programmed cell death 5 1.4 other

128925 R67419 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 1.9 other

128946 Y13153 Hs.107318 kynurenine 3-monooxygenase (kynurenine 3 7.3 ?

128949 AA009647 Hs.8850 a disintegrin and metalloproteinase doma 2.5 other

128959 AI580127 Hs.107381 hypothetical protein FLJ11200 1.3 other

128965 AW150697 Hs.107418 ESTs 1.4 ?

128970 AI375672 Hs.165028 ESTs 1.3 other

128975 BE560779 Hs.284233 NICE-5 protein 14 other

128979 AW271217 Hs.281434 Homo sapiens cDNA FLJ 14028 fis, clone HE 1.6 TM

128995 AI816224 Hs.107747 DKFZP566C243 protein 1.9 other

129019 AI950087 gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien 2.9 other

129021 AL044675 Hs.173081 KIAA0530 protein 3.8 other

129032 R80088 Hs.108104 ubiquitin-conjugating enzyme E2L 3 3.4 other

129076 AW296806 Hs.326234 ESTs, Highly similarto T46422 hypotheti 5 other

129078 AI351010 Hs.102267 lysosomal 2.1 other

129088 AA744610 Hs.194431 palladin 17.1 other

129095 L12350 Hs.108623 thrombospondin 2 2.7 other

129096 AA463189 Hs.288906 WW Domain-Containing Gene 20.9 TM

129097 BE243933 Hs.108642 zinc finger protein 22 (KOX 15) 3 other

129099 AF146074 Hs.108660 ATP-binding cassette, sub-family C (CFTR 5.8 TM

129136 W93048 Hs.250723 hypothetical protein MGC2747 6 other

129149 AA356620 Hs.108947 KIAA0050 gene product 6.4 TM

129172 AW162916 Hs.241576 hypothetical protein PR02577 1.8 TM

129192 AA286914 Hs.183299 ESTs 2.1 9

129194 AA150797 Hs.109276 latexin protein 3.3 SS.TM

129198 N57532 Hs.109315 KIAA1415 protein 5.9 other

129207 AI934365 Hs.109439 osteoglycin (osteoinductive factor, mime 8.1 other

129228 U40714 Hs.239307 tyrosyl-tRNA synthetase 2.9 other

129229 AF013758 Hs.109643 polyadenylate binding protein-interacfin 3.3 9

129254 AA252468 Hs.1098 DKFZp434J1813 protein 2.6 SS.TM

129255 AI961727 Hs.109804 H1 histone family, member X 7.4 other

129288 W26392 Hs.110080 ESTs, Weakly similarto S13495 pregnancy 9.6 other

129296 AI051967 Hs.110122 ESTs 1.2 other

129323 AA287239 Hs.5518 Homo sapiens cDNA FLJ11311 fis, clone PL 5.2 other

129340 H75334 Hs.11050 F-box only protein 9 4.7 SS,

129347 BE614192 Hs.279869 melanoma-associated antigen recognised b 7.7 TM

129362 U30246 Hs.110736 solute carrier family 12 (sodium/potassi 6.7 TM

129366 BE220806 Hs.184697 Homo sapiens done 23785 mRNA sequence 8.6 SS,

129370 AI686379 Hs.110796 SAR1 protein 1.4 TM

129372 NM_016039 Hs. 10803 CGI-99 protein 2 other

129403 AF149785 Hs.111126 pituitary tumor-transforming 1 interacti 7.5 other

129404 AI267700 Hs.317584 ESTs 5.1 other

129423 AA204686 Hs.234149 hypothetical protein FLJ20647 10.2 other

129482 AA188185 Hs.289043 spindlin 6.8 other

129513 AW843633 Hs.306163 hypothetical protein AL110115 7.1 SS,

129515 AF255303 Hs.112227 membrane-associated nucleic acid binding 2.5 other

129527 AA769221 Hs.270847 delta-tubulin 3.2 other

129559 W01296 Hs.11360 hypothetical protein FLJ14784 7.5 other

129560 AA317841 Hs.7845 hypothetical protein MGC2752 6.8 other

129570 AI923097 Hs.11441 chromosome 1 open reading frame 8 2.1 other

129575 F08282 Hs.278428 progestin induced protein 1.6 other 129587 H14718 Hs.11506 Human clone 23589 mRNA sequence 6.8 other

129588 BE408300 Hs.301862 postmeiotic segregation increased 2-like 1.4 TM

129591 N57423 Hs.179898 HSPC055 protein 7.4 other

129594 AW403724 Hs.36989 coagulation factor VII (serum prothrombi 9 9

129596 AF035537 Hs.115521 REV3 (yeast homologj-like, catalytic sub 1.6 other

129628 U38945 Hs.1174 cyclin-dependent kinase inhibitor 2A (me 2.2 other

129649 AD000092 Hs.16488 calreticulin 3.3 other

129675 NM_015556 Hs.172180 KIAA0440 protein 13.4 other

129680 U03749 gb:Human chromogranin A (CHGA) gene, pro 14.1 9

129689 AW748482 Hs.77873 B7 homolog 3 2.6 other

129702 AI304966 Hs.12035 ESTs, Weakly similar to I38022 hypotheti 7.5 TM

129720 AA156214 Hs.12152 APMCF1 protein 2 other

129721 NM 001415 Hs.211539 eukaryotic translation initiation factor 1.7 TM

129778 AK001676 Hs.12457 hypothetical protein FLJ10814 1.8 other

129779 AA394090 Hs.12460 Homo sapiens clone 23870 mRNA sequence 5.5 TM

129800 AF052112 Hs.12540 lysosomal 1.7 9

129806 AB023148 Hs.173373 KIAA0931 protein 1.2 other

129815 BE565817 Hs.26498 hypothetical protein FLJ21657 3.1 other

129840 NM 06590 Hs.12820 SnRNP assembly defective 1 homolog 1.8 other

129861 AL049999 Hs.85963 DKFZP564M182 protein 2.3 other

129864 AI393237 Hs.129914 runt-related transcription factor 1 (acu 1.7 SS,

129869 AI222069 Hs.13015 hypothetical protein similarto mouse Dn 2.8 TM

129945 BE514376 Hs.165998 PAI-1 mRNA-binding protein 1.8 other

129953 AA412195 Hs.13740 ESTs 2.5 other

129972 AW753185 Hs.180628 dynamin 1-like 1.8 9

129983 U09848 Hs.132390 zinc finger protein 36 (KOX 18) 1.3 other

130010 AA301116 Hs.142838 nucleolar phosphoprotein Nopp34 1.6 other

130081 AA287325 Hs.14713 ESTs 4.1 other

130082 S73265 Hs.1473 gastrin-releasing peptide 1.9 other

130097 AL046962 Hs.14845 forkhead box 03A 2.8 other

130100 AL135561 Hs.14891 hypothetical protein FLJ21047 2.3 other

130111 X53002 Hs.149846 integrin, beta 5 2.3 other

130112 AA916785 Hs.180610 splicing factor proline/glutamine rich ( 3 other

130128 L76937 Hs.150477 Werner syndrome 1.8 other

130135 AA311426 Hs.21635 tubulin, gamma 1 6.1 other

130211 NM 03358 Hs.23703 ESTs, Moderately similar to CEGT HUMAN C 1.6 other

130212 D80001 Hs.152629 KIAA0179 protein 1.3 other

130236 R85367 Hs.51957 splicing factor, arginine/serine-rich 2, 2 other

130241 AL035588 Hs.153203 MyoD family inhibitor 3.2 other

130242 X79201 Hs.153221 synovial sarcoma, translocated to X chro 5.4 9

130249 D81983 Hs.322852 GAS2-related on chromosome 22 4.9 other

130263 NM 002497 Hs.153704 NIMA (never in mitosis gene a)-related k 1.4 other

130287 AA479005 Hs.154036 tumor suppressing subtransferabte candid 2.6 other

130310 AB011121 Hs.154248 amyotrophic lateral sclerosis 2 (juvenil 6.3 other

130353 Z19084 Hs.172210 MUF1 protein 6.2 other

130356 AF127577 Hs.155017 nuclear receptor interacting protein 1 2.4 other

130357 AJ224442 Hs.155020 putative ethyltransferase 3.5 TM

130359 NM 013449 Hs.277401 bromodomain adjacent to zinc finger doma 8.5 other

130367 AL135301 Hs.8768 hypothetical protein FLJ10849 1.4 other

130372 AI077464 Hs.5011 RNA binding motif protein 9 3.3 ?

130393 N89487 Hs.155291 KIAA0005 gene product 1.8 other

130399 AW374106 Hs.155356 hypothetical protein MGC2840 similarto 3.4 other

130407 BE385099 Hs.334727 hypothetical protein MGC3017 2.3 other

130409 NMJ01197 Hs.155419 BCL2-interacting killer (apoptosis-induc 2.7 TM

130419 AF037448 Hs.155489 NS1-associated protein 1 1.8 other

130441 U63630 Hs.155637 protein kinase, DNA-activated, catalytic 2.3 other

130448 BE513202 Hs.15589 PPAR binding protein 4 TM

130455 D90041 Hs.155956 N-acetylfransferase 1 (arylamine N-acety 33.6 9

130485 BE245851 Hs.180779 H2B histone family, member B 5 other

130487 U49844 Hs.77613 ataxia telangiectasia and Rad3 related 4.4 other

130498 L38951 Hs.180446 karyopherin (importin) beta 1 1.6 SS.TM

130503 BE208491 Hs.295112 KIAA0618 gene product 16.1 other

130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pse 6.1 other

130526 AW876523 Hs.15929 hypothetical protein FLJ12910 2.1 other

130544 AA321238 Hs.4310 eukaryotic translation initiation factor 1.5 other

130553 AF062649 Hs.252587 pituitary tumor-transforming 1 14.4 ?

130556 AI907018 Hs.15977 Empirically selected from AFFX single pr 4.8 other 130567 AA383092 Hs.1608 replication protein A3 (14kD) 8 other

130568 AA232119 Hs.16085 putative G-protein coupled receptor 3.4 other

130574 AF083208 Hs.16178 apoptosis antagonizing transcription fac 1.2 other

130598 AL042210 Hs.16493 hypothetical protein DKFZp762N2316; KIAA 1.4 other

130601 AA609738 Hs.16525 ESTs 1.5 TM

130614 AI354355 Hs.16697 down-regulator of transcription 1, TBP-b 1.3 other

130617 M90516 Hs.1674 glutemine-fructose-6-phosphate transarnin 12.1 TM

130618 AA383439 Hs.16758 Spir-1 protein 15.9 other

130667 BE246961 Hs.17639 Homo sapiens ubiquitin protein ligase (U 13.9 other

130674 AL048842 Hs.194019 attractin 1.5 other

130675 AA442233 Hs.17731 hypothetical protein FLJ12892 5.4 other

130692 AA652501 Hs.13561 hypothetical protein MGC4692 5 other

130693 R68537 Hs.17962 ESTs 2 other

130712 AJ271881 Hs.279762 bromodomain-containing 7 1.8 TM

130714 AI348274 Hs.18212 DNA segment on chromosome X (unique) 987 2 TM

130730 AB007920 Hs.18586 KIAA0451 gene product 3.8 9

130744 H59696 Hs.18747 POP7 (processing of precursor, S. cerevi 3.2 9

130751 AF052105 Hs.18879 chromosome 12 open reading frame 1.4 other

130757 AL036067 Hs.18925 protein x 0001 5.7 other

130768 AF258627 Hs.211562 ATP-binding cassette, sub-family A (ABC1 5.2 ?

130789 AK000355 Hs.8899 sirtuin (silent mating type information 1.6 other

130836 J05068 Hs.2012 transcobalamin I (vitamin B12 binding pr 15.7 SS,

130841 AL157468 Hs.325825 Homo sapiens cDNA FLJ20848 fis, clone AD 2.8 other

130843 AA447492 Hs.20183 ESTs, Weakly similarto AF164793 1 prate 1.5 other

130844 U76248 Hs.20191 seven in absentia (Drosophila) homolog 2 3.5 other

130855 AJ243706 Hs.143323 putative DNA/chromatin binding motif 1.7 other

130861 NM_016578 Hs.20509 HBV pX associated protein-8 1.9 other

130879 NM 003416 Hs.2076 zinc finger protein 7 (KOX 4, clone HF.1 1.4 other

130880 BE514434 Hs.20830 kinesin-like 2 2.1 TM

130892 AL120837 Hs.20993 high-glucose-regulated protein 8 2.5 other

130898 AB033078 Hs.186613 sphingosine-1 -phosphate lyase 1 1.7 other

130911 BE409769 Hs.21189 DnaJ (Hsp40) homolog, subfamily A, membe 1.8 other

130919 N79110 Hs.21276 collagen, type IV, alpha 3 (Goodpasture 2.3 TM

130944 BE382657 Hs.21486 signal transducer and activator of trans 5.4 other

130971 N39842 Hs.301444 KIAA1673 2.2 SS,

130993 T97401 Hs.21929 ESTs 1.6 other

131005 AV658308 Hs.2210 thyroid hormone receptor interactor 3 1.6 9

131028 AI879165 Hs.2227 CCAAT/enhancer binding protein (C/EBP), 1.2 other

131042 AI826288 Hs.171637 hypothetical protein MGC2628 1.6 other

131046 AA321649 Hs.2248 small inducible cytokine subfamily B (Cy 7.4 ?

131060 AA194422 Hs.22564 myosin VI 5.1 other

131070 N53344 Hs.22607 ESTs 7.1 other

131076 AA749230 Hs.26433 doliehyl-phosphate (UDP-N-acetylglucosam 2.1 TM

131099 AL133353 Hs.226581 COX15 (yeast) homolog, cytochrome c oxid 7.1 other

131174 NM 006540 Hs.29131 nuclear receptor coactivator 2 1.9 9

131185 BE280074 Hs.23960 cyclin B1 5.8 9

131206 AW138839 Hs.24210 ESTs 2 other

131213 AA885699 Hs.24332 CGI-26 protein 7.1 TM

131225 H62087 Hs.31659 thyroid hormone receptor-associated prat 7.6 ?

131231 N47468 Hs.59757 zinc finger protein 281 2.9 other

131233 D89053 Hs.268012 fatty-acid-Coenzyme A ligase, long-chain 3.5 other

131243 AW383256 Hs.24752 spectrin SH3 domain binding protein 1 2.8 ?

131245 AL080080 Hs.24766 thioredoxin domain-containing 2.8 SS.TM

131247 AL043100 Hs.326190 fatty acid amide hydrolase 5.6 other

131281 AA251716 Hs.25227 ESTs 5.8 other

131283 X80038 Hs.339713 Homo sapiens clone F19374 APO E-C2 gene 1.3 other

131305 AV656017 Hs.184325 CGI-76 protein 5 ?

131320 AA505691 Hs.145696 splicing factor (CC1.3) 1.8 TM

131339 AF058696 Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 2.6 other

131375 AW293165 Hs.143134 ESTs 5.4 other

131390 BE269388 Hs.182698 mitochondrial ribosomal protein L20 5.3 other

131410 BE259110 Hs.279836 HSPC166 protein 2.2 other

131412 NMJJ12247 Hs.124027 SELENOPHOSPHATE SYNTHETASE ; Human selen 2

131429 AL046302 Hs.26750 hypothetical protein FLJ21908 1.4 other

131458 BE297567 Hs.27047 hypothetical protein FLJ20392 1.7 other

131475 AA992841 Hs.27263 KIAA1458 protein 2 other

131501 AV661958 Hs.8207 GK001 protein 2.6 other 131511 AA732153 Hs.27865 Homo sapiens cDNA: FLJ21333 fis, clone C 2 other

131528 AU076408 Hs.28309 UDP-glucose dehydrogenase 1.6 TM

131532 BE268278 Hs.28393 hypothetical protein MGC2592 7.4 other

131543 AW966881 Hs.41639 programmed cell death 2 2.2 other

131544 AL355715 Hs.28555 programmed cell death 9 (PDCD9) 2.1 other

131562 NMJ03512 Hs.28777 H2A histone family, member L 1.7 other

131564 T93500 Hs.28792 Homo sapiens cDNA FLJ11041 fis, clone PL 5.2 other

131569 AL389951 Hs.271623 nucleoporin 50kD 5 other

131618 BE393822 Hs.29645 Homo sapiens mRNA; cDNA DKFZp761C029 (fr 1.8 other

131622 R78195 Hs.29692 Homo sapiens cDNA FLU 1436 fis, clone HE 1.3 other

131623 AB037791 Hs.29716 hypothetical protein FLJ10980 2.2 TM

131643 AW410601 Hs.30026 HSPC182 protein 3 other

131653 AW960597 Hs.30164 ' ESTs 1.3 other

131656 AI218918 Hs.30209 KIAA0854 protein 2.8 other

131669 X52486 Hs.3041 uracil-DNA glycosyiase 2 2.8 other

131692 BE559681 Hs.30736 KIAA0124 protein 5.6 ?

131714 AA642831 Hs.31016 putative DNA binding protein 2.9 9

131722 D13757 Hs.311 phosphoribosyl pyrophosphate amidotransf 3.4 other

131737 AK001641 Hs.31323 inhibitor of kappa light polypeptide gen 3.9 ?

131763 AI878932 Hs.317 topoisomerase (DNA) 1 3.4 other

131772 AA382590 Hs.170980 KIAA0948 protein 25.5 other

131787 D87077 Hs.196275 KIAA0240 protein 2.4 SS,

131793 AW966127 Hs.32246 Homo sapiens cDNA FLJ14656 fis, clone NT 8 TM

131795 BE501849 Hs.32317 high-mobility group 20B 1.5 other

131798 X86098 Hs.301449 adenovirus 5 E1A binding protein 4.2 other

131817 U20536 Hs.3280 caspase 6, apoptosis-related cysteine pr 4.3 other

131824 U28838 Hs.32935 TATA box binding protein (TBP)-associate 3.5 other

131850 AI251317 Hs.33184 ESTs 5.2 TM

131878 AA083764 Hs.6101 hypothetical protein MGC3178 5.9 other

131885 BE502341 Hs.3402 ESTs 13.7 other

131900 AA099014 Hs.231029 Homo sapiens, clone MGC:15961, mRNA, com 8.7 other

131904 AF078866 Hs.284296 Homo sapiens cDNA: FLJ22993 fis, clone K 5.5 other

131905 AA1 9298 Hs.3439 stomatin-like 2 11.3 other

131913 AW207440 Hs.185973 degenerative spermatocyte (homolog Droso 1.7 SS,

131916 AA025976 Hs.34569 ESTs 5.2 TM

131925 AF151048 Hs.183180 anaphase promoting complex subunit 11 (y 2.8 other

131929 BE541211 Hs.34804 Homo sapiens cDNA FLJ11472 fis, clone HE 5.4 TM

131941 BE252983 Hs.35086 ubiquitin specific protease 1 2.4 other

131950 AA355113 Hs.35380 x 001 protein 1.5 ?

131962 AK000046 Hs.267448 hypothetical protein FLJ20039 2.3 other

131965 W79283 Hs.35962 ESTs 1.4 other

131971 BE567100 Hs.154938 hypothetical protein MDS025 3.5 other

131977 U90441 Hs.3622 procollagen-proline, 2-oxoglutarate 4-di 6.6 TM

131985 AA503020 Hs.36563 hypothetical protein FLJ22418 2.4 ?

131991 AF053306 Hs.36708 budding uninhibited by benzimidazoles 1 2.2 SS.TM

132019 H56995 Hs.37372 Homo sapiens DNA binding peptide mRNA, p 3.3 TM

132062 BE266155 Hs.3832 clathrin-associated protein AP47 1.5 other

132084 NM 002267 Hs.3886 karyopherin alpha 3 (importin alpha 4) 3.7 other

132103 BE171921 Hs.3991 ESTs 1.5 other

132105 AV646076 Hs.39959 ESTs 5.8 TM

132116 AW960474 Hs.40289 ESTs 1.7 other

132176 AA857025 Hs.8878 kinesin-like 1 3.4 other

132180 NM 004460 Hs.418 fibroblast activation protein, alpha 14.7 SS,

132194 R42432 Hs.4212 ESTs 2.2 other

132207 BE206939 Hs.42287 E2F transcription factor 6 1.5 other

132235 AV658411 Hs.42656 KIAA1681 protein 5.7 other

132252 AI566004 Hs.141269 Homo sapiens cDNA: FLJ21550 fis, clone C 2.1 other

132266 AA301228 Hs.43299 hypothetical protein FLJ12890 1.5 other

132273 AA227710 Hs.43658 DKFZP586L151 protein 10 other

132276 AA653507 Hs.285711 hypothetical protein FLJ 13089 2 other

132288 N36110 Hs.305971 solute carrier family 2 (facilitated glu 9.2 other

132294 AB023191 Hs.44131 KIAA0974 protein 2 other

132298 NM 015986 Hs.7120 cytokine receptor-like molecule 9 6.6 SS,

132299 AW405882 Hs.44205 cortistatin 3.8 other

132325 N37065 Hs.44856 hypothetical protein FLJ12116 1.5 other

132370 AW572805 Hs.46645 ESTs 28.3 ?

132374 AF155582 Hs.46744 core1 UDP-galactose:N-acetylgalactosamin 1.9 other 132376 AI279892 Hs.46801 sorting nexin 14 2 ?

132384 AA312135 Hs.46967 HSPC034 protein 6.1 ?

132393 AL135094 Hs.47334 hypothetical protein FLJ14495 1.7 other

132450 AA100012 Hs.48827 hypothetical protein FLJ12085 8.6 other

132452 AW973521 Hs.247324 mitochondrial ribosomal protein S14 5.3 other

132456 AB011084 Hs.48924 KIAA0512 gene product; ALEX2 1.5 other

132470 AI224456 Hs.4934 H.sapiens polyA site DNA 2 other

132484 X16660 Hs.119007 RAB4, member RAS oncogene family 2.9 SS,

132518 AW885606 Hs.5064 ESTs 2.2 other

132530 AA306105 Hs.50785 SEC22, vesicle trafficking protein (S. c 1.7 other

132532 AA454132 Hs.5080 mitochondrial ribosomal protein L16 7.2 TM

132534 BE388673 Hs.5086 hypothetical protein MGC10433 2.2 SS,

132543 BE568452 Hs.5101 protein regulator of cytokinesis 1 2.2 other

132574 AW631437 Hs.5184 TH1 drosophila homolog 14 9

132596 AK001484 Hs.5298 CGI-45 protein 1.9 other

132611 AA345547 Hs.53263 hypothetical protein FLJ 13287 2.6 TM

132612 H12751 Hs.5327 PR01914 protein 2 other

132616 BE262677 Hs.283558 hypothetical protein PR01855 3.1 other

132638 AI796870 Hs.54277 DNA segment on chromosome X (unique) 992 12.4 TM

132668 AB018319 Hs.5460 KIAA0776 protein . 2.8 SS,

132692 AW191962 Hs.249239 collagen, type VIII, alpha 2 3 other

132715 F11875 Hs.5534 Homo sapiens cDNA FLJ12961 fis, clone NT 1.8 other

132718 NM_004600 Hs.554 Sjogren syndrome antigen A2 (60kD, ribon 3.7 other

132724 AI142265 Hs.55498 geranylgeranyl diphosphate synthase 1 1.8 TM

132731 AI189075 Hs.301872 hypothetical protein MGC4840 5.9 other

132744 AA010233 Hs.55921 glutamyl-prolyl-tRNA synthetase 8.7 other

132760 AA125985 Hs.56145 thymosin, beta, identified in neuroblast 3.6 other

132771 Y10275 Hs.56407 phosphoserine phosphatase 2.8 TM

132773 AA459713 Hs.295901 KIAA0493 protein 14.6 other

132784 AI142133 Hs.56845 GDP dissociation inhibitor 2 1.7 other

132798 AI026701 Hs.5716 KIAA0310 gene product 2.5 other

132807 U07418 Hs.57301 mutL (E. coli) homolog 1 (colon cancer, 1.4 other

132810 AB007944 Hs.5737 KIAA0475 gene product 4.3 SS,

132813 BE313625 Hs.57435 solute carrier family 11 (proton-coupled 2.8 other

132815 AI815189 Hs.57475 sex comb on midleg homolog 1 1.6 other

132817 N27852 Hs.57553 tousled-like kinase 2 1.4 other

132821 AJ251595 Hs.169610 CD44 antigen (homing function and Indian 5.4 other

132833 U78525 Hs.57783 eukaryotic translation initiation factor 6.1 9

132842 NM 016154 Hs.279771 Homo sapiens clone PP1596 unknown mRNA 7.2 other

132844 F12200 Hs.5811 chromosome 21 open reading frame 59 2.9 other

132851 U09716 Hs.287912 lectin, mannose-binding, 1 6.1 other

132869 AW963217 Hs.203961 ESTs, Moderately similar to AF116721 89 1.8 other

132873 AW007683 Hs.58598 KIAA1266 protein 2.2 other

132875 NM 004850 Hs.58617 Rho-associated, coiled-coil containing p 5 TM

132891 BE267143 Hs.59271 U2(RNU2) small nuclear RNA auxiliary fac 2.7 9

132897 AW503667 Hs.59545 ring finger protein 15 5.4 9

132902 A1936442 Hs.59838 hypothetical protein FLJ10808 3.2 other

132912 AW732760 Hs.167578 Homo sapiens cDNA FLJ11095 fis, clone PL 1.4 other

132913 W78714 Hs.60257 Homo sapiens cDNA FLJ 13598 fis, clone PL 3 other

132940 T79136 Hs.127243 Homo sapiens mRNA for KIAA1724 protein, 10.3 other

132942 AA554458 Hs.197751 KIAA0666 protein 2.1 SS,

132952 AI658580 Hs.61426 Homo sapiens mesenchymal stem cell prate 1.3 other

132962 AA576635 Hs.6153 CGI-48 protein 4.9 other

132972 AA034365 Hs.288924 Homo sapiens cDNA FLJ11392 fis, clone HE 3.6 TM

132973 AA035446 Hs.323277 ESTs 13.1 other

132977 AA093322 Hs.301404 RNA binding motif protein 3 1.3 other

132980 AA040696 Hs.62016 ESTs 2.3 ?

132994 AA112748 Hs.279905 clone HQ0310 PRO0310p1 17.1 other

133012 AA847843 Hs.62711 Homo sapiens, clone IMAGE:3351295, mRNA 1.9 other

133015 AJ002744 Hs.246315 UDP-N-acetyl-alpha-D-galactosamine:polyp 5 TM

133062 AW500374 Hs.64056 PRO0149 protein 6.1 other

133069 BE247441 Hs.6430 protein with polyglutamine repeat; calci 1.5 TM

133091 AK001628 Hs.64691 KIAA0483 protein 1.4 other

133110 AA808177 Hs.65228 ESTs 5.6 other

133134 AF198620 Hs.65648 RNA binding motif protein 8A 1.9 other

133145 H94227 Hs.6592 Homo sapiens, clone IMAGE:2961368, mRNA, 4.8 9

133152 Z11695 Hs.324473 mitogen-activated protein kinase 1 5 other 133174 AA431620 Hs.324178 hypothetical protein MGC2745 2.7 other

133175 AW955632 Hs.66666 ESTs, Weakly similar to S19560 proline-r 9.3 other

133177 X97795 Hs.66718 RAD54 (S.cerevisiae)-like 4.5 TM

133208 A1801777 Hs.6774 ESTs 5.5 TM

133226 AW954569 Hs.296287 Homo sapiens, Similarto bromodomain-con 2.7 other

133228 AI492924 Hs.6831 golgi phosphoprotein 1 1.7 ?

133254 AI567421 Hs.273330 Homo sapiens, clone IMAGE:3544662, mRNA, 1.3 other

133268 AW956781 Hs.293937 ESTs, Weakly similarto FXD2JHUMAN FORKH 12.2 other

133291 BE297855 Hs.69855 NRAS-related gene 1.2 other

133314 AA102670 Hs.70725 gamma-aminobutyric acid (GABA) A recepto 1.7 TM

133321 T79526 Hs.179516 integral type 1 protein 11.1 ?

133327 AL390127 Hs.7104 Kruppel-like factor 13 2.9 other

133347 BE257758 Hs.71475 acid cluster protein 33 2.5 9

133360 AI016521 Hs.71816 v-akt murine thymoma viral oncogene homo 1.5 other

133366 AA292811 Hs.72050 non-metastatic cells 5, protein expresse 2.1 other

133367 AF231919 Hs.18759 KIAA0539 gene product 1.3 other

133370 AF245505 Hs.72157 DKFZP564I1922 protein 2.2 other

133390 AI950382 Hs.72660 phosphatidylserine receptor 5.7 TM

133391 AW103364 Hs.727 inhibin, beta A (activin A, activin AB a 25.5 other

133394 AA305127 Hs.237225 hypothetical protein HT023 3.3 other

133437 AL031591 Hs.7370 phosphotidylinositol transfer protein, b 1.6 other

133452 NM_002759 Hs.274382 protein kinase, interferon-inducible dou 4.1 other

133453 AI659306 Hs.73826 protein tyrosine phosphatase, non-recept 1.5 other

133500 AW964804 Hs.74280 hypothetical protein FLJ22237 6.3 TM

133529 W45623 Hs.74571 ADP-ribosylation factor 1 4 9

133543 AU077073 Hs.108327 damage-specific DNA binding protein 1 (1 1.8 9

133578 AU077050 Hs.75066 translin 1.5 other

133579 X75346 Hs.75074 mitogen-activated protein kinase-activat 3.5 TM

133582 BE391579 Hs.75087 Fas-activated serine/threonine kinase 6.8 TM

133594 AW160781 Hs.172589 nuclear phosphoprotein similarto S. cer 2.6 TM

133595 AA393273 Hs.75133 transcription factor 6-like 1 (mitochond 1.4 other

133599 NM_002885 Hs.75151 RAP1, GTPase activating protein 1 8.1 other

133621 NM 004893 Hs.75258 H2A histone family, member Y 13.5 other

133627 NM_002047 Hs.75280 glycyl-tRNA synthetase 2.2 other

133631 NM 00401 Hs.75334 exostoses (multiple) 2 1.8 other

133649 U25849 Hs.75393 acid phosphatase 1, soluble 2 other

133690 AV661185 Hs.75574 mitochondrial ribosomal protein L19 2.8 other

133720 L27841 Hs.75737 pericentriolar material 1 6.8 other

133722 AW969976 Hs.279009 matrix Gla protein 2.5 other

133751 AW402048.comp Hs.334787 Homo sapiens, Similarto likely ortholog 3.1 TM

133757 T52946 Hs.196209 RAE1 (RNA export 1, S.pombe) homolog 1.4 9

133760 BE271766 Hs. 81357 laminin receptor 1 (67kD, ribosomal prot 5.4 other

133765 M62194 Hs.75929 cadherin 11 , type 2, OB-cadherin (osteob 5 other

133780 AA557660 Hs.76152 decorin 3.8 other

133797 AL133921 Hs.76272 retinoblastoma-binding protein 2 3.1 9

133822 D50525 Hs.699 peptidylprolyl isomerase B (cyclophilin 9.7 ?

133842 AW797468 Hs.285013 putative human HLA class II associated p 2.4 other

133845 AA147026 Hs.76704 ESTs 2.5 other

133865 AB011155 Hs.170290 discs, large (Drosophila) homolog 5 5 other

133867 AW340125 Hs.76989 KIAA0097 gene product 2.5 ?

133868 AB012193 Hs.183874 cullin 4A 2.1 other

133922 U30825 Hs.77608 splicing factor, arginine/serine-rich 9 2.8 TM

133924 D86326 Hs.325948 vesicle docking protein p115 1.8 SS,

133929 NM 006306 Hs.211602 SMC1 (structural maintenance of chromoso 2 ?

133936 L17128 Hs.77719 gamma-glutamyl carboxylase 2.6 other

133941 BE244332 Hs.77770 adaptor-related protein complex 3, mu 2 2.9 other

133959 X81789 Hs.77897 splicing factor 3a, subunit 3, 60kD 10.4 other

133976 AI908165 Hs.169946 GATA-binding protein 3 (T-cell receptor 1.9 other

133989 AL040328 Hs.78202 SWI/SNF related, matrix associated, adi 2.6 SS,

133997 AI824113 Hs.78281 regulator of G-protein signalling 12 13 other

134010 AB016092 Hs.197114 RNA binding protein; AT-rich element bin 8.8 other

134015 D31764 Hs.278569 sorting nexin 17 1.5 SS,

134070 NM 03590 Hs.78946 cullin 3 8.3 other

134110 U41060 Hs.79136 LIV-1 protein, estrogen regulated 2.7 other

134129 NM_014742 Hs.79305 KIAA0255 gene product 4.2 other

134134 H86504 Hs.173328 protein phosphatase 2, regulatory subuni 1.7 other

134200 BE559598 Hs.197803 KIAA0160 protein 2.6 other 134206 AF107463 Hs.79968 splicing factor 30, survival of motor ne 1.3 other

134219 NM 000402 Hs.80206 glucose-6-phosphate dehydrogenase 1.9 other

134234 BE300078 Hs.80449 Homo sapiens, clone IMAGE:3535294, mRNA, 10.3 SS,

134275 AI878910 Hs.3688 cisplatin resistance-associated overexpr 2.5 other

134292 AI906291 Hs.81234 immunoglobulin superfamily, member 3 1.3 TM

134301 AW502505 Hs.81360 Homo sapiens cDNA: FLJ21927 fis, clone H 1.6 TM

134305 U61397 Hs.81424 ubiquitin-like 1 (sentrin) 2.1 TM

134324 AB029023 Hs.179946 KIAA1100 protein 5.3 ?

134326 AW903838 Hs.81800 chondroitin sulfate proteoglycan 2 (vers 2.5 TM

134329 N92036 Hs.81848 RAD21 (S. pombe) homolog 3.9 ?

134337 NM 004922 Hs.81964 SEC24 (S. cerevisiae) related gene famil 2.4 TM

134348 AW291946 Hs.82065 interleukin 6 signal transducer (gp130, 6.8 TM

134367 AA339449 Hs.82285 phosphoribosylglycinamide formyltransfer 2.3 TM

134376 X06560 Hs.82396 2',5'-oligoadenylate synthetase 1 (40-46 5.5 other

134379 AW362124 Hs.323193 hypothetical protein MGC3222 5.9 TM

134384 AI589941 Hs.8254 Homo sapiens, Similar to tumor different 2.2 other

134391 AA417383 Hs.82582 integrin, beta-like 1 (with EGF-like rep 2.1 other

134395 AA456539 Hs.8262 lysosomal 2.3 other

134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 other

134411 BE272095 Hs.167791 reticulocalbln 1, EF-hand calcium bindin 4.4 other

134415 AI750762 Hs.82911 protein tyrosine phosphatase type IVA, m 2.3 other

134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.8 ?

134424 Z44190 Hs.83023 peroxisomal biogenesis factor 11 B 2.4 other

134446 AA112036 Hs.83419 KIAA0252 protein 2.9 other

134447 M58603 Hs.83428 nuclear factor of kappa light polypeptid 6.7 other

134470 X54942 Hs.83758 CDC28 protein kinase 2 2.4 other

134480 NM 005000 Hs.83916 Empirically selected from AFFX single pr 6.3 ?

134485 X82153 Hs.83942 cathepsin K (pycnodysostosis) 1.9 other

134498 AW246273 Hs.84131 threonyl-tRNA synthetase 1.8 other

134513 AA425473 Hs.84429 KIAA0971 protein 1.4 other

134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 other

134520 BE091005 Hs.74861 activated RNA polymerase II transcriptio 5.6 other

134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 9

134577 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor 1.7 other

134582 AA927177 Hs.86041 CGG triplet repeat binding protein 1 1.7 TM

134612 AW068223 Hs.171581 ubiquitin C-terminal hydrolase UCH37 2.1 other

134624 AF035119 Hs.8700 deleted in liver cancer 1 1.3 other

134632 X78520 Hs.174139 chloride channel 3 2.1 ?

134654 AK001741 Hs.8739 hypothetical protein FLJ10879 2.3 other

134666 BE391929 Hs.8752 transmembrane protein 4 4 other

134687 U62317 Hs.88251 arylsulfatase A 6.2 other

134692 NM 003474 Hs.8850 a disintegrin and metalloproteinase doma 2 other

134705 BE161887 Hs.88799 anaphase-promoting complex subunit 10 1.3 SS,

134714 Y14768 Hs.890 lysosomal 7.2 ?

134719 AA852985 Hs.89232 chromobox homolog 5 (Drosophila HP1 alph 3.2 other

134722 AF129536 Hs.284226 F-box only protein 6 2.5 other

134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 5 other

134751 AW630803 Hs.89497 lamin B1 6.1 other

134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM

134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other

134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 other

134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonUde 2.4 other

134880 AI879195 Hs.90606 15 kDa selenoprotein 2.7 other

134925 AW885909 Hs.6975 PRO1073 protein 1.5 other

134955 AW401361 Hs.91773 protein phosphatase 2 (formerly 2A), cat 4.9 other

134971 AI097346 Hs.286049 phosphoserine aminotransferase 2 other

134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM

135011 AB037835 Hs.92991 KIAA1414 protein 1.4 9

135022 NM 000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ?

135032 AW301984 Hs.173685 hypothetical protein FLJ 12619 1.4 other

135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other

135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other

135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM

135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other

135153 AI093155 Hs.95420 JM27 protein 4.4 ?

135181 BE250865 Hs.279529 px19-like protein 14.9 9

135199 AA477514 Hs.96247 translin-associated factor X 1.3 other 135207 N26427 Hs.9634 ESTs, Highly similarto C10JHUMAN PUTATI 1.7 other

135214 T78802 Hs.96560 hypothetical protein FLJ11656 6.2 other

135243 BE463721 Hs.97101 putative G protein-coupled receptor 2.8 TM

135245 AI028767 Hs.262603 ESTs 12.2 TM

135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.7 TM

135263 AI088775 Hs.55498 geranylgeranyl diphosphate synthase 1 1.8 other

135274 AA448460 Hs.112017 GE36gene 4.2 SS,

135294 AA150320 Hs.9800 protein kinase Njmu-R1 1.2 other

135295 AI090838 Hs.98006 ESTs 4.9 other

135307 AI743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.9 ?

135321 AI652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 TM

135354 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.8 ?

135361 AA373452 Hs.167700 Homo sapiens cDNA FLJ10174 fis, clone HE 8.1 other

135389 U05237 Hs.99872 fetal Alzheimer antigen 1.9 other

135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9 TM

302256 AA857131 Hs.171595 HIV TAT specific factor 1 1.6 other

302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c-erb-b2, 5.3 other

303135 AW592789 Hs.279474 HSPC070 protein 2.2 TM

303686 AK000714 Hs.109441 MSTP033 protein 1.4 SS,

310085 R43191 Hs.101248 Homo sapiens clone IMAGE:32553, mRNA seq 5.2 other

315518 AA808229 Hs.167771 ESTs 2.3 9

317781 NM_007057 Hs.42650 ZW10 interactor 2.9 9

320836 AI268997 Hs.197289 rab3 GTPase-activating protein, non-cata 2 other

321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.6 SS,

322221 N24236 Hs.179662 nucleosome assembly protein 1 -like 1 1.4 ?

322474 AF118083 Hs.29494 PR01912 protein 1.3 other

322556 BE041451 Hs.177507 hypothetical protein 2.9 SS,

323541 AF292100 Hs.104613 RP42 homolog 1.6 other

407827 BE278431 Hs.40323 BUB3 (budding uninhibited by benzimidazo 1.8 other

408196 AL034548 Hs.43627 SRY (sex determining region Y)-box 22 1.6 other

408813 AI580090 Hs.48295 RNA helicase family 6.2 other

409176 R73727 Hs.101617 ESTs, Weakly similarto T32527 hypotheti 5.7 other

409487 H19886 gb:yn57a05.r1 Soares adult brain N2b5HB5 2.7 other

413670 AB000115 Hs.75470 hypothetical protein, expressed in osteo 2.6 9

414108 AI267592 Hs.75761 SFRS protein kinase 1 2.4 TM

414846 AW304454 Hs.77495 UBX domain-containing 1 2.4 other

416040 AW819158 Hs.289044 Homo sapiens cDNA FLJ 12048 fis, clone 2.3 other

416980 AA381133 Hs.80684 high-mobility group (nonhistone chromoso 4.2 TM

417378 R57256 Hs.82037 TATA box binding protein (TBP)-associate 23.6 other

418283 S79895 Hs.83942 cathepsin K (pycnodysostosis) 5.8 other

418467 NM_006910 Hs.85273 retinoblastoma-binding protein 6 1.3 other

420269 U72937 Hs.96264 alpha thalassemia/mental retardation syn 1.6 9

420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3 ?

421225 AA463798 Hs.102696 MCT-1 protein 1.6 9

421642 AF172066 Hs.106346 retinoic acid repressible protein 3.5 other

421828 AW891965 Hs.279789 histone deacetylase 3 5 other

421983 AI252640 Hs.110364 peptidylprolyl isomerase C (cyclophilin 3.1 TM

422052 AA302744 Hs.104518 ESTs 1.9 TM

422055 NM_014320 Hs.111029 putative heme-binding protein 2.4 other

423750 AF165883 Hs.298229 prefoldin 2 4.2 9

424001 W67883 Hs.137476 paternally expressed 10 (PEG10; KIAA105 7.1 ?

425182 AF041259 Hs.155040 zinc finger protein 217 2.3 other

425284 AF155568 Hs.155489 NS1 -associated protein 1 3.5 other

426372 BE304680 Hs.169531 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 1.9 ?

428049 AW183765 Hs.182238 GW128 protein 7.6 ?

428477 AW500533 Hs.11482 splicing factor, arginine/serine-rich 11 1.7 other

437562 AB001636 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 2.4 other

438449 AK001333 Hs.6216 Homo sapiens hepatocellular carcinoma-as 3.8 other

441560 F13386 Hs.7888 Homo sapiens clone 23736 mRNA sequence 5.6 other

445580 AF167572 Hs.12912 skbl (S. pombe) homolog 2 TM

446999 AA151520 Hs.334822 hypothetical protein MGC4485 7.6 other

447111 AI017574 Hs.17409 cysteine-rich protein 1 (intestinal) 2.2 other

447778 BE620592 Hs.71190 ESTs, Weakly similarto S16506 hypotheti 2.9 other

448873 NMJ03677 Hs.22393 density-regulated protein 1.8 other

449687 W68520 Hs.331328 intermediate filament protein syncoilin 5.9 other

450701 H39960 Hs.288467 Homo sapiens cDNA FLJ12280 fis, clone MA 5.7 other

450703 AA011202 Hs.184771 nuclear factor l/C (CCAAT-binding transc 1.4 other 452461 N78223 Hs.108106 transcription factor 4.8 ?

452511 BE408178 Hs.285165 Homo sapiens cDNA FLJ20845 fis, clone AD 2.9 other

453157 AF077036 Hs.31989 DKFZP586G1722 protein 12.1 SS,TM

453658 BE541906 Hs.87819 Homo sapiens, clone MGC:2492, mRNA, comp 4.8 other

100685 AA328229 Hs.184582 ribosomal protein L24 1.8 TM

100690 AA383256 Hs.1657 estrogen receptor 1 1.6 other

100833 AF135168 Hs.108802 N-ethylmaleimide-sensitive factor 1.3 other

100850 AA836472 Hs.297939 cathepsin B 1.7 ?

101161 NM 006262 Hs.37044 peripherin 16.9 other

102481 U50360 gb:Human calcium, calmodulin-dependent p 3.2 other

102831 AA262170 Hs.80917 adaptor-related protein complex 3, sigma 2 9

103549 BE270465 Hs.78793 protein kinase C, zeta 8 other

103749 AL135301 Hs.8768 hypothetical protein FLJ 10849 1.8 other

104331 AB040450 Hs.279862 cdk inhibitor p21 binding protein 2 9

104532 AI498763 Hs.203013 hypothetical protein FLJ12748 2.1 other

104563 AL117403 Hs.306189 DKFZP434F1735 protein 1.2 other

105032 AA127818 gb:zl12a02.s1 Soares pregnant_uterus NbH 7 9

105039 AA907305 Hs.36475 ESTs 2.6 ?

106531 AA454036 Hs.8832 ESTs 1.6 other

106977 AL043152 Hs.50421 KIAA0203 gene product 4.9 other

107298 N95657 Hs.6820 ESTs, Moderately similar to YOJ1_CAEEL H 2.5 TM

108717 AA122393 Hs.70811 hypothetical protein FLJ20516 1.3 other

110018 AW579842 Hs.104557 hypothetical protein FLJ10697 5.3 TM

110330 AI288666 Hs.16621 DKFZP434I116 protein 6.3 other

111391 NM 003896 Hs.225939 sialyltransferase 9 (CMP-NeuAc:lactosylc 5.1 SS,

111392 W46342 Hs.325081 Homo sapiens, clone IMAGE:3659680, mRNA, 8.4 other

113554 AW503990 Hs.142442 HP1-BP74 3.7 TM

113722 AV653556 Hs.184411 albumin 1.3 other

115008 AK001827 Hs.87889 helicase-moi 2 other

115062 AA253314 Hs.154103 LIM protein (similarto rat protein kina 1.5 other

115121 AI634549 Hs.88155 ESTs 2.8 other

117881 AF161470 Hs.260622 butyrate-induced transcript 1 5.8 TM

119075 M10905 Hs.287820 fibronectin 1 5.7 other

119615 AL034423 Hs.75875 ubiquitin-conjugating enzyme E2 variant 1.3 other

120253 AA131376 Hs.326401 fibroblast growth factor 12B 38.9 other

125006 BE065136 Hs.145696 splicing factor (CC1.3) 2.9 9

127609 X80031 Hs.530 collagen, type IV, alpha 3 (Goodpasture 1.8 other

128868 AA419008 Hs.106730 chromosome 22 open reading frame 3 3 other

128891 F34856 Hs.292457 Homo sapiens, clone MGC:16362, mRNA, com 13.3 other

128959 AI580127 Hs.107381 hypothetical protein FLJ11200 10.9 other

129209 R62676 Hs.17820 Rho-associated, coiled-coil containing p 2.4 other

129449 AI096988 Hs.111554 ADP-ribosylation factor-like 7 8.2 TM

129453 AW974265 Hs.111632 Lsm3 protein 3.3 9

129629 AK000398 Hs.11747 hypothetical protein FLJ20391 3.9 other

129917 M30773 Hs.278540 protein phosphatase 3 (formerly 2B), reg 5.3 TM

129922 AF042379 Hs.13386 gamma-tubulin complex protein 2 4.6 other

129989 AB015856 Hs.247433 activating transcription factor 6 4 SS,

130182 BE267033 Hs.192853 ubiquitin-conjugating enzyme E2G 2 (homo 4.6 other

130365 W56119 Hs.155103 eukaryotic translation initiation factor 11 other

130471 AL121438 Hs.183706 adducin 1 (alpha) 2.7 other

130542 U64675 Hs.179825 RAN binding protein 2-like 1 7.9 other

130586 AB007891 Hs.16349 KIAA0431 protein 5.6 TM

130768 AF258627 Hs.211562 ATP-binding cassette, sub-family A (ABC1 5.2 other

130992 BE398091 Hs.74316 des oplakin (DPI, DPII) 1.8 TM

131047 H23230 Hs.22481 ESTs, Moderately similarto A46010 X-lin 1.7 ?

131135 NM_016569 Hs.267182 TBX3-iso protein 3.3 TM

131339 AF058696 Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 2.6 other

131760 X76732 Hs.3164 nucleobindin 2 2.9 TM

131774 BE267158 Hs.169474 DKFZP586J0119 protein 5.6 other

131853 AI681917 Hs.3321 ESTs, Highly similar to IRX1_HUMAN IROQU 1.3 other

131881 AW361018 Hs.3383 upstream regulatory element binding prat 3.2 TM

131887 W17064 Hs.332848 SWI/SNF related, matrix associated, acti 3.2 other

132031 AF193844 Hs.3758 COP9 complex subunit 7a 5.9 ?

132192 AA206153 Hs.4209 mitochondrial ribosomal protein L37 2.2 TM

132203 NM 004782 Hs.194714 synaptosomal-associated protein, 29kD 7.9 9

132240 AB018324 Hs.42676 KIAA0781 protein 4.3 other

132348 AW067708 Hs.170311 heterogeneous nuclear ribonucleoprotein 12.5 other 132528 T78736 Hs.50758 SMC4 (strudural maintenance of chromoso 7.4 ?

132571 AW674699 Hs.5169 suppressor of G2 allele of SKP1 , S. cere 6.9 other

132726 N52298 Hs.55608 hypothetical protein MGC955 14.3 ?

132863 BE268048 Hs.236494 RAB10, member RAS oncogene family 10.3 other

133016 AI439688 Hs.6289 hypothetical protein FLJ20886 4.4 other

133053 AI065016 Hs.6390 Homo sapiens clone FLB3344 PRO0845 mRNA, 1.8 SS.TM

133197 AI275243 Hs.180201 hypothetical protein FLJ20671 1.8 other

133240 AK001489 Hs.242894 ADP-ribosylation factor-like 1 1.8 other

133266 AI160873 Hs.69233 zinc finger protein 16.1 other

133285 M76477 Hs.289082 GM2 ganglioside adivator protein 10.4 SS,

133383 BE313555 Hs.7252 KIAA1224 protein 1.5 ?

133540 AL037159 Hs.74619 proteasome (prosome, macropain) 26S subu 1.7 other

133784 BE622743 Hs.301064 arfaptin 1 12.1 other

133791 M34338 Hs.76244 spermidine synthase 9.7 other

133850 W29092 Hs.7678 cellular retinoic acid-binding protein 1 4.2 SS,

133859 U86782 Hs.178761 26S proteasome-associated padl homolog 2.2 other

133881 U30872 Hs.77204 centromere protein F (350/400kD, mitosin 9.1 other

134208 NM 000288 Hs.79993 peroxisomal biogenesis fador 7 3.2 other

134403 AA334551 Hs.82767 sperm specific antigen 2 1.4 other

134724 AF045239 Hs.321576 ring finger protein 22 1.4 other

134806 AD001528 Hs.89718 spermine synthase 2.6 other

134859 D26488 Hs.90315 KIAA0007 protein 13.3 other

135193 X95525 Hs.96103 TATA box binding protein (TBP)-associate 3.1 other

AA243007 ESTs 1.6 9

T70541 ESTs 2.5 SS,

X57766 Human stromelysin-3 mRNA 4.5 other

S66431 Homo sapiens clone 23592 mRNA sequence 3.1 other

AA453483 ESTs 4.6 TM

R63925 ESTs 1.4 other

AA173417 ESTs 1.9 other

AA280588 ESTs 2.2 other

AA504223 ESTs Highly similarto CHROMOSOME 2.4 other

AA609996 ESTs Highly similarto Surf-4 protein [M.musculus] 5.5 ?

F02907 ESTs 2.3 TM

AA480103 ESTs Weakly similar to 111! ALU SUBFAMILY J 2.8 TM

AA024664 Human NADH:ubiquinoπe oxidoreductase subunit 6.2 other

AA251776 ESTs 2.3 other

AA399047 ESTs 2.4 other

N34059 EST - RC.N34059 3.3 other

U95367 Human GABA-A receptor pi subunit mRNA complete eds 1.7 TM

AA490899 ESTs 3.3 other

T54762 ESTs 2.9 9

Z41963 Homo sapiens HP protein (HP) mRNA complete eds 1.3 ?

AA521186 ESTs 1.6 TM

AA400195 ESTs 1.3 other

AA045083 VITAMIN K-DEPENDENT GAMMA-CARBOXYLASE 2.5 other

AA099589 Homo sapiens mRNA for GDP dissociation inhibitor beta 1.6 TM

W85712 ESTs Weakly similarto PROCOLLAGEN ALPHA 2(IV 2.6 TM

W45728 ESTs Highly similarto HETEROGENEOUS 3.7 other

U61232 Human tubulin-folding cofactor E mRNA complete eds 2.1 other

AA425154 ESTs 5.3 other

T39176 ESTs Weakly similar to ZK1058.4 [C.elegans] 2.6 SS.TM

AA496000 ESTs 1.9 SS,

W38150 EST- RC_W38150 1.7 9

T96595 EST - RC_T96595 1.8 TM

AA227463 ESTs Weakly similarto No definition line found [C.elegans] 1.9 ?

R46025 ESTs 2.8 SS,

AA233177 ESTs 2 other

AA338760 ESTs 1.3 9

AA412106 ESTs 6.2 other

L47276 EST - L47276 3.4 other

D82307 ESTs Weakly similarto TH1 protein [D.melanogaster] 11.4 other

AA293568 ESTs 1.5 other

R37778 ESTs 2.4 other

AA250843 Interferon regulatory factor 5 14.6 ?

W49521 Human prolyl 4-hydroxylase alpha (II) subunit 6.5 9

D80000 Human mRNA for KIAA0178 gene partial eds 2 other R99978 ESTs Weakly similarto line-1 protein ORF2 [H.sapiens] 6.1

AA195036 Human Ro/SSA ribonucleoprotein homolog (RoRel I 5.3 ?

Z38501 ESTs Weakly similar to PROBABLE E5 1.4 other

U37547 Human IAP homolog B (MIHB) mRNA complete eds 3.2 other

AA479961 ESTs 1.7 other

X57579 Inhibin beta A (activin A activin AB alpha polypeptide) 15.8

AA449071 ESTs 1.3 TM

N51855 ESTs Moderately similarto NAD(+) ADP- 1.3 other

AA421213 ESTs Weakly similar to F28F8.3 [C.elegans] 3.2 other

AA355201 ESTs 1.2 SS M

N78717 H.sapiens mRNA for t anslin 1.5 9

N73808 ESTs 5 9

U86782 Human 26S proteasome-associated padl 2.2 other

AA234817 ESTs 1.3 other

D13666 Homo sapiens mRNA for osteoblast specific 7.5 SS,

AA236177 ESTs 7.1 9

U50648 Protein kinase interferon-induclble double 4.1 ?

M28211 Homo sapiens GTP-binding protein (RAB4) 2.9 other

AA446949 ESTs 2.2 other

W03007 ESTs 1.2 other

W61011 ESTs 1.2 other

W87544 ESTs 1.2 other

X02751 Neuroblastoma RAS viral (v-ras) oncogene homolog 1.2 9

Z14077 YY1 transcription factor 1.2 other

Z38839 ESTs 1.2 9

AA410894 ESTs 1.7 other

AA504499 ESTs Highly similar to probable chloride channel 3 [H.sap 1.3 other

TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigenelD's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

102481 31281_-28 U50360 105032 genbank_AA127818 AA127818

409487 1134778J H 19886 AW402806T10231

TABLE 8: Figure 8 from BRCA 001-1 US

Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue. Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal body tissue

R2: Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD Unigene Title R1 R2

100075 AF152333 Hs.284160 protocadherin gamma subfamily B, 4 1 3.8 100229 AV652249 Hs.180107 polymerase (DNA directed), beta 1.7 5.3 100262 D38500 Hs.278468 postmeiotic segregation increased 2-like 0.8 4.8 100271 BE160081 Hs.256290 S100 calcium-binding protein A11 (calgiz 3.2 2.3 100355 AI907114 Hs.71465 squalene epoxidase 3.3 1.4 100522 X51501 Hs.99949 proladin-induced protein 11.9 0.4 100552 AA019521 Hs.301946 lysosomal 3.8 1.2 100599 X77343 Hs.334334 transcription factor AP-2 alpha (activat 9.4 9.4 100676 X02761 Hs.287820 fibronectin 1 3 7.8 100690 AA383256 Hs.1657 estrogen receptor 1 4.4 4.4 100895 U01351 Hs.75772 nuclear receptor subfamily 3, group C, m 1 3.9 101046 K01160 NM_002122:Homo sapiens major histocompatl .7 4 101086 AA382524 Hs.250959 histatin 1 0.8 4.1 101148 NM_002923 Hs.78944 regulator of G-proteln signalling 2, 24k 1.2 12 101161 NMJ06262 Hs.37044 peripherin 3.1 1.1 101201 L22524 Hs.2256 matrix metalloproteinase 7 (MMP7; uterin 4.4 0.6 101212 AI186220 Hs.83164 collagen, type XV, alpha 1 3.1 3.4 101441 AW468397 Hs.100000 S100 calcium-bin ing protein A8 (calgran 0.9 4.2 101447 M21305 gb:Human alpha satellite and satellite 3 29.9 0.3 101469 AA310162 Hs.169248 cytochrome c 0.8 4.9 101567 M33552 Hs.56729 lysosomal 1 5.9 101600 BE561617 Hs.119192 H2A histone family, member Z 2.8 4 101624 M55998 gb:Human alpha-1 collagen type I gene, 3 3.1 1.7 101674 NM_002291 Hs.82124 laminin, beta 1 1.5 4.1 101861 AA350659 Hs.83347 angio-associated, migratory cell protein 3.1 1.4 101977 AF112213 Hs.184062 putative Rab5-interacting protein 1.3 6.9 102193 AL036335 Hs.313 secreted phosphoprotein 1 (osteopontin, 1.9 4.9 102199 AA334592 Hs.79914 lumican 2.2 3.8 102304 AF015224 Hs.46452 mammaglobin 1 4.2 0.7 102345 NM_003480 Hs.300946 Microfibril-associated glycoprotein-2 1.1 4.2 102457 NMJJ01394 Hs.2359 dual specificity phosphatase 4 4.5 0.5 102534 U96759 Hs.198307 von Hippel-Lindau binding protein 1 1.4 4.2 102541 AI379954 Hs.79025 KIAA0096 protein 0.9 3.9 102827 BE244588 Hs.6456 chaperonin containing TCP1, subunit 2 (b 1.5 10.9 102962 R50032 Hs.159263 collagen, type VI, alpha 2 2.2 6.2 102991 AW293542 Hs.75309 eukaryotic translation elongation factor 5.6 5.7 103119 X63629 Hs.2877 cadherin 3, type 1, P-cadherin (placenta 3.7 0.5 103175 X69089 Hs.79227 myo esiπ (M-prateiπ) 2 (165kD) 1.3 4 103286 D38616 Hs.54941 phosphoiylase kinase, alpha 2 (liver) 1.3 3.8 103319 X83492 Hs.82359 tumor necrosis factor receptor superfami 0.8 4.6 103372 BE536700 Hs.4888 seryl-tRNA synthetase 0.9 8 103419 T34708 Hs.272927 Sec23 (S. cerevisiae) homolog A 1.1 5.1 103471 Y00815 Hs.75216 protein tyrosine phosphatase, receptor t 3.7 1.2 103546 Z14244 Hs.75752 cytochrome c oxidase subunit Vllb 0.9 4.4 103658 NM 000088 Hs.172928 collagen, type I, alpha 1 3.2 3

103758 AA084874 gb:zn13e04.r1 Stratagene hNT neuron (937 0.9 10

103774 H24185 Hs.92918 hypothetical protein 1.9 15.9

103821 AA095971 Hs.198793 Homo sapiens cDNA: FLJ22463 fis, clone H 1.2 3.9

103869 BE439604 Hs.24322 ATPase, H+ transporting, lysosomal (vacu 1.4 3.9

103980 AW130242 Hs.293476 hypothetical protein FKSG44 1.6 4.1

104054 AK001913 Hs.7100 hypothetical protein 1.5 4.3

104115 AF183810 Hs.26102 opposite strand to trichorhinophalangeal 7 7

104189 AB040927 Hs.301804 KIAA1494 protein 2 4.6

104230 AB002347 Hs.15303 KIAA0349 protein 0.7 4.5

104278 AW583693 Hs.109253 N-terminal acetyltransferase complex ard 3.3 3.3

104295 AW365522 Hs.103657 hypothetical protein PR02219 2.3 4.2

104319 AW804296 Hs.9950 Sec61 gamma 3.1 7

104425 AF283775 Hs.35380 x 001 protein 4 1.3

104432 X51501 Hs.99949 prolactin-induced protein 3.8 0.6

104464 AW966728 Hs.54642 methionine adenosyltransferase II, beta 0.8 6.7

104479 AK001731 Hs.106390 Homo sapiens mRNA; cDNA DKFZp586H0924 (f 1.7 4.8

104505 W94824 Hs.11565 RIKEN cDNA 2010100012 gene 2 7.5

104592 AW630488 Hs.325820 protease, serine, 23 1.9 7.4

104613 AF123303 Hs.24713 hypothetical protein 1.1 6.3

104636 R82252 Hs.106106 protein kinase (cAMP-dependent, catalyti 1.2 4

104782 AW270555 Hs.171774 hypothetical protein 1.4 3.9

104792 AA960961 Hs.305953 zinc finger protein 83 (HPF1 ) 1.5 4.2

104848 AA305351 Hs.274369 uncharacterized hypothalamus protein HAR 1.1 4.1

104849 AI279065 Hs.241507 ribosomal protein S6 1.3 4.6

104850 AL133035 Hs.8728 hypothetical protein DKFZp434G171 1.2 3.6

104852 W70164 Hs.20107 ESTs 0.8 4.2

104861 AA058630 Hs.29759 RNA POLYMERASE I AND TRANSCRIPT RELEASE 1.7 5.1

104873 W03831 Hs.20597 host cell factor homolog 0.8 5.4

104891 W44626 Hs.30627 ESTs 0.7 6.8

104920 AW955089 Hs.306083 Novel human gene mapping to chomosome 22 1 3.9

104926 BE298808 Hs.33363 DKFZP434N093 protein 3.3 3.3

104952 AW076098 Hs.74316 des oplakin (DPI, DPII) 1.2 3.7

104963 AB029020 Hs.173694 KIAA1097 protein 1.1 5.5

104977 AI392640 Hs.18272 amino acid transporter system A1 3.2 1.4

105030 BE613061 Hs.337772 Homo sapiens, Similarto RIKEN cDNA 0610 1.6 11.4

105035 N39760 Hs.8859 Homo sapiens, Similar to RIKEN cDNA 5830 1.5 7.2

105068 BE410438 Hs.9006 VAMP (vesicle-associated membrane protei 1.1 3.5

105159 AF146277 Hs.265561 CD2-associated protein 1.2 10

105178 AA313825 Hs.21941 AD036 protein 3.6 8.3

105182 BE407961 Hs.18271 golgi phosphoprotein 3 1.7 6.8

105274 AI554929 Hs.281866 ATPase, H+ transporting, lysosomal (vacu 1.1 3.7

105303 BE243327 Hs.182626 chromosome 22 open reading frame 5 1.5 4

105413 AI015709 Hs.172089 Homo sapiens mRNA; cDNA DKFZp586l2022 (f 1.5 14

105426 W20027 Hs.23439 ESTs 4.3 2.9

105432 W03516 Hs.76698 stress-associated endoplasmic reticulum 1.5 5

105443 AA252372 Hs.12144 KIAA1033 protein 1.2 3.6

105483 AL137257 Hs.23458 Homo sapiens cDNA: FLJ23015 fis, clone L 1.7 15.8

105492 AI805717 Hs.289112 CGI-43 protein 2 4.8

105495 AL037715 Hs.28785 microfibrillar-associated protein 3 1.3 3.9

105539 AB040884 Hs.109694 KIAA1451 protein 2.7 11.4

105594 AB024334 Hs.25001 tyrosine 3-monooxygenase/tryptophan 5-mo 1.3 6.1

105623 BE504200 Hs.30127 hypothetical protein 1.7 4.5

105807 AA788946 Hs.16869 ESTs, Moderately similar to CA1C RAT COL 3.9 24.6

105812 BE614149 Hs.20814 CGI-27 protein 1.8 3.6

105823 AI559444 Hs.293960 ESTs 1.9 6.6

105831 AA329449 Hs.247302 twisted gastrulation 1.5 4.3

105851 AI827976 Hs.24391 hypothetical protein FLJ13612 3.8 1.9

105879 BE392914 Hs.30503 Homo sapiens cDNA FLJ11344 fis, clone PL 1.7 4

105918 AW028485 Hs.26136 hypothetical protein MGC14156 1.7 7.4

105939 AL137728 Hs.12258 Homo sapiens mRNA; cDNA DKFZp434B0920 (f 1.2 3.8

105941 AB033075 Hs.10669 development and differentiation enhancin 1.3 4.6

105969 AB030656 Hs.17377 coronin, actin-binding protein, 1C 1.1 5.9

105990 A1690586 Hs.29403 hypothetical protein FLJ22060 2 4.6

106012 AI240665 Hs.8895 ESTs 4.1 1.2

106060 NM 001329 Hs.1 1391 C-terminal binding protein 2 2.6 7

106070 T74445 Hs.5957 Homo sapiens clone 24416 mRNA sequence 1.4 10.7 106083 H62087 Hs.31659 thyroid hormone receptor-associated prat 1.5 3.6

106155 AA425414 Hs.33287 nuclear factor l/B 5.4 1.2

106255 BE613206 Hs.279607 calpastatin 1.8 4

106414 BE568205 Hs.28827 mitogen-adivated protein kinase kinase 5.1 6.1

106538 AK000274 Hs.278635 HDCMA18P protein 1.2 5.9

106568 AW051564 Hs.28285 patched related protein translocated in 1.8 5.4

106574 BE044325 Hs.227280 U6 snRNA-associated Sm-like protein 2.3 11.2

106613 N88604 Hs.30212 thyroid receptor interacting protein 15 1.2 3.6

106617 H09548 Hs.5367 ESTs, Weakly similarto I38022 hypotheti 0.9 4.4

106619 AA459480 Hs.23956 hypothetical protein FLJ20502 1.3 3.6

106701 BE387614 Hs.25797 splicing factor 3b, subunit 4, 49kD 1.6 7.3

106721 AA741038 Hs.6670 ESTs 1.7 6.1

106776 AA206079 Hs.6693 hypothetical protein FLJ20420 1 5.4

106866 AA487416 Hs.268231 Homo sapiens cDNA: FLJ23111 fis, clone L 1.6 5.4

106868 BE185536 Hs.301183 molecule possessing ankyrin repeats indu 3.3 1.2

106887 BE503373 Hs.334335 hypothetical protein FLJ13576 1.4 6.3

106940 T85594 Hs.339808 hypothetical protein FLJ10120 3.3 1.8

106968 AF216751 Hs.26813 CDA14 3 3

107052 BE391904 Hs.12482 glyceronephosphate O-acyltransferase 1.7 7.6

107061 BE147611 Hs.6354 stromal cell derived factor receptor 1 1.2 4.3

107149 AI289507 Hs.299883 hypothetical protein FLJ23399 1.8 6.5

107222 BE172058 Hs.82689 tumor rejection antigen (gp96) 1 1.2 6.9

107233 BE267795 Hs.22595 hypothetical protein FLJ10637 1.4 3.5

107295 AA186629 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp 2.6 4.3

107679 AA011510 Hs.60512 ESTs 1.8 4

107914 AA027229 Hs.61329 ESTs, Weakly similarto T16370 hypotheti 1.3 3.5

107965 AF109219 Hs.108787 phosphatidylinositol glycan, class N 1.6 3.5

108033 AW368993 Hs.323748 Homo sapiens clone CDABP0086 mRNA sequen 1.8 8.1

108060 AA291440 Hs.73149 paired box gene 8 1.1 3.5

108081 AA093668 Hs.28578 muscleblind (Drosophila)-like 0.7 5.6

108137 AI283611 Hs.263479 ESTs, Weakly similarto HMG1_HUMAN HIGH 1.2 5.6

108186 AW068579 Hs.7780 Homo sapiens mRNA; cDNA DKFZp564A072 (fr 3.1 6.9

108215 AI879238 Hs.299315 collapsin response mediator protein-5; C 1.5 4.6

108297 AA333660 Hs.71331 hypothetical protein MGC5350 1.5 4

108339 AW151340 Hs.51615 ESTs, Weakly similarto ALU7 HUMAN ALU S 6.3 4.7

108371 AA074374 Hs.67639 ESTs 1.3 3.8

108399 AF086070 Hs.237519 EST 1 3.6

108469 AA079487 gb:zm97f08.s1 Stratagene colon HT29 (937 1.5 3.6

108470 AA079500 gb:zm96h10.s1 Stratagene colon HT29 (937 1.1 4.3

108564 M23114 Hs.1526 ATPase, Ca++ transporting, cardiac muscl 2 4.9

108641 AA112059 Hs.429 ATP synthase, H+ transporting, mitochond 1.1 3.5

108668 AA058522 Hs.185751 ESTs 1.2 3.6

108694 AA036725 Hs.61847 ESTs 1.4 3.6

108824 AK001332 Hs.44672 hypothetical protein FLJ10470 1.4 3.5

108863 AA133456 Hs.102548 glucocorticoid receptor DNA binding fact 1.2 4

108893 BE276891 Hs.194691 retinoic acid induced 3 1.3 3.6

108992 AA152312 Hs.72047 ESTs 1.1 4.1

109072 AI732585 Hs.22394 hypothetical protein FLJ 10893 1.2 3.5

109097 AA167512 gb:zp10f12.s1 Stratagene fetal retina 93 1.3 5

109160 BE220601 Hs.301997 hypothetical protein FLJ 13033 4 6.1

109244 BE179030 Hs.64239 Human DNA sequence from clone RP5-1174N9 1.7 7.4

109481 AA878923 Hs.289069 hypothetical protein FLJ21016 3.8 7.7

109484 AA366263 Hs.72531 hypothetical protein FLJ11838 1.9 4

109795 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (f 3.7 1.3

110009 BE075297 Hs.6614 ESTs, Weakly similarto A43932 mucin 2 p 4.6 7.4

110107 AW151660 Hs.31444 ESTs 1.2 3.5

110411 AW001579 Hs.9645 Homo sapiens mRNA for KIAA1741 protein, 3.7 3.3

110731 NM 014899 Hs.188006 KIAA0878 protein 2.8 3.7

110756 N21207 Hs.182999 ESTs 1.6 3.5

110930 BE242691 Hs.14947 ESTs 3.1 1.2

110935 AI753230 Hs.323562 hypothetical protein DKFZp564K142 1.9 7.5

111051 AI681293 Hs.12186 hypothetical protein FLJ22558 2 4

111110 AK001566 Hs.23618 hypothetical protein FLJ10704 1.1 3.8

111356 BE301871 Hs.4867 mannosyi (alpha-1,3-)-glycoprotein beta- 1 8.2

111357 BE314949 Hs.87128 hypothetical protein FLJ23309 3.3 6.1

111770 R27975 Hs.269401 ESTs, Moderately similar to S65657 alpha 1.2 5.4

111900 AF131784 Hs.25318 Homo sapiens clone 25194 mRNA sequence s 3.2 0.8 111903 NM 014906 Hs.166351 KIAA1072 protein 1 5.4

111951 NM_014927 Hs.100527 KIAA0902 protein 1 3.8

112141 AW137198 Hs.278682 Phosphatidylglyceraphosphate Synthase 1.4 3.5 112193 R49499 Hs.138238 ESTs 1.5 3.6

112197 NM_003655 Hs.5637 ESTs 4.6 2

112610 AW500106 Hs.23643 serine/threonine protein kinase MASK 3.3 10.5

112971 Z42387 Hs.83883 transmembrane, prostate androgen induced 3.2 3

112984 T16971 Hs.289014 ESTs, Weakly similar to A43932 mucin 2 p 3.7 10.8

113056 AF019226 Hs.8036 glioblastoma overexpressed 4.5 3.7

113449 AW160683 Hs.158006 hypothetical protein 1.2 4.4

113497 AF143321 Hs.15572 hypothetical protein IMAGE 109914 0.9 3.6

113508 AL042936 Hs.211571 holocytochrome c synthase (cytochrome c 1.1 3.5

113531 AK001898 Hs.16740 hypothetical protein FLJ11036 1.2 3.9

113604 AI075407 Hs.296083 ESTs, Moderately similarto I54374 gene 1.7 5.3

113674 NM_014214 Hs.5753 inositol(myo)-1(or4)-monophosphatase 2 0.8 6.1

113841 W30681 Hs.146233 Homo sapiens cDNA: FLJ22130 fis, clone H 1.7 6.2

113857 AW243158 Hs.5297 DKFZP564A2416 protein . 1.2 4.6

113931 BE255499 Hs.3496 hypothetical protein MGC15749 1.5 4

113936 W17056 Hs.83623 nuclear receptor subfamily 1, group I, m 3.8 1

113987 AA345519 Hs.9641 complement component 1, q subcomponent, 1.2 4.7

114132 AI342493 Hs.24192 Homo sapiens cDNA FLJ20767 fis, clone CO 0.3 4.3

114156 BE179882 Hs.336920 glutathione peroxidase 3 (plasma) 1.1 4.3

114213 N58309 Hs.19575 CGI-11 protein 1.6 9.2

114636 AA075488 gb:zm88d01.s1 Stratagene ovarian cancer ' 1.6 3.7

114760 AI929382 Hs.252692 hypothetical protein FLJ20343 1.4 4

114781 T10446 Hs.95388 ESTs 1 4.3

114795 AB037858 Hs.173484 hypothetical protein FLJ10337 1.6 9.2

114901 AV660012 Hs.196437 hypothetical protein FLJ10788 1.4 5.2

115096 AI683069 Hs.175319 ESTs 3.7 1

115518 BE541042 Hs.23240 Homo sapiens cDNA: FLJ21848 fis, clone H 3.2 4.2

115646 N36110 Hs.305971 solute carrier family 2 (facilitated glu 1.5 3.9

115764 AW582256 Hs.91011 anterior gradient 2 (Xenepus laevis) horn 1.3 5.9

115802 AW410233 Hs.206521 YME1 (S.cerevisiae)-like 1 1.7 6.6

115994 AB037836 Hs.109315 KIAA1415 protein 1.5 9.1

116032 BE383668 Hs.42484 hypothetical protein FLJ10618 0.9 4.3

116046 BE395293 Hs.94491 hypothetical protein FLJ20297 1.6 5.5

116274 AI129767 Hs.182874 guanine nucleotide binding protein (G pr 3.2 2.4

116310 Z24854 Hs.42299 ESTs 0.8 4.7

116356 AI371223 Hs.288671 Homo sapiens cDNA FLH 1997 fis, clone HE 2.4 3.9

116429 AF191018 Hs.279923 putative nucleotide binding protein, est 5.5 5.5

116461 AA313607 Hs.58633 Homo sapiens cDNA: FLJ22145 fis, clone H 5 1.3

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 8.7 4.5

116578 D21262 Hs.75337 πucleolar and coiled-body phosphprotein 3.2 6.9

116579 AW888411 Hs.81915 leukemia-associated phosphoprotein p18 ( 3.2 3

116589 AI557212 Hs.17132 ESTs, Moderately similarto I54374 gene 3.1 8.3

116786 H25836 Hs.301527 ESTs, Moderately similarto unknown [H.s 3.2 4.5

117170 N25929 Hs.42500 ADP-ribosylation factor-like 5 7 5.5

117215 N20066 Hs.133207 PTPRF interacting protein, binding prate 1.2 6.2

117280 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C 4.5 2.4

117576 AI383467 Hs.44597 ESTs 1.4 4.2

117667 U59305 Hs.44708 Ser-Thr protein kinase related to the my 4.3 0.5

117881 AF161470 Hs.260622 butyrate-induced transcript 1 2.1 5.7

118336 BE327311 Hs.47166 HT021 3.6 7.7

118475 N66845 gb:za46d 1 ,s1 Soares fetal liver spleen 4.2 0.5

118493 AL353944 Hs.50115 Homo sapiens mRNA; cDNA DKFZp761J111 I2 (f 3.5 3.3

118505 N67343 gb:yz50b07.s1 Morton Fetal Cochlea Homo 2.1 3.8

119159 AF142419 Hs.15020 homolog of mouse quaking QKI (KH domain 3.7 1.5

119307 BE048061 Hs.37054 ephrin-A3 3 1.1

119355 BE218319 Hs.5807 GTPase Rab14 1.1 5.6

119462 BE041667 Hs.314544 Homo sapiens cervical cancer suppressor- 1.4 4.3

119771 AI905687 Hs.2533 EST 3.2 1

119940 AL050097 Hs.272531 DKFZP586B0319 protein- 4.3 0.7

119943 BE565849 Hs.14158 copine III 3.5 1.9

120407 AA235207 Hs.250456 hypothetical protein DKFZp762F2011 1.5 3.7

120493 AW968080 Hs.152939 Homo sapiens clone 24630 mRNA sequence i 4 1.4

120677 AF150208 Hs.108327 damage-specific DNA binding protein 1 (1 1.6 6.8

120867 AA350781 Hs.96967 ESTs 1.1 3.6 121368 BE262956 Hs.178292 KIAA0180 protein 1.5 4.1

121603 AA416785 Hs.249495 heterogeneous nuclear ribonucleoprotein 2.2 5.5

121723 AA243499 Hs.104800 hypothetical protein FLJ10134 3.4 3.2

122223 AF169797 Hs.27413 adaptor protein containing pH domain, PT 3.9 3.9 122378 AB032948 Hs.21356 hypothetical protein DKFZp762K2015 1.4 7.1

122946 AI718702 Hs.308026 major histocompatibility complex, class 1.4 3.7

123155 AF121856 Hs.284291 sorting nexin 6 1.2 4.9

123158 AF161426 Hs.218329 hypothetical protein 2.4 3.6

123327 AA421581 Hs.178443 ESTs 0.9 5.2 123495 W28673 Hs.106747 serine carboxypeptidase 1 precursor prat 1.3 5.1

123526 AA608657 gb:ae55d04.s1 Stratagene lung carcinoma 2.1 5.2

123533 AA608751 gb:ae56h07.s1 Stratagene lung carcinoma 2.1 9.3

123768 AI932318 Hs.188762 ESTs, Moderatelysimilarto H2BL_HUMAN H 1.1 3.6

123961 AL050184 Hs.21610 DKFZP434B203 protein 1.1 3.5 123999 AF084555 Hs.7351 cyclic AMP phosphoprotein, 19 kD 1.4 3.8

124000 BE563957 Hs.74861 activated RNA polymerase II transcriptio 1.9 11.2

124038 AB037860 Hs.173933 nuclear factor l/A 1.5 4.4

124059 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypotheti 14.8 11.5

124083 AW195237 Hs.7734 hypothetical protein FLJ22174 1.2 6.2 124148 BE300094 Hs.227751 lectin, galactoside-binding, soluble, 1 2.5 12.7

124153 AU077333 Hs.160483 erythrocyte membrane protein band 7.2 (s 1 4.1

124252 BE613340 Hs.334725 Homo sapiens, Similar to RIKEN cDNA 9430 1.5 8.4

124314 AK001552 Hs.215766 GTP-binding protein 1.8 10.2

124375 D87454 Hs.192966 KIAA0265 protein 1.1 4.8 124432 N39016 Hs.268869 ESTs, Weakly similar to ALUC_HUMAN 111! 1.3 4.1

124447 N48000 gb:yy98e12.s1 Soares_multiple_sclerosis_ 2.7 4.3

124539 D54120 Hs.146409 cell division cycle 42 (GTP-binding prat 2.1 5.7

124543 AI393320 Hs.104573 ESTs 1 4.1

124564 H66409 Hs.108275 ESTs 1.4 4 124574 AL036596 Hs.42322 A kinase (PRKA) anchor protein 2 0.7 4

124605 AA749315 Hs.77171 minichromosome maintenance deficient (S. 1.1 3.5

124639 H60193 Hs.21143 DKFZP586C1324 protein 1.4 3.6

124659 AI680737 Hs.289068 Homo sapiens CDNA FLJ11918 fis, clone HE 1.5 9.9

124737 BE270465 Hs.78793 protein kinase C, zeta 0.7 4 124760 AW408586 Hs.91052 ESTs, Moderately similar to ALU5JHUMAN A 0.9 3.6

124763 BE410405 Hs.76288 calpain 2, (m/ll) large subunit 1.3 3.9

124792 R44357 Hs.48712 hypothetical protein FLJ20736 1.8 4.2

124842 R56485 gb:yg93h09.s1 Soares infant brain 1NIB H 1 3.6

124940 AF068846 Hs.103804 heterogeneous nuclear ribonucleoprotein 3.2 3.4 124949 AI903210 Hs.336780 tubulin, beta polypeptide 1 4.4

124960 AL023513 Hs.194766 seizure related gene 6 (mouse)-like 0.9 5.2

124995 T52700 Hs.110044 ESTs 0.9 3.5

125030 AA610577 Hs.187775 ESTs 1.2 5

125034 BE548446 Hs.5167 Homo sapiens mRNA; cDNA DKFZp434F152 (fr 1.5 3.7 125058 T83731 Hs.3343 phosphoglycerate dehydrogenase 0.9 6

125076 AA973971 gb:oq02h08.s1 NCI_CGAP_Lu5 Homo sapiens 1 3.7

125090 T91518 gb:ye20f05.s1 Stratagene lung (937210) H 3.2 2.5

125103 AA570056 Hs.122730 ESTs, Moderately similar to KIAA1215 pro 5.3 6.6

125154 W38419 gb:zc78a07.s1 Pancreatic Islet Homo sapi 0.9 6.1 125155 AA837043 Hs.143669 ESTs 1.1 4.3

125159 AK000669 Hs.274428 TRF2-interacting telomeric RAP1 protein 1.1 4.1

125170 AL020996 Hs.8518 selenoprotein N 1.1 3.8

125181 R40815 Hs.12396 ESTs, Weakly similar to 2004399A chromos 1 3.6

125193 W67577 Hs.84298 CD74 antigen (invariant polypeptide of m 1.2 7.8 125260 H05635 Hs.294030 topoisomerase-related function protein 4 1 4.9

125262 AW884980 Hs.171957 triple functional domain (PTPRF interact 1.3 4.8

125272 BE612888 Hs.180224 myosin regulatory light chain 1.1 16.1

125388 W27235 Hs.64311 a disintegrin and metalloproteinase doma 1.4 5.3

125824 Z45258 Hs.286013 short coiled-coil protein 2.4 8.7 125852 AW630088 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564B1264 (f 1.8 4.6

125970 AW504721 Hs.177516 high density lipoprotein binding protein 1.9 3.8

126192 AW160399 Hs.30376 hypothetical protein 1.4 4.1

126469 BE384361 Hs.182885 ESTs, Weakly similarto JC5024 UDP-galac 2 3.7

126510 AA057593 Hs.334762 hypothetical protein FLJ14735 1.3 4.1 127095 AA340277 Hs.10248 Homo sapiens CDNA FLJ20167 fis, clone CO 1.3 5

127524 AI243596 Hs.94830 ESTs, Moderately similar to T03094 A-kin 4.3 0.9

128312 J04182 Hs.150101 lysosomal 1.5 4.7 128453 X02761 Hs.287820 fibronectin 1 1.2 4.3

128460 T16206 Hs.237164 ESTs, Highly similar to LDHH_HUMAN L-LAC3.1 44.4

128491 H08379 Hs.165563 hypothetical protein DKFZp434N1429 0.6 13.1

128495 NM 005904 Hs.100602 MAD (mothers against decapentaplegic, Dr 1.3 4

128546 NM 03478 Hs.101299 cullin 5 1 5.1

128574 AI185977 Hs.38260 ubiquitin specific protease 18 0.8 4

128611 NM_014721 Hs.102471 KIAA0680 gene product 1.3 3.7

128652 AA432202 Hs.103147 hypothetical protein FLJ21347 1.4 3.9

128653 D87432 Hs.10315 solute carrier family 7 (cationic amino 1.2 3.6

128655 AI246669 Hs.324275 WW domain-containing protein 1 0.8 4.1

128684 BE246444 Hs.283685 hypothetical protein FLJ20396 3 1.6

128717 AK001564 Hs.104222 hypothetical protein FLJ10702 2.8 4.8

128774 AA476220 Hs.54457 CD81 antigen (target of antiproliferativ 1.1 10.6

128790 AF026692 Hs.105700 secreted frizzled-related protein 4 1 3.8

128805 AA194554 Hs.183434 ATPase, H+ transporting, lysosomal (vacu 5.3 5.3

128827 AI638184 Hs.106334 Homo sapiens clone 23836 mRNA sequence 2.2 5.3

128840 AI917602 Hs.106440 ESTs 1 4.5

128869 AA768242 Hs.80618 hypothetical protein 0.8 3.6

128889 D60985 Hs.106909 DKFZP566D193 protein 4.6 3.7

128890 AI222020 Hs.182364 CocoaCrisp 3 1.5

128915 AK000140 Hs.107139 hypothetical protein 0.2 3.9

128920 AA622037 Hs.166468 programmed cell death 5 2.5 15.2

128926 AF155096 Hs.107213 hypothetical protein FLJ20585 4 4

128930 AA298958 Hs.10724 MDS023 protein 1.2 4.5

128942 AW247536 Hs.10729 hypothetical protein 1.4 5

128948 AW953622 Hs.223025 RAB31 , member RAS oncogene family 2.3 5.6

128953 AB020716 Hs.107362 KIAA0909 protein 0.9 3.9

128979 AW271217 Hs.281434 Homo sapiens cDNA FLJ14028 fis, clone HE ; 1.5 3.6

128980 AA258924 Hs.10758 NM_002495*:Homo sapiens NADH dehydrogena 0.8 3.8

129005 AI770025 Hs.13323 hypothetical protein FLJ22059 1.2 5.7

129009 C15105 Hs.330716 Homo sapiens cDNA FLJ14368 fis, clone HE 2.1 9.9

129013 AA371156 Hs.107942 DKFZP564M112 protein 2.4 3.8

129068 AI634522 Hs.152925 KIAA1268 protein 1.2 3.8

129106 AW504486 Hs.108689 sterol regulatory element binding transc 1.2 5.5

129113 BE543205 Hs.288771 DKFZP586A0522 protein 0.5 3.7

129125 AB002450 Hs.278391 CGI-109 protein 1 5.2

129126 AW881089 Hs.108806 Homo sapiens mRNA; cDNA DKFZp566M0947 (f 1.5

129151 N23018 Ηs.171391 C-terminal binding protein 2 2.1 9.7

129230 AA335362 Hs.109646 Empirically selected from AFFX single pr 0.9 8.6

129234 M18916 Hs.282997 glucosidase, beta; acid (includes glucos 1.1 3.5

129238 BE542214 Hs.109697 ESTs 1.1 12.8

129239 W57656 Hs.109701 ubiquitin-like 5 3.2 5.1

129241 AI878857 Hs.109706 hematological and neurological expressed 1.9 5.7

129243 BE169531 Hs.109727 TAK1 -binding protein 2; KIAA0733 protein 1.2 6.6

129247 R49920 Hs.109733 CGI-131 protein 1.5 3.5

129250 AA344367 Hs.109760 Empirically selected from multiple AFFX 1 5.4

129258 AA250970 Hs.251946 poly(A)-binding protein, cytoplasmic 1-1 1.3 4.1

129260 AF077200 Hs.279813 hypothetical protein 1.6 3.9

129270 AA357185 Hs.109918 ras homolog gene family, member H 1.8 4.2

129277 AB007896 Hs.110 putative L-type neutral amino acid trans 1.1 6.1

129284 AA318224 Hs.296141 ESTs 2.5 4.8

129300 W94197 Hs.110165 ribosomal protein L26 homolog 1.6 5.1

129318 AF189062 Hs.285976 tumor metastasis-suppressor 1.8 6.5

129352 AW511656 Hs.170177 Meis (mouse) homolog 0.9 4

129362 U30246 Hs.110736 solute carrier family 12 (sodium/potassi 1.4 9.2

129379 BE278964 Hs.11085 CGI-111 protein 1 4.8

129390 AA318271 Hs.250905 hypothetical protein 1 4.1

129416 AA016188 Hs.111244 hypothetical protein 1.8 10.7

129427 AI498631 Hs.111334 fem'tin, light polypeptide 1.1 4.8

129470 W92931 Hs.250899 heat shock fador binding protein 1 1.8 9.3

129472 AL050260 Hs.323817 DKFZP547E1010 protein 1 5

129475 NM 004477 Hs.203772 FSHD region gene 1 1.1 4.2

129498 AA449789 Hs.75511 connective tissue growth factor 1.9 6.8

129501 AI631811 Hs.180403 STRIN protein 1.1 9.7

129527 AA769221 Hs.270847 delta-tubulin 1.1 4.3

129545 R18087 Hs.323769 cisplatin resistance related protein CRR 1 4.2

129579 AW517695 Hs.286218 junctional adhesion molecule 1 2.3 3.5 129606 AW968941 Hs.166254 hypothetical protein DKFZp566H33 2.4 4.4

129619 AA209534 Hs.284243 tetraspan NET-6 protein 3.2 13

129620 D79338 Hs.239720 CCR4-NOT transcription complex, subunit 1.6 4.6

129621 AL110212 Hs.301005 purine-rich element binding protein B 1.1 5.7

129634 AB020335 Hs.181300 sel-1 (suppressor of lin-12, C.elegans)- 0.9 4.3

129663 AI207406 Hs.11866 translocase of inner mitochondrial membr 1.9 4.8

129679 AW889132 Hs.11916 ribokinase 0.9 4.1

129688 U53209 Hs.24937 transformer-2 alpha (htra-2 alpha) 1.3 4.7

129691 M26939 Hs.119571 collagen, type III, alpha 1 (Ehlers-Danl 4.7 3.7

129712 U46386 Hs.12102 sorting nexin 3 1.2 3.6

129747 AL050272 Hs.12305 DKFZP566B183 protein 1 8.9

129788 BE397454 Hs.124969 Homo sapiens clone 24707 mRNA sequence s 1.4 3.6

129796 BE218319 Hs.5807 GTPase Rab14 2.9 5.1

129797 M62839 Hs.1252 apolipoprotein H (beta-2-glycoprotein I) 0.3 5.1

129800 AF052112 Hs.12540 lysosomal 1.6 8.8

129834 AL080084 Hs.296155 CGI-100 protein 0.9 5.3

129836 AW410233 Hs.206521 YME1 (S.cerevisiae)-iike 1 1.8 9.9

129843 NM 014840 Hs.200598 KIAA0537 gene product 0.9 3.6

129874 AA626937 Hs.181551 hypothetical protein MGC2594 1.4 9.5

129878 Z43161 Hs.283714 30 kDa protein 1.1 6.3

129904 AL119499 Hs.13285 neuronal potassium channel alpha subunit 1 3.5

129917 M30773 Hs.278540 protein phosphatase 3 (formerly 2B), reg 2 5.1

129976 X14008 Hs.234734 lysosomal 0.9 4.9

129982 Z14221 gb:H.sapiens germline transcript of Ig h 1.2 3.6

130007 R15917 Hs.142570 Homo sapiens clone 24629 mRNA sequence i 4.3 1.3

130060 BE277024 Hs.146381 RNA binding motif protein, X chromosome 1.6 3.8

130064 X57815.comf ) Empirically selected from AFFX single pr 1.2 8.2

130068 M93143 Hs.262869 plasminogen-like 1.4 7.9

130090 H97878 Hs.132390 zinc finger protein 36 (KOX 18) 1.4 12.3

130095 AK001635 Hs.14838 hypothetical protein FLJ10773 0.2 4.6

130102 W61005 Hs.14896 DHHC1 protein 1 . 4.1

130112 AA916785 Hs.180610 splicing factor proline/glutamine rich ( 1.2 5.3

130115 T47294 Hs.149923 X-box binding protein 1 3.8 0.8

130123 NM 005095 Hs.150390 zinc finger protein 262 1 4.2

130150 BE094848 Hs.15113 homogentisate 1,2-dioxygenase (homogenti 0.5 4

130161 R42678 Hs.151385 KIAA0564 protein 1 3.7

130210 M23115 Hs.1526 ATPase, Ca-w- transporting, cardiac muscl 0.4 4.4

130213 BE278370 Hs.15265 heterogeneous nuclear ribonucleoprotein 1.7 7.5

130215 BE301883 Hs.152707 glioblastoma amplified sequence 1 5.6

130232 U29463 gb:Human cytochrome b561 gen 1.2 4.2

130252 U92014 Hs.153527 Homo sapiens pTM5 mariner-like transposo 1.3 3.6

130281 W78907 Hs.15395 similarto arginyl-tRNA synthetase (argi 1.5 4.4

130343 AB040914 Hs.278628 KIAA1481 protein 2.9 7.5

130385 AW067800 Hs.155223 stanniocalcin 2 3.2 0.2

130414 AW842182 Hs.241392 small inducible cytokine A5 (RANTES) 1.4 10.6

130417 AW163518 Hs.155485 huntingtin interacting protein 2 1.7 11.7

130440 AA852868 Hs.132853 KIAA0171 gene product 1.1 5

130442 NM 06245 Hs.118244 protein phosphatase 2, regulatory subuni 1.4 4.3

130465 AW362955 Hs.15641 Homo sapiens cDNA FLJ14415 fis, clone HE 1.6 7.6

130479 R44163 Hs.12457 hypothetical protein FLJ10814 0.9 4.1

130499 AB007915 Hs.158286 KIAA0446 gene produd 1 3.8

130546 AI598022 Hs.193989 TAR DNA binding protein 1.3 4.7

130568 AA232119 Hs.16085 putative G-protein coupled receptor 1.2 9.4

130606 AI652143 Hs.288382 hypothetical protein FLJ13111 1 4.1

130612 BE242873 Hs.16677 WD repeat domain 15 1.1 3.6

130616 AL049963 Hs.284205 up-regulated by BCG-CWS 0.6 3.8

130623 AL045128 Hs.1691 glucan (1,4-alpha-), branching enzyme 1 0.9 6.6

130629 AL042896 Hs.1697 ATPase, H+transporting, lysosomal (vacu 0.9 3.9

130632 AW073971 Hs.238954 ESTs, Weakly similar to KIAA1204 protein 0.9 6.9

130639 AI557212 Hs.17132 ESTs, Moderately similar to 154374 gene 2.6 3.9

130641 AF158555 Hs.239189 glufaminase 1.2 13.8

130653 AI861791 Hs.278479 TSPY-like 1.3 4

130655 AI831962 Hs.17409 cysteine-rich protein 1 (intestinal) 2.5 4

130666 AL117508 Hs.194035 KIAA0737 gene product 1.3 6.2

130669 AI928985 Hs.17680 hypothetical protein MGC1314 similarto 1.4 3.9

130693 R68537 Hs.17962 ESTs 3.2 0.8

130694 NM 014827 Hs.17969 KIAA0663 gene product 1.1 4.8 130696 AA325308 Hs.18016 Homo sapiens mRNA; cDNA DKFZp586H0324 (f 1.8

130701 Z98883 Hs.18079 phosphatidylinositol glycan, class Q 1.1 6.7

130707 AW190925 Hs.203559 hypothetical protein FLJ12701 1.2 4.1

130731 AI932971 Hs.18593 Homo sapiens cDNA: FLJ21449 fis, clone C 1.4 6.9

130787 AF072813 Hs.252831 reticulon 3 1.2 11.2

130796 AA088809 Hs.19525 hypothetical protein FLJ22794 1.8 6.8

130808 NM 001761 Hs.1973 cyclin F 1.3 4.1

130863 Y10805 Hs.20521 HMT1 (hnRNP methyltransferase, S. cerevi 3.2 5.9

130902 AB037750 Hs.21061 KIAA1329 protein 1 3.8

130908 AW195747 Hs.21122 hypothetical protein FLJ 11830 similar to 1.3 7.9

130911 BE409769 Hs.21189 DnaJ (Hsp40) homolog, subfamily A, membe 2.7 3.7

130913 BE390905 Hs.21198 translocase of outer mitochondrial membr 1.9 4

130923 H96115 Hs.21293 UDP-N-acteylglucosamine pyrophosphorylas i 1.9 10.3

130959 AB023182 Hs.184523 KIAA0965 protein 1.5 6.8

130967 AA393071 Hs.182579 leucine aminopeptidase 1.4 5.5

130975 AA099923 Hs.283728 PEST-containing nuclear protein 1.3 3.8

131037 BE243101 Hs.22391 chromosome 20open reading frame 3 1.9 4.1

131039 D87436 Hs.166318 lipin 2 1.6 3.5

131060 AA194422 Hs.22564 myosin VI 4.5 5

131097 AL137682 Hs.22937 l-kappa-B-interacting Ras-like protein 2 2 3.7

131101 BE387561 Hs.22981 DKFZP586M1523 protein 1.6 4.5

131104 W27770 Hs.301756 ESTs, Weakly similar to T31475 hypotheti 0.9 3.5

131107 BE620886 Hs.75354 GCN1 (general control of amino-acid synt 2.1 4.5

131109 BE564123 Hs.23060 DKFZP564F0522 protein 1.1 4.6

131136 AB033099 Hs.23413 KIAA1273 protein 1.2 4.2

131148 AW953575 Hs.303125 p53-induced protein PIGPC1 4.5 13.5

131150 X77753 Hs.23582 tumor-associated calcium signal transduc 3.4 0.4

131156 AI472209 Hs.323117 ESTs 0.8 4.9

131164 AW013807 Hs.182265 keratin 19 3.3 2.4

131181 H25094 Hs.293663 ESTs, Moderately similarto I38022 hypot 0.6 4

131194 AW864222 Hs.24083 KIAA0997 protein 1.4 3.8

131199 AW979155 Hs.298275 amino acid transporter 2 1.2 8.5

131215 AL050107 Hs.24341 transcriptional co-activator with PDZ-bi 0.7 4.7

131216 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE 2.1 8.2

131233 D89053 Hs.268012 fatty-acid-Coenzyme A ligase, long-chain 1.7 3.5

131237 AW956868 Hs.24608 DKFZP564D177 protein 1.3 5.4

131262 AU077 58 Hs.24930 tubulin-specific chaperone a 1.6 4.8

131263 AU077002 Hs.24950 regulator of G-protein signalling 5 1.4 4.4

131367 AI750575 Hs.173933 nuclear factor l/A 3.3 2.2

131372 AW293399 Hs.144904 nuclear' receptor co-repressor 1 1.6 3.9

131373 NM_006052 Hs.26146 Down syndrome critical region gene 3 1 11.1

131388 NM 014810 Hs.92200 KIAA0480 gene product 5 2

131492 AI452601 Hs.288869 nuclear receptor subfamily 2, group F, m 0.9 3.5

131493 AW960146 Hs.284137 hypothetical protein FLJ 12888 1 3.5

131514 BE270734 Hs.2795 lactate dehydrogenase A 2 6.5

131524 AB040927 Hs.301804 KIAA1494 protein 1.5 10.7

131528 AU076408 Hs.28309 UDP-glucose dehydrogenase 1.3 4.7

131534 AF157326 Hs.184786 TBP-interacting protein 1.3 4.9

131555 T47364 Hs.278613 interferon, alpha-inducible protein 27 1.5 8

131578 AA936296 Hs.234265 DKFZP586G011 protein 1.8 3.5

131589 C18825 Hs.29191 epithelial membrane protein 2 1.3 8.2

131609 D83032 Hs.169984 nuclear protein 2.8 3.9

131626 BE514605 Hs.289092 Homo sapiens cDNA: FLJ22380 fis, clone H 1.3 11.2

131670 H03514 Hs.10130 ESTs 1.3 4.8

131697 C19034 Hs.288613 Homo sapiens cDNA FLJ14175 fis, clone NT ' 3.2 9.7

131701 AF103798 Hs.30819 hypothetical protein 1.3 5.2

131703 AW160865 Hs.30888 cytochrome c oxidase subunit Vila polype 1.3 7.8

131739 AF017986 Hs.31386 secreted frizzled-related protein 2 10.6 14.7

131764 AI805664 Hs.31731 peroxiredoxin 5 1.1 3.6

131781 AF077036 Hs.31989 DKFZP586G1722 protein 1.6 37

131791 X62111 gb:H.sapiens VII-5 gene for immunoglobul 1.1 3.5

131853 AI681917 Hs.3321 ESTs, Highly similar to IRX1_HUMAN IROQU 5.3 1.2

131870 NM_014874 Hs.3363 KIAA0214 gene product 0.6 4.2

131903 NMJ04642 Hs.3436 deleted in oral cancer (mouse, homolog) 2.4 4.9

131913 AW207440 Hs.185973 degenerative spermatocyte (homolog Droso 2.4 6

131930 AA772603 Hs.69476 Homo sapiens cDNA FLJ12758 fis, clone NT 1.7 9.2

131941 BE252983 Hs.35086 ubiquitin specific protease 1 0.5 5.2 131947 AI123939 Hs.182997 ESTs 0.7 4.1

131961 AA129782 Hs.3576 Homo sapiens mRNA full length insert cDN 0.9 4.8

131964 AW381148 Hs.198365 2,3-bisphosphoglycerate mutase 1.1 6.1

131974 AF208856 Hs.268122 hypothetical protein 1.3 3.9

131983 AF119665 Hs.184011 pyrophosphatase (inorganic) 3.3 6.9

131997 AF229181 Hs.136644 CS box-containing WD protein 0.9 5.2

132006 AW162336 Hs.3709 low molecular mass ubiquinone-binding pr 1.2 3.6

132063 BE277910 Hs.3833 3'-phosphoadenosine 5'-phosphosulfate sy 3.2 1.8

132065 BE379335 Hs.211594 proteasome (prosome, macropain) 26S subu i 1.2 3.6

132071 AF217798 Hs.3850 LIS1-interading protein NUDEL; endoolig 0.7 5.2

132079 AI701457 Hs.38694 ESTs 2 5.3

132094 NM 016045 Hs.3945 CGI-107 protein 1.2 4.3

132116 AW960474 Hs.40289 ESTs 3.1 3.1

132164 AI752235 Hs.41270 pracollagen-lysine, 2-oxoglutarate 5-dio 1.8 3.7

132181 AW961231 Hs.16773 Homo sapiens clone TCCC1A00427 mRNA sequ 1.2

132208 AL031709 Hs.241575 hypothetical protein CAB56184 1.4 4.2

132258 AA306325 Hs.4311 SUMO-1 adivating enzyme subunit 2 2 10.3

132303 BE177330 Hs.325093 Homo sapiens cDNA: FLJ21210 fis, clone C 1.2 4.1

132316 U28831 Hs.44566 KIAA1641 protein 5.9 1.6

132358 NM 003542 Hs.46423 H4 histone family, member G 5.8 1.5

132384 AA312135 Hs.46967 HSPC034 protein 2.1 9.3

132397 AA021160 Hs.4750 hypothetical protein DKFZp564K0822 1.3 4.6

132413 AW361383 Hs.260116 metalloprotease 1 (pitrilysin family) 2 4.9

132442 AW970859 Hs.313503 ESTs 1.2 5

132534 BE388673 Hs.5086 hypothetical protein MGC10433 2 3.9

132540 BE396290 Hs.5097 synaptogyrin 2 1.4 5.1

132554 AF065391 Hs.194718 zinc finger protein 265 1.2 4

132575 AV660538 Hs.284162 60S ribosomal protein L30 isolog 3 1.7

132585 AF029750 Hs.179600 TAP binding protein (tapasin) 1.8 4.7

132602 AW606927 Hs.5306 hypothetical protein DKFZp586F1122 simil 1.6 4.9

132608 AA353044 Hs.5321 ARP3 (actin-related protein 3, yeast) ho 1.8 8.1

132718 NM 004600 Hs.554 Sjogren syndrome antigen A2 (60kD, ribon 4.2 2

132719 AI264357 Hs.55405 hypothetical protein MGC16212 1.1 5.3

132730 AK000868 Hs.5570 hypothetical protein FLJ10006 1.4 5.2

132765 BE222975 Hs.56205 insulin induced gene 1 1.1 5.8

132782 F07424 Hs.279840 zinc finger protein 222 1.3 3.7

132793 AB020713 Hs.56966 KIAA0906 protein 2.3 6.3

132805 AW975748 Hs.5724 sclerostin 0.7 7.7

132863 BE268048 Hs.236494 RAB10, member RAS oncogene family 1.8 6.2

132894 D63209 Hs.5944 solute earner family 11 (proton-coupled 1.5 20.8

132930 AA579258 Hs.6083 Homo sapiens cDNA: FLJ21028 fis, clone C 1 3.8

132932 AW118826 Hs.6093 Homo sapiens cDNA: FLJ22783 fis, clone K 0.7 5.4

132933 BE263252 Hs.6101 hypothetical protein MGC3178 1.6 4.1

132965 AI248173 Hs.191460 hypothetical protein MGC12936 1 4.2

132984 BE539199 Hs.62112 zinc finger protein 207 1.5 4.4

132990 X77343 Hs.334334 transcription fador AP-2 alpha (activat 13.9 0.8

132998 Y00062 Hs.170121 protein tyrosine phosphatase, receptor t 0.6 4.6

133002 AW499985 Hs.42915 ARP2 (actin-related protein 2, yeast) ho 1.5 11.1

133011 NM 006379 Hs.171921 sema domain, immunoglobulin domain (Ig), 3.5 1

133012 AA847843 Hs.62711 Homo sapiens, clone IMAGE:3351295, mRNA1 4.5

133040 AW502761 Hs.30909 KIAA0430 gene product 0.9 5.5

133056 H12028 Hs.6396 jumping translocation breakpoint 1.7 5.3

133063 AI654133 Hs.30212 thyroid receptor interacting protein 15 0.6 4.9

133067 AK000708 Hs.169764 hypothetical protein FLJ20701 1.2 3.5

133080 AF089816 Hs.6454 chromosome 19 open reading frame 3 1.2 17.5

133110 AA808177 Hs.65228 ESTs 0.9 5.1

133150 AV655783 Hs.661 Empirically selected from AFFX single pr 1.1 4.5

133175 AW955632 Hs.66666 ESTs, Weakly similar to S19560 praline-r 1.5 4.8

133199 AF231981 Hs.250175 homolog of yeast long chain polyunsatura 5.5 5.9

133203 AA464362 Hs.6748 hypothetical protein PP1665 1.2 3.7

133206 AB037773 Hs.6762 hypothetical protein 1.6 8.6

133221 W32474 Hs.301746 RAP2A, member of RAS oncogene family 2.4 4.8

133229 AL137480 Hs.6834 KIAA1014 protein 1 4.2

133241 AW796524 Hs.68644 Homo sapiens microsomal signal peptidase 1.3 3.9

133257 BE617892 Hs.6895 actin related protein 2/3 complex, subun 1.4 5.4

133271 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.1 0.7

133273 N27672 Hs.69469 dendritic cell protein 2.5 6.5 133287 AW797437 Hs.69771 B-factor, properdin 1.3 4

133291 BE297855 Hs.69855 NRAS-related gene 1.4 5

133292 AA304961 Hs.699 peptidylprolyl isomerase B (cyclophilin 2.2 6.8

133294 AJ001388 Hs.69997 zinc finger protein 238 1.5 4.3

133300 AF116666 Hs.70333 hypothetical protein MGC10753 1.4 6.3

133302 X04898 Hs.237658 apolipoprotein A-ll 0.2 3.6

133308 U56979 Hs.250651 H factor 1 (complement) 0.6 5

133347 BE257758 Hs.71475 add cluster protein 33 1.2 4.2

133370 AF245505 Hs.72157 DKFZP564I1922 protein 3.7 5.8

133404 AB007916 Hs.214646 KIAA0447 gene product 1.4 5.1

133408 AI738719 Hs.198427 hexokinase 2 0.9 6.3

133422 AB033061 Hs.73287 KIAA1235 protein 1.2 3.7

133442 AL137663 Hs.7378 Homo sapiens mRNA; cDNA DKFZp434G227 (fr 0.7

133448 M27749 Hs.288168 immunoglobulin lambda-like polypeptide 1 1.1 4.3

133449 AF038962 Hs.7381 voltage-dependent anion channel 3 0.7 4.2

133501 AI962602 Hs.74284 hypothetical protein MGC2714 3.1 5.9

133504 NM 004415 Hs.74316 desmoplakin (DPI, DPII) 4.3 11.5

133506 BE562958 Hs.74346 hypothetical protein MGC14353 1.8 19.7

133532 D87452 Hs.74579 KIAA0263 gene product 1.2 5.4

133574 H97991 Hs.193313 Empirically selected from AFFX single pr 1.4 3.9

133586 AI929645 Hs.225936 synapsin l 0.8 4.9

133589 L37368 Hs.75104 RNA-binding protein S1 , serine-rich doma 2 10.8

133591 AI423369 Hs.75111 protease, serine, 11 (IGF binding) 2.1 4.5

133606 U10564 Hs.75188 wee1+ (S. pombe) homolog 3.3 1.1

133617 BE244334 Hs.75249 ADP-ribosylation factor-like 6 interacti 2.3 5.6

133651 AI301740 Hs.173381 dihydrapyrimidinase-like 2 0.8 13.5

133660 H14843 Hs.303154 popeye protein 3 1 9.1

133663 AJ006239 Hs.75438 quinoid dihydropteridine reductase 0.5 5.8

133668 L77964 Hs.271980 mitogen-activated protein kinase 6 1.1 6.9

133671 AW503116 Hs.301819 zinc finger protein 146 1.8 3.8

133681 AI352558 Hs.75544 tyrosine 3-monooxygenase/tryptophan 5-mo 1.5 11.1

133694 W17187.comp Hs.232400 heterogeneous nuclear ribonucleoprotein 2 3.9

133708 AI018666 , Hs.75667 synaptophysin 0.6 3.5

133737 AW001130 Hs.75824 KIAA0174 gene product 1.2 7.2

133743 AI929587 Hs.75847 CREBBP/EP300 inhibitory protein 1 1.5 5

133750 BE410769 Hs.75873 zyxin 1.2 4.8

133765 M62194 Hs.75929 cadherin 11 , type 2, OB-cadherin (osteob 3.2 4.1

133776 BE268649 Hs.177766 ADP-ribosyltransferase (NAD+; poly (ADP- 2.1 3.8

133799 W24087 Hs.76285 DKFZP564B167 protein 1.9 12.6

133800 AF075337 Hs.76293 thymosin, beta 10 2.6 6.6

133802 AW239400 Hs.76297 G protein-coupled receptor kinase 6 1 4.9

133806 D25969 Hs.76325 step II splicing factor SLU7 0.5 3.8

133817 AW578716 Hs.7644 H1 histone family, member 2 1.5 4.5

133829 AW630088 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564B1264 (f 3.7 5.6

133841 AA345824 Hs.76688 carboxyiesterase 1 (monocyte/macrophage 0.3 4.4

133845 AA147026 Hs.76704 ESTs 5.5 2.9

133863 AI815523 Hs.76930 synuclein, alpha (non A4 component of am 0.6 4.8

133887 X07767 Hs.77271 protein kinase, cAMP-dependent, catalyti 1 10.2

133892 AW859528 Hs.301497 arginyltransferase 1 0.9 4.8

133913 AU076964 Hs.7753 calumenin 2.8 10.5

133914 AI458213 Hs.77542 ESTs 1.8 5.6

133917 AL031177 Hs.7756 proteasome (prosome, macropain) 26S subu i 1.5 6.6

133947 L41066 Hs.77810 nuclear factor of activated T-cells, cyt 1.5 3.8

133986 M54968 Hs.184050 v-Ki-ras2 Kirsten rat sarcoma 2 viral on 0.9 4.3

133987 L15409 Hs.174007 von Hippel-Lindau syndrome 2.3 4.3

133989 AL040328 Hs.78202 SWI/SNF related, matrix associated, acti 3.3 3.4

133990 R48316 Hs.7822 Homo sapiens mRNA; cDNA DKFZp564C1216 (f 1.3 5.7

134029 BE150882 Hs.143601 hypothetical protein hCLA-iso 1 6.5

134040 NM 003470 Hs.78683 ubiquitin specific protease 7 (heφes vi 1.7 3.6

134042 AI027881 Hs.7869 lysosomal 1 7.5

134049 AF117236 Hs.78825 matrin 3 1.2 4

134095 NM 004354 Hs.79069 cyclin G2 2.7 4.8

134098 BE513171 Hs.79086 mitochondrial ribosomal protein L3 3.3 2.1

134207 Z43039 Hs.170198 KIAA0009 gene product 1.3 3.5

134210 AF035606 Hs.80019 programmed cell death 6 1.7 6.9

134218 U77735 Hs.80205 pim-2 oncogene 0.8 5.3

134270 X68194 Hs.80919 synaptophysin-like protein 1.4 11.4 134277 NM 004369 Hs.80988 collagen, type VI, alpha 3 2.6 3.5

134280 NM 000712 Hs.81029 biliverdin reductase A 1.8 5.8

134288 AI022650 Hs.8117 erbb2-interacting protein ERBIN 1.1 3.6

134296 R00603 Hs.8128 phosphatidylserine decarboxylase 1.1 5.9

134300 NM_001430 Hs.8136 endothelial PAS domain protein 1 0.5 4.8

134310 AL037800 Hs.8148 selenoprotein T 1.7 7.9

134343 D50683 Hs.82028 transforming growth fador, beta recepto 0.8 7.6

134364 X76534 Hs.82226 glycoprotein (transmembrane) nmb 2.2 3.6

134374 N22687 Hs.8236 ESTs 1.9 3.6

134378 AL035786 Hs.82425 actin related protein 2/3 complex, subun 1.5 8.3

134382 BE512856 Hs.109051 SH3 domain binding glutamic acid-rich pr 1.1 3.6

134415 AI750762 Hs.82911 protein tyrosine phosphatase type IVA, m 1.9 4.6

134417 NM 006416 Hs.82921 solute earner family 35 (CMP-sialic aci 1.2 7.5

134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.6 8.7

134439 Z23024 Hs.138860 Rho GTPase activating protein 1 2 3.9

134454 NM_013230 Hs.286124 CD24 antigen (small cell lung carcinoma 3.5 1.1

134494 D86981 Hs.84084 amyloid beta precursor protein (cytoplas 1.5 4.4

134501 W84869 Hs.211568 eukaryotic translation initiation factor 1.2 5.7

134505 AW960673 Hs.177530 ATP synthase, H+transporting, mitochond 1.3 3.9

134520 BE091005 Hs.74861 adivated RNA polymerase II transcriptio 1.8 4.3

134528 M23161 Hs.84775 Human transposon-like element mRNA 0.8 5.6

134545 AI902899 Hs.85155 butyrate response factor 1 (EGF-response 1.4 5

134553 AI203545 Hs.296169 S-phase response (cyclin-related) 0.8 3.9

134573 NM 016142 Hs.279617 steroid dehydrogenase homolog 1.3 5.7

134576 AB033017 Hs.8594 KIAA1191 protein 0.9 3.7

134577 BE244323 Hs.85951 exportin, tRNA (nuclear export receptor 4 6.8

134579 AW936928 Hs.85963 DKFZP564M182 protein 2.2 4.3

134582 AA927177 Hs.86041 CGG triplet repeat binding protein 1 1.6 3.6

134600 AF078859 Hs.86347 hypothetical protein 2.1 3.5

134655 AF265208 Hs.123090 SWI/SNF related, matrix associated, acti 1.7 4.2

134700 AK000606 Hs.8868 golgi SNAP receptor complex member 1 4.4 0.9

134737 D17530 Hs.89434 drebrin 1 3.1 1.6

134762 T51986 Hs.283108 hemoglobin, gamma G 0.5 4.6

134843 AA428520 Hs.90061 progesterone binding protein 1.3 3.7

134854 J03464 Hs.179573 collagen, type I, alpha 2 8.7 17.3

134865 AA587775 Hs.66295 multi-PDZ-domain-containing protein 1.7 4

134868 AB020689 Hs.90419 KIAA0882 protein 3.4 0.9

134874 AI803761 Hs.90458 serine palmitoyltransferase, long chain 1.3 6.9

134885 AJ002030 Hs.9071 progesterone membrane binding protein 1.4 9.6

134891 R51083 Hs.90787 ESTs 1 10.1

134908 BE089782 Hs.9877 hypothetical protein 1.9 3.9

134934 AF005043 Hs.91390 poly (ADP-ribose) glycohydrolase 1 4.3

134970 BE560779 Hs.284233 NICE-5 protein 1.4 10.4

134982 AK002085 Hs.92308 Homo sapiens cDNA FLJ 11223 fis, clone PL 1.6 4.1

135011 AB037835 Hs.92991 KIAA1414 protein 1.2 5.6

135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.7 7.6

135035 AL034344 Hs.284186 forkhead box C1 3.2 0.6

135051 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 4.2 4.1

135060 AK001887 Hs.259842 protein kinase, AMP-adivated, gamma 2 n 1.3 4.8

135062 AK000967 Hs.93872 KIAA1682 protein 2 3.7

135077 AW503733 Hs.9414 KIAA1488 protein 2.8 3.7

135082 AB017363 Hs.94234 frizzled (Drosophila) homolog 1 2.4 4.8

135107 T97257 Hs.337531 ESTs, Moderately similarto I38022 hypot 1.4 5.8

135143 AA132813 Hs.69559 KIAA1096 protein 1.8 8.5

135156 BE563088 Hs.9552 binder of Art Two 1.2 6.8

135172 AB028956 Hs.12144 KIAA1033 protein 3.1 1.4

135181 BE250865 Hs.279529 px19-like protein 1.3 7.5

135222 AA534009 Hs.183487 interferon stimulated gene (20kD) 1.3 3.8

135232 AL038812 Hs.96800 ESTs, Moderately similar to ALU7.HUMAN A 2.1 3.9

135289 AW372569 Hs.9788 hypothetical protein MGC10924 similar to 0.9 8.4

135290 AA331901 Hs.184736 hypothetical protein FLJ10097 1 3.8

135291 T83882 Hs.97927 ESTs 1.2 3.5

135349 AA114212 Hs.9930 serine (or cysteine) proteinase inhibito 2.6 8.9

135357 AI565004 Hs.79572 cathepsin D (lysosomal aspartyl protease 2.5 5.4

135398 M16029 Hs.287270 ret proto-oncogene (multiple endocrine n 0.4 7.9

135399 W79431 Hs.326249 ribosomal protein L22 1.5 4.5

135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 3.2 1.8 302665 R99693 Hs.224410 Homo sapiens CDNA FLJ12843 fis, clone NT 3.6 3.6

302892 AW176909 Hs.42346 calcineurin-binding protein calsarcin-1 3.3 1.6

302963 AW673106 Hs.151945 mitochondrial ribosomal protein L43 0.9 4.2

303131 AW081061 Hs.103180 DC2 protein 3 17.3

303150 AA887146 Hs.8217 stromal antigen 2 6.2 4

310125 AA147979 Hs.285005 mitochondrial import receptor Tom22 1.2 6.6

312662 AA233808 Hs.286241 protein kinase, cAMP-dependent, regulato 1 3.5

319429 BE616412 Hs.286218 i junctional adhesion molecule 1 1.5 4.7

320591 AA054761 Hs.169149 karyopherin alpha 1 (importin alpha 5) 1.2 -. 5.6

406779 AA412048 Hs.279574 CGI-39 protein; cell death-regulatory pr 1.3 3.5

410691 AW239226 Hs.65450 reticulon 4 1.2 13.9

410763 AF279145 Hs.8966 hypothetical protein FLJ21776 2 5.1

415738 BE539367 Hs.295953 ESTs, Weakly similar to AF220049 1 uneha 1.3 3.9

420186 NM_015925 Hs.95697 liver-specific bHLH-Zip transcription fa 1.5 6.2

422055 NM_014320 Hs.111029 putative heme-binding protein 2 11.3

425815 R94023 Hs.337531 ESTs, Moderately similar to I38022 hypot 17 3.6

426218 AF119043 Hs.168005 Homo sapiens cDNA FLJ13372 fis, clone PL 3.3 2.8

427397 AI929685 Hs.177656 calmoduUn 1 (phosphorylase kinase, delt 1.3 4.7

427466 AA523543 Hs.7678 cellular retinoic acid-binding protein 1 1.1 3.7

427505 AA361562 Hs.178761 26S proteasome-associated padl homolog 3.2 2.5

427723 AI355260 Hs.279789 histone deacetylase 3 2.8 22

428673 AW601325 Hs.324278 : Homo sapiens mRNA; cDNA DKFZp566M063 (fr 1.1 5.2

430219 X99209 Hs.235887 ' HMT1 (hnRNP methyltransferase, S. cerevi 1.8 8.8

430450 R23553 Hs.241489 hypothetical protein 1.1 5.6

432866 BE395875 Hs.279609 mitochondrial carrier homolog 2 1.5 6.1

433423 BE407127 Hs.8997 heat shock 70kD protein 1A 1.3 7.6

437562 AB001636 Hs.5683 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep 1.6 6.5

437667 BE616412 Hs.286218 junctional adhesion molecule 1 1.3 3.5

437754 R60366 Hs.5822 Homo sapiens cDNA: FLJ22120 fis, clone H 2 5.7

440252 BE513940 Hs.6101 hypothetical protein MGC3178 1.1 6.2

441471 AL042986 Hs.7857 erythrocyte membrane protein band 0.5 3.7

448292 BE281316 Hs.47334 hypothetical protein FLJ14495 2.5 4.9

449404 H51066 Hs.23581 leptin receptor gene-related protein 1.1 3.6

449964 AW001 41 Hs.273193 hypothetical protein FLJ10706 1.4 3.5

451389 N73222 Hs.279009 matrix Gla protein 4 11.2

452685 AI634651 Hs.30250 v-maf musculoaponeurotic fibrosarcoma (a 0.8 5.6

RCH15847 j peptidylprolyl isomerase B (cyclophilin B) 1.8 4.8

RC_W84712 calumenin 3.5 4.6

X14008 rna1 f lysozyme (renal amyloidosis) 0.9 4.5

RC H86543 f ESTs 1.8 6.6

H07011 ESTs; Weakly similarto SAS [H.sapiens] 1.8 3.9

RC_AA164586 s ESTs 6.2 0.8

RC AA070485 Homo sapiens clone 23967 3.4 2.6

RC H98714 s ESTs 1.6 3.5

RO.AA406145 f ESTs 4.6

AA458584 SRY (sex determining region Y)-box 4 3.4 0.4

AA031548 cell division cycle 42 (GTP-binding protein; 25kD) 3.1 3.9

X02761 fibronectin 1 3.6 15.2

RC_AA487193 secreted frizzled-related protein 4 4.7 4

R25326 Homo sapiens mRNA for putative vacuolar 0.9 5

RC_AA393805 ESTs; Weakly similar to (defline not 1.1 8.4

RC AA44933; i ESTs 2.9 4.6

RC_AA28768" Ls ESTs 1.3

RC AA490864 ESTs; Highly similar to heat shock factor 1.4 5

RC C14243 f ESTs; Highly similar to heat shock factor 1.7 5

R21443 ESTs 1.6 3.7

RC AA251902 Homo sapiens lysophospholipase (LPL1) 2.2 3.8

M21121 s small inducible cytokine A5 (RANTES) 0.9 9.9

C00038 s ESTs 2.8 4.8

Y00503 keratin 19 3.1 1.1

RC_R27006 f ESTs 1.6 3.7

RC AA416886 ESTs; Weakly similarto predicted using 3.1 3.1

RC_AA46045( ) fibroblast growth factor receptor 2 (bacteria- 1.5 3.7

RC AA48843: ) ESTs; Weakly similarto deduced amino acid 1.1 4

RC AA278400 f Homo sapiens HF 1.5 3.6

U28831 Human protein immuno-reactivewith anti-PTH4.4 0.6

RC AA19958! i Homo sapiens actin-related protein Arp3 (AR P3) 1.8 4.7 AF006082 Homo sapiens actin-related protein Arp2 (ARP2) 1.6 10.9

RCH90899 desmoplakin (DPI; DPII) 5.4 5.5

RC W95070 desmoplakin (DPI; DPII) 5 2.6

RC 90946 f Human mRNA for KIAA263 gene; complete eds 1.1 3.9

D87258 protease; serine; 11 (IGF binding) 2.4 3.5

AA313414 s ESTs; Weakly similar to cDNA EST EMBLT1157 1.5 5.3

RCJH73484 s ESTs; Weakly similar to similar to Yeast 1.3 6.3

AFFX-HUMISGF3A/M97935 3 2.3 13.5

AFFX-HUMRGE/M10098 5 1.1 7.9

AFFX-M27830 5 0.5 7.4

AFFX-M27830 5 0.6 5.4

RC AA063431 f ESTs 0.8 4.1

RC T63769 f ferritin; light polypeptide 1.1 3.7

TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigenelD's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and AUgnment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accessions

108469 116761J AA079487 AA128547 AA128291 AA079587 AA079600 125076 190299J AA973971 T88817 AA253263

114636 109698J AA075488 AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519 AA074510 AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335 AA078829 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296 123526 genbank_AA608657 AA608657 123533 genbank_AA608751 AA608751

125090 genbank_T91518 T91518

125154 genbank_W38419 W38419

118475 genbank_N66845 N66845

118505 genbank_N67343 N67343 101046 entrez_K01160K01160

129982 221 67 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165

AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991

AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 A1268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080

D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520

AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664

AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM 002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 108470 genbank_AA079500 AA079500

101447 entrez_M21305 M21305

124447 genbank_N48000 N48000

101624 entrez_M55998 M55998

131791 221 260 X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288

AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903 H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043 H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 AI735017 T47421 R48719 H27570 H44599 AI459598 H42347 H41938 H24993 AA345888 H22339 AI538691 AJ012264 AA664201 AI880450 AA327310 AI991250 AI833028 AW001210 AI956075 H30467 AA326915 H41943 AI749266 AI744441 AA327377 AW512326 AI735170 H01634 AI587047 AI571623 AA327486 AA327103 AA327195 AA326973 T28143

124842 217726 R56485 R37248 R59992

103758 AA084874_f_at AA084874J

130064 221_264 X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406

U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063704 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500

AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z74694 AF194588 AF194601 U09901 U09911 U09892 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599

AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF093581 AF103620 AW405934 AI445389 AW383753 AA360256 AF099676 H21654 H39501 AI820828 H53689 W26785 AW384496 AW407708 AA541663 AA911602 AI821461 AA588300 AA327050 H42717 AI951280 AA421322 AI923193

AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450

130232 18831_2 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060

T88946 F10106 AA232161 AA243117 AA158937 AA100864

109097 genbank_AA167512 AA167512

TABLE 9: Figure 9 from BRCA 001-2 US

Table 9 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

Pkey ExAccn UnigenelD UnigeneTitle

100690 AA383256 Hs.1657 estrogen receptor 1

102211 BE314524 Hs.78776 putative transmembrane protein

103587 BE270266 Hs.82128 5T4 oncofetal trophoblast glycoprotein

104115 AF183810 Hs.26102 opposite strand to trichorhinophalangeal syndrome I

105038 AW503733 Hs.9414 KIAA1488 protein

105500 AW602166 Hs.222399 CEGP1 protein

105990 AI690586 Hs.29403 hypothetical protein FLJ22060

106155 AA425414 Hs.33287 nuclear factor l/B

106373 AW503807 Hs.21907 histone acetyltransferase

106414 BE568205 Hs.28827 mitogen-activated protein kinase kinase kinase 2

110009 BE075297 Hs.6614 ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal

111900 AF131784 Hs.25318 Homo sapiens clone 25194 mRNA sequence

114540 AI904232 Hs.75323 prohibitin

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4

117280 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone COL03924

119771 AI905687 Hs.2533 EST

121723 AA243499 Hs.104800 hypothetical protein FLJ10134

124059 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypothetical protein YGL050W

131148 AW953575 Hs.303125 p53-induced protein PIGPC1

132371 AA235448 Hs.46677 PRO2000 protein

134169 AI690916 Hs.178137 transducer of ERBB2, 1

302235 AL049987 Hs.166361 Homo sapiens mRNA; cDNA DKFZp564F112

452410 AL133619 Hs.29383 Homo sapiens mRNA; cDNA DKFZp434

TABLE 10: Figure 10 from BRCA 001-3 PCT

Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene lie

R1 : Ratio of tumor to normal body tissue

R2: Ratio of 90"1 percentile tumor to body R3: Ratio of 75"1 percentile body to tumor

R4: Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD Unigene Title R1 R2 R3 R4

100082 AA130080 Hs.4295 proteasome (prosome, macropain) 26S subu 4.2 152 36 12.2

100103 AA380887 Hs.5085 doliehyl-phosphate mannosyltransferase p 9.8 123 13 5

100131 D12485 Hs.11951 ectonucleotide pyrophosphatase/phosphodi 13.2 244 19 9.9

100147 D13666 Hs.136348 osteoblast specific factor 2 (fasciclin 15.7 1030 66 5

100154 H60720 Hs.81892 KIAA0101 gene product 4.1 320 78 10.6

100157 D14661 Hs.119 Wilms' tumour 1 -associating protein 4.7 119 26 3

100169 AL037228 Hs.82043 D123 gene product 5.1 106 21 9.2

100203 BE242284 Hs.172199 adenylate cyclase 7 4.7 47 1 4.3

100210 D26361 Hs.3104 KIAA0042 gene product 4.7 47 4 0.7

100219 AW972300 Hs.118110 bone marrow stromal cell antigen 2 3.8 350 93 1.9

100234 D29677 Hs.3085 KIAA0054 gene product; Helicase 4.1 64 16 3

100248 NM 015156HS.78398 KIAA0071 protein 3.4 77 23 5.9

100252 NM 006207HS.170040 platelet-derived growth factor receptor- 4.5 45 4 4

100260 D38491 Hs.322478 KIAA0117 protein 5.9 59 1 2.6

100279 D42084 Hs.82007 KIAA0094 protein 3.5 96 28 1.3

100286 BE247550 Hs.86859 growth factor receptor-bound protein 7 3.1 306 98 1.5

100294 AA331881 Hs.75454 peroxiredoxin 3 12.8 128 1 11.7

100335 AW247529 Hs.6793 platelet-activating factor acetylhydrola 4.2 187 44 5.4

100365 AI878927 Hs.79284 mesoderm specific transcript (mouse) horn 4.5 129 29 3.1

100375 D80004 Hs.75909 KIAA0182 protein 3.5 78 23 4.8

100409 D86957 Hs.80712 KIAA0202 protein 10.2 102 1 4.8

100410 D86961 Hs.79299 lipoma HMGIC fusion partner-like 2 4 40 1 3.8

100414 NM 014735HS.82292 KIAA0215 gene product 3.2 32 2 2.9

100418 D86978 Hs.84790 KIAA0225 protein 3.6 36 7 3.2

100438 AA013051 Hs.91417 topoisomerase (DNA) II binding protein 5.6 76 14 2

100439 AA347720 Hs.122669 KIAA0264 protein 3.5 35 9 3.1

100448 AF234887 Hs.57652 cadherin, EGF LAG seven-pass G-type rece 5.5 145 27 2.2

100449 D87470 Hs.75400 KIAA0280 protein 3.4 34 1 1.2

100522 X51501 Hs.99949 prolactin-induced protein 22.7 760 34 1.4

100552 AA019521 Hs.301946 lysosomal 14.4 144 9 4.7

100643 NM_005032Hs.4114 plastin 3 (T isoform) 4.1 259 63 1.9

100661 BE623001 Hs.132748 Homo sapiens ribosomal protein L39 mRNA, 3.3 116 36 2.2

100666 L05424 Hs.169610 CD44 antigen (homing function and Indian 8.5 85 1 3.2

100667 L05424 Hs.169610 CD44 antigen (homing function and Indian 3 594 201 2.3

100745 BE207168 Hs.144630 nuclear receptor subfamily 2, group F, m 5 82 17 0.9

100774 J05581 Hs.89603 mucin l, transmembrane 3.5 37 11 2.8

100783 AF078847 Hs.191356 general transcription factor IIH, polype 9.7 97 10 7.2

100821 M26460 gb:Homo sapiens (clone 104) retinoblasto 3.3 33 1 0.8

100864 BE563957 Hs.74861 activated RNA polymerase II transcriptio 3.7 477 130 3.1

100877 X80821 Hs.27973 KIAA0874 protein 6.3 63 4 5.7

100892 BE245294 Hs.180789 S164 protein 4.7 47 1 4.2

101038 BE297139 Hs.79411 replication protein A2 (32kD) 3.8 115 30 7.1

101046 K01160 NM_Q02122:Homo sapiens major histocompat 3.9 390 100 11.1

101079 BE264901 Hs.250502 carbonic anhydrase VIII 3.9 39 8 3.6 101084 AW409934 Hs.75528 nucleolar GTPase 4.1 53 13 4

101104 AW862258 Hs.169266 neuropeptide Y receptor Y1 15.3 153 1 14.1

101185 NM_001621Hs.170087 aryl hydrocarbon receptor 11.3 113 8 3.9

101188 L20320 Hs.184298 cyclin-dependent kinase 7 (homolog of Xe 3.1 118 38 2

101201 L22524 Hs.2256 matrix metalloproteinase 7 (MMP7; uterin 8.2 396 48 0.9

101232 AU077288 Hs.242894 ADP-ribosylation factor-like 1 4 110 28 10.7

101275 BE545277 Hs.3273 Ts translation elongation factor, mitoch 4.2 50 12 4.4

101300 BE535511 Hs.74137 transmembrane trafficking protein 6.6 135 21 13.1

101396 BE267931 Hs.78996 proliferating cell nuclear antigen 6.4 249 39 22.4

101447 M21305 gb:Human alpha satellite and satellite 3 6.5 878 135 0.8

101448 NM 000424HS.195850 keratin 5 (epidermolysis bullosa simplex 4.8 622 130 0.7

101470 NM 000546HS.1846 tumor protein p53 (Li-Fraumeni syndrome) 5.1 97 19 9.3

101478 NM_.002890Hs.758 RAS p21 protein activator (GTPase activa 9.6 96 1 8.5

101484 AA053486 Hs.20315 interferon-induced protein with tetratri 11.2 112 8 5.9

101507 X16896 Hs.82112 interleukin 1 receptor, type I 3.9 39 2 3.5

101621 BE391804 Hs.62661 guanylate binding protein 1, interferon- 3.6 36 1 2.6

101624 M55998 gb:Human alpha-1 collagen type I gene, 3 3.1 2898 923 2.2

101664 AA436989 Hs.121017 H2A histone family, member A 6.9 103 15 8.4

101684 M63256 Hs.75124 cerebellar degeneration-related protein 6.4 64 2 4.9

101724 L11690 Hs.620 bullous pemphlgoid antigen 1 (230/240kD) 9.4 94 1 0.3

101754 S70114 Hs.239489 TIA1 cytotoxic granule-associated RNA-bi 8.9 89 5 8

101767 M81057 Hs.180884 carboxypeptidase B1 (tissue) 3.6 824 227 1.4

101791 M83822 Hs.62354 cell division cycle 4-like 9 144 16 13

101794 M84605 Hs.957 putative opioid receptor, neuromedin K ( 3.3 36 11 2.4

101803 AW024390 Hs.155691 pre-B-cell leukemia transcription factor 5.4 180 34 15.9

101809 M86849 Hs.323733 gap junction protein, beta 2, 26kD (conn 12 120 8 9

101839 AA446644 Hs.692 GA733-2 antigen; epithelial glycoprotein 3.1 353 116 2.8

101888 AL049610 Hs.95243 transcription elongation factor A (Sll)- 7.3 73 1 5,3

101960 AL036287 Hs.194662 calponin 3, acidic 3.8 399 105 3.3

102009 BE245149 Hs.82643 protein tyrosine kinase 9 4.6 148 32 11.3

102095 U11313 Hs.75760 sterol carrier protein 2 9.5 95 4 8.8

102123 NM 001809Hs.1594 centromere protein A (17kD) 4.2 42 7 3.4

102125 NM 006456HS.288215 sialyltransferase 9.3 93 4 3

102139 NM_004419Hs.2128 dual specificity phosphatase 5 5.4 137 26 2.5

102162 AA450274 Hs.1592 CDC16 (cell division cycle 16, S. cerevi 4.6 151 33 2

102165 BE313280 Hs.159627 death associated protein 3 9.3 93 5 8

102193 AL036335 Hs.313 secreted phosphoprotein 1 (osteopontin, 45.7 457 1 39.7

102211 BE314524 Hs.78776 putative transmembrane protein 3.9 442 114 1.3

102221 NM_.006769Hs.3844 LIM domain only 4 4.9 49 1 3.6

102242 U27185 Hs.82547 retinoic acid receptor responder (tazaro 3.1 31 1 1.3

102258 NM 001546HS.34853 inhibitor of DNA binding 4, dominant neg 3.8 163 43 0.5

102302 AA306342 Hs.69171 protein kinase C-like 2 4.5 45 1 3.6

102304 AF015224 Hs.46452 mammaglobin 1 8.5 2058 243 1.4

102348 U37519 Hs.87539 aldehyde dehydrogenase 3 family, member 6.4 428 67 2.3

102369 U39840 Hs.299867 hepatocyte nuclear factor 3, alpha 6.7 67 9 6.3

102407 AW602154 Hs.82143 E74-like factor 2 (ets domain transcript 5.3 53 1 4.8

102409 BE300330 Hs.118725 selenophosphate synthetase 2 3.3 111 34 7.5

102457 NM_.001394Hs.2359 dual specificity phosphatase 4 20.2 202 5 1.3

102544 NM 003937HS.169139 kynureninase (L-kynurenine hydrolase) 3.8 38 1 1.5

102567 U63830 Hs.146847 TRAF family member-associated NFKB activ 8.2 82 1 6.8

102580 U60808 Hs.152981 CDP-diacylglycerol synthase (phosphatida 4.1 41 1 3.3

102618 AL037672 Hs.81071 extracellular matrix protein 1 10.2 628 62 17.2

102638 U67319 Hs.9216 caspase 7, apoptosis-related cysteine pr 5 66 13 5.3

102663 NM_002270Hs,168075 karyopherin (importin) beta 2 6.1 126 21 2.4

102669 U71207 Hs.29279 eyes absent (Drosophila) homolog 2 4.5 45 1 2.8

102742 U79293 Hs.159264 Human clone 23948 mRNA sequence 4.1 41 1 2.4

102784 U85658 Hs.61796 transcription factor AP-2 gamma (activat 4.4 255 58 1.6

102805 U90304 Hs.25351 iroquois homeobox protein 5 3.6 142 39 1.6

102813 BE242035 Hs.151461 embryonic ectoderm development 3.5 35 1 2.7

102823 D85390 Hs.5057 carboxypeptidase D 5.6 56 1 5.3

102825 BE262386 Hs.7137 clones 23667 and 23775 zinc finger prate 4.2 42 7 3.7

102899 AI815559 Hs.75730 signal recognition particle receptor ('d 3.2 58 18 5

102913 NM_002275Hs.80342 keratin 15 5.8 753 131 0.4

102927 BE512730 Hs.65114 keratin 18 3.1 815 266 1.7

102961 AL119505 Hs.198166 activating transcription factor 2 3.2 32 4 2.6

102968 AU076611 Hs.154672 methylene tetrahydrofolate dehydrogenase 5.7 251 44 6.6

103003 AI910275 Hs.1406 trefoil factor 1 (pS2) 5.6 1346 239 5.4 103023 AW500470 Hs.117950 multifunctional polypeptide similar to S 5.8 218 38 13

103024 NM 002343Hs.105938 lactotransfem'n 3.7 1421 388 1.9

103036 M13509 Hs.83169 matrix metalloproteinase 1 (MMP1; inters 3.1 94 30 5.8

103038 AA926960 Hs.334883 CDC28 protein kinase 1 3.5 332 94 3.1

103119 X63629 Hs.2877 cadherin 3, type 1, P-cadherin (placenta 4.8 312 65 30.9

103134 X65724 Hs.2839 Norrie disease (pseudoglioma) 5.2 331 64 1.5

103134 X65724 Hs.2839 Norrie disease (pseudoglioma) 4.9 49 5 3.8

103171 AW583058 Hs.234726 serine (or cysteine) proteinase inhibito 3.3 1497 458 2.1

103206 X72755 Hs.77367 moπokine induced by gamma interferon 3.5 796 228 3.2

103208 AW411340 Hs.31314 retinoblastoma-binding protein 7 5.6 191 34 3.5

103226 X75042 Hs.44313 v-rel avian reticuloendotheliosis viral 4.1 53 13 4.9

103333 AA206186 Hs.79889 monocyte to macrophage differentiation-a 3.4 34 8 2.3

103346 X87613 Hs.5464 thyroid hormone receptor coactivating pr 3.9 43 11 1

103352 H09366 Hs.78853 uracil-DNA glycosylase 9.3 93 8 8.2

103375 NM 005982HS.54416 sine oculis homeobox (Drosophila) homolo 9.7 97 1 9.3

103376 AL036166 Hs.323378 coated vesicle membrane protein 6.3 98 16 9.1

103391 X94453 Hs.114366 pyrroline-5-carboxylate synthetase (glut 4.3 77 18 7.2

103438 AW175781 Hs.152720 M-phase phosphoprotein 6 4.9 153 31 2.4

103453 AI878922 Hs.180139 SMT3 (suppressor of mif two 3, yeast) ho 4.9 261 53 3.7

103471 Y00815 Hs.75216 protein tyrosine phosphatase, receptor t 3.5 564 162 1.7

103500 AW408009 Hs.22580 alkylglycerone phosphate synthase 3.9 49 13 2.5

103557 AL133415 Hs.297753 vimentin 7.5 136 18 3.4

103587 BE270266 Hs.82128 5T4 oncofetal trophoblast glycoprotein 7.9 79 2 6.9

103605 BE409838 Hs.194657 cadherin 1, type 1, E-cadherin (epifheli 3.3 745 229 1.8

103606 AW403814 Hs.41714 BCL2-associated athanogene 3.2 41 13 2.8

103613 NM_000346Hs.2316 SRY (sex determining region Y)-box 9 (ca 7.3 73 1 5.2

103658 NM_000088Hs.172928 collagen, type 1, alpha 1 3.8 1612 429 3.1

103666 NM 003528HS.2178 H2B histone family, member Q 3.2 32 5 2.8

103988 AA314389 Hs.42500 ADP-ribosylation factor-like 5 3.2 32 9 2.7

103990 AB033112 Hs.42179 bromodomain and PHD finger containing, 3 4.9 49 1 4.2

104052 NM_002407Hs.97644 mammaglobin 2 7.2 498 69 9.3

104115 AF183810 Hs.26102 opposite strand to trichorhinophalangeal 29 290 1 26.8

104129 H63349 Hs.98806 hypothetical protein 3.7 37 7 2.1

104146 AW880614 Hs.146381 RNA binding motif protein, X chromosome 5.2 52 1 4.3

104147 BE081342 Hs.283037 HSPC039 protein 8 84 11 6.3

104209 AB012113 Hs.16530 small inducible cytokine subfamily A (Cy 5.8 58 1 3.2

104239 AB002367 Hs.21355 doublecortin and CaM kinase-like 1 6.4 64 8 3

104278 AW583693 Hs.109253 N-terminal acetyltransferase complex ard 4.7 229 49 7.9

104309 AI337300 Hs.284123 hypothetical protein MGC4604 3.2 32 7 2.4

104394 AA129551 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C 5.3 144 27 13.1

104432 X51501 Hs.99949 prolactin-induced protein 6.9 1494 218 1.3

104558 R56678 Hs.88959 hypothetical protein MGC4816 7.7 77 8 6.9

104567 AA040620 Hs.5672 hypothetical protein AF140225 3.7 37 5 2.5

104590 AW373062 Hs.83623 nuclear receptor subfamily 1 , group I, m 6.1 493 81 0.7

104602 H47610 gb:yp75f03.s1 Soares fetal liver spleen 3.8 38 4 1.2

104613 AF123303 Hs.24713 hypothetical protein 4.8 231 49 7.3

104633 H00820 Hs.30977 ESTs, Weakly similar to B34087 hypotheti 3.4 154 46 3

104636 R82252 Hs.106106 protein kinase (cAMP-dependent, catalyti 5 468 94 4.7

104660 BE298665 Hs.14846 Homo sapiens mRNA; cDNA DKFZp564D016 (fr 3.8 82 22 3.1

104667 AI239923 Hs.30098 ESTs 14.9 149 1 6.4

104766 BE244072 Hs.20815 macrophage erythroblast attacher 6.3 165 26 3.2

104787 AA027317 gb:ze97d11.s1 Soares_fetal_heart_NbHH19W 3.8 40 11 3.8

104804 AI858702 Hs.31803 ESTs, Weakly similar to N-WASP [H.sapien 7.7 77 1 5.1

104807 AI139058 Hs.125790 leucine-rich repeat-containing 2 7 70 1 6.5

104846 AI250789 Hs.32478 ESTs 4.7 201 43 4.5

104896 AW015318 Hs.23165 ESTs 7.4 74 1 6

104919 AA026880 Hs.25252 prolactin receptor 3.9 280 72 3.3

104926 BE298808 Hs.33363 DKFZP434N093 protein 4.2 135 32 4

104943 AF072873 Hs.114218 frizzled (Drosophila) homolog 6 16.2 162 1 4.2

104968 AI249502 Hs.29669 ESTs 3.8 38 1 2.4

104977 AI392640 Hs.18272 amino acid transporter system A1 3.2 522 165 1.9

104997 AA121686 Hs.10592 ESTs 3.2 32 4 2.9

105029 AI122691 Hs.13268 ESTs 3.7 157 43 3.6

105038 AW503733 Hs.9414 KIAA1488 protein 5.5 55 1 5.2

105041 AB037716 Hs.26204 KIAA1295 protein 10.3 103 - 1 3.9

105086 AA148710 Hs.79914 lumican 6.6 66 1 5.4

105088 H58589 Hs.35156 Homo sapiens cDNA FLJ11027 fis, clone PL 3.1 31 1 2.5 105091 AA148859 Hs.179909 hypothetical protein FLJ22995 3.2 32 1 3 105143 AI368836 Hs.24808 ESTs, Weakly similar to I38022 hypotheti 7.3 73 1 3.8 105154 AA307279 Hs.35947 methyl-CpG binding domain protein 4 4.2 90 22 2.8 105162 AL133033 Hs.4084 KIAA1025 protein 6 60 6 4.6 105167 AW612147 Hs.32058 Homo sapiens C1orf19 mRNA, partial eds 3.8 38 2 3.2 105178 AA313825 Hs.21941 AD036 protein 9.3 436 47 5.8 105195 AA975096 Hs.19522 hypothetical protein PR02849 5.7 57 8 5.3 105200 AA328102 Hs.24641 cytoskeleton associated protein 2 4.5 45 1 3.6 105248 AW952479 Hs.22826 tropomodulin 3 (ubiquitous) 4.3 43 1 3.9 105252 AB039670 Hs.9728 ALEX1 protein 8 80 6 7.3 105253 AW997484 Hs.5003 KIAA0456 protein 3.9 39 6 3.2 105280 AA894638 Hs.14600 ESTs 3.5 35 7 2.7 105288 N99673 Hs.3585 ESTs, Weakly similar to AF126743 1 DNAJ 4.5 45 10 0.5 105309 AK000796 Hs.4104 hypothetical protein 3.8 93 25 7.5 105329 AA234561 Hs.22862 ESTs 2.8 131 47 3.9 105344 AF151073 Hs.8645 hypothetical protein 3.9 79 20 6.5 105376 AW994032 Hs.8768 hypothetical protein FLJ10849 5.1 181 36 15.8 105386 AW500718 Hs.8115 Homo sapiens, clone MGC:16169, mRNA, com 4.1 41 2 3.3 105400 AF198620 Hs.65648 RNA binding motif protein 8A 6.2 , 62 6 5.6 105426 W20027 Hs.23439 ESTs 3.3 206 63 2.2 105483 AL137257 Hs.23458 Homo sapiens cDNA: FLJ23015 fis, clone L 3.2 466 146 8.4 105496 AL117441 Hs.301997 hypothetical protein FLJ 3033 16.6 166 8 12.7 105500 AW602166 Hs.222399 CEGP1 protein 25.4 508 20 3 105508 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (f ' 99 117 13 10.6 105511 AB037829 Hs.3862 regulator of nonsense transcripts 2; DKF 3.2 32 6 1.5 105516 AK001269 Hs.30738 hypothetical protein FLJ10407 8.3 83 3 1.8 105539 AB040884 Hs.109694 KIAA1451 protein 3.5 73 21 1.6 105564 BE616694 Hs.288042 hypothetical protein FLJ14299 5.8 336 58 2 105610 AA280072 Hs.99872 fetal Alzheimer antigen 3.2 32 1 1 105616 R35343 Hs.24968 Human DNA sequence from clone RP1-233G16 4.8 79 17 5.2 105627 AA281279 Hs.23317 hypothetical protein FLJ 14681 4 75 19 1.7 105640 AA001021 Hs.6685 thyroid hormone receptor interactor 8 4.5 45 1 3.7 105645 AW294631 Hs.11325 ESTs 3.6 36 1 0.1 105674 AI609530 Hs.279789 histone deacetylase 3 6.4 64 8 6 105687 NM 014517Hs.28423 upstream binding protein 1 (LBP-1a) 4.7 152 33 5.3 105691 AI680737 Hs.289068 Homo sapiens cDNA FLJ11918 fis, one HE 5.7 57 8 4.1

105730 AW377314 Hs.5364 DKFZP564I052 protein 6.9 69 1 4.4

105731 AA834664 Hs.29131 nuclear receptor coactivator 2 3.4 34 1 3.1 105743 BE246502 Hs.9598 sema domain, immunoglobulin domain (Ig), 3 30 10 0.9 105759 A1123118 Hs.15159 chemokine-like factor, alternatively spl 5.4 54 1 4.4 105772 H57111 Hs.221132 ESTs 5.3 67 13 5.3 105774 AW369278 Hs.23412 hypothetical protein FLJ20160 4.9 49 1 4.5 105784 W84446 Hs.226434 hypothetical protein MGC4643 3.3 98 30 4.7 105795 AA878183 Hs.17448 Homo sapiens cDNA FLJ13618 fis, clone PL 3.2 143 46 3.6 105806 AF206019 Hs.110347 REV1 (yeast homolog)- like 4 40 3 3.2 105807 AA788946 Hs.16869 ESTs, Moderately similarto CA1C RAT COL 4.7 747 158 5.7 105823 AI559444 Hs.293960 ESTs 3.9 371 94 4.6 105832 AW802282 Hs.22265 pyruvate dehydrogenase phosphatase 3.6 68 19 6 105840 AA601518 Hs.22209 secreted modular calcium-binding protein 4.8 134 28 3.2 105851 AI827976 Hs.24391 hypothetical protein FLJ13612 4.3 772 179 1.7 105864 AI640775 Hs.28332 Homo sapiens cDNA: FLJ21560 fis, clone C 4.3 43 1 3.7

105870 AW021691 Hs.101067 GCN5 (general control of amino-acid synt 3.6 36 7 3.1

105875 AK001708 Hs.32271 hypothetical protein FLJ10846 3.4 34 8 2.9

105886 AK001735 Hs.22983 UDP-glucose:glycoprotein glucosyltransfe 3.6 45 13 1.3 105906 N25986 Hs.22380 ESTs 3.4 34 1 1.5 106012 AI240665 Hs.8895 ESTs 21.2 212 6 17.4 106020 AA043039 Hs.7870 hypothetical protein 3.9 47 12 4.4 106024 AL122072 Hs.103804 heterogeneous nuclear ribonucleoprotein 4.4 174 40 1.6 106034 AW952005 Hs.14928 hypothetical protein FLJ12903 4.7 47 1 4 106036 AA382267 Hs.10653 ESTs 3.4 49 15 4.4 106055 AA417034 gb:zu04f10.s1 Soares estis_NHT Homo sap 3.5 53 15 1.2 106057 BE614474 Hs.289074 F-box only protein 22 3.4 116 35 2.2 106060 NM_001329Hs.171391 C-terminal binding protein 2 3.6 444 125 4.6 106070 T74445 Hs.5957 Homo sapiens clone 24416 mRNA sequence 3.6 365 103 6.9 106095 AF115402 Hs.11713 E74-like factor 5 (ets domain transcript 26.3 356 14 1 106096 AW379378 Hs.170121 protein tyrosine phosphatase, receptor t 3.2 267 83 2.3 106126 AA576953 Hs.22972 hypothetical protein FLJ13352 3.8 38 1 3.3 106155 AA425414 Hs.33287 nuclear factor l/B 9.9 483 49 1.8 106157 W37943 Hs.34892 KIAA1323 protein 6.7 94 14 8 106198 AI244563 Hs.325531 Homo sapiens clone 015h12 My015 protein 3.3 95 29 4.4 106236 AB040896 Hs.21104 KIAA1463 protein 3.8 83 22 7.5 106286 AI765107 Hs.274422 hypothetical protein FLJ20550 3.3 97 30 6.4 106290 AW961393 Hs.16364 hypothetical protein FLJ10955 4.5 116 26 4.5 106310 R98185 Hs.17240 ESTs 7 70 3 1.3 106323 AB007866 Hs.158249 KIAA0406 gene product 3.2 37 12 2.6 106330 AW977397 Hs.35580 ESTs 3.8 38 1 1.9 106383 AA447453 Hs.27860 Homo sapiens mRNA; cDNA DKFZp586M0723 (f 16 255 16 6.6 106389 AW748420 Hs.6236 Homo sapiens cDNA: FLJ21487 fis, clone C 4.9 337 70 2.7 106394 Z42993 Hs.25320 Homo sapiens clone 25142 mRNA sequence 3.1 72 23 5 106432 AK000310 Hs.17138 hypothetical protein FLJ20303 3.1 165 54 1.6 106459 AA789081 Hs.4029 glioma-amplified sequence-41 3.1 31 1 2.6 106503 AB033042 Hs.29679 cofactor required for Sp1 transcriptiona 5.5 147 27 4.4 106508 AI205785 Hs.30348 ESTs 4.4 222 51 1.8 106565 NM_014892Hs.227602 KIAA1116 protein 7.4 74 3 1.7 106586 AA243837 Hs.57787 ESTs 15.2 152 1 12.6 106589 AK000933 Hs.28661 Homo sapiens cDNA FLJ10071 fis, clone HE 3.3 263 69 3.9 106596 AA452379 Hs.293552 ESTs, Moderately similar to ALU7_HUMAN A 4.9 49 1 4.1 106611 R49131 Hs.26267 ATP-dependant interferon response protei 5.8 58 5 3.1 106628 AW188205 Hs.12311 Homo sapiens clone 23570 mRNA sequence 5.3 166 32 14.9 106650 AL049951 Hs.22370 Homo sapiens mRNA; cDNA DKFZp564O0122 (f5.4 75 14 0.8 106683 BE296396 Hs.14512 DIPB protein 3.6 210 58 4.7 106698 N28524 Hs.29403 hypothetical protein FLJ22060 5.7 57 10 4.8 106710 N38902 Hs.334437 hypothetical protein MGC4248 4.4 371 84 3.2 106717 AA600357 Hs.239489 TIA1 cytotoxic granule-associated RNA-bi 4.3 101 24 1.6 106747 NM_007118Hs.171957 triple functional domain (PTPRF interact 4.6 46 1 106834 AL044182 Hs.28070 KIAA0753 gene product 3.5 58 17 1.6 106846 AB037744 Hs.34892 KIAA1323 protein 5.4 192 36 4.4 106868 BE185536 Hs.301183 molecule possessing ankyrin repeats indu 3.3 696 214 1.8 106882 AA149537 Hs.26994 hypothetical protein FLJ20477 3.8 38 1 1.6 106893 AA835868 Hs.25253 mannosidase, alpha, class 1A, member 1 4.3 43 10 2.2 106895 AK001826 Hs.25245 hypothetical protein FLJ 11269 3.6 36 1 1.2 106897 AF039023 Hs.167496 RAN binding protein 6 4.5 45 1 3.8 106916 AA134329 Hs.24170 Homo sapiens, clone IMAGE:3685398, mRNA, 5.7 94 17 7.3 106962 AI868648 Hs.22315 ESTs 3.5 180 52 2.3 106968 AF216751 Hs.26813 CDA14 5.5 130 24 12.5 106990 AA280722 Hs.24758 ESTs, Weakly similar to I38022 hypotheti 3.2 266 83 1.8 107008 AL157479 Hs.23740 KIAA1598 protein 5.1 298 59 4.4 107014 AA598820 gb:ae36h12.s1 Gessler Wilms tumor Homo s 3.3 228 69 2.8 107032 AV650537 Hs.247309 succinate-CoA ligase, GDP-forming, beta 3.1 55 18 3.8 107056 AW401864 Hs.18720 programmed cell death 8 (apoptosis-induc 3.1 75 24 2.2 107071 AW385224 Hs.35198 ectonucleotide pyrophosphatase/phosphodi 3.1 367 119 2.3 107080 AL122043 Hs.19221 hypothetical protein DKFZp566G1424 3.9 98 25 8.6 107102 AB037765 Hs.30652 KIAA1344 protein 6.3 63 1 5.4 107109 AA249096 Hs.32793 ESTs 4.6 71 16 3.6 107136 AV661958 Hs.8207 GK001 protein 2.5 392 155 4.3 107151 AW378065 Hs.8687 ESTs 15.6 156 7 10.8 107217 AL080235 Hs.35861 DKFZP586E1621 protein 4.8 48 3.1 107222 BE172058 Hs.82689 tumor rejection antigen (gp96) 1 3.4 251 74 23.7 107240 AI290284 Hs.159872 ESTs 3.6 36 6 0.5 107248 AW263124 Hs.315111 nuclear receptor co-repressor/HDAC3 comp 5.4 483 90 4 107295 AA186629 Hs.80120 UDP-N-acetyl-alpha-D-galactosamine:polyp 4.6 199 44 19.2 107299 BE277457 Hs.30661 hypothetical protein MGC4606 12.5 156 13 2.9 107316 T63174 Hs.193700 Homo sapiens mRNA; cDNA DKFZp586l0324 (f 3.2 110 35 9.6 107318 T74445 Hs.5957 Homo sapiens clone 24416 mRNA sequence 3.5 35 1 2.6 107485 AL042613 Hs.262476 S-adenosylmethionine decarboxylase 1 5.8 151 26 11.4 107612 AI498986 Hs.60090 Homo sapiens cDNA FLJ13595 fis, clone PL 3.2 32 5 2.1 107638 A1580492 Hs.42743 hypothetical protein 4.4 73 17 6.2 107727 AA149707 Hs.173091 ubiquitin-like 3 3.5 282 80 3.7 107859 AW732573 Hs.47584 potassium voltage-gated channel, delayed 5.7 85 15 7.8 107876 AW372451 Hs.61184 CGI-79 protein 3.5 35 1 1 107884 AA054949 Hs.61307 ESTs 4.3 43 10 2.7 107886 AA025782 Hs.61284 ESTs 3.1 31 9 2.2 107908 AF087999 Hs.42826 ESTs 4.7 47 4.3 107922 BE153855 Hs.61460 Ig superfamily receptor LNIR 9 90 5.5 107994 AA036811 Hs.48469 LIM domains containing 1 4.5 45 1 3.8

108040 AL121031 Hs.159971 SWI/SNF related, matrix associated, acti 6.5 65 2 6

108055 AJ404672 Hs.334483 hypothetical protein FLJ23571 7.4 74 8 6

108063 BE548479 Hs.14838 hypothetical protein FLJ 10773 3.4 34 1 2.3

108339 AW151340 Hs.51615 ESTs, Weakly similarto ALU7JHUMAN ALU S 18.7 187 1 17

108467 AI478658 Hs.94631 brefeldin A-inhibited guanine nucleotide 3.8 38 1 3.2

108539 AA084677 Hs.54558 hypothetical protein FLJ22222 5.7 57 1 4.9

108634 AW022410 Hs.69507 ESTs 3.2 32 5 1.7

108647 BE546947 Hs.44276 homeo box C10 8.7 247 29 5.7

108695 AB029000 Hs.70823 KIAA1077 protein 3.7 625 168 3.8

108778 AF133123 Hs.90847 general transcription factor IIIC, polyp 3.7 37 1 3.2

108806 AF070578 Hs.71168 Homo sapiens clone 24674 mRNA sequence 3.4 34 1 2.8

108807 AI652236 Hs.49376 hypothetical protein FLJ20644 3.5 35 1 3.2

108810 AW295647 Hs.71331 hypothetical protein MGC5350 5.3 53 1 2.8

108846 AL117452 Hs.44155 DKFZP586G1517 protein 4.8 96 20 6.5

108857 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), act 5.4 54 1 4

108893 BE276891 Hs.194691 retinoic acid induced 3 3.1 529 170 4.1

108917 AI380268 Hs.173648 ESTs, Weakly similar to Zinc-finger prot 3.3 33 5 1.7

109010 NM_007240Hs.44229 dual specificity phosphatase 12 3.4 34 1 2.6

109060 BE062109 Hs.241551 chloride channel, calcium activated, fam 3.1 31 8 2

109101 AW608930 Hs.52184 hypothetical protein FLJ20618 3.4 71 21 2.4

109112 AW419196 Hs.257924 hypothetical protein FLJ13782 4.1 334 82 3.4

109124 AK000684 Hs.183887 hypothetical protein FLJ22104 3.3 33 1 2.9

109128 H89083 Hs.181915 ESTs 4 40 7 1.1

109160 BE220601 Hs.301997 hypothetical protein FLJ13033 3.8 233 62 3.8

109166 AA219691 Hs.73625 RAB6 interacting, kinesin-like (rabkines 8.8 199 23 16.1

109173 AA179962 Hs.73643 EST 3.2 32 1 2.2

109178 AW976516 Hs.283707 Homo sapiens cDNA: FLJ21354 fis, clone C 3.2 32 10 2.9

109235 AI381800 Hs.300684 calcitonin gene-related peptide-receptor 4.9 121 25 10.4

109273 AA375752 Hs.82719 Homo sapiens mRNA; cDNA DKFZp586F1822 (f 2.9 114 39 9.9

109292 AW975746 Hs.188662 KIAA1702 protein 7.1 71 1 6.5

109391 AL096858 Hs.184245 KIAA0929 protein Msx2 interacting nudea 6.9 69 5 6.2

109411 R98881 Hs.109655 sex comb on midleg (Drosophila)-like 1 3.3 39 12 1.5

109412 BE543313 Hs.209473 hypothetical protein FLJ 10520 4.2 56 14 2.2

109415 U80736 Hs.110826 trinucleotide repeat containing 9 12.3 123 1 11.3

109481 AA878923 Hs.289069 hypothetical protein FLJ21016 3.2 286 91 5.7

109517 AI631874 Hs.155140 casein kinase 2, alpha 1 polypeptide 8.3 83 8 1.9

109597 AA989362 Hs.293780 ESTs 5.9 59 10 4.2

109729 F10024 Hs.268740 ESTs 3.2 41 13 3.3

109795 AA173942 Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (f 5.9 208 36 1.8

109799 AW965076 Hs.180378 hypothetical protein 669 5 50 5 4.1

109883 R68827 Hs.95011 syntrophin, beta 1 (dystrophin-associate 37 37 4 2

109912 AW390822 Hs.301528 L-kynurenine/alpha-aminoadipate aminotra 14.2 142 1 9.5

109937 AI084066 Hs.20072 myosin regulatory light chain inferacfin 4.1 41 7 1.7

109958 AA001266 Hs.133521 ESTs 4.2 58 14 0.8

109984 AI796320 Hs.10299 Homo sapiens cDNA FLJ 13545 fis, clone PL 3.2 136 43 3.6

110009 BE075297 Hs.6614 ESTs, Weakly similar to A43932 mucin 2 p 6.3 693 110 7.2

110240 AI668594 Hs.176588 ESTs, Weakly similar to CP4Y_HUMAN CYTOC 4.6 913 199 2.9

110369 AK000768 Hs.107872 hypothetical protein FLJ20761 3.8 38 7 2.8

110426 AI610702 Hs.28212 ESTs, Weakly similarto TRHYJHUMAN TRICH 6.7 78 12 3

110478 H11236 Hs.31034 peroxisomal biogenesis factor 11 A 3.7 37 1 2.1

110481 AF075089 Hs.36823 ESTs 3.6 36 10 2.5

110581 H61560 gb:yr22g03.s1 Soares fetal liver spleen 3.3 33 1 1.8

110674 AA071276 Hs.19469 KIAA0859 protein 3.5 35 8 1.9

110705 AB007902 Hs.32168 KIAA0442 protein 3.6 282 79 1.7

110721 H97678 Hs.31319 ESTs 4.4 103 24 3.8

110731 NM_014899Hs.188006 KIAA0878 protein 3.3 138 42 3.6

110769 BE000831 Hs.23837 Homo sapiens cDNA FLJ11812 fis, clone HE 13.5 135 1 5.1

110775 N22414 gb:yw39a07.s1 Weizmann Olfactory Epithel 5.4 54 1 3.7

110787 AA831267 Hs.12244 hypothetical protein FLJ20097 4.7 47 4 4.2

110799 AI089660 Hs.323401 dpy-30-like protein 5 50 1 4.3

110818 AL157503 Hs.27552 Homo sapiens mRNA; cDNA DKFZp586N2424 (f 3.1 31 1 2.7

110839 AF153330 Hs.30246 solute carrier family 19 (thiamine trans 8.4 84 1 5.3

110844 AI740792 Hs.167531 methylcrotonoyl-Coenzyme A carboxylase 2 10.5 105 4 7.1

110854 BE612992 Hs.27931 hypothetical protein FLJ10607 similarto 7.9 79 1 6.2

110882 AW963705 Hs.301183 molecule possessing ankyrin repeats indu 3.9 353 90 1.2

110908 AI433165 Hs.9856 ESTs 3.1 31 1 1.3 10915 BE092285 Hs.29724 hypothetical protein FLJ13187 20.9 209 1 19.5 10930 BE242691 Hs.14947 ESTs 3.4 115 34 2.4 10970 Y19062 Hs.96870 staufen (Drosophila, RNA-binding protein 3.5 35 9 3.2 11084 H44186 Hs.15456 PDZ domain containing 1 4.3 43 1 2 11125 N63823 Hs.269115 ESTs, Moderately similarto Z195_HUMAN Z 5.4 54 1 4.3 11132 AB037807 Hs.83293 hypothetical protein 7.2 72 10 6.1 11164 N46180 Hs.122489 Homo sapiens cDNA FLJ13289 fis, clone OV 7.7 77 1 5 11179 AK000136 Hs.10760 asporin (LRR class 1) 25.1 288 12 6.7 11184 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE 3.9 146 37 9.8 11190 AK002055 Hs.151046 hypothetical protein FLJ11193 6.3 63 1 5.8 11221 AB037782 Hs.15119 KIAA1361 protein 3.7 119 33 6.7 11223 AA852773 Hs.334838 KIAA1866 protein 3.6 402 112 4.9 11229 AW389845 Hs.110855 ESTs 4.3 43 1 1 11234 AA902656 Hs.21943 NIF3 (Ngg1 interacting factor 3, S.pombe 3.3 33 1 1.1 11241 AA345644 Hs.288880 PAN2 protein 4.8 61 13 5.6 11345 AW263155 Hs.14559 hypothetical protein FLJ10540 4.3 43 5 2.2 11353 W20090 Hs.6616 ESTs 4.1 41 1 2.6 11357 BE314949 Hs.87128 hypothetical protein FLJ23309 3.8 425 111 4 11378 AW160993 Hs.326292 hypothetical gene DKFZp434A1114 4.3 65 15 5.7 11389 AK000987 Hs.169111 oxidation resistance 1 3.4 314 91 2.4 11540 U82670 Hs.9786 zinc finger protein 275 3.5 35 1 2.1 11806 BE071382 Hs.279008 hypothetical protein FLJ20170 3.5 105 30 9.6 11884 AW502285 Hs.127236 hypothetical protein FLJ 12879 3.2 37 12 3.5 11923 BE383234 Hs.25925 Homo sapiens, clone MGC:15393, mRNA, com 6.2 62 2 5.9 11929 AF027208 Hs.112360 prominin (mouse)-like 1 8.1 328 41 1.7 11942 R40576 Hs.21590 hypothetical protein DKFZp564O0523 4.2 125 30 7.4 11987 NM 15310HS.6763 KIAA0942 protein 6.5 65 10 1.5 12092 R44538 gb:yg29c02.s1 Soares infant brain 1N1B H 3.3 33 10 2.3 12134 R41823 Hs.7413 ESTs; calsyntenin-2 6.1 185 31 6.6

12197 NM_.003655Hs.5637 ESTs 3.5 507 145 3.3

12198 AI432672 Hs.288539 hypothetical protein FLJ22191 3.5 40 12 2.5 12244 AB029000 Hs.70823 KIAA1077 protein 5.7 567 100 6.7 12253 R51818 gb:yg77h12.s1 Soares infant brain 1NIB H 4 70 18 6.8

12269 R53734 Hs.25978 ESTs, Weakly similar to 2109260A B cell 3.7 37 1 3 12275 AW972635 Hs.301904 hypothetical protein FLJ12671 4.3 45 11 4.4 12280 AA863360 Hs.26040 ESTs, Weakly similar to fatty acid omega 2.8 751 270 1.3 12305 AK000914 Hs.26244 hypothetical protein FLJ10052 3.5 41 12 3.7 12483 AW969785 Hs.285885 Homo sapiens cDNA FLJ11321 fis, clone PL 4.2 42 6 3.6 12513 R68425 Hs.13809 hypothetical protein FLJ10648 4.7 54 12 4.5 12571 AA412205 Hs.140996 ESTs 4.8 48 2 3.4 12971 Z42387 Hs.83883 transmembrane, prostate androgen induced 4.5 390 87 5.3 13023 AL134324 Hs.7312 ESTs 3.2 99 31 3.1 13047 AI571940 Hs.7549 ESTs 9.6 124 13 9 13073 N39342 Hs.103042 microtubule-associated protein 1B 9.1 91 6 8.3 13083 AA283057 Hs.266957 hypothetical protein FLJ 14281 6.5 65 6 4.8 13287 T66847 Hs.194040 ESTs, Weakly similar to I38022 hypotheti 3.5 35 1 1.4 13296 AW449560 Hs.89576 inner mitochondrial membrane peptidase 2 3.5 35 4 3.3 13523 AI791905 Hs.95549 hypothetical protein 7.6 76 1 4.2 13604 AI075407 Hs.296083 ESTs, Moderately similar to I54374 gene 3.1 453 148 7 13617 AI869372 Hs.17207 Homo sapiens cDNA FLJ11922 fis, clone HE 3.6 36 4 2.6 13702 T97307 gb:ye53h05.s1 Soares fetal liver spleen 12.3 129 11 11.7 13783 AL359588 Hs.7041 hypothetical protein DKFZp762B226 4.6 46 4 4.3 13791 AI269096 Hs.135578 chitobiase, di-N-acetyl- 3.6 36 1 1.2 13794 T62849 Hs.11090 membrane-spanning 4-domains, subfamily A 3.3 744 227 2.5 13804 BE247683 Hs.14611 dual specificity phosphatase 11 (RNA/RNP 3.3 180 54 2.1 13808 W44735 Hs.9286 Homo sapiens cDNA: FLJ21278 fis, clone C 5.1 51 5 4.5 13847 NM_005032Hs.4114 plastin 3 (T isoform) 3.2 238 75 2.1 13849 AA457211 Hs.8858 bromodomain adjacent to zinc finger doma 4.3 43 8 3.6 13867 AW002834 Hs.24095 ESTs 6.1 110 18 10.2 13886 W76027 Hs.23920 hypothetical protein FLJ11105 4 48 12 4 13923 AW953484 Hs.3849 hypothetical protein FLJ22041 similarto 3.7 239 65 3.6 13936 W17056 Hs.83623 nuclear receptor subfamily 1, group I, m 4.3 819 191 1.2 13950 AI267652 Hs.30504 Homo sapiens mRNA; cDNA DKFZp434E082 (fr 10.7 123 12 7 14030 AI825386 Hs.164478 hypothetical protein FLJ21939 similarto 4.4 44 6 2.3 14051 AB026436 Hs.177534 dual specificity phosphatase 10 4.5 45 4 2.6 14057 AF116653 Hs.34192 Homo sapiens PRO0823 mRNA, complete eds 3.5 35 6 3.2 14082 AK001612 Hs.26962 Homo sapiens cDNA FLJ10750 fis, clone NT 3.1 31 5 1.5 114124 W57554 Hs.125019 lymphoid nuclear protein (LAF-4) mRNA 24.2 242 10 5.6

114138 AW384793 Hs.15740 Homo sapiens mRNA; cDNA DKFZp434E033 (fr 6.7 67 1 6.3

114162 AF155661 Hs.22265 pyruvate dehydrogenase phosphatase 3.8 73 19 1.8

114196 AF017445 Hs.150926 fucose-1 -phosphate guanylyltransferase 4.4 104 24 5.1 114208 AL049466 Hs.7859 ESTs 5.7 57 1 4.9

114239 AL137667 Hs.267445 Homo sapiens mRNA; cDNA DKFZp434B231 (fr 3.3 33 1 2.4

114251 H15261 Hs.21948 ESTs 4.2 46 11 1.4

114306 AF100143 Hs.6540 fibroblast growth factor 13 4.5 45 2 3

114460 AF183810 Hs.26102 trichorhinophalangeal syndrome I 4.4 44 1 3 114542 AW970128 Hs.91011 anterior gradient 2 (Xenepus laevis) horn 4.7 770 166 5.8

114652 AI521936 Hs.107149 novel protein similar to archaeal, yeast 5.2 52 3 2.3

114767 AI859865 Hs.154443 minichromosome maintenance deficient (S. 4.6 196 43 10

114768 AF212848 Hs.182339 ets homologous factor 13.7 137 1 8.9 114774 AV656017 Hs.184325 CGI-76 protein 3.3 168 51 7.3 114798 AA159181 Hs.54900 serologically defined colon cancer antig 7.4 137 19 1.8

114821 AI648602 Hs.55468 ESTs 4.7 57 12 4.7

114860 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 9.1 91 1 7.6

114918 BE165762 Hs.23518 hypothetical protein from BCRA2 region 10.1 111 11 10.2

114940 BE092696 Hs.75928 ESTs 6.4 67 11 5 114965 AI733881 Hs.72472 BMP-R1B 35.9 359 10 29.7

114969 AW162998 Hs.24684 KIAA1376 protein 9.4 94 8 7.3

114988 AA251089 gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens 11.5 115 1 6.9

115004 AA329340 Hs.4867 mannosyi (alpha-1,3-)-glycoprotein beta- 4.2 42 9 1.1

115054 AW265668 Hs.87729 hypothetical protein FLJ12428 5.1 51 1 4.2 115061 AI751438 Hs.41271 Homo sapiens mRNA full length insert cDN 4.5 290 65 3.7

115140 NM_014158Hs.279938 HSPC067 protein 4.8 48 1 4.4

115142 AI623693 Hs.191533 ESTs 3.2 49 16 4.2

115188 AK000219 Hs.88367 hypothetical protein FLJ20212 3.3 33 1 3

115206 AW183695 Hs.186572 ESTs 5.8 58 1 5 115221 AW365434 Hs.79741 hypothetical protein FLJ10116 5.5 343 62 2.5

115262 AI422867 Hs.88594 ESTs 11.2 112 1 10.3

115291 BE545072 Hs.122579 hypothetical protein FLJ10461 4.5 96 21 7.8

115536 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), act 5.9 59 1 4.2

115583 NM_012317Hs.45231 leucine zipper, down-regulated in cancer 9.8 98 1 8.8 115600 AA081395 Hs.42173 Homo sapiens cDNA FLJ10366 fis, clone NT 4.6 46 2 1.8

115622 AI088691 Hs.208414 Homo sapiens mRNA; cDNA DKFZp564D0472 (f 4.4 44 7 1.1

115646 N36110 Hs.305971 solute earner family 2 (facilitated glu 3.2 372 115 2.1

115674 AW992356 Hs.8364 Homo sapiens pyruvate dehydrogenase kina 10.2 506 50 2.8

115675 W87707 Hs.82065 interleukin 6 signal transducer (gp130, 5.2 405 78 10.1 115719 AW992405 Hs.59622 Homo sapiens, clone IMAGE:3507281 , mRNA, 7.6 144 19 13.9

115725 AW899053 Hs.76917 F-box only protein 8 3.1 58 19 2.5

115764 AW582256 Hs.91011 anterior gradient 2 (Xenepus laevis) horn 5.7 368 65 28.5

115821 AW338063 Hs.130965 zinc-finger protein ZBRK1 3.9 39 2.2

115825 R50956 Hs.159993 gycosyltransferase 4.2 79 1.9 115839 BE300266 Hs.28935 transducin-like enhancer of split 1 , horn 5.8 58 4.4

115844 A1373062 Hs.332938 hypothetical protein MGC5370 6.2 62 5.4

115892 AA291377 Hs.50831 ESTs 3.2 40 0.7

115967 AI745379 Hs.42911 ESTs 8.4 101 8.7

116093 AW673312 Hs.50848 hypothetical protein FLJ20331 3.6 36 2 116097 AI198719 Hs.176376 ESTs 5.1 51 2

116107 AL133916 Hs.172572 hypothetical protein FLJ20093 3.4 34 1

116127 AF126743 Hs.279884 DNAJ domain-containing 3.5 35 3.3

116129 AF189011 Hs.49163 putative ribonuclease III 4.5 45 3.4

116204 AW861622 Hs.108646 Homo sapiens CDNA FLJ14934 fis, clone PL 5.2 52 4 3.9 116226 AW976438 Hs.17428 RBP1-like protein 3.8 38 7 2.1

116238 AV660717 Hs.47144 DKFZP586N0819 protein 5.1 198 39 17.9

116250 N76712 Hs.44829 ESTs, Weakly similar to I38022 hypotheti 13.3 133 8 3.2

116256 AA328153 Hs.88201 ESTs, Weakly similar to A Chain A, Cryst 3.3 106 33 9.8

116298 AI955411 Hs.94109 Homo sapiens CDNA FLJ13634 fis, clone PL 4.8 179 38 2.8 116336 AL133033 Hs.4084 KIAA1025 protein 3.2 173 55 3

116351 AL133623 Hs.82501 similar to mouse Xm1 /Dhm2 protein 3.7 37 1 1.8

116365 N50174 Hs.46765 ESTs 39 39 10 0.6

116379 AA448588 Hs.71252 hypothetical protein DKFZp761C169 5.6 106 19 9

116429 AF191018 Hs.279923 putative nucleotide binding protein, est 3.6 256 72 3.7 116450 AI654450 Hs.47274 Homo sapiens mRNA; cDNA DKFZp564B176 (fr 3.1 119 39 2

116461 AA313607 Hs.58633 Homo sapiens cDNA: FLJ22145 fis, clone H 5.5 315 58 3.1

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 3.4 496 144 1.6 116507 AI418366 Hs.68501 ESTs 3.1 31 4 1.9

116579 AW888411 Hs.81915 leukemia-associated phosphoprotein p18 ( 3.3 931 279 5.6

116625 F01601 Hs.241567 RNA binding motif, single stranded inter 3.6 36 1 1.9

116674 AI768015 Hs.92127 ESTs 4.5 96 22 6.9

116680 AW902848 Hs.273829 ESTs 4.2 42 1 2.7

116710 F10577 Hs.306088 v-crk avian sarcoma virus CT10 oncogene 7.1 71 9 6.9

116724 AA741307 Hs.65641 hypothetical protein FLJ20073 4.3 190 44 5.4

116786 H25836 Hs.301527 ESTs, Moderately similarto unknown [H.s 22.8 228 9 12.4

116787 AW362955 Hs.15641 Homo sapiens cDNA FLJ 14415 fis, clone HE 4.9 108 22 9

116790 AW161357 Hs.101174 microtubule-associated protein tau 4.6 163 35 7.3

116844 H64938 Hs.337434 ESTs, Weakly similar to A46010 X-linked 6.9 69 10 2.4

117027 AW085208 Hs.130093 ESTs 4.8 48 1 2.5

117067 H91164 Hs.335797 ESTs 3.3 33 1 2.3

117129 H95785 Hs.167652 ESTs, Highly similarto 1819485A CENP-E 3.1 38 13 1.7

117147 AW901347 Hs.38592 hypothetical protein FLJ23342 4.8 48 1 0.9

117170 N25929 Hs.42500 ADP-ribosylation factor-like 5 3.1 295 96 27.9

117209 W03011 Hs.306881 MSTP043 protein 3.6 41 12 2.8

117280 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C 3.9 322 83 4.4

117367 AI041793 Hs.42502 ESTs 3.5 72 21 1.3

117412 N32536 Hs.42645 solute earner family 16 (monocarboxylic 17.4 174 9 6.9

117475 N30205 Hs.93740 ESTs, Weakly similarto I38022 hypotheti 3.2 35 11 0.7

117634 AW341639 Hs.13323 hypothetical protein FLJ22059 5 50 1 4.7

117667 U59305 Hs.44708 Ser-Thr protein kinase related to the my 4.5 211 i 47 5

117852 AW877787 Hs.136102 KIAA0853 protein 4.6 46 1 3.8

117873 N49967 Hs.46624 HSPC043 protein 3.1 31 1 2.7

117924 AI521436 Hs.38891 ESTs 4.9 49 1 4.4

118138 AA374756 Hs.93560 Homo sapiens mRNA for KIAA1771 protein, 5 50 2 3.1

118449 AI813865 Hs.164478 hypothetical protein FLJ2 939 similarto 3.6 89 25 0.9

118467 AF091434 Hs.43080 platelet derived growth factor C 3.2 378 117 2.8

118472 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 14.5 145 1 2.4

118475 N66845 gb:za46c11.s1 Soares fetal liver spleen 3.1 199 64 1

118509 N22617 Hs.43228 Homo sapiens cDNA FLJ 11835 fis, clone HE 6 60 5 3.7

118528 A1949952 Hs.49397 ESTs 3.3 81 25 1.5

118828 N79496 Hs.50824 EST, Moderately similarto I54374 gene N 3.4 740 217 2.8

118836 AW134482 Hs.173001 hypothetical protein FLJ13964 4.3 162 38 12.1

118854 T58283 Hs.10450 Homo sapiens cDNA: FLJ22063 fis, clone H 3.4 118 35 2.3

118873 AI824009 Hs.44577 ESTs 3.5 35 1 2.9

118888 AI191811 Hs.54629 ESTs 8.4 84 10 0.8

118901 AW292577 Hs.94445 ESTs 7.3 73 3 5.4

118981 N29309 Hs.39288 ESTs 5 50 5 4.7

118991 NM 016657HS.250696 KDEL (Lys-Asp-Glu-Leu) endoplasmic retic 3.7 37 6 0.5

119023 N98488 gb:zb82h01.s1 Soares_senescent_fibroblas 3.3 36 11 0.6

119088 R39261 Hs.90790 Homo sapiens cDNA: FLJ22930 fis, clone K 3.3 167 51 2.6

119126 R45175 Hs.117183 ESTs 5.3 53 6 2.3

119128 H09334 Hs.92482 ESTs 3.7 37 4 3

119271 AI061118 Hs.65328 Fanconi anemia, complementation group F 8.2 82 1 6.4

119298 NM_001241Hs.155478 cyclin T2 4 40 4 1.2

119307 BE048061 Hs.37054 ephrin-A3 3.3 571 171 2

119367 T78324 Hs.250895 ribosomal protein L34 3.4 34 3 2.4

119427 AW474547 Hs.53565 Homo sapiens PIG-M mRNA for mannosyltran 4.6 60 13 4.8

119580 AL079310 Hs.92260 high-mobility group protein 2-like 1 8.1 94 12 6.5

119586 AF088033 Hs.159225 ESTs 3.3 33 8 0.9

119638 NM 016122HS.56148 NY-REN-58 antigen 3.3 33 10 0.5

119676 AA243837 Hs.57787 ESTs 5.4 54 1 4.1

119717 AA918317 Hs.57987 B-cell CLL/lymphoma 11B (zinc finger pro 4.6 46 7 0.8

119771 AI905687 Hs.2533 EST 3.5 2073 595 2.1

119780 NM 016625HS.191381 hypothetical protein 4.4 44 1 3.1

119786 AL133396 Hs.121281 prion protein 2 (dublet) 3.4 34 1 2.5

119805 AJ223810 Hs.43213 ESTs, Weakly similarto IEFS_HUMAN TRANS 3.6 36 1 2.9

119859 AW245741 Hs.58461 ESTs, Weakly similar to A35659 krueppel- 5.2 52 6 1.8

119899 AI057404 Hs.58698 ESTs 3.7 37 4 1.9

119940 AL050097 Hs.27253 DKFZP586B0319 protein 6.9 162 24 2.6

119943 BE565849 Hs.14158 copine III 3.7 590 159 3.8

120132 W57554 Hs.125019 lymphoid nuclear protein (LAF-4) mRNA 6.9 319 47 2.1

120150 BE005771 Hs.153746 hypothetical protein FLJ22490 5.3 53 5 0.9

120215 AF109219 Hs.108787 phosphatidylinositol glycan, class N 3.2 106 34 3.3

120260 AK000061 Hs.101590 hypothetical protein 3.4 34 1 1.7 120296 AW995911 Hs.299883 hypothetical protein FLJ23399 4.2 124 30 1.8

120352 R06859 Hs.193172 ESTs, Weakly similarto I38022 hypotheti 7.5 112 15 2.5

120378 AA223249 Hs.285728 abl-interactor 12 (SH3-containing protei 3.3 33 10 2.8

120418 AW966893 Hs.26613 Homo sapiens mRNA; cDNA DKFZp586F1323 (f 4.8 48 1 0.5

120473 AA251973 Hs.269988 ESTs 3.4 34 4 0.1

120493 AW968080 Hs.152939 Homo sapiens clone 24630 mRNA sequence 3.9 161 42 2

120524 AA261852 Hs.192905 ESTs 6.8 68 1 0.2

120554 AA284447 Hs.271887 ESTs 3.2 32 5 0.6

120562 BE244580 Hs.302267 hypothetical protein FLJ10330 8.5 127 15 1.6

120571 AB037744 Hs.34892 KIAA1323 protein 3.7 37 1 0.5

120572 H39599 Hs.294008 ESTs 3.6 36 8 0.2

120588 AA703226 Hs.16193 Homo sapiens mRNA; cDNA DKFZp586B211 (fr 5.6 101 18 1.6

120649 AA687322 Hs.192843 leucine zipper protein FKSG14 5.4 54 10 2.5

120658 AI952639 Hs.98267 ESTs 3.2 32 8 3

120713 AW449855 Hs.96557 Homo sapiens cDNA FLJ12727 fis, clone NT 5.3 58 11 3.3

120821 Y19062 Hs.96870 staufen (Drosophila, RNA-binding protein 3.3 33 3 0.2

120822 AA347422 Hs.238040 EST, Weakly similarto B34087 hypothetic 3.8 38 7 0.2

120915 AL135556 Hs.97104 ESTs 3.5 37 11 0.1

120922 AA481003 Hs.97128 ESTs 3.1 31 1 0.4

120977 AA398155 Hs.97600 ESTs 7.9 79 1 2.7

120999 AI972375 Hs.29626 hypothetical brain protein my038 5.1 51 1 2.4

121125 AL042981 Hs.251278 KIAA1201 protein 3.7 37 10 1

121176 AL121523 Hs.97774 ESTs 7 70 1 0.9

121202 AA970946 Hs.97794 ESTs 3.9 39 1 0.2

121429 AA406293 Hs.41167 ESTs 3.4 34 1 0.8

121448 AF044197 Hs.100431 B-cell attracting chemokiπe 1 (CXC 13; 3.5 35 1 2.6

121463 AK000282 Hs.239681 hypothetical protein FLJ20275 10.3 103 1 9.3

121517 AI002968 Hs.235402 ESTs, Weakly similar to T26525 hypotheti 3.5 143 41 2.6

121553 AA412488 Hs.48820 TATA box binding protein (TBP)-associate 4.6 46 3 0.8

121556 AA412494 Hs.98152 EST 4.2 77 19 1,4

121581 AA416568 gb:zu05c10.s1 Soares testis NHT Homo sap 3.2 32 1 0.8

121709 AI338247 Hs.98314 Homo sapiens mRNA; cDNA DKFZp586L0120 (f 3.4 34 10 0.7

121723 AA243499 Hs.104800 hypothetical protein FLJ10134 2.9 214 74 3.7

121831 AA449644 Hs.193063 Homo sapiens cDNA FLJ14201 fis, clone NT 3.9 39 1 0.2

121853 AA425887 Hs.98502 hypothetical protein FLJ14303 4.4 48 11 0.9

121873 AV650929 Hs.145696 splicing factor (CC1.3) 3.6 150 42 3.2

121913 A1249368 Hs.98558 ESTs; protease inhibitor 15 (PI15) 2.7 864 321 0.6

121916 AW117207 Hs.98523 ESTs 3.5 35 3 2.3

122004 A1810721 Hs.95424 ESTs 4.9 49 7 3.7

122063 AW794215 Hs.301226 KIAA1085 protein 3.2 88 28 1.2

122223 AF169797 Hs.27413 adaptor protein containing pH domain, PT 12.6 126 7 7.5

122235 AA436475 Hs.112227 membrane-associated nucleic acid binding 4.1 43 11 1.6

122273 AI298368 Hs.150926 fucose-1 -phosphate guanylyltransferase 3.1 31 1 1

122383 AA446189 Hs.99051 ESTs 3.3 53 16 4

122507 BE567620 Hs.99210 ESTs 3.2 291 91 4

122524 AA449453 Hs.192915 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.1 31 6 0.8

122636 AW651706 Hs.99519 hypothetical protein FLJ14007 3.5 35 1 3

122637 AA454149 Hs.99357 EST 3.2 32 10 3.1

122798 AW366286 Hs.145696 splicing factor (CC1.3) 3.2 36 11 2.5

122861 AA335721 Hs.119394 ESTs 5.6 108 20 1.8

122873 AA749382 Hs.118797 ubiquitin-conjugating enzyme E2D 3 (homo 3.6 36 1 3.4

122946 AI718702 Hs.308026 major histocompatibility complex, class 3.7 162 44 12.4

122963 AA478446 Hs.69559 KIAA1096 protein 7.2 72 1 5.7

122974 AA447871 Hs.194215 ESTs, Weakly similarto I38022 hypotheti 4.7 59 13 4.7

123016 AW338067 Hs.323231 Homo sapiens cDNA FLJ11946 fis, clone HE 3.3 207 63 3.5

123090 AL135185 Hs.48778 niban protein 3.8 207 55 5.5

123137 A1073913 Hs.100686 ESTs, Weakly similar to JE0350 Anterior 9.9 351 36 13.9

123255 AA830335 Hs.105273 ESTs 4.1 72 18 1.5

123284 AA488988 Hs.293796 ESTs 3.7 41 11 1.6

123442 AA299652 Hs.111496 Homo sapiens cDNA FLJ11643 fis, clone HE 6.7 67 2 2.1

123449 AL049325 Hs.112493 Homo sapiens mRNA; cDNA DKFZp564D036 (fr 3.4 34 1 2.6

123475 BE439553 Hs.250528 Homo sapiens, clone IMAGE:4098694, mRNA, 9.7 102 11 6

123494 AW179019 Hs.112110 mitochondrial ribosomal protein L42 4.2 42 7 2.9

123503 AW975051 Hs.293156 ESTs, Weakly similarto I78885 serine/th 3.9 39 1 3.2

123516 AB037860 Hs.173933 nuclear factor l/A 4.3 43 1 3.5

123518 AL035414 Hs.21068 hypothetical protein 5.8 58 1 4.9

123523 AA608588 gb:ae54e06.s1 Stratagene lung carcinoma 3.1 927 295 2.1 123527 AF150208 Hs.108327 damage-specific DNA binding protein 1 (1 5 121 25 5.9

123570 AA608955 Hs.109653 ESTs 6.8 68 10 6.1

123619 AA602964 gb:no97c02.s1 NCI CGAP Pr2 Homo sapiens 8.5 85 1 4.3

123673 BE550112 Hs.158549 ESTs, Weakly similarto T2D3 HUMAN TRANS 3.9 39 5 3.7

123709 AA706910 Hs.112742 ESTs 3.9 60 16 4.8

123926 AA425769 Hs.227933 Alg5, S. cerevisiae, homolog of 3.4 80 24 3.8

123960 AW082862 Hs.287733 hypothetical protein FLJ23189 4.5 45 2 3.6

124006 A1147155 Hs.270016 ESTs 5.8 321 55 17

124059 BE387335 Hs.283713 ESTs, Weakly similarto S64054 hypotheti 10.4 880 85 5.3

124287 H88296 Hs.5123 inorganic pyrophosphatase 3.1 41 14 2.7

124292 H11341 Hs.13366 Homo sapiens cDNA: FLJ23567 fis, clone L 3.2 32 1.5

124308 AA249027 Hs.241507 ribosomal protein S6 10.5 105 9.9

124315 NM 005402HS.288757 v-ral simian leukemia viral oncogene horn 12.8 141 11 12.2

124461 AF283776 Hs.80285 Homo sapiens mRNA; cDNA DKFZp586C1723 (f 3.1 31 1.8

124483 AI821780 Hs.179864 ESTs 3.3 33 1.7

124677 R01073 gb:ye84c03.s1 Soares fetal liver spleen 4.2 42 7 3

124777 R41933 Hs.140237 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.4 210 63 3.3

124940 AF068846 Hs.103804 heterogeneous nuclear ribonucleoprotein 6.5 162 25 14.7

125079 T90298 Hs.271396 ESTs 3.1 31 6 2.4

125091 T91518 gb:ye20f05.s1 Stratagene lung (937210) H 3.4 985 286 2.8

125103 AA570056 Hs.122730 ESTs, Moderately similar to KIAA1215 pro 3.6 224 63 4

125144 AB037742 Hs.24336 KIAA1321 protein 6.3 63 6 5

125150 W38240 Empirically selected from AFFX single pr 3.6 38 11 2.6

125156 W93048 Hs.250723 hypothetical protein MGC2747 3.1 31 1 2.8

125226 AA782536 Hs.122647 N-myristoyltransferase 2 3.2 37 12 3.6

125279 AW401809 Hs.4779 KIAA1150 protein 13.1 131 1 5.1

125299 T32982 Hs.102720 ESTs 7.7 81 11 7.6

125303 AA173319 Hs.288193 hypothetical protein MGC12217 14.3 143 9 13.1

125377 W72949 Hs.77495 UBX domain-containing 1 3.3 34 11 3.2

125390 AL038165 Hs.75187 translocase of outer mitochondrial membr 8.2 124 15 11.5

125471 AA421691 Hs.152601 UDP-glucose ceramide glucosyltransferase 3.7 224 61 21

125617 AA287921 Hs.164950 ESTs 6.7 67 1 6

125621 T62641 Hs.278544 acetyl-Coenzyme A acetyltransferase 2 (a 5.5 55 10 4.2

125628 AA418069 Hs.241493 natural killer-tumor recognition sequenc 5.5 63 12 1

125660 AW292171 Hs.23978 scaffold attachment factor B 4.3 68 16 2.8

125698 AF078847 Hs.191356 general transcription factor IIH, polype 4.8 48 5 4.1

125745 AI858032 Hs.75722 ribophorin II 6.8 223 33 2.8

125770 AA143045 Hs.81665 v-kit Hardy-Zuckerman 4 feline sarcoma v 8.3 87 11 0.4

125827 NM 003403Hs.97496 YY1 transcription factor 11.3 124 11 9.7

125852 AW630088 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564B1264 (f 30.6 306 4 26.5

126349 T30968 Hs.13531 hypothetical protein FLJ10971 4.9 68 14 1.4

126384 AW090198 Hs.4779 KIAA1150 protein 6.4 74 12 6.6

126590 W78968 Hs.181307 H3 histone, family 3A 5 264 53 3.4

126645 AA316181 Hs.61635 six transmembrane epithelial antigen of 3.8 38 1 2.7

126663 AW518478 Hs.181297 ESTs 3.6 36 6 2.9

126695 AA643322 Hs.172028 a disintegrin and metalloproteinase doma 3.1 31 1 2.5

126764 AA036755 Hs.102178 syntaxin 16 4.4 76 18 1

126801 AW663887 Hs.7337 hypothetical protein FLJ10936 3.8 38 1 3

126813 AW163483 Hs.48320 double ring-finger protein, Dorfin 6.7 155 23 1.4

126838 AL043489 Hs.279609 mitochondrial earner homolog 2 8.8 110 13 10.5

126855 AA129640 Hs.128065 ESTs 3.6 36 10 1.9

126971 T26989 Hs.283664 aspartate beta-hydroxylase 5.5 79 15 4.4

127167 AA625690 Hs.190272 ESTs 3.1 33 11 2.3

127251 AA936428 Hs.128638 ESTs 3.5 35 1 3.1

127349 AA412108 Hs.269350 ESTs 4.8 106 22 1

127439 D60237 Hs.14368 SH3 domain binding glutamic acid-rich pr 7.5 75 1 6.5

127537 AI926047 Hs.162859 ESTs 3.8 38 7 3.4

127542 AA703684 Hs.245474 ESTs, Moderately similar to ALU5_HUMAN A 3.3 33 9 0.9

127677 AF175265 Hs.264190 vacuolar protein sorting 35 (yeast homol 4.3 152 35 12.5

127774 AA313639 Hs.119488 cystein-rich hydrophobic domain 2 5.4 73 14 6.8

127999 AW978827 Hs.69851 nucleolar protein family A, member 1 (H/ 5.2 81 16 1.1

128218 AA186733 Hs.292154 stromal cell protein 3.9 220 57 2.5

128305 AI954968 Hs.279009 matrix Gla protein 9.4 94 3 5.3

128470 AL049974 Hs.100261 Homo sapiens mRNA; cDNA DKFZp564B222 (fr 4.6 46 8 3.9

128482 AI694143 Hs.296251 programmed cell death 4 7.2 72 1 5.8

128501 AL133572 Hs.199009 protein containing CXXC domain 2 3.8 38 1 0.9

128517 AW994403 Hs.100861 hypothetical protein FLJ14600 5.6 73 13 6.1 128530 AI932995 Hs.183475 Homo sapiens clone 25061 mRNA sequence 4.2 104 25 7.8

128579 N25956 Hs.101810 Homo sapiens cDNA FLJ 14232 fis, clone NT 3.1 172 55 3.1

128595 U31875 Hs.272499 short-chain alcohol dehydrogenase family 3.3 105 32 3

128610 N48373 Hs.10247 activated leucocyte cell adhesion molecu 7.3 106 15 5

128653 D87432 Hs.10315 solute earner family 7 (cationic amino 3.1 31 1 2.2

128742 AA307211 Hs.251531 proteasome (prosome, macropain) subunit, 3.6 130 36 3.5

128773 NM_004131Hs.1051 granzyme B (granzyme 2, cytotoxic T-lymp 3.9 43 11 1.8

128790 AF026692 Hs.105700 secreted frizzled-related protein 4 17.4 409 24 7.8

128793 AB011125 Hs.105749 KIAA0553 protein 3.1 34 11 2.7

128794 NM_014720Hs.105751 Ste20-related serine/threonine kinase 3.6 36 5 1.5

128835 AK001731 Hs.106390 Homo sapiens mRNA; cDNA DKFZp586H0924 (f 3.3 288 87 7.9

128906 R57988 Hs.10706 epithelial protein lost in neoplasm beta 11.3 113 8 2.5

128925 R67419 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 7.1 392 56 3.6

128949 AA009647 Hs.8850 a disintegrin and metalloproteinase doma 4.6 132 29 9.7

129017 AA115333 Hs.107968 ESTs 8.2 82 1 7.4

129075 BE250162 Hs.83765 dihydrofolate reductase 5 50 1 3.3

129095 L12350 Hs.108623 thrombospondin 2 3.2 814 257 2.4

129151 N23018 Hs.171391 C-terminal binding protein 2 4.4 44 1 3.8

129168 AI132988 Hs.109052 chromosome 14 open reading frame 2 14.2 142 6 9.4

129229 AF013758 Hs.109643 polyadenylate binding protein-interactin 7.1 71 1 6.2

129243 BE169531 Hs.109727 TAK1-binding protein 2; KIAA0733 protein 5 64 13 6.3

129259 AF220050 Hs.181385 uncharacterized hematopoietic stem/proge 5.2 75 15 6.4

129278 NM_015344Hs.11000 leptin receptor overlapping transcπ'pt-l 3.7 39 11 3.2

129337 NM_014918Hs.110488 K1AA0990 protein 9.5 95 1 8.5

129351 AL049538 Hs.62349 ras association (RalGDS/AF-6) domain con 7.6 92 12 1.4

129366 BE220806 Hs.184697 Homo sapiens clone 23785 mRNA sequence 7.1 150 21 14.5

129393 BE219987 Hs.166982 phosphatidylinositol glycan, class F 3.9 54 14 5.1

129457 X61959 Hs.207776 aspartylglucosaminidase 3.6 36 1 2.7

129486 NM_005754Hs.220689 Ras-GTPase-activating protein SH3-domain 4 40 4 3.2

129586 AW964541 Hs.11500 hypothetical protein FLJ21127 4.6 199 44 2.3

129598 N30436 Hs.11556 Homo sapiens cDNA FLJ12566 fis, clone NT 4.2 42 1 3.8

129691 M26939 Hs.119571 collagen, type III, alpha 1 (Ehlers-Danl 6.4 1111 175 5

129698 BE242144 Hs.12013 ATP-binding cassette, sub-family E (OABP 4.8 48 8 3.8

129721 NM_001415Hs.211539 eukaryotic translation initiation factor 5.8 171 30 2.9

129740 BE165866 Hs.83623 nuclear receptor subfamily 1, group I, m 4.5 45 1 2.4

129755 R42216 Hs.12342 Homo sapiens clone 24538 mRNA sequence 5.3 53 9 3.6

129801 R39246 Hs.239666 Homo sapiens cDNA FLJ13495 fis, clone PL 3.1 31 2 2.5

129821 AB028945 Hs.12696 corta in SH3 domain-binding protein 11.4 114 1 10

129869 AI222069 Hs.13015 hypothetical protein similar to mouse Dn 4.7 556 119 4.5

129965 T71333 Hs.13854 ESTs 3.1 31 3 3

129977 NM 000399HS.1395 early growth response 2 (Krox-20 (Drosop 3.2 32 1 0.2

130036 BE061916 Hs.125849 chromosome 8 open reading frame 2 6.7 67 1 5.7

130057 AF027153 Hs.324787 solute carrier family 5 (inositol transp 1 1 1 1

130095 AK001635 Hs.14838 hypothetical protein FLJ10773 14.6 219 15 7.6

130115 T47294 Hs.149923 X-box binding protein 1 3.1 1336 434 1.4

130170 AW977534 Hs.151469 calcium/calmodulin-dependent serine prat 5.3 53 9 3.2

130173 U38847 Hs.151518 TAR (HIV) RNA-binding protein 1 4.2 46 11 1.1

130343 AB040914 Hs.278628 KIAA1481 protein 13.2 331 25 12.4

130356 AF127577 Hs.155017 nuclear receptor interacting protein 1 3.3 354 108 4

130367 AL135301 Hs.8768 hypothetical protein FLJ10849 8.1 81 9 5.5

130385 AW067800 Hs.155223 stanniocalcin 2 72.2 722 1 1.9

130407 BE385099 Hs.334727 hypothetical protein MGC3017 6.5 65 4 5.3

130417 AW163518 Hs.155485 huntingtin interacting protein 2 3.5 79 23 2.5

130441 U63630 Hs.155637 protein kinase, DNA-activated, catalytic 6.1 61 1 5.7

130455 D90041 Hs.155956 N-acetyltransferase 1 (arylamine N-acety 10.8 706 66 9.2

130466 W19744 Hs.180059 Homo sapiens cDNA FLJ20653 fis, clone KA 3.9 39 1 1.9

130526 AW876523 Hs.15929 hypothetical protein FLJ12910 3.9 39 1 2.6

130567 AA383092 Hs. 608 replication protein A3 (1 kD) 4.4 44 1 4.1

130604 AA383256 Hs.1657 estrogen receptor 1 32.2 322 1 4.7

130614 AI354355 Hs.16697 down-regulator of transcription 1, TBP-b 5.2 251 48 21

130617 M90516 Hs.1674 glutamine-fructose-6-phosphate transamin 10 100 1 7.6

130619 AI963376 Hs.12532 chromosome 1 open reading frame 21 3.9 39 1 3.4

130625 AF176012 Hs.260720 J domain containing protein 1 10.5 105 1 9

130677 AL161961 Hs.17767 KIAA1554 protein 6.8 129 19 12.1

130681 R62676 Hs.17820 Rho-associated, coiled-coil containing p 4.1 41 1 3.6

130693 R68537 Hs.17962 ESTs 9.2 234 26 16.8

130712 AJ271881 Hs.279762 bromodomain-containing 7 17.5 175 2 12.8 130723 BE247676 Hs.18442 E-1 enzyme 8.1 81 3 2.8

130751 AF052105 Hs.18879 chromosome 12 open reading frame 4.9 49 1 4.3

130780 AA197226 Hs.19347 hypothetical protein MGC11321 3.6 100 28 6.6

130863 Y10805 Hs.20521 HMT1 (hnRNP methyltransferase, S. cerevi 3.4 525 154 5.3

130871 AF080158 Hs.226573 inhibitor of kappa light polypeptide gen 10.5 121 12 1.6

130888 AL044315 Hs.173094 Homo sapiens mRNA for KIAA1750 protein, 6 202 34 3.7

130974 NM_003528Hs.217B H2B histone family, member Q 7.1 100 14 7.5

130979 NM_012446Hs.169833 single-stranded-DNA-binding protein 3.2 87 27 1.7

130987 BE613269 Hs.21893 hypothetical protein DKFZp761N0624 3.5 124 35 6.5

130993 T97401 Hs.21929 ESTs 4.5 45 1 2.5

131076 AA749230 Hs.26433 doliehyl-phosphate (UDP-N-acetylglucosam 3.2 210 66 3.8

131085 BE207357 Hs.3454 KIAA1821 protein 3.8 42 11 0.6

131126 NM 016156HS.181326 KIAA1073 protein 6.7 67 6 1.9

131129 BE541042 Hs.23240 Homo sapiens cDNA: FLJ21848 fis, clone H 5.8 115 20 2.5

131148 AW953575 Hs.303125 p53-induced protein PIGPC1 3.8 585 153 3.7

131164 AW013807 Hs.182265 keratin 19 5.2 1320 256 3.2

131176 AA465113 Hs.23853 ESTs, Weakly similar to A34615 profilagg 3.8 38 1 3.3

131200 BE540516 Hs.293732 hypothetical protein MGC3195 4.8 48 1 4.1

131216 AI815486 Hs.243901 Homo sapiens cDNA FLJ20738 fis, clone HE 6.1 343 56 16.4

131245 AL080080 Hs.24766 thioredoxin domain-containing 8 100 13 2.9

131248 AI038989 Hs.332633 Bardet-Biedl syndrome 2 4 95 24 1.1

131273 AW206008 Hs.283378 Homo sapiens cDNA: FLJ21778 fis, clone H 4.6 239 53 3.5

131319 NM_003155Hs.25590 stanniocalcin 1 3.5 402 114 2.1

131367 AI750575 Hs.173933 nuclear factor l/A 3.3 775 233 2.4

131375 AW293165 Hs.143134 ESTs 3.8 38 1 3

131379 AK001123 Hs.26176 hypothetical protein FLJ10261 3.9 116 30 0.5

131388 NM 014810Hs.92200 KIAA0480 gene product 7.6 76 1 5

131475 AA992841 Hs.27263 KIAA1458 protein 5.1 113 22 6.1

131492 AI452601 Hs.288869 nuclear receptor subfamily 2, group F, m 8.4 169 20 4.6

131501 AV661958 Hs.8207 GK001 protein 3.1 197 63 18.7

131535 N22120 Hs.75277 hypothetical protein FLJ13910 5.9 59 1 4.4

131544 AL355715 Hs.28555 programmed cell death 9 (PDCD9) 5.1 51 1 3.9

131546 AA093668 Hs.28578 muscleblind (Drosophila)-like 3.8 79 21 6.9

131562 NM_003512Hs.28777 H2A histone family, member L 4 350 88 3

131564 T93500 Hs.28792 Homo sapiens cDNA FLJ 1041 fis, clone PL 4.7 381 81 6.4

131604 AA306477 Hs.29379 hypothetical protein FLJ10687 4.6 46 7 3.8

131684 NM 002104Hs.3066 granzyme K (serine protease, granzyme 3; 3.2 82 26 6.6

131687 BE297635 Hs.3069 heat shock 70kD protein 9B (mortalin-2) 6.7 93 14 8.4

131689 AB012124 Hs.30696 transcription factor-like 5 (basic helix 3.8 51 14 1.7

131693 AW963776 Hs.110796 SAR1 protein 7.2 72 4 5.7

131739 AF017986 Hs.31386 secreted frizzled-related protein 2 2.1 1561 757 1.7

131742 AA961420 Hs.31433 ESTs 11.7 117 1 10.1

131775 AB014548 Hs.31921 KIAA0648 protein 4.8 48 1 4.6

131787 D87077 Hs.196275 KIAA0240 protein 3.2 207 64 5.5

131798 X86098 Hs.301449 adenovirus 5 E1A binding protein 3.4 115 34 9.1

131836 W00712 Hs.32990 DKFZP566F084 protein 5.8 91 16 1.4

131853 AI681917 Hs.3321 ESTs, Highly similarto 1RX1_HUMAN IROQU 4.9 632 129 1.7

131877 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 6.8 68 1 5.6

131881 AW361018 Hs.3383 upstream regulatory element binding prat 4 140 35 1.8

131885 BE502341 Hs.3402 ESTs 5.7 57 1 4.5

131904 AF078866 Hs.284296 Homo sapiens cDNA: FLJ22993 fis, clone K 5.5 90 17 2.9

131919 T15803 Hs.272458 protein phosphatase 3 (formerly 2B), cat 5.6 95 17 9.1

131941 BE252983 Hs.35086 ubiquitin specific protease 1 7.4 103 14 6.5

131945 NM 002916HS.35120 replication factor C (activator 1) 4 (37 3.7 37 1 3.4

131949 AK000010 Hs.258798 hypothetical protein FLJ20003 3.5 35 1 2.5

131965 W79283 Hs.35962 ESTs 5.5 168 31 4.4

131977 U90441 Hs.3622 procollagen-proline, 2-oxoglutarate 4-di 3.7 37 9 2.8

131985 AA503020 Hs.36563 hypothetical protein FLJ22418 40.2 402 1 4

131993 AI878910 Hs.3688 cisplatin resistance-associated overexpr 7.3 73 1 1.2

132064 AA121098 Hs.3838 serum-inducible kinase 22.6 226 10 0.9

132094 NM_016045Hs.3945 CGI-107 protein 3.1 227 73 16.8

132109 AW190902 Hs.40098 cysteine knot superfamily 1, BMP antagon 3.5 73 21 6.3

132116 AW960474 Hs.40289 ESTs 3.6 141 39 12.6

132143 D52059 Hs.7972 KIAA0871 protein 4.9 49 1 4.1

132160 W26406 Hs.295923 seven in absentia (Drosophila) homolog 1 4.4 53 12 2.1

132164 AI752235 Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dio 5 225 45 9.1

132180 NM_004460Hs.418 fibroblast activation protein, alpha 10.7 433 41 7.2 132197 AI699482 Hs.42151 ESTs 3.4 58 17 4

132256 AI078645 Hs.431 murine leukemia viral (bmi-1) oncogene h 4.2 42 1 2.2

132298 NM_015986Hs.7120 cytokine receptor-like molecule 9 3.4 34 2 3

132316 U28831 Hs.44566 KIAA1641 protein 18.6 186 10 1.5

132325 N37065 Hs.44856 hypothetical protein FLJ 12116 5.5 323 59 10.5

132358 NM 003542Hs.46423 H4 histone family, member G 3.3 979 298 2.2

132384 AA312135 Hs.46967 HSPC034 protein 3.6 36 1 3.1

132388 W32624 Hs.278626 Arg/Abl-interacting protein ArgBP2 5.9 186 32 3.7

132393 AL135094 Hs.47334 hypothetical protein FLJ14495 4.2 159 38 7.1

132407 BE613126 Hs.47783 B aggressive lymphoma gene 4.6 46 1 4.3

132425 N87549 Hs.125287 zinc finger protein ZNF140-like protein 3.6 146 41 1.1

132440 AB020699 Hs.1 2751 KIAA0892 protein 3.3 33 4 2.9

132465 AW169847 Hs.49169 KIAA1634 protein 8.3 145 18 3.7

132522 AB023164 Hs.5070 KIAA0947 protein 4.6 46 1 4.4

132528 T78736 Hs.50758 SMC4 (structural maintenance of chromoso 9.3 93 1 8.4

132530 AA306105 Hs.50785 SEC22, vesicle trafficking protein (S. c 4.9 49 1 4.4

132543 BE568452 Hs.5101 protein regulator of cytokinesis 1 11.8 201 17 19.1

132572 AI929659 Hs.237825 signal recognition particle 72kD 3.8 38 1 3

132592 AW803564 Hs.288850 Homo sapiens cDNA: FLJ22528 fis, clone H 4.8 93 20 3.1

132602 AW606927 Hs.5306 hypothetical protein DKFZp586F1122 simil 6.1 61 2 5.9

132616 BE262677 Hs.283558 hypothetical protein PR01855 3.4 193 58 12.3

132617 AF037335 Hs.5338 carbonic anhydrase XII 14.2 390 28 22.5

132618 AL050025 Hs.279916 hypothetical protein FLJ20151 3.3 909 274 3.2

132632 AU076916 Hs.5398 guanine monphosphate synthetase 5 50 1 4.1

132668 AB018319 Hs.5460 KIAA0776 protein 4.2 171 41 12.6

132742 AA025480 Hs.292812 ESTs, Weakly similar to T33468 hypotheti 6.5 65 1 5.6

132790 AW242243 Hs.168670 peroxisomal famesylated protein 3.7 37 1 2.2

132811- U25435 Hs.57419 CCCTC-binding factor (zinc finger protei 7 115 17 5.4

132852 AL120050 Hs.58220 Homo sapiens cDNA: FLJ23005 fis, clone L 3.3 61 19 5.1

132856 NM 001448HS.58367 glypican 4 4.8 48 1 3.6

132880 BE077155 Hs.177537 hypothetical protein DKFZp761B1514 12.6 126 8 9.9

132902 AI936442 Hs.59838 hypothetical protein FLJ10808 11 187 17 10.4

132906 BE613337 Hs.234896 geminin 3.3 106 33 2.6

132914 AL047045 Hs.60293 Homo sapiens clone 122482 unknown mRNA 3.5 110 32 2.1

132968 AF234532 Hs.61638 myosin X 4.1 62 15 4.9

132977 AA093322 Hs.301404 RNA binding motif protein 3 22.1 221 9 17.8

132990 X77343 Hs.334334 transcription factor AP-2 alpha (activat 12.7 311 25 2.4

132994 AA112748 Hs.279905 clone HQ0310 PRO0310p1 3 380 127 5.5

133011 NM 006379HS.171921 sema domain, immunoglobulin domain (Ig), 7.3 271 37 2.3

133015 AJ002744 Hs.246315 UDP-N-acetyl-alpha-D-galactosamine:polyp 4.6 427 93 10.4

133070 U92649 Hs.64311 a disintegrin and metalloproteinase doma 3.6 36 1 3.1

133091 AK001628 Hs.64691 KIAA0483 protein 5.2 117 23 5

133192 AA218564 Hs.67052 vacuolar protein sorting 26 (yeast homol 3.1 359 118 2.5

133197 AI275243 Hs.180201 hypothetical protein FLJ20671 5.1 58 12 5.7

133199 AF231981 Hs.250175 homolog of yeast long chain polyunsatura 3 816 275 3.9

133221 W32474 Hs.301746 RAP2A, member of RAS oncogene family 3.1 234 76 8.6

133240 AK001489 Hs.242894 ADP-ribosylation factor-like 1 8.1 81 1 4.6

133271 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 12.4 124 6 10.8

133291 BE297855 Hs.69855 NRAS-related gene 3.3 33 1 2.9

133294 AJ001388 Hs.69997 zinc finger protein 238 7.9 234 30 18.9

133350 AI499220 Hs.71573 hypothetical protein FLJ 10074 4.6 46 5 3.5

133362 AK001519 Hs.7194 CGI-74 protein 5 110 22 9.7

133370 AF245505 Hs.72157 DKFZP564I1922 protein 3.2 725 227 3.2

133407 AF017987 Hs.7306 secreted frizzled-related protein 1 4.1 374 91 1.1

133422 AB033061 Hs.73287 KIAA1235 protein 4.3 43 1 3.9

133435 AI929357 Hs.323966 Homo sapiens clone H63 unknown mRNA 5.5 186 34 16.5

133479 W01556 Hs.238797 ESTs, Moderately similarto I38022 hypot 3.5 35 7 2.1

133493 AW998046 Hs.194369 arginine-glutamic acid dipeptide (RE) re 3.6 39 11 0.4

133504 NM 004415HS.74316 desmoplakin (DPI, DPII) 4.1 640 158 3

133517 NM 000165HS.74471 gap junction protein, alpha 1, 43kD (con 3.2 351 111 5.2

133536 W25797 Hs.177486 amyloid beta (A4) precursor protein (pro 3.2 226 71 2.8

133578 AU077050 Hs.75066 translin 3.4 178 53 8.8

133633 D21262 Hs.75337 nucleolarand coiled-body phosphprotein 4.7 47 1 4

133640 AW246428 Hs.75355 ubiquitin-conjugating enzyme E2N (homolo 8.5 85 1 7.2

133669 NM_006925Hs.166975 splicing factor, arginine/serine-rich 5 3.6 36 1 0.4

133681 AI352558 Hs.75544 tyrosine 3-monooxygenase/tryptophan 5-mo 3.4 234 68 10.7

133746 AW410035 Hs.75862 MAD (mothers against decapentaplegic, Dr 9.3 93 1 7.8 133765 M62194 Hs.75929 cadherin 11, type 2, OB-cadherin (osteob 3.2 560 174 2.6

133780 AA557660 Hs.76152 decorin 5.4 144 27 13.3

133784 BE622743 Hs.301064 arfaptin 1 4.7 47 1 4.1

133814 NM_002462Hs.76391 myxovirus (influenza) resistance 1, homo 3.3 380 114 4.9

133829 AW630088 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564B1264 (f 6.7 304 46 7.8

133845 AA147026 Hs.76704 ESTs 6.2 600 97 4.1

133913 AU076964 Hs.7753 calumenin 3.3 889 267 5

133968 AA355986 Hs.232068 transcription factor 8 (represses interi 3.7 91 25 2.6

133990 R48316 Hs.7822 Homo sapiens mRNA; cDNA DKFZp564C1216 (f 3.4 91 27 8.5

133999 AA535244 Hs.78305 RAB2, member RAS oncogene family 7.8 78 1 5.6

134032 NM 05025HS.78589 serine (or cysteine) proteinase inhibito 5.9 59 1 3.3

134064 AF091622 Hs.78893 KIAA0244 protein 5.8 58 1 4.9

134087 U51166 Hs.173824 thymine-DNA glycosylase 6.4 100 16 4.4

134089 R51273 Hs.79029 ESTs 5.1 51 9 3.8

134095 NM_004354Hs.79069 cyclin G2 5 50 1 3.2

134098 BE513171 Hs.79086 mitochondrial ribosomal protein L3 4.8 246 51 3.9

134110 U41060 Hs.79136 LIV-1 protein, estrogen regulated 4.5 1472 330 2.1

134125 NM 014781HS.50421 KIAA0203 gene product 4.6 69 15 5.8

134246 D28459 Hs.80612 ubiquitin-conjugating enzyme E2A (RAD6 h 7 97 14 7.5

134257 C05768 Hs.8078 Homo sapiens clone FBD3 Cri-du-chat crit 3.4 34 5 2.6

134272 X76040 Hs.278614 protease, serine, 15 3.6 36 1 2.8

134282 R45621 Hs.81057 hypothetical protein MGC2718 6.7 67 9 5.7

134288 AI022650 Hs.8117 erbb2-interacting protein ERBIN 4.5 137 31 12

134321 BE538082 Hs.8172 ESTs, Moderately similarto A46010 X-lin 5.2 52 1 4.9

134326 AW903838 Hs.81800 chondroitin sulfate proteoglycan 2 (vers 8.6 568 66 22.4

134328 AW959281 Hs.8184 ESTs 4.8 53 11 3.7

134348 AW291946 Hs.82065 interleukin 6 signal transducer (gp130, 7.1 71 4 6.4

134359 NM 001982Hs.199067 v-erb-b2 avian erythroblastic leukemia v 3 68 23 2.8

134367 AA339449 Hs.82285 phosphoribosylglycinamide formyltransfer 4.4 44 1 4.1

134374 N22687 Hs.8236 ESTs 13.3 445 34 6

134380 AU077143 Hs.179565 minichromosome maintenance deficient (S. 4.5 45 2 3.4

134395 AA456539 Hs.8262 lysosomal 6 60 5 5.9

134401 AI916662 Hs.211577 kinectin 1 (kinesin receptor) 4.1 301 73 6.1

134405 AW067903 Hs.82772 collagen, type XI, alpha 1 4.6 1216 267 4.4

134415 AI750762 Hs.82911 protein tyrosine phosphatase type IVA, m 4.9 163 34 15.1

134417 NM_006416Hs.82921 solute earner family 35 (CMP-sialic aci 4.9 49 3 3.8

134419 W95642 Hs.82961 trefoil factor 3 (intestinal) 3.2 1872 592 3.3

134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.3 1075 171 3.8

134436 U29344 Hs.83190 fatty add synthase 3.3 710 217 2

134485 X82153 Hs.83942 cathepsin K (pycnodysostosis) 34.3 411 12 5.1

134487 AF061739 Hs.83954 protein associated with PRK1 4.8 153 32 4.3

134495 D63477 Hs.84087 KIAA0143 protein 3.1 147 48 12.7

134520 BE091005 Hs.74861 activated RNA polymerase II transcriptio 3.3 33 1 2

134542 M14156 Hs.85112 insulin-like growth factor 1 (somatomedi 4.2 42 5 2.6

134570 U66615 Hs.172280 SWI/SNF related, matrix associated, acti 3.9 39 1 2.5

134590 AW903849 Hs.173840 HUEL (C4orf1)-interacting protein 3.7 41 11 0.6

134604 NM_002884Hs.865 RAP1A, member of RAS oncogene family 5.2 52 1 3

134612 AW068223 Hs.171581 ubiquitin C-terminal hydrolase UCH37 4.9 49 1 3.7

134643 AW299723 Hs.87223 bone moφhogenetic protein receptor, typ 5.2 52 5 3.5

134654 AK001741 Hs.8739 hypothetical protein FLJ10879 6.4 64 1 5.1

134656 AI750878 Hs.87409 thrombospondin 1 12.6 126 1 10.8

134672 AF271212 Hs.322901 disrupter of silencing 10 5.4 81 15 2.6

134700 AK000606 Hs.8868 golgi SNAP receptor complex member 1 3.4 179 52 1.5

134711 X04011 Hs.88974 cytochrome b-245, beta polypeptide (chro 3.2 143 45 13.9

134722 AF129536 Hs.284226 F-box only protein 6 7 70 6 6

134856 BE281128 Hs.9030 TONDU 3.1 31 1 2.3

134880 AI879195 Hs.90606 15 kDa selenoprotein 5.7 57 1 5

134917 X87241 Hs.166994 FAT tumor suppressor (Drosophila) homolo 3.2 153 48 4.7

134921 AL137491 Hs.125511 Homo sapiens mRNA; cDNA DKFZp434P1530 (f 4 452 114 2

134982 AK002085 Hs.92308 Homo sapiens cDNA FLJ11223 fis, clone PL 5.1 150 30 7.2

134989 AW968058 Hs.92381 nudix (nucleoside diphosphate linked moi 8.2 114 14 9.9

135029 H58818 Hs.187579 hydroxysteroid (17-beta) dehydrogenase 7 11.5 115 1 10

135035 AL034344 Hs.284186 forkhead box C1 5.4 259 48 1.4

135051 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 3.3 1296 394 2.2

135062 AK000967 Hs.93872 KIAA1682 protein 3.8 240 64 3.2

135073 W55956 Hs.94030 Homo sapiens mRNA; cDNA DKFZp586E1624 (f 8.1 101 13 7.9

135098 AW274526 Hs.277721 ovarian carcinoma antigen CA125 3.3 33 1 2.6 135117 W52493 Hs.94694 Homo sapiens cDNA FLJ10561 fis, clone NT 5.3 53 1 4.1

13*5144 NM 016255Hs.95260 Autosomal Highly Conserved Protein 7.4 74 5 2.4

135154 AK001835 Hs.267812 sorting nexin 4 6.6 69 11 6.3

135155 AI207958 Hs.166556 Homo sapiens, Similar to TEA domain fami 6.1 61 1 5.1

135172 AB028956 Hs.12144 KIAA1033 protein 3.4 88 26 1.4

135242 AI583187 Hs.9700 cyclin E1 3.1 31 1 2.3

135243 BE463721 Hs.97101 putative G protein-coupled receptor 3.4 169 50 9.1

135269 NM_003403Hs.97496 YY1 transcription factor 3.4 475 142 2.5

135356 BE312948 Hs.18104 hypothetical protein FLJ11274 3.1 31 10 1.7

135357 AI565004 Hs.79572 cathepsin D (lysosomal aspartyl protease 4.7 710 151 2.5

135389 U05237 Hs.99872 fetal Alzheimer antigen 20.6 206 4 19.1

135397 L14922 Hs.166563 replication factor C (activator 1) 1 (14 3.2 32 1 2.4

135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 3.2 117 37 9.4

AI471525 Hs.247486 ESTs 3.8 58 16 5.5

X70683 Hs.93668 ESTs 1.8 1047 596 1.6

L14922 Hs.82128 5T4 oncofetal trophoblast glycoprotein 5 285 58 1.2

M23263 Hs.904 amylo-1 ;6-glucosidase; 4-alpha-glucanotransferas 3.1 31 1 2.6

AI267886 Hs.148027 polymerase (RNA) II (DNA directed) polypeptide B 7.8 137 18 11.9

AA044840 Hs.241676 stromal cell-derived fador 1 4.7 114 25 0.9

N90960 Hs.227459 ESTs; Moderately similarto !!!! ALU SUBFAMILY 4.7 151 32 9.3

AA873285 Hs.137947 ESTs 4.7 47 3 4.4

T56679 Hs.865 RAP1A; member of RAS oncogene family 4 40 1 3.4

AA305536 "EST176522 Colon carcinoma (Caco-2) cell line II 3.6 121 34 11.8

AI369384 arylsulfafase D 3.5 113 33 1.7

AA219081 Hs.242396 ESTs; Moderately similarto HI! ALU SUBFAMILY] 3.4 107 32 9.9

TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigenelD's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

123619 371681 1 AA602964 AA609200 104602 524482_2 H47610 R86920 121581 283769J AA416568 AA442889 AA417233 AA442223 123523 genbank_AA608588 AA608588 100821 tigr_HT4306 M26460 U09116 125091 genbank_T91518 T91518 125150 NOT_FOUND_entrez_W38240 W38240 118475 genbank_N66845 N66845 104787 genbank_AA027317 AA027317 106055 genbank_AA417034 AA417034 113702 genbank_T97307 T97307 101046 entrez_K01160 K01160 101447 entrez_M21305 M21305 101624 entrez_M55998 M55998 124677 genbank_R01073 R0 073 110581 genbank_H61560 H61560 119023 genbank_N98488 N98488 110775 genbank_N22414 N22414 112092 genbank_R44538 R44538 112253 genbank_R51818 R51818 107014 geπbaπk_AA598820 AA598820 114988 genbank_AA251089 AA251089

TABLE 11: Figure 11 from BRCA 001-3 PCT

Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R 1 : Ratio of tumor to normal body tissue

R2: Ratio of 90th percentile tumor to normal body R3: Ratio of 75* percentile normal body to tumor

R4: Ratio oftumorto normal breasttissue

Pkey ExAccn UnigenelD Unigene Title R1 R2 R3 R4

100131 D12485 Hs.11951 ectonucleoiide pyrophosphatase/phosphodi 13.2 244 19 9.9 100147 D13666 Hs.136348 osteoblast specific factor 2 (fasciclin 15.7 103066 5 100522 X51501 Hs.99949 prolactin-induced protein 22.7 760 34 1.4 100666 L05424 Hs.169610 CD44 antigen (homing function and Indian 8.5 85 1 3.2 101104 AW862258 Hs.169266 neuropeptide Y receptor Y1 15.3 153 1 14.1 101478 NM_002890Hs.758 RAS p21 protein activator (GTPase activa 9.6 96 1 8.5 101724 L11690 Hs.620 bullous pemphigoid antigen 1 (230/240kD) 9.4 94 1 0.3 101754 S70114 Hs.239489 T1A1 cytotoxic granule-associated RNA-bi 8.9 89 5 8 101888 AL049610 Hs.95243 transcription elongation factor A (Sll)- 7.3 73 1 5.3 102165 BE313280 Hs.159627 death associated protein 3 9.3 93 5 8 102304 AF015224 Hs.46452 mammaglobin 1 8.5 2058243 1.4 102348 U37519 Hs.87539 aldehyde dehydrogenase 3 family, member 6.4 428 67 2.3 102457 NM_001394Hs.2359 dual specificity phosphatase 4 20.2 202 5 1.3 102567 U63830 Hs.146847 TRAF family member-associated NFKB activ 8.2 82 1 6.8 102823 D85390 Hs.5057 carboxypeptidase D 5.6 56 1 5.3 103557 AL133415 Hs.297753 vimentin 7.5 136 18 3.4 103613 NM_000346Hs.2316 SRY (sex determining region Y)-box 9 (ca 7.3 73 1 5.2 104115 AF183810 Hs.26102 opposite strand to trichorhinophalangeal 29 290 1 26.8 104667 AI239923 Hs.30098 ESTs 14.9 149 1 6.4 104804 AI858702 Hs.31803 ESTs, Weakly similarto N-WASP [H.sapien 7.7 77 1 5.1 104807 AI139058 Hs.125790 leucine-rich repeat-containing 2 7 70 1 6.5 104896 AW015318 Hs.23165 ESTs 7.4 74 1 6 104943 AF072873 Hs.114218 frizzled (Drosophila) homolog 6 16.2 162 1 4.2 105038 AW503733 Hs.9414 KIAA1488 protein 5.5 55 1 5.2 105329 AA234561 Hs.22862 ESTs 2.8 131 47 3.9 105500 AW602166 Hs.222399 CEGP1 protein 25.4 508 20 3 105516 AK001269 Hs.30738 hypothetical protein FLJ 10407 8.3 83 3 1.8 105730 AW377314 Hs.5364 DKFZP5641052 protein 6.9 69 1 4.4 106012 AI240665 Hs.8895 ESTs 21.2 212 6 17.4 106095 AF115402 Hs.11713 E74-like factor 5 (ets domain transcript 26.3 356 14 1 106155 AA425414 Hs.33287 nuclear factor l/B 9.9 483 49 1.8 107102 AB037765 Hs.30652 KIAA1344 protein 6.3 63 1 5.4 107136 AV661958 Hs.8207 GK001 protein 2.5 392 155 4.3 107151 AW378065 Hs.8687 ESTs 15.6 156 7 10.8 107922 BE153855 Hs.61460 Ig superfamily receptor LNIR 9 90 1 5.5 108339 AW151340 Hs.51615 ESTs, Weakly similarto ALU7JHUMAN ALU S 18.7 187 1 17 109112 AW419196 Hs.257924 hypothetical protein FLJ 13782 4.1 334 82 3.4 109292 AW975746 Hs.188662 KIAA1702 protein 7.1 71 1 6.5 109415 U80736 Hs.110826 trinucleotide repeat containing 9 12.3 123 1 11.3 109912 AW390822 Hs.301528 L-kynurenine/alpha-aminoadipate aminotra 14.2 142 1 9.5 110009 BE075297 Hs.6614 ESTs, Weakly similar to A43932 mucin 2 p 6.3 693 110 7.2 110915 BE092285 Hs.29724 hypothetical protein FLJ13187 20.9 209 1 19.5 111164 N46180 Hs.122489 Homo sapiens cDNA FLJ13289 fis, clone OV 7.7 77 1 5 111179 AK000136 Hs.10760 asporin (LRR class 1) 25.1 288 12 6.7

111190 AK002055 Hs.151046 hypothetical protein FLJ11193 6.3 63 1 5.8

111223 AA852773 Hs.334838 KIAA1866 protein 3.6 402 112 4.9

111357 BE314949 Hs.87128 hypothetical protein FLJ23309 3.8 425 111 4

112244 AB029000 Hs.70823 KIAA1077 protein 5.7 567 100 6.7

113047 AI571940 Hs.7549 ESTs 9.6 124 13 9

113702 T97307 gb:ye53h05.s1 Soares fetal liver spleen 12.3 129 11 11.7

114124 W57554 Hs.125019 lymphoid nuclear protein (LAF-4) mRNA 24.2 242 10 5.6

114138 AW384793 Hs.15740 Homo sapiens mRNA; cDNA DKFZp434E033 (fr 6.7 67 1 6.3

114768 AF212848 Hs.182339 ets homologous factor 13.7 137 1 8.9

114860 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 9.1 91 1 7.6

114965 AI733881 Hs.72472 BMP-R1B 35.9 359 10 29.7

114988 AA251089 gb:zs04f05.s1 NCI CGAP GCB1 Homo sapiens 11.5 115 1 6.9

115206 AW183695 Hs.186572 ESTs 5.8 58 1 5

115719 AW992405 Hs.59622 Homo sapiens, clone IMAGE:3507281, mRNA, 7.6 144 19 13.9

115844 AI373062 Hs.332938 hypothetical protein MGC5370 6.2 62 1 5.4

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 1.8 1047 596 1.6

116786 H25836 Hs.301527 ESTs, Moderately similar to unknown [H.s 22.8 228 9 12.4

117280 M18217 Hs.172129 Homo sapiens cDNA: FLJ21409 fis, clone C 3.9 322 83 4.4

117412 N32536 Hs.42645 solute carrier family 16 (monocarboxylic 17.4 174 9 6.9

118472 AL157545 Hs.42179 bromodomain and PHD finger containing, 3 14.5 145 1 2.4

119271 AI061118 Hs.65328 Fanconi anemia, complementation group F 8.2 82 1 6.4

119771 A1905687 Hs.2533 EST 3.5 2073 595 2.1

120562 BE244580 Hs.302267 hypothetical protein FLJ 10330 8.5 127 15 1.6

121463 AK000282 Hs.239681 hypothetical protein FLJ20275 10.3 103 1 9.3

121723 AA243499 Hs.104800 hypothetical protein FLJ10134 2.9 214 74 3.7

122963 AA478446 Hs.69559 KIAA1096 protein 7.2 72 1 5.7

123137 AI073913 Hs.100686 ESTs, Weakly similar to JE0350 Anterior 9.9 351 36 13.9

123619 AA602964 gb:no97c02.s1 NCLCGAP Pr2 Homo sapiens 8.5 85 1 4.3

123709 AA706910 Hs.112742 ESTs 3.9 60 16 4.8

124006 AI147155 Hs.270016 ESTs 5.8 321 55 17

124059 BE387335 Hs.283713 ESTs, Weakly similar to S64054 hypotheti 10.4 880 85 5.3

124308 AA249027 Hs.241507 ribosomal protein S6 10.5 105 1 9.9

125279 AW401809 Hs.4779 KIAA1150 protein 13.1 131 1 5.1

125617 AA287921 Hs.164950 ESTs 6.7 67 1 6

127439 D60237 Hs.14368 SH3 domain binding glutamic acid-rich pr 30.6 306 4 26.5

128305 AI954968 Hs.279009 matrix Gla protein 7.5 75 1 6.5

128482 AI694143 Hs.296251 programmed cell death 4 7.2 72 1 5.8

128790 AF026692 Hs.105700 secreted frizzled-related protein 4 17.4 409 24 7.8

128925 R67419 Hs.21851 Homo sapiens CDNA FLJ12900 fis, clone NT 7.1 392 56 3.6

129017 AA115333 Hs.107968 ESTs 8.2 82 1 7.4

129229 AF013758 Hs.109643 polyadenylate binding protein-interactin 7.1 71 1 6.2

129337 NM_014918Hs.110488 KIAA0990 protein 9.5 95 1 8.5

129366 BE220806 Hs.184697 Homo sapiens clone 23785 mRNA sequence 7.1 150 21 14.5

129821 AB028945 Hs. 2696 cortactin SH3 domain-binding protein 11.4 114 1 10

130036 BE061916 Hs.125849 chromosome 8 open reading frame 2 6.7 67 1 5.7

130057 AF027153 Hs.324787 solute carrier family 5 (inositol transp 1 1 1 1

130095 AK001635 Hs.14838 hypothetical protein FLJ10773 14.6 219 15 7.6

130343 AB040914 Hs.278628 KIAA1481 protein 13.2 331 25 12.4

130385 AW067800 Hs.155223 stanniocalcin 2 72.2 722 1 1.9

130407 BE385099 Hs.334727 hypothetical protein MGC3017 6.5 65 4 5.3

130441 U63630 Hs.155637 protein kinase, DNA-activated, catalytic 6.1 61 1 5.7

130455 D90041 Hs.155956 N-acetyltransferase 1 (arylamine N-acety 10.8 706 66 9.2

130604 AA383256 Hs.1657 estrogen receptor 1 32.2 322 1 4.7

130617 M90516 Hs.1674 glutamine-fructose-6-phosphate transamin 10 100 1 7.6

130712 AJ271881 Hs.279762 bromodomain-containing 7 17.5 175 2 12.8

131148 AW953575 Hs.303125 p53-induced protein PIGPC1 3.8 585 153 3.7

131388 NM_014810Hs.92200 KIAA0480 gene product 7.6 76 1 5

131564 T93500 Hs.28792 Homo sapiens cDNA FLJ11041 fis, clone PL 4.7 381 81 6.4

131742 AA961420 Hs.31433 ESTs 11.7 117 1 10.1

131877 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 6.8 68 1 5.6

131985 AA503020 Hs.36563 hypothetical protein FLJ22418 40.2 402 1 4

132316 U28831 Hs.44566 KIAA1641 protein 18.6 186 10 1.5

132528 T78736 Hs.50758 SMC4 (structural maintenance of chromoso 9.3 93 1 8.4

132742 AA025480 Hs.292812 ESTs, Weakly similar to T33468 hypotheti 6.5 65 1 5.6

132990 X77343 Hs.334334 transcription factor AP-2 alpha (activat 12.7 311 25 2.4

133015 AJ002744 Hs.246315 UDP-N-acetyl-alpha-D-galactosamine:polyp 4.6 427 93 10.4 133199 AF231981 Hs.250175 homolog of yeast long chain polyunsatura 3 816 275 3.9

133240 AK001489 Hs.242894 ADP-ribosylation factor-like 1 8.1 81 1 4.6

133271 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 12.4 124 6 10.8

133640 AW246428 Hs.75355 ubiquitin-conjugating enzyme E2N (homolo 8.5 85 1 7.2

133746 AW410035 Hs.75862 MAD (mothers against decapentaplegic, Dr 9.3 93 1 7.8

133999 AA535244 Hs.78305 RAB2, member RAS oncogene family 7.8 78 1 5.6

134110 U41060 Hs.79136 LIV-1 protein, estrogen regulated 4.5 1472 330 2.1

134485 X82153 Hs.83942 cathepsin K (pycnodysostosis) 34.3 411 12 5.1

134654 AK001741 Hs.8739 hypothetical protein FLJ10879 6.4 64 1 5.1

134880 AI879195 Hs.90606 15 kDa selenoprotein 5.7 57 1 5

135029 H58818 Hs.187579 hydroxysteroid (17-beta) dehydrogenase 7 11.5 115 1 10

135389 U05237 Hs.99872 fetal Alzheimer antigen 20.6 206 4 19.1

128305 AI954968 Hs.279009 matrix Gla protein 9.4 94 3 5.3

TABLE 11 A

Table 11 A shows the accession numbers for those pkeys lacking unigenelD's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

123619 371681 1 AA602964 AA609200

113702 genbank_T97307 T97307

114988 genbank_AA251089 AA251089

TABLE 12: Figure 12 from BRCA 001-3 PCT

Table 12 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal body tissue

R2: Ratio of 901" percentile tumor to body R3: Ratio of 75lh percentile body to tumor

R4: Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD Unigene Title R1 R2 R3 R4 100131 D12485 Hs.11951 phosphodiesterase I (PC-1) 13.2 244 19 9.9

105500 AW602166 Hs.222399 ESTs 25.4 508 20 3

112244 AB029000 Hs.70823 KIAA1077 protein 5.7 567 100 6.7

114124 W57554 Hs.125019 ESTs 24.2 242 10 5.6

119771 AI905687 Hs.2533 ESTs 3.5 2073 595 2.1 121723 AA243499 Hs.104800 ESTs 2.9 214 74 3.7

128790 AF026692 Hs.105700 secreted frizzled-related protein 4 17.4 409 24 7.8

131148 AW953575 Hs.303125 ESTs 3.8 585 153 3.7

131985 AA503020 Hs.36563 ESTs 40.2 402 1 4

133199 AF231981 Hs.250175 Homo sapiens clone 23904 mRNA sequence 3 816 275 3.9

TABLE 13: Table 1 from BRCA 001-5 US Table 13 depicts a preferred group of genes upregulated in breast cancer cells.

Pkey Unique Eos probeset identifier number

ExAccn Exemplar Accession number, Genbank accession number

UnigenelD Unigene number

Unigene Title Unigene gene title

R1 Ratio of tumor to normal body tissue

Pkey ExAccn UniGene lD Unigene Title R1

100038 M97935 control 167

100039 M97935 control 63

100040 M97935 control 83

100041 M97935 control 148

100082 AB003103 Hs 4295 proteasome (prosome, macropain) 26S sub 75

100091 AF000177 Hs 111783 Lsm1 protein 49

100100 AF006084 Hs 11538 actin related protein 2/3 complex, subunit 47

100103 AF007875 Hs 5085 doliehyl-phosphate mannosyltransferase p 134

100114 D00596 Hs 82962 thymidylate synthetase 159

100121 D10495 Hs 155342 protein kinase C, delta 46

100123 D10523 Hs 168669 oxoglutarate dehydrogenase (lipoamide) 75

100128 D11094 Hs 61153 proteasome (prosome, macropain) 26S sub 44

100131 D12485 Hs 11951 phosphodiesterase l/nucleotιde pyrophosp 87

100137 D13627 Hs 15071 chaperonin containing TCP1, subunit 8 (t 95

100144 D13643 Hs 75616 Human mRNA for KIAA0018 gene, comp 6

100147 D13666 Hs 136348 osteoblast specific factor 2 (fasciclin l-like 85

100154 D14657 Hs 81892 KIAA0101 gene product 105

100164 D14812 Hs 173714 MORF-related gene X 46

100169 D14878 Hs 82043 D123 gene product 79

100190 D21090 Hs 178658 RAD23 (S cerevisiae) homolog B 56

100203 D25538 Hs 172199 adenylate cyclase 7 99

100209 D26308 Hs 76289 biliverdm reductase B (flavin reductase (N 49

100215 D26598 Hs 82793 proteasome (prosome, macropain) subunit 142

100216 D26599 Hs 1390 proteasome (prosome, macropain) subunit 11 3

100219 D28137 Hs 118110 bone marrow stromal cell antigen 2 57

100227 D28915 Hs 82316 interferon-induced, hepatitis C-associated 57

100248 D31888 Hs 78398 KIAA0071 protein 74

100287 D43950 Hs 1600 chaperonin containing TCP1, subunit 5 (e 56

100294 D49396 Hs 75454 antioxidant protein 1 129

100307 D50525 Hs 699 hypothetical protein 84

100335 D63391 Hs 6793 platelet-activating factor acetylhydrolase, 68

100340 D63487 Hs 82563 KIAA0153 protein 44

100355 D78129 Hs 71465 Homo sapiens mRNA for squalene epoxid 126

100363 D78514 Hs 78563 ubiquitin-conjugating enzyme E2G 1 (horn 46

100368 D79987 Hs 153479 extra spindle poles, S cerevisiae, homolo 65

100372 D79997 Hs 184339 KIAA0175 gene product 84

100375 D80004 Hs 75909 KIAA0182 protein 45

100379 D82060 Hs 278721 Ke4 gene, mouse, human homolog of 8 1

100387 D83777 Hs 75137 KIAA0193 gene product 107

100393 D84145 Hs 39913 novel RGD-containing protein 72

100398 D84557 Hs 155462 minichromosome maintenance deficient (m 72

100405 D86425 Hs 82733 mdogen 2 54

100406 D86479 Hs 118397 AE-binding protein 1 43

100409 D86957 Hs 80712 KIAA0202 protein 11 9

100421 D86985 Hs 79276 Human mRNA for KIAA0232 gene, comp 97

100446 D87464 Hs 10037 KIAA0274 gene product 64

100447 D87465 Hs 74583 KIAA0275 gene product 10

100448 D87469 Hs 57652 EGF-like-domam, multiple 2 62 100467 D89052 Hs.7476 ATPase; H+transporting; lysosomal (vacu 7.5

100468 D89289 Hs.118722 fucosyltransferase 8 (alpha (1;6) fucosyltr 5

100486 HT1112 Hs.10842 Ras-Like Protein Tc4 16.9

100497 HT1400 Hs.79137 Carboxyl Methyltransferase, Aspartate, A 5.6

100618 HT2710 Hs.114599 Collagen, Type Viii, Alpha 1 7.5

100661 HT3018 Hs.132748 Ribosomal Protein L39 Homolog 4.4

100667 HT3127 Hs.169610 Epican, Alt. Splice 11 4.6

100668 HT3938 Hs.169610 Epican, Alt. Splice 12 4.4

100676 HT3742 Hs.287820 Fibronectin, Alt. Splice 1 9

100775 HT26388 Hs.89603 Muciπ 1, Epithelial, Alt. Splice 9 4.7

100783 HT4018 Hs.191356 Basic Transcription Factor, 44 Kda Subun 13.7

100829 HT4343 Hs.278544 Cytosolic Acetoacetyl-Coenzyme A Thio 10.6

100830 HT4344 Hs.4756 Rad2 5.5

100840 HT4392 Hs.183418 Protein Kinase Pitslre, Alpha, Alt. Splice 4.1

100850 HT417 Hs.297939 Cathepsin B 4

100866 HT4582 Hs.75113 Transcription Factor liia 4.9

100906 HT5158 Hs.5398 Guanosine 5'-Monophosphate Synthase 8.7

100914 HT511 Hs.324178 Ras Inhibitor Inf 7.2

100916 HT544 Hs.73946 Endothelial Cell Growth Factor 1 5.9

100945 HT884 Hs.180686 Oncogene E6-Ap, Papillomavirus 4.6

100975 J02923 Hs.76506 lymphocyte cytosolic protein 1 (L-plastin 30.1

100988 J03589 Hs.76480 ubiquitin-like 4 8.3

100996 J03909 Hs.14623 interferon; gamma-inducible protein 30 6.9

100999 J03934 Hs.80706 diaphorase (NADH/NADPH) (cytochrom 4.3

101011 J04430 Hs.1211 acid phosphatase 5; tartrate resistant 5.9

101017 J04599 Hs.821 biglycan 5.1

101031 J05070 Hs.151738 matrix metalloproteinase 9 (gelatinase B; 37.2

101038 J05249 Hs.79411 replication protein A2 (32kD) 6.1

101054 K02405 Hs.73931 Human MHC class II HLA-DQ-beta mRN 4.3

101061 K03515 Hs.180532 glucose phosphate isomerase 4.3

101091 L06132 Hs.149155 voltage-dependent anion channel 1 7.4

101097 L06797 Hs.89414 chemokine (C-X-C motif); receptor 4 (fus 4.6

101104 L07615 Hs.169266 Human neuropeptide Y receptor Y1 (NPY 18.3

101143 L12723 Hs.90093 heat shock 70kD protein 4 17.4

101152 L13800 Hs.9884 Homo sapiens liver expressed protein gen 7.6

101183 L19779 Hs.795 H2A histone family; member 0 10.9

101216 L25876 Hs.84113 cyclin-dependent kinase inhibitor 3 (CDK 7.4

101233 L29008 Hs.878 sorbitol dehydrogenase 14.6

101247 L33801 Hs.78802 glycogen synthase kinase 3 beta 7.5

101282 L38810 Hs.79387 proteasome (prosome; macropain) 26S sub 4.4

101326 L42572 Hs.78504 inner membrane protein; mitochondrial (m 5.8

101332 L47276 Hs.156346 Homo sapiens (cell line HL-6) alpha topo 18.9

101348 L77213 Hs.30954 phosphomevalonate kinase 7.5

101352 L77701 Hs.16297 COX17 (yeast) homolog; cytochrome c ox 9.3

101378 M13755 Hs.833 interferon-stimulated protein; 15 kDa 18.1

101396 M15796 Hs.78996 proliferating cell nuclear antigen 8.6

101404 M16342 Hs.182447 heterogeneous nuclear ribonucleoprotein C 4.5

101439 M20902 Hs.268571 apolipoprotein C-l 6.1

101464 M22538 Hs.51299 NADH dehydrogenase (ubiquinone) flavo 8.7

101469 M22877 Hs.169248 Human somatic cytochrome c (HCS) gene 4.2

101472 M22960 Hs.118126 ' protective protein for beta-galactosidase ( 6.5

101478 M23379 Hs.758 RAS p21 protein activator (GTPase activa 14

101484 M24594 Hs.20315 interferon-induced protein 56 9.2

101539 M30818 Hs.926 myxovirus (influenza) resistance 2; homol 5.1

101540 M30938 Hs.84981 X-ray repair complementing defective rep 4.7

101544 M31169 Human propionyl-CoA carboxylase beta-s 5.5

101552 M31642 Hs.82314 hypoxanthine phosphoribosyltransferase 1 8.5

101580 M34677 Hs.83363 DNA segment on chromosome X (unique) 4.5

101600 M37583 Hs.119192 H2A histone family; member Z 5.7

101663 M60750 Hs.2178 H2B histone family; member A 5.8

101664 M60752 Hs.121017 H2A histone family; member A 13.5

101667 M60858 Hs.79110 nucleolin 4

101684 M63256 Hs.75124 cerebellar degeneration-related protein (62 7.6

101702 M64929 Hs.179574 protein phosphatase 2 (formerly 2A); regu 4.2

101754 M77142 Hs.239489 TIA1 cytotoxic granule-associated RNA-b 4.5

101758 M77836 Hs.79217 pyrroline-5-carboxylate reductase 1 5.7

101767 M81057 Hs.180884 carboxypeptidase B1 (tissue) 21.7 101770 M81601 Hs.78869 transcription elongation factor A (SH); 1 4.6

101791 M83822 Hs.62354 cell division cycle 4-like 9.7

101803 M86546 Hs.155691 pre-B-cell leukemia transcription factor 1 5.5

101809 M86849 Hs.323733 Homo sapiens connexin 26 (GJB2) mRNA 22.5

101839 M93036 Hs.692 membrane component; chromosomal 4; su 4

101851 M94250 Hs.82045 midkine (neurite growth-promoting factor 7.6

101888 M99701 Hs.95243 transcription elongation factor A (Sll)-like 11.4

101973 S82597 Hs.80120 UDP-N-acetyl-alpha-D-galadosamine'.po 4.6

101991 U00968 Hs.166 Human SREBP-1 mRNA; complete eds 4.1

102009 U02680 Hs.82643 protein tyrosine kinase 9 4.4

102025 U03911 Hs.78934 mutS (E. coli) homolog 2 (colon cancer; n 4

102047 U07158 Hs.83734 syntaxin 4A (placenta!) 6.1

102051 U07550 Hs.1197 heat shock 10kD protein 1 (chaperonin 10 4.4

102083 U10323 Hs.75117 interleukin enhancer binding fador 2; 45k 10.4

102095 U11313 Hs.75760 sterol carrier protein 2 9.5

102130 U15009 Hs.1575 small nuclear ribonucleoprotein D3 polyp 6.6

102133 U15173 Hs.155596 BCL2/adenovirus E1B 19kD-interacting p 4.3

102148 U16954 Hs.75823 ALL1-fused gene from chromosome 1q 6.9

102179 U19713 Hs.76364 allograft inflammatory factor 1 4.8

102180 U19718 Hs.83551 microfibrillar-associated protein 2 7.2

102193 U20758 Hs.313 secreted phosphoprotein 1 (osteopontin; b 7.2

102198 U21090 Hs.74598 polymerase (DNA directed); delta 2; regu 4.3

102202 U21931 Hs.574 fructose-bisphosphatase 1 4.5

102209 U22970 Hs.265827 interferon; alpha-inducible protein (clone 9.9

102211 U23070 Hs.78776 putative transmembrane protein 4.9

102220 U24389 Hs.65436 iysyl oxidase-like 1 8.5

102224 U24704 Hs.148495 proteasome (prosome; macropain) 26S sub 5.4

102234 U26312 Hs.278554 chramobox homolog 3 (Drosophila HP1 g 7.7

102250 U28014 Hs.74122 caspase 4; apoptosis-related cysteine prat 5.4

102260 U28386 Hs.159557 karyopherin alpha 2 (RAG cohort 1; impo 6.3

102261 U28488 Hs.155935 complement component 3a receptor 1 5.7

102273 U30888 Hs.75981 ubiquitin specific protease 14 (tRNA-guan 6.1

102298 U32849 Hs.54483 N-myc (and STAT) interactor 4.1

102302 U33052 Hs.69171 protein kinase C-like 2 4.3

102305 U33286 Hs.90073 chromosome segregation 1 (yeast homolo 5.4

102320 U34683 Hs.82327 glutathione synthetase 4.1

102330 U35451 Hs.77254 chramobox homolog 1 (Drosophila HP1 b 4

102348 U37519 Hs.87539 aldehyde dehydrogenase 8 9.4

102361 U39400 Hs.75859 chromosome 1 open reading frame 4 5.2

102362 U39412 Hs.75932 N-ethylmaleimide-sensitive factor attachm 9.3

102369 U39840 Hs.299867 hepatocyte nuclear factor 3; alpha 7.7

102395 U41767 Hs.92208 a disintegrin and metalloproteinase domai 10.4

102409 U43286 Hs.118725 setenophosphate synthetase 2 6.2

102418 U43923 Hs.79058 suppressor of Ty (S.cerevisiae) 4 homolog 4.1

102425 U44772 Hs.3873 palmitoyl-protein thioesterase (ceroid-lipo 4.8

102457 U48807 Hs.2359 dual specificity phosphatase 4 6.3

102465 U49352 Hs.81548 2;4-dienoyl CoA reductase 1; mitochondri 9.4

102495 U51240 Hs.79356 Lysosomal-associated multispanning mem 6.5

102534 U56833 Hs.198307 von Hippel-Lindau binding protein 1 8.6

102546 U57877 Hs.3577 succinate dehydrogenase complex; subuni 4.3

102549 U58046 Hs.198899 eukaryotic translation initiation factor 3; s 6.3

102557 U58766 Hs.264428 tissue specific transplantation antigen P35 5

102562 U59309 Hs.75653 fumarate hydratase 6

102568 U59877 Hs.223025 RAB31; member RAS oncogene family 9.1

102580 U60808 Hs.152981 CDP-diacylglycerol synthase (phosphatid 7.9

102581 U61145 Hs.77256 enhancer of zeste (Drosophila) homolog 2 7.6

102590 U62136 Hs.79300 Homo sapiens enterocyte differentiation a 7

102591 U62325 Hs.324125 amyloid beta (A4) precursor protein-bindi 4

102592 U62389 Hs.11223 Human putative cytosolic NADP-depende 5

102617 U65928 Hs.198767 Jun activation domain binding protein 6.1

102618 U65932 Hs.81071 extracellular matrix protein 1 23.2

102638 U67319 Hs.9216 caspase 7; apoptosis-related cysteine prat 8.9

102663 U70322 Hs.168075 karyopherin (importin) beta 2 7,1

102666 U70660 Hs.279910 ATX1 (antioxidant protein 1; yeast) homo 4.7

102679 U72661 Hs.11342 ninjurin 1; nerve injury-induced protein-1 4.7

102687 U73379 Hs.93002 ubiquitin carrier protein E2-C 7.7

102704 U76638 Hs.54089 BRCA1 associated RING domain 1 5.6 102705 U77180 Hs.50002 small inducible cytokine subfamily A (Cy 11.8

102721 U79241 Hs.118666 Human clone 23759 mRNA; partial eds 15

102729 U79254 Hs.181311 asparaginyl-tRNA synthetase 5

102739 U79282 Hs.155572 Human clone 23801 mRNA sequence 6

102742 U79293 Hs.159264 Human clone 23948 mRNA sequence 13.1

102761 U82130 Hs.118910 tumor susceptibility gene 101 7

102788 U86602 Hs.74407 nucleolar protein p40 4.1

102790 U87269 Hs.154196 E4F transcription factor 1 7.1

102801 U89606 Hs.38041 pyridoxal (pyridoxine; vitamin B6) kinase 4.7

102808 U90426 Hs.179606 nuclear RNA helicase; DECD variant of D 7.5

102817 U90904 Hs.83724 Human clone 23773 mRNA sequence 15.2

102823 U90914 Hs.5057 carboxypeptidase D 6.6

102827 U91327 Hs.6456 chaperonin containing TCP1; subunit 2 (b 6

102838 U94592 Hs.80658 Human uncoupling protein homolog (UCP 6.1

102841 U95006 Hs.37616 Human D9 splice variant B mRNA; comp 4.2

102844 U96113 Hs.324275 Homo sapiens Nedd-4-like ubiquitin-prot 6.8

102868 X02419 Hs.77274 plasminogen activator; urokinase 4

102907 X06985 Hs.202833 heme oxygenase (decycling) 1 22.7

102919 X12447 aldolase A; fructose-bisphosphate 9.9

102929 X13238 Hs.74649 cytochrome c oxidase subunit Vic 5.4

102973 X16663 Hs.14601 hematopoietic cell-specific Lyn substrate 4.8

102983 X17620 Hs.118638 non-metastatic cells 1; protein (NM23A)

102985 X17644 Hs.2707 G1 to S phase transition 1 20.6

103003 X52003 Hs.1406 trefoil factor 1 (breast cancer; estrogen-ind 10.7

103018 X53296 Hs.81134 interleukin 1 receptor antagonist 5.8

103023 X53793 Hs.117950 multifunctional polypeptide similarto SA 4

103036 X54925 Hs.83169 matrix metalloproteinase 1 (interstitial col 7.3

103060 X57766 Hs.155324 matrix metalloproteinase 11 (stromelysin 17.8

103073 X59417 Hs.74077 proteasome (prosome; macropain) subunit 5.6

103075 X59543 Hs.2934 nbonucleotide reductase M1 polypeptide 4.2

103080 X59798 Hs.82932 cyclin D1 (PRAD1: parathyroid adenomat 6.7

103094 X60787 Hs.296281 interleukin enhancer binding fador 1 5.7

103105 X61970 Hs.76913 proteasome (prosome; macropain) subunit 5.8

103121 X63679 Hs.4147 translocating chain-associating membrane 4.2

103149 X66363 Hs.171834 PCTAIRE protein kinase 1 12

103180 X69433 Hs.5337 isocitrate dehydrogenase 2 (NADP+); mit 18.9

103182 X69819 Hs.99995 intercellular adhesion molecule 3 107

103188 X70040 Hs.2942 macrophage stimulating 1 receptor (c-met 4.1

103191 X70218 Hs.2903 protein phosphatase 4 (formerly X); cataly 10.7

103193 X70476 Hs.75724 coatomer protein complex; subunit beta 2 8.2

103194 X70649 Hs.78580 DEAD/H (Asp-Glu-Ala-Asp/His) box pol 13.7

103195 X70940 Hs.2642 eukaryotic translation elongation factor 1 13.4

103206 X72755 Hs.77367 monokine induced by gamma interferon 15.1

103207 X72790 Human endogenous retrovirus mRNA for 5.3

103208 X72841 Hs.31314 retinoblastoma-binding protein 7 12.3

103216 X74262 Hs.16003 retinoblastoma-binding protein 4 4.1

103226 X75042 Hs.44313 v-rel avian reticuloeπdotheliosis viral onco 6.9

103230 X75861 Hs.74637 testis enhanced gene transcript 7.9

103262 X78565 Hs.289114 hexabrachion (tenascin C; cytotactin) 5

103278 X79882 Hs.80680 lung resistance-related protein 5.7

103297 X81788 Hs.9078 immature colon carcinoma transcript 1 4.6

103302 X82103 Hs.3059 coatomer protein complex; subunit beta 4.5

103316 X83301 Hs.324728 SMA5 7.1

103330 X85373 Hs.77496 small nuclear ribonucleoprotein polypepti 4

103349 X89059 serine/threonine kinase 9 4.7

103352 X89398 Hs.78853 uracil-DNA glycosylase 5.3

103364 X90872 Hs.279929 SULT1C sulfotransferase 4

103374 X91788 Hs.84974 chloride channel; nucleotide-sensitive; 1A 4.2

103380 X92396 Hs.24167 synaptobrevin-like 1 13.6

103395 X94754 Hs.279946 methionine-tRNA synthetase 14.2

103402 X95404 Hs.180370 cofilin 1 (non-muscle) 4.6

103410 X96506 Hs.295362 DR1-associated protein 1 (negative cofact 8.3

103420 X97065 Hs.173497 Sec23 (S. cerevisiae) homolog B 4.9

103421 X97074 Hs.119591 adaptor-related prateiπ complex 2; sigma 5

103427 X97303 Hs.250655 H.sapiens mRNA for Ptg-12 protein 7

103430 X97544 Hs.20716 translocase of inner mitochondrial membr 4.5

103438 X98263 Hs.152720 M-phase phosphoprotein 6 4.5 103464 Y00285 Hs.76473 insulin-like growth factor 2 receptor 4.2

103470 Y00796 Hs.174103 integrin; alpha L (antigen CD11A (p180); 4.5

103494 Y08991 Hs.83050 phosphatidylinositol 3-kinase-associated p 4.1

103505 Y09912 Hs.33102 transcription factor AP-2 beta (activating 4.5

103547 Z14982 Hs.180062 proteasome (prosome; macropain) subunit 4.3

103551 Z15115 Hs.75248 topoisomerase (DNA) II beta (180kD) 4

103565 Z22548 Hs.146354 thioredoxin-dependent peroxide reductase 7.6

103587 Z29083 Hs.82128 5T4 oncofetal trophoblastglycoprotein 14.6

103621 Z47727 Hs.150675 polymerase (RNA) II (DNA directed) pol 6.3

103622 Z48042 Hs.278672 membrane component; chromosome 11; s 4.4

103658 Z74615 Hs.172928 collagen; type I; alpha 1 5.9

103680 Z93784 Homo sapiens DNA sequence from PAC 4.4

103772 AA092473 Hs.278554 chramobox homolog 3 (Drosophila HP1 g 4.9

103774 AA092898 Hs.92918 ESTs; Weakly similar to R07G3.8 [C.eleg 6.1

103821 AA157623 Hs.198793 KIAA0750 gene product 23.3

103835 AA172215 Hs.93748 ESTs; Moderately similar to TRANSCRIP 4

103886 AA236384 Hs.105737 ESTs; Weakly similarto gene 9306 protei 4.9

103890 AA236843 Hs.72085 ESTs; Weakly similarto unknown [S.cere 7.8

103892 AA243523 Hs.239189 ESTs 4.8

104054 AA393432 Hs.7100 hypothetical protein 5.3

104115 AA428090 Hs.26102 ESTs 28.7

104136 AA442669 Hs.268371 zv68f6.r1 Soares_total_fetus_Nb2HF8_9w 5.7

104147 AA451992 Hs.283037 ESTs; Highly similarto HSPC039 protein 6.9

104173 AA476564 Hs.76561 ESTs; Weakly similarto finger protein HZ 5.2

104181 AA479521 Hs.283740 ESTs 7.8

104183 AA480838 Hs.114309 ESTs 5.1

104192 AA486946 Hs.21321 Homo sapiens mRNA; cDNA DKFZp564 4.3

104209 AB000221 Hs.16530 small inducible cytokine subfamily A (Cy 12.3

104234 AB002357 Hs.168212 kinesin family member 3B 6.2

104271 C01687 Hs.7381 ATP synthase; H+transporting; mitochon 4.2

104278 C02582 Hs.109253 ESTs; Highly similar to N-terminal acetyl 4.5

104307 D52818 Hs.111680 endosulfine alpha 4.7

104309 D55869 Hs.284123 Homo sapiens mRNA full length insert cD 4.2

104370 H19378 Hs.21851 Homo sapiens mRNA; cDNA DKFZp586 6.4

104446 L44497 Hs.7351 ESTs 4.9

104453 M19169 Hs.123114 cystatin SN 11.6

104476 N33807 Hs.324275 protease; serine; 15 5.6

104558 R56678 Hs.88959 Human DNA sequence from clone 967N2 6.3

104592 R81003 Hs.325820 serine protease; umbilical endothelium 13.6

104634 AA004274 Hs.19151 ESTs 6.3

104636 AA004415 Hs.106106 ESTs 10.1

104658 AA007145 Hs.27268 Homo sapiens mRNA; cDNA DKFZp564 4.3

104667 AA007234 Hs.30098 ESTs 16.6

104675 AA009596 Hs.301553 ESTs; Moderately similarto !!!! ALU SU 4.6

104767 AA025534 Hs.8852 ESTs 4.8

104785 AA027163 Hs.7942 ESTs 8.1

104791 AA029046 Hs.301871 ESTs; Moderately similarto cAMP indue 10.9

104804 AA031357 Hs.31803 ESTs; Weakly similar to N-WASP [H.sap 5.5

104807 AA032147 Hs.23296 ESTs 10.4

104837 AA039469 Hs.21126 ESTs; Weakly similar to KIAA0299 [H.s 4.6

104849 AA040270 Hs.241507 Homo sapiens mRNA; cDNA DKFZp564 4.3

104867 AA045481 Hs.225979 Human gene from PACs 37M17 and 305B 4.5

104884 AA053021 Hs.14511 SCO (cytochrome oxidase deficient; yeast 4.7

104906 AA055809 Hs.26802 ESTs; Weakly similar to phosphoprotein [ 8.8

104919 AA057193 Hs.25252 ESTs 5.5

104921 AA057839 Hs.1508 ESTs 4.2

104926 AA058846 Hs.33363 DKFZP434N093 protein 7

104938 AA064627 Hs.318725 ESTs; Highly similarto CGI-72 protein [H 7.1

104943 AA065217 Hs.114218 ESTs 5.7

104957 AA074919 Hs.10026 ESTs; Weakly similar to ORF YJL063c [S 4.7

104961 AA076672 Hs.33905 ESTs 5.5

104968 AA084602 Hs.29669 ESTs 4.3

104975 AA086071 Hs.50758 chromosome-associated polypeptide C 8.3

104977 AA088228 Hs.18272 ESTs 6.2

104978 AA088458 Hs.19322 ESTs 6.7

104987 AA101723 Hs.11861 ESTs 9.2

105002 AA113266 Hs.182704 ESTs; Moderately similarto alternatively 6.9 105012 AA116036 Hs.9329 chromosome 20 open reading frame 1 10.7 105019 AA121879 Hs.9280 proteasome (prosome; macropain) subunit 5.7 105029 AA126855 Hs.13268 ESTs 4.4 105033 AA127964 Hs.274329 TP53 target gene 1 6.3 105035 AA128486 Hs.8859 ESTs 6.5 105039 AA130349 Hs.36475 ESTs 4 105062 AA134968 Hs.36529 ESTs 4.3 105076 AA142858 Hs.37810 ESTs 6.4 105087 AA147884 Hs.9812 ESTs 9.2 105091 AA148859 Hs.179909 ESTs; Weakly similarto !!!! ALU SUBFA 5.7 105093 AA149051 Hs.32405 ESTs 6.3 105107 AA152302 Hs.25035 DKFZP566G223 protein 6.2 105127 AA158132 Hs.301957 ESTs; Weakly similar to contains similari 5.7 105132 AA159501 Hs.247280 HBV associated factor 4.2 105143 AA165333 Hs.24808 ESTs 4.7 105154 AA171736 Hs.35947 methyl-CpG binding domain protein 4 9 105162 AA176690 Hs.4084 KIAA1025 protein 9.1 105186 AA191512 Hs.28005 Homo sapiens mRNA; cDNA DKFZp564 19.3 105209 AA205072 Hs.227743 KIAA0980 protein 7.4 105223 AA211388 Hs.7750 ESTs 5.1 105252 AA227428 Hs.9728 ESTs; Weakly similar to KIAA0512 prate 11.1 105253 AA227448 Hs.5003 KIAA0456 protein 6.4 105261 AA227871 Hs.6361 MEK partner 1 9.1 105263 AA227926 Hs.6682 ESTs 6.7 105274 AA228122 Hs.281866 ATPase; H+ transporting; lysosomal (vacu 5.3 105297 AA233451 Hs.183858 transcriptional intermediary factor 1 8.7 105309 AA233790 Hs.4104 ESTs; Weakly similar to cDNA EST yk38 7.4 105312 AA233854 Hs.23348 S-phase kinase-associated protein 2 (p45) 5.8 105342 AA235286 Hs.157078 ESTs 4.5 105376 AA236559 Hs.8768 ESTs; Weakly similar to III! ALU SUBFA 5.8 105386 AA236950 Hs.8115 ESTs 5.5 105397 AA242868 Hs.7395 ESTs; Weakly similarto house-keeping p 7.7 105399 AA243007 Hs.16420 ESTs; Highly similarto SH3 domain-bind 5.6 105400 AA243052 Hs.65648 RNA binding motif protein 8 5.8 105404 AA243303 Hs.21187 ESTs 9.1 105409 AA243562 Hs.301855 ESTs 4.4 105436 AA252172 Hs.237856 ESTs; Moderately similarto cAMP indue 5.1 105483 AA255874 Hs.23458 ESTs 4.9 105493 AA256268 Hs.10283 ESTs 6 105495 AA256317 Hs.28785 Homo sapiens mRNA; cDNA DKFZp586 5.2 105496 AA256323 Hs.301997 DKFZP434N126 protein 8.7 105500 AA256485 Hs.222399 CGI-96 protein 9.5 105507 AA256678 Hs.226318 ESTs; Moderately similarto CCR4-associ 4.1 105538 AA258860 Hs.32597 ring finger protein (C3H2C3 type) 6 4.1 105544 AA261954 Hs.24678 ESTs 8 105546 AA262032 Hs.268281 ESTs; Weakly similar to 62D9.a [D.melan 8.1 105549 AA262417 Hs.5415 ESTs 4.6 105551 AA262477 Hs.25292 ribonuclease HI; large subunit 9.1 105560 AA262783 Hs.306915 ESTs 4.5 105565 AA278302 Hs.18349 ESTs; Weakly similarto partial CDS [Ce 4.2 105566 AA278323 Hs.17481 Homo sapiens clone 24606 mRNA sequen 11.9 105575 AA278717 Hs.12772 ESTs 5.9 105584 AA279012 Hs.3454 ESTs; Weakly similar to KIAA0665 prate 4.4 105596 AA279418 Hs.18490 ESTs 4 105604 AA279787 Hs.15467 ESTs; Moderately similar to putative pho 5.6 105610 AA279991 Hs.99872 ESTs; Weakly similarto trithorax homolo 5.3 105621 AA280865 Hs.6375 Homo sapiens mRNA; cDNA DKFZp564 4.8 105627 AA281245 Hs.23317 ESTs 7.5 105638 AA281599 Hs.247817 Homo sapiens mRNA for for histone H2B 5.9 105645 AA282138 Hs.11325 ESTs 6.4 105650 AA282347 Hs.25635 ESTs; Highly similar to HSPC003 [H.sap 11.3 105666 AA283930 Hs.34906 ESTs 4.7 105674 AA284755 Hs.279789 CDW52 antigen (CAMPATH-1 antigen) 8 105687 AA286809 Hs.28423 ESTs 7.1 105700 AA287643 Hs.35254 ESTs; Weakly similar to hypothetical pro 4.9 105705 AA290767 Hs.101282 Homo sapiens mRNA; cDNA DKFZp434 8 105709 AA291268 Hs.26761 DKFZP586L0724 protein 6.8 105731 AA292711 Hs.29131 ESTs 6.4

105753 AA299789 Hs.110857 ESTs 7

105774 AA348014 Hs.23412 ESTs 7.1

105784 AA350771 Hs.17850 ESTs 13.4

105791 AA358038 Hs.14368 SH3-biπding domain glutamic acid-rich p 4.3

105807 AA393803 Hs.16869 ESTs; Moderately similarto COLLAGEN 5.3

105808 AA393808 Hs.286131 KIAA0438 gene product 4.1

105812 AA394126 Hs.20814 ESTs; Highly similar to CGI-27 protein [H 14.6

105813 AA394140 Hs.18585 ESTs 4.9

105819 AA397920 Hs.28783 Homo sapiens mRNA; cDNA DKFZp564 4.9

105870 AA399623 Hs.101067 ESTs 4.8

105874 AA400074 Hs.171118 ESTs 4

105896 AA400999 Hs.7838 Human ring zinc-finger protein (ZNF127- 4.8

105934 AA404248 Hs.16577 ESTs 5.2

105935 AA404277 Hs.263727 ESTs; Weakly similar to bisphosphate 3'- 4

105966 AA406105 Hs.5344 adaptor-related protein complex 1; gamma 8.3

105974 AA406321 Hs.6224 KIAA0895 protein 4.6

105990 AA410336 Hs.29403 ESTs; Weakly similar to PROBABLE AT 4.5

105995 AA410510 Hs.5345 ESTs 4.9

106000 AA410972 Hs.20726 ESTs 5.8

106007 AA411462 Hs.11042 ESTs; Weakly similarto veli 1 [H.sapiens 6,9

106016 AA411819 Hs.8164 KIAA0898 protein 5

106034 AA412473 Hs.14928 ESTs 6.6

106042 AA412700 Hs.169895 ubiquitin-conjugating enzyme E2L 6 4.6

106057 AA417067 Hs.289074 ESTs 4.5

106065 AA417558 Hs.25206 ESTs 12.3

106070 AA417761 Hs.5957 Homo sapiens clone 24416 mRNA sequen 5

106103 AA421104 Hs.12094 ESTs 15.4

106126 AA424006 Hs.22972 ESTs; Moderately similarto H5AR [M.m 6.4

106154 AA425304 Hs.6994 ESTs 5.1

106157 AA425367 Hs.34892 ESTs 11.1

106166 AA425872 Hs.19561 NADH dehydrogenase (ubiquinone) 1 alp 19.3

106204 AA428024 Hs.21479 ESTs 4.7

106210 AA428239 Hs.10338 ESTs 5.7

106220 AA428582 Hs.32196 ESTs; Moderately similarto metargidin p 7.7

106236 AA429951 Hs.21104 ESTs 8

106240 AA430074 Hs.18552 ESTs; Weakly similar to Ylr218cp [S.cere 4.4

106263 AA431462 Hs.28329 ESTs 4.9

106288 AA435536 Hs.24336 ESTs 8.8

106293 AA435591 Hs.301444 signal sequence receptor; gamma (transloc 8.7

106310 AA436244 Hs.17240 ESTs 4.5

106317 AA436568 Hs.108124 ESTs 4

106328 AA436705 Hs.28020 KIAA0766 gene produd 4.4

106341 AA441798 Hs.5243 ESTs; Moderately similar to plL2 hypoth 23.7

106348 AA442253 Hs.10702 ESTs 4.7

106350 AA442763 Hs. 94698 cyclin B2 6.1

106371 AA443923 Hs.170310 ESTs 6.8

106389 AA446949 Hs.6236 ESTs 4.7

106394 AA447223 Hs.25320 Homo sapiens clone 25142 mRNA sequen 4.4

106426 AA448282 Hs.16206 ESTs; Weakly similar to F55C12.5 [C.ele 4.5

106459 AA449741 Hs.4029 glioma-amplified sequence-41 4.8

106462 AA449912 Hs.30532 ESTs; Highly similarto CGI-77 protein [H 5.2

106468 AA450047 Hs.14770 ESTs 6.8

106479 AA450351 Hs.75251 ESTs 12.4

106494 AA452108 Hs.18387 transcription factor AP-2 alpha (activating 4.5

106503 AA452411 Hs.29679 ESTs; Highly similarto mediator [H.sapie 5.1

106507 AA452584 Hs.267819 protein phosphatase 1; regulatory (inhibito 4.9

106533 AA453786 Hs.145998 ESTs 8.3

106568 AA455970 Hs.28285 patched related protein translocated in ren 7.6

106586 AA456598 Hs.57787 ESTs 8.2

106589 AA456646 Hs.28661 ESTs 4.8

106606 AA457730 Hs.283437 Homo sapiens clone 23851 mRNA sequen 4.4

106611 AA458904 Hs.26267 ESTs; Weakly similarto torsinA [H.sapie 7

106614 AA458934 Hs.256150 ESTs 4.5

106628 AA459657 Hs.12311 Homo sapiens clone 23570 mRNA sequen 6.5

106637 AA459961 Hs.250824 ESTs 5.5

106644 AA460239 Hs.12680 ESTs 4.4 106664 AA460969 Hs.7510 mitogen-activated protein kinase kinase ki 8.4

106698 AA463745 Hs.29403 ESTs; Weakly similarto PROBABLE AT 5.3

106719 AA465171 Hs.236844 ESTs 5.6

106726 AA465339 Hs.3886 ESTs 10.1

106747 AA476473 Hs.171957 triple functional domain (PTPRF interacti 10.4

106759 AA477263 Hs.25584 ESTs 4.2

106765 AA477717 Hs.306117 interleukin 13 receptor; alpha 1 6.9

106784 AA478558 Hs.227913 API5-like 1 5.1

106831 AA482014 Hs.29463 centrin; EF-hand protein; 3 (CDC31 yeast 5.1

106836 AA482112 Hs.238707 ESTs 4.8

106840 AA482548 Hs.5534 ESTs 10.3

106856 AA486183 Hs.285123 ESTs; Weakly similar to similar to oxyste 6.2

106865 AA487228 Hs.19479 ESTs 4.5

106878 AA488872 Hs.12314 Homo sapiens mRNA; cDNA DKFZp586 7.9

106888 AA489101 Hs.24734 oxysterol binding protein 6.4

106895 AA489665 Hs.25245 ESTs 4.6

106909 AA490323 Hs.250747 SUMθ-1 activating enzyme subunit 1 4.2

106919 AA490885 Hs.21766 ESTs 12.3

106920 AA490899 Hs.296323 ESTs 6.2

106941 AA496204 Hs.237971 ESTs 4

106942 AA496347 Hs.31314 retinoblastoma-binding protein 7 4.8

106948 AA496788 Hs.21077 KIAA0532 protein 4

106968 AA504631 Hs.26813 ESTs; Weakly similarto hypothetical 43.2 4.4

106973 AA505141 Hs.11923 Human DNA sequence from clone 167A1 5.4

106980 AA521121 Hs.8858 bromodomain adjacent to zinc finger dom 4.1

106981 AA521157 Hs.74101 ESTs 5.7

106998 AA598461 Hs.195464 insulin-like growth fador binding protein 18.7

107008 AA598710 Hs.23740 ESTs 6.2

107028 AA599214 Hs.24143 ESTs 4.1

107032 AA599472 Hs.247309 succinate-CoA ligase; GDP-forming; beta 5.3

107052 AA600134 Hs.12482 glyceronephosphate O-acyltransferase 4.8

107053 AA600147 Hs.5741 ESTs; Weakly similar to NADH-cytochro 5.8

107056 AA600310 Hs.18720 programmed cell death 8 (apoptosis-induc 4.9

107080 AA609210 Hs.19221 ESTs 8.4

107102 AA609723 Hs.30652 ESTs 8

107109 AA609943 Hs.32793 ESTs 9.5

107129 AA620553 Hs.4756 flap structure-specific endonuclease 1 4.9

107132 AA620598 Hs.9052 ESTs 5.3

107136 AA620795 Hs.8207 ESTs 4

107140 AA620889 Hs.170088 ESTs 6.7

107151 AA621169 Hs.8687 ESTs 19

107159 AA621340 Hs.10600 ESTs; Weakly similarto ORF YKR081c [ 8.1

107174 AA621714 Hs.25338 ESTs 8.5

107217 D51095 Hs.35861 DKFZP586E1621 protein 7.2

107252 D59971 Hs.25925 ESTs 7.9

107295 T34527 Hs.80120 UDP-N-acetyl-alpha-D-galaotosamine:po 5.6

107299 T40327 Hs.30661 lung resistance-related protein 8.4

107324 T81665 Hs.278422 DKFZP586G1122 protein 7.5

107372 U85625 Hs.8297 ribonuclease 6 precursor 4.7

107373 U85773 Hs.154695 phosphomannomutase 2 4.8

107481 W58247 Hs.279766 Homo sapiens kinesin superfamily motor 6.3

107531 Y13936 Hs.1 883 protein phosphatase 1G (formerly 2C); ma 8.3

107859 AA024835 Hs.47584 potassium voltage-gated channel; delayed 7.3

107890 AA026030 Hs.61311 ESTs; Weakly similarto CALPAIN 2; LA 7.3

107908 AA026894 Hs.42826 ESTs 4.9

108039 AA041341 Hs.46670 ESTs 5.4

108040 AA041551 Hs.159971 ESTs 8.4

108102 AA046424 Hs.49433 ESTs; Weakly similar to HYPOTHETICA 6.6

108217 AA058686 Hs.62588 ESTs 7.7

108255 AA063157 Hs.172608 ESTs 4

108358 AA071514 Hs.1634 ESTs 4

108609 AA100694 Hs.69499 Human DNA sequence from BAC 15E1 o 5.5

108647 AA112396 Hs.44276 ESTs; Moderately similarto HOMEOBO 14.3

108676 AA115562 Hs.274417 Homo sapiens mRNA; cDNA DKFZp564 5.2

108687 AA120785 Hs.54347 ESTs 5.6

108695 AA121315 Hs.70823 KIAA1077 protein 10.5

108733 AA126422 zn84f1.s1 Stratagene lung carcinoma 9372 4.4 108774 AA128125 Hs.71040 ESTs; Moderately similar to CELL GROW 4.6

108828 AA131584 Hs.273344 DKFZP564O0463 protein 5.5

108872 AA134063 Hs.111680 ESTs 7.2

108884 AA134958 Hs.293591 ESTs 11.3

108893 AA135894 Hs.194691 retinoic acid induced 3 8.9

109008 AA156360 Hs.87128 ESTs 14.7

109010 AA156460 Hs.44229 dual specificity phosphatase 12 4.9

109011 AA156542 Hs.72127 ESTs 4.6

109042 AA159525 Hs.71779 Homo sapiens DNA from chromosome 19 7.2

109086 AA166695 Hs.270737 tumor necrosis factor (ligand) superfamily 4

109090 AA167006 Hs.70499 ESTs 5.9

109101 AA167708 Hs.52184 ESTs 4.2

109112 AA169379 Hs.257924 ESTs 4

109160 AA179387 Hs.301997 DKFZP434N126 protein 4

109166 AA179845 Hs.73625 RAB6 interacting; kinesin-like (rabkinesin 13.6

109178 AA181600 Hs.283707 ESTs 11.8

109179 AA181902 Hs.192789 ESTs; Weakly similar to 111! ALU SUBFA 5.4

109261 AA195255 Hs.61779 ESTs 6.7

109270 AA195515 Hs.3585 ESTs; Weakly similarto alternatively spli 4.9

109277 AA196332 Hs.86043 ESTs 5.4

109313 AA206800 Hs.86276 ESTs; Moderately similar to zinc finger p 5.5

109415 AA227219 Hs.110826 trinucieotide repeat containing 9 20.1

109454 AA232255 Hs.295232 ESTs 4.7

109467 AA232904 Hs.63187 ESTs 6.8

109481 AA233342 Hs.289069 ESTs; Weakly similar to WD40 protein C 10.6

109508 AA233892 Hs.55902 ESTs; Weakly similar to III! ALU SUBFA 8

109514 AA234087 Hs.262346 ESTs; Weakly similar to ORF2: function 8.2

109572 F02027 Hs.171937 ESTs 4.8

109632 F04165 Hs.235873 ESTs; Weakly similarto K11C4.2 [C.eleg 5.2

109644 F04477 Hs.291531 ESTs; Moderately similar to GLYCERAL 6.6

109703 F09684 Hs.24792 ESTs; Weakly similar to ORF YOR283W 7.1

109726 F10009 Hs.9196 ESTs 5

109747 F10161 Hs.22969 ESTs 4.7

109799 F10770 Hs.180378 Homo sapiens clone 669 unknown mRNA 4.5

109814 F10979 Hs.153106 Homo sapiens clone 23728 mRNA sequen 8.7

110189 H20543 Hs.6278 DKFZP586B 621 protein 16.6

110240 H25577 Hs.176588 ESTs; Weakly similarto CYTOCHROME 6.2

110280 H29285 Hs.32468 ESTs 4.5

110520 H56965 Hs.4082 yr09f06.s1 Soares fetal liver spleen 1NFL 5.7

110561 H59617 Hs.5199 ESTs; Weakly similarto UBIQUITIN-CO 19.5

110707 H95079 Hs.15617 ESTs; Weakly similar to )!!! ALU SUBFA 6.2

110734 H98714 Hs.24131 ESTs 30.2

110770 N22262 Hs.131705 ESTs 5.8

110780 N23174 Hs.22891 solute carrier family 7 (cationic amino aci 8.2

110787 N24716 Hs.12244 ESTs; Weakly similarto C44B9.1 [C.eleg 6.7

110794 N25262 Hs.27931 ESTs 5.9

110799 N26101 Hs.323401 Human ring zinc-finger protein (ZNF127- 4

110818 N29454 Hs.27552 ESTs; Weakly similarto putative p150 [H 4.3

110839 N30856 Hs.30246 solute carrier family 19 (thiamine transpo 12.8

110844 N31952 Hs.167531 Homo sapiens mRNA full length insert cD 10.1

110854 N32919 Hs.27931 ESTs 4.7

110856 N33063 ESTs; Weakly similarto S164 [H.sapiens 4.2

110860 N33438 Hs.170065 ESTs 12.5

110897 N39148 Hs.6880 DKFZP434D156 protein 4

110915 N46252 Hs.29724 ESTs 23.2

110935 N48787 Hs.305979 protease inhibitor 1 (anti-elastase); alpha- 4.8

110970 N51374 Hs.96870 Homo sapiens mRNA full length insert cD 5.4

111006 N53375 Hs.166146 Homer; neuronal immediate early gene; 3 4.7

111008 N53388 Hs.7222 ESTs 13.3

111018 N54067 Hs.3628 mitogen-activated protein kinase kinase ki 57

111084 N59543 Hs.15456 PDZ domain containing 1 8.3

111100 N62522 Hs.20450 ESTs 14.3

111125 N63823 Hs.269115 ESTs 7.9

111132 N64378 Hs.83293 ESTs; Highly similarto unknown fundion 4.4

111139 N64683 Hs.290943 ESTs 6

111164 N66857 Hs.14808 ESTs; Weakly similar to 111! ALU CUSS 4.1

111172 N67102 Hs.21851 Homo sapiens mRNA; cDNA DKFZp586 5.5 111178 N67227 Hs.24633 ESTs 5.7

111179 N67239 Hs.10760 ESTs 37

111181 N67278 Hs.171802 ESTs; Weakly similar to hypothetical pro 5.6

111184 N67437 Hs.243901 Homo sapiens mRNA; cDNA DKFZp564 8.7

111221 N68869 Hs.15119 ESTs 7.3

111223 N68921 Hs.297939 ESTs; Weakly similar to neogeπin [H.sap 9

111229 N69113 Hs.110855 ESTs 8.9

111241 N69514 Hs.288880 ESTs; Weakly similarto CGl-82 protein [ 6.9

111268 N70481 Hs.26118 Homo sapiens clone 24766 mRNA sequen 4.5

111295 N73275 Hs.21275 ESTs; Weakly similarto ubiquitin-conjug 5.6

111299 N73808 Hs.24936 ESTs 8.5

111336 N79565 Hs.29894 ESTs 6.7

111357 N91023 Hs.87128 ESTs 15

111370 N92915 Hs.94631 brefeldin A-inhibited guanine nucleotide-e 5.2

111806 R33468 Hs.279008 ESTs 10

111825 R35885 Hs.286 48 stromal antigen 1 4.5

111836 R36228 Hs.25119 ESTs 7.2

111890 R38678 Hs.12365 ESTs 17.3

111923 R39995 Hs.25925 Homo sapiens clone 23860 mRNA sequen 7.3

111942 R40576 Hs.21590 ESTs 9.2

111987 R42036 Hs.6763 KIAA0942 protein 10.6

112101 R44793 Hs.296341 adenylyl cyclase-associated protein 2 5.3

112134 R46025 Hs.7413 ESTs 17.4

112197 R49482 Hs.5637 ESTs 4.4

112244 R51309 Hs.70823 KIAA1077 protein 11

112253 R51818 Homo sapiens mRNA; cDNA DKFZp566 9.3

112305 R54822 Hs.26244 ESTs 4.4

112449 R63802 Hs.124186 ring finger protein 2 6.3

112483 R66534 Hs.285885 ESTs 4.9

112519 R68631 Hs.11861 ESTs 14.3

112610 R79392 Hs.23643 ESTs 5.2

112693 R88741 Hs.91065 ESTs; Moderately similar to proliferation 4.6

112751 R93507 Hs.8207 ESTs 5.6

112801 R97486 Hs.157160 protein kinase; DNA-activated; catalytic p 8.7

112869 T03313 Hs.4747 dyskeratosis congenita 1; dyskerin 5.9

112871 T03352 Hs.12285 ESTs 5.8

112908 T10065 Hs.3530 TLS-associated serine-arginine protein 4.1

112966 T17119 Hs.102548 glucocorticoid receptor DNA binding fact 5.7

112971 T17185 Hs.83883 ESTs 6.4

112995 T23528 Hs.7155 ESTs; Weakly similar to TYKi protein [M 9.1

113047 T25867 Hs.7549 ESTs 5.4

113075 T34660 Hs.6986 ESTs; Weakly similarto IN! ALU SUBFA 5.7

113117 T47819 Hs.159153 ESTs 5.8

113206 T58044 Hs.241471 ESTs; Moderately similar to !!!! ALU SU 6.4

113248 T63857 yc16els1 Stratagene lung (#93721) Homo 4.6

113260 T64896 Hs.287420 ESTs 6.9

113277 T65797 Hs.11774 protein (peptidyl-prolyl cis/trans iso eras 5.6

113278 T65802 Hs.11135 yc11h10.s1 Stratagene lung (#937210) Ho 4.5

113440 T86121 Hs.191445 ESTs 6.4

113523 T90037 Hs.95549 ESTs 6.4

113604 T92735 Hs.296083 ESTs 8.7

113702 T97307 ESTs; Moderately similarto !!!! ALU SU 9.5

113783 W19222 Hs.7041 ESTs; Weakly similarto Nil ALU SUBFA 5.2

113794 W37382 Hs.11090 ESTs 11.9

113808 W44735 Hs.9286 ESTs 16.7

113811 W44928 Hs.6994 ESTs 4

113822 W47350 Hs.17466 retinoic acid receptor responder (tazaroten 4.8

113823 W47388 Hs.55099 rabδ GTPase activating protein (GAP and 4

113836 W56792 Hs.12040 ESTs; Weakly similar to KIAA0881 prate 4.1

113857 W65477 Hs.5297 Homo sapiens mRNA; cDNA DKFZp564 4.3

113886 W72471 Hs.23920 ESTs 4.6

113895 W73738 Hs.12921 ESTs 7.1

113923 W80763 Hs.3849 ESTs; Weakly similarto FK506-binding p 6.8

113931 W81205 Hs.3496 ESTs 6.1

113950 W85765 Hs.30504 Homo sapiens mRNA; cDNA DKFZp434 14

113970 W86748 Hs.8109 ESTs 15

114051 W94942 Hs.177534 dual specificity phosphatase 10 5.4 114057 W96222 Hs.34192 ESTs 4.8

114086 Z38266 Hs.288649 Homo sapiens PAC clone DJ0777O23 fro 5.1

114098 Z38347 Hs.118338 ESTs; Weakly similarto similarto S. cere 6.2

114109 Z38435 Hs.184108 ribosomal protein L21 4.6

114124 Z38595 Hs.125019 ESTs; Highly similar to KIAA0886 prate 22

114138 Z38763 Hs.15740 amyloid beta (A4) precursor protein-bindi 8.8

114149 Z38814 Hs.27196 ESTs 4

114162 Z38909 Hs.22265 ESTs 7.2

114177 Z39062 Hs.23740 ESTs 5.3

114196 Z39211 Hs.150926 fucose-1-phosphate guanylyltransferase 4.4

114208 Z39301 Hs.7859 ESTs 5.1

114250 Z39897 Hs.13297 ESTs 7.2

114251 Z39898 Hs.21948 ESTs 14.7

114292 Z40715 Hs.184641 delta-6 fatty acid desaturase 19.4

114297 Z40758 Hs.173091 DKFZP434K151 protein 8.9

114334 Z41342 Hs.22941 ESTs 13.7

114460 AA024604 Hs.26102 ESTs 10.1

114471 AA028074 Hs.104613 ESTs 5.7

114480 AA032243 Hs.151678 UDP-N-acetyl-alpha-D-galactosamine:po 7.3

114518 AA046407 Hs.106469 suppressor of varl (S.cerevlsiae) 3-like 1 4.3

114542 AA055768 Hs.293380 ESTs 11.7

114549 AA056484 Hs.292833 ESTs 7.3

114652 AA101416 Hs.107149 ESTs; Weakly similar to PTB-ASSOCIAT 6.1

114673 AA113303 Hs.95583 transmembrane 4 superfamily member (te 4.3

114698 AA126951 Hs.110857 ESTs; Highly similarto putative DNA-dir 7.1

114767 AA148885 Hs.154443 minichromosome maintenance deficient (S 5.3

114799 AA159323 Hs.109929 ESTs 4.2

114804 AA160363 Hs.269956 ESTs 4.8

114811 AA161161 Hs.95907 multiple inositol polyphosphate phosphate 7.1

114821 AA165313 Hs.55468 ESTs 4.4

114852 AA235035 Hs.38260 ESTs; Moderately similar to ubiquitin spe 5

114901 AA236276 Hs.196437 ESTs; Weakly similar to R26660 1; parti 16.9

114902 AA236359 Hs.39504 ESTs 5.1

114940 AA243012 Hs.75928 ESTs 8.5

114965 AA250737 Hs.72472 ESTs 35.1

115047 AA252627 Hs.82916 homeo box B5 5.7

115054 AA252863 Hs.87729 ESTs 6.2

115061 AA253217 Hs.41271 ESTs 13

115082 AA255557 Hs.198269 NADH dehydrogenase (ubiquinone) 1 alp 28.2

115116 AA256486 Hs.62275 ESTs 8.8

115140 AA258030 Hs.279938 ESTs; Weakly similarto supported by GE 4.1

115205 AA262470 Hs.284216 ESTs 8.3

115206 AA262491 Hs. 86572 ESTs 5.1

115239 AA278650 Hs.73291 ESTs; Weakly similarto similarto the bet 4.6

115242 AA278755 Hs.283732 ESTs 8.3

115249 AA278961 Hs.71124 ESTs 10.1

115259 AA279071 Hs.13453 splicing factor 3b; subunit 1; 155kD 9.5

115285 AA279799 Hs.293736 ESTs 5.8

115291 AA279943 Hs.122579 ESTs 5.1

115357 AA281793 Hs.72988 ESTs 5

115377 AA282247 Hs.193063 ESTs 6.1

115400 AA283198 Hs.89113 ESTs 4.9

115439 AA284561 Hs.193090 ESTs 5.8

115471 AA287138 Hs.59346 ESTs; Weakly similar to ASPARTYL-TR 11.7

115506 AA292537 Hs.45207 Human DNA sequence from clone 620E1 6.8

115522 AA331393 Hs.47378 ESTs 5.8

115572 AA398392 Hs.59594 ESTs; Weakly similar to F33G12.3 gene p 9.7

115587 AA399264 Hs.283037 ESTs; Highly similarto HSPC039 protein 8.7

115600 AA400247 Hs.42173 ESTs 4

115612 AA400948 Hs.71243 ESTs; Weakly similar to zinc finger prate 8.4

115646 AA404352 Hs.305971 ESTs 5.3

115652 AA405098 Hs.381 8 ESTs 16.1

115657 AA405620 Hs.55158 ESTs; Weakly similar to weak similarity t 4.7

115658 AA405625 Hs.183056 Human DNA sequence from clone 34B21 5.1

115675 AA406546 Hs.82065 Homo sapiens mRNA; cDNA DKFZp564 20.5

115721 AA417102 Hs.90960 ESTs 4.8

115763 AA421560 ESTs 7 115764 AA421562 Hs.91011 anterior gradient 2 (Xenepus laevis) homo 41.6

115835 AA428576 Hs.41371 ESTs 4.2

115844 AA430124 Hs.7773 ESTs 11.9

115875 AA433943 Hs.43946 ESTs; Weakly similar to Weak similarity 33.5

115888 AA435839 Hs.76591 KIAA0887 protein 7.2

115922 AA441911 Hs.71869 ESTs; Weakly similar to KIAA0926 prate 5.1

115941 AA443602 Hs.46679 ESTs 4.8

115947 AA443793 Hs.94761 ESTs 8.3

115948 AA443798 Hs.43445 poly(A)-specific ribonuclease (deadenylat 13.5

115951 AA443918 Hs.301048 cofilin 1 (non-muscle) 7.5

115967 AA446887 Hs.42911 ESTs 8.8

115984 AA447687 Hs.91109 ESTs 13.1

116009 AA449448 Hs.44238 ESTs 5.5

116024 AA451748 Hs.83883 Human DNA sequence from clone 718J7 7.5

116028 AA452112 Hs.42644 thioredoxin-like 12.7

116050 AA453656 Hs.88417 ESTs 7.2

116097 AA456099 Hs.176376 ESTs 11.8

116108 AA457566 Hs.28777 ESTs 4.5

116121 AA459254 Hs.48855 ESTs 4.5

116127 AA459703 Hs.279884 v-myc avian myelocytomatosis viral onco 4.3

116129 AA459956 Hs.49163 ESTs; Highly similar to putative ribonucle 7.6

116142 AA460649 Hs.39457 ESTs 4.8

116204 AA465701 Hs.108646 ESTs 6.8

116221 AA478397 Hs.50180 ESTs 4.9

116222 AA478415 Hs.89986 ESTs 4

116238 AA479362 Hs.47144 DKFZP586N0819 protein 4.6

116246 AA479961 Hs.250646 ESTs; Highly similarto ubiquitin-conjuga 4

116249 AA480886 Hs.86693 ESTs 18.5

116250 AA480975 Hs.44829 ESTs 10.8

116254 AA481146 Hs.41086 ESTs; Weakly similarto OXYSTEROL-B 9.1

116256 AA481256 Hs.88201 ESTs; Weakly similar to lysophospholipa 8.4

116264 AA482594 Hs.272239 Homo sapiens mRNA; cDNA DKFZp586 7.2

116265 AA482595 Hs.55189 ESTs; Weakly similar to F25B5.3 [C.eleg 11.1

116282 AA486550 Hs.204501 ESTs; Weakly similar to Wiskott-Aldrich 6.2

116298 AA489046 Hs.94109 ESTs 4.9

116300 AA489194 Hs.159471 ESTs; Weakly similar to snRNP protein B ' 4.6

116327 AA490959 Hs.28005 Homo sapiens mRNA; cDNA DKFZp564 5.8

116334 AA491457 Hs.48948 ESTs 4.3

116337 AA496127 Hs.44070 ESTs 8.4

116351 AA504116 Hs.82501 Homo sapiens mRNA; cDNA DKFZp434 5.3

116357 AA504806 Hs.90797 Homo sapiens clone 23620 mRNA sequen 5.2

116415 AA609204 Hs.27973 KIAA0874 protein 6.6

116443 AA620313 Hs.190488 ESTs; Weakly similar to KERATIN; TYP 4.5

116470 C13992 Hs.83484 ESTs 4.5

116480 C14088 glyceraldehyde-3-phosphate dehydrogena 5.6

116578 D51272 Hs.75337 nu eolar phosphoprotein p130 4.1

116579 D51276 Hs.81915 leukemia-associated phosphoprotein p18 5.8

116626 F02028 Hs.81907 ESTs 4.9

116647 F03069 Hs.15395 ESTs; Weakly similar to ARGINYL-TRN 6.1

116674 F04816 Hs.92127 ESTs 10.6

116680 F08813 Hs.273829 LINE retrotransposable element 1 4.2

116700 F09983 Hs.317589 ESTs 13

116724 F13665 Hs.65641 ESTs 8.5

116726 F13681 Hs.53913 ESTs 5.6

116732 F13779 Hs.165909 ESTs 11.6

116734 F13789 Hs.93796 DKFZP586D2223 protein 5.4

116760 H11054 Hs.155342 protein kinase C; delta 4.3

116780 H22566 Hs.30098 ESTs 5.7

116786 H25836 Hs.301527 tumor necrosis factor (ligand) superfamily 8.8

116787 H28581 Hs.15641 ESTs 8.6

116790 H29532 Hs.101174 microtubule-associated protein tau 22.2

116803 H47357 Hs.109701 ESTs; Moderately similar to weak similar 6.7

116877 H68116 Hs.168732 ESTs 6.5

116921 H72948 Hs.821 biglycan 20.7

117216 N20083 Hs.42792 ESTs 4.4

117232 N20579 Hs.61153 ESTs 7.4

117284 N22162 Hs.183779 ESTs; Weakly similar to cDNA EST yk33 4.1 117344 N24046 Hs.210706 ESTs 7.4

117367 N24954 Hs.42502 ESTs 10.5

117392 N26175 Hs.93405 ESTs 5.8

117394 N26257 Hs.39871 KIAA0727 protein 8.4

117412 N26722 Hs.42645 ESTs 18.1

117498 N31726 Hs.44268 ESTs; Highly similar to myelin gene expr 5.8

117557 N33920 Hs.44532 diubiquitin 12.3

117634 N36421 Hs.13323 ESTs; Weakly similar to SODIUM- AND 4.4

117639 N36923 Hs.44833 ESTs 6

117754 N47469 Hs.59757 ESTs 7.6

117852 N49408 Hs.136102 KIAA0853 protein 5.9

117879 N50050 Hs.303025 ESTs; Weakly similar to keratin; 67K typ 7.9

117924 N51056 Hs.38891 ESTs 7.9

117950 N51394 Hs.75478 KIAA0956 protein 5

117992 N52000 Hs.172089 Homo sapiens mRNA; cDNA DKFZp586 7

118138 N57773 Hs.93560 ESTs; Weakly similarto trg [R.norveglcu 4.8

118215 N62195 Hs.77910 3-hydroxy-3-methylglutaryl-CoenzymeA 13.4

118229 N62339 Hs.166254 heat shock 90kD protein 1 ; alpha 5.4

118265 N62827 Hs.48645 EST 4.2

118336 N63604 Hs.47166 ESTs 7.2

118363 N64168 Hs.48938 ESTs 6

118429 N66158 Hs.74649 ESTs 4.1

118470 N66769 Hs.291033 ESTs 5.4

118472 N66818 Hs.42179 ESTs 10.8

118475 N66845 ESTs; Weakly similar to llll ALU CLASS 4.5

118493 N67149 Hs.50115 ESTs 5.3

118528 N67889 Hs.49397 ESTs 10.4

118542 N68010 Hs.49427 ESTs 7.9

118600 N69222 ESTs 9.2

118695 N71781 Hs.50081 Homo sapiens mRNA full length insert cD 9.8

118698 N72113 Hs.50187 ESTs 4.3

118901 N90719 Hs.94445 ESTs 8.1

118952 N92966 ESTs; Highly similar to CGI-90 protein [H 12.5

118976 N93629 Hs.93391 ESTs 5

118986 N94362 Hs.125830 ESTs 7.3

118989 N94439 Hs.45105 ESTs 8.2

119027 N99256 Hs.114611 ESTs 5

119042 R05316 Hs.5472 ESTs 4

119075 R36451 Hs.287820 fibronectin 1 6

119260 T15916 Hs.102950 ESTs; Highly similarto coat protein gamm 4.1

119271 T16387 Hs.65328 ESTs 12.1

119298 T23820 Hs.155478 cyclin T2 5.6

119302 T25725 ESTs 14.3

119341 T62571 Hs.146388 microtubule-associated protein 7 4

119495 W35390 Hs.55533 ESTs 5.3

119580 W42451 Hs.92260 high-mobility group protein 2-like 1 5.6

119602 W46286 Hs.233694 ESTs; Weakly similar to ZK1058.5 [C.ele 6.5

119620 W47620 Hs.56009 2'-5'oligoadenylate synthetase 3 8.1

119676 W60473 Hs.57787 ESTs 5.5

119717 W69134 Hs.57987 ESTs 4.6

119729 W69747 Hs.94806 KIAA1062 protein 4

119805 W73788 Hs.43213 ESTs 4

119859 W80702 Hs.58461 ESTs 4.8

119867 W80852 Hs.250696 KDEL (Lys-Asp-Glu-Leu) endoplasmic re 4.2

119873 W81129 Hs.44865 Homo sapiens mRNA; cDNA DKFZp586 4.8

119899 W84767 Hs.58698 ESTs 5.9

119940 W86779 Hs.272531 DKFZP586B0319 protein 9

119943 W86835 Hs.14158 copine III 4.8

119970 W87812 Hs.93581 Homo sapiens mRNA; cDNA DKFZp586 4

120131 Z38656 Hs.75887 coatomer protein complex; subunit alpha 4.2

120150 Z39549 Hs.153746 ESTs 11

120206 Z40805 Hs.91668 ESTs 8.2

120241 Z41815 Hs.65946 ESTs 15.6

120255 AA169752 : Hs.5672 ESTs; Weakly similar to Similarity to Yea 4.2

120314 AA194166 Hs.221040 KIAA1038 protein 6.8

120325 AA195651 Hs.104106 ESTs 15.2

120352 AA211400 Hs.193172 ESTs 6.8 120428 AA236822 Hs.173694 KIAA1097 protein 5.6

120524 AA261852 Hs.192905 ESTs 5.6

120528 AA262107 Hs.104413 ESTs 4.5

120571 AA280738 Hs.34892 ESTs 4.9

120649 AA287115 Hs.192843 ESTs 4.5

120655 AA287347 Hs.238205 ESTs 6.7

120668 AA287833 Hs.292913 ESTs 8.3

120712 AA292654 Hs.102506 eukaryotic translation initiation factor 2 al 4.6

120713 AA292655 Hs.96557 ESTs 10.6

120724 AA293470 Hs.100747 ESTs 5.4

120873 AA358015 EST 7.1

120885 AA365515 Hs.301872 ESTs; Moderately similarto ill! ALU SU 4.6

120919 AA381125 Hs.301 44 ESTs 8.2

120948 AA397822 Hs.104650 ESTs; Highly similar to similar to mago n 8.6

120969 AA398116 Hs.129206 casein kinase 1; gamma 3 10.5

120977 AA398155 Hs.97600 ESTs 10.9

121103 AA398936 Hs.97697 EST 7.4

121291 AA401753 Hs.8186 lung cancer candidate 5.3

121320 AA403008 Hs.301927 T-cell receptor; alpha (V;D;J;C) 13.5

121463 AA411745 Hs.239681 ESTs; Weakly similarto KIAA0554 prate 8.9

121596 AA416740 Hs.174104 ESTs 22.6

121723 AA419622 Hs.104800 ESTs; Weakly similarto Mouse 19.5 mRN 8

121748 AA421171 Hs.234545 ESTs 5.6

122125 AA434411 Hs.98806 ESTs 5.3

122522 AA449444 Hs.98969 ESTs 4

122655 AA454756 Hs.97837 ESTs 4

122704 AA456326 Hs.99445 ESTs 6.2

122782 AA459894 Hs.99472 ESTs 5.3

122856 AA463740 Hs.75367 Sro-like-adapter 13.1

122882 AA465381 Hs.108812 ESTs; Weakly similarto B0041.5 [C.eleg 5.5

122928 AA476578 Hs.101840 ESTs 6.3

122974 AA478625 Hs.194215 ESTs 6

122997 AA479295 Hs.106290 Kelch motif containing protein 12.5

123016 AA480103 Hs.323231 ESTs; Weakly similar to alternatively spli 4.4

123107 AA486071 Hs.104207 ESTs 8.3

123111 AA486273 Hs.191721 ESTs 4.2

123114 AA486407 Hs.129928 ESTs; Moderately similar to KIAA0454 p 5.2

123136 AA487449 Hs.194024 ESTs 4.2

123137 AA487468 Hs.100686 ESTs; Weakly similarto secreted cement 14.6

123169 AA488892 ESTs; Weakly similar to Gag-Pol polypro 4.5

123176 AA489020 Hs.69233 ESTs 5.2

123338 AA504249 Hs.187585 ESTs 4

123436 AA598714 Hs.223014 protease; serine; 15 7.3

123442 AA598803 Hs.111496 ESTs 5.9

123449 AA598899 Hs.112493 Homo sapiens mRNA; cDNA DKFZp564 , 4.1

123494 AA599786 Hs.112110 ESTs 4

123503 AA600121 Hs.293156 ESTs 12.8

123533 AA608751 ESTs; Weakly similarto !!!! ALU SUBFA 7.9

123619 AA609200 ESTs 23.1

123673 AA609471 Hs.158549 ESTs 6.6

123729 AA609778 Hs.278672 membrane component; chromosome 11; s 4.7

123819 AA620636 Hs.112264 ESTs 4

123960 AA621785 Hs.287733 methylmalonate-semialdehydedehydroge 7.6

124000 D57317 Hs.74861 activated RNA polymerase II transcription 4.4

124006 D60302 Hs.270016 ESTs 20.6

124012 D80240 Hs.241471 HUM5G11A Human fetal brain (TFujiwa 6.7

124021 F02859 Hs.13974 ESTs 4.7

124049 F10523 Hs.74519 primase; polypeptide 2A (58kD) 4.7

124059 F13673 Hs.283713 ESTs 7.7

124243 H66710 Hs.133525 ESTs 5.5

124308 H93575 Hs.241507 Homo sapiens mRNA; cDNA DKFZp564 11.4

124314 H94877 Hs.215766 GTP-binding protein 13.7

124315 H94892 Hs.288757 v-ral simian leukemia viral oncogene horn 14

124350 N21359 Hs.101282 Homo sapiens mRNA; cDNA DKFZp434 8.6

124352 N21626 Hs.102406 ESTs 7.2

124357 N22401 yw37g07.s1 Morton Fetal Cochlea Homo 5.2

124390 N29325 Hs.7535 ESTs; Highly similar to COBW-like place 7.9 124438 N40188 Hs.11090 ESTs 9.5

124447 N48000 Homo sapiens mRNA; cDNA DKFZp586 4.8

124457 N50114 Hs.266175 ESTs 6.1

124539 N63172 Hs.146409 cell division cycle 42 (GTP-binding prate 5.6

124626 N74604 Hs.11090 ESTs 12.8

124632 N79515 Hs.306117 interleukin 13 receptor; alpha 1 6.4

124644 N91279 Hs.109654 ESTs; Moderately similar to outer membr 8.3

124676 R01037 Hs.181013 phosphoglycerate mutase 1 (brain) 12.3

124677 R01073 ESTs; Weakly similar to 111! ALU CLASS 5.4

124724 R12405 Hs.112423 Homo sapiens mRNA; cDNA DKFZp586 6.6

124773 R40923 Hs.106604 ESTs 4.9

124777 R41933 ESTs 7.2

124792 R44357 Hs.48712 ESTs; Weakly similar to cDNA EST EMB 8.6

124857 R63652 Hs.137190 ESTs 4.9

124911 R88992 Hs.180612 ESTs 4.7

124955 T10598 Hs.324841 ESTs; Weakly similar to III! ALU SUBFA 4.4

124958 T11134 Hs.431 murine leukemia viral (bmi-1) oncogene h 12.6

125038 T78089 Hs.270134 ESTs 4.1

125092 T92544 Hs.137548 CD84 antigen (leukocyte antigen) 14.8

125132 W15495 Hs.129781 chromosome 21 open reading frame 5 6.7

125144 W37999 Hs.24336 ESTs 4.8

125154 W38419 ESTs 5.3

125243 W86423 Hs.105413 ESTs 6.6

125279 W93640 Hs.4779 ESTs; Moderately similarto similarto AD 5.8

125299 Z39436 Hs.102720 ESTs 12.2

125303 Z39821 Hs.288193 ESTs 10.2

125304 Z39833 Hs.124940 GTP-binding protein 6.8

125474 AA151216 Hs.75103 tyrosine 3-monooxygenase/tryptophan 5-m 8

125509 AA044232 Hs.288967 ESTs 5.4

125580 AA126504 Hs.267812 sorting nexin 4 4.1

125582 AA507383 Hs.74649 cytochrome c oxidase subunit Vic 11.5

125670 AI432621 Hs.82685 CD47 antigen (Rh-related antigen; integri 4

125698 AA748483 Hs.191356 general transcription factor IIH; polypepti 9.4

125745 AI283493 Hs.75722 ribophorin II 6.2

125852 H09290 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564 25.9

125972 AA434562 Hs.35406 ESTs 4.1

126160 N90960 Hs.265398 ESTs; Weakly similarto transformation-r 16.4

126257 N99638 Hs.124084 tumor necrosis factor receptor superfamily 9.5

126337 AI066486 Hs.40500 similar to S. cerevisiae RER1 5.6

126405 U46278 Hs.122489 ESTs 7.5

126537 W40262 Hs.146310 ESTs; Weakly similarto putative p150 [H 4.1

126590 W78968 Hs.181307 H3 histone; family 3A 4.5

126712 AA205862 Hs.7942 ESTs 5.2

126721 T72569 Hs.125359 Thy-1 cell surface antigen 4.4

126764 AI334393 Hs.102178 ESTs 4.6

126804 AI203334 Hs.160628 ESTs 11.7

126819 AA305536 Hs.279607 ESTs 4

126877 AI052047 Hs.26102 ESTs 7

126991 R31652 Hs.821 biglycan 5.6

127479 AA513722 Hs.179729 collagen; type X; alpha 1 (Schmid metaph 14.3

127514 AA826926 Hs.204214 ESTs 4.5

127663 W07286 Hs.10340 ESTs; Weakly similar to weak similarity t 5.1

127677 AA916752 Hs.264190 ESTs; Highly similarto MEM3 [M.muscu 17.3

127814 AA761755 Hs.136713 ESTs; Weakly similarto V4-1 [H.sapiens 4.1

127997 AI281549 Hs.311054 ESTs 5.5

128092 AA904617 Hs.166229 ESTs 5.8

128218 H02682 Hs.292154 ESTs; Moderately similar to recombinatio 5.8

128466 D59653 Hs.241471 EST 7.4

128482 U83908 Hs.296251 programmed cell death 4 5.8

128517 AA280617 Hs.100861 ESTs; Weakly similarto p60 katanin [H.s 8.3

128530 AA504343 Hs.183475 Homo sapiens clone 25061 mRNA sequen 6.6

128559 AA226801 Hs.101448 metastasis associated 1 5.2

128574 AA412048 Hs.38260 keratin 8 5.1

128595 U31875 Hs.152677 short-chain alcohol dehydrogenase family 27.1

128610 L38608 Hs.10247 activated leucocyte cell adhesion molecule 13.2

128629 AA399187 Hs.102708 DKFZP434A043 protein 6.7

128649 AA142853 Hs.103106 Homo sapiens mRNA for G7b protein (G 4.5 128651 AA446990 Hs.103135 ESTs 6.1

128653 R48943 Hs.10315 solute earner family 7 (cationic amino aci 4.4

128656 AA458542 Hs.10326 coatomer protein complex; subunit epsilon 14.3

128717 T30617 Hs.104222 Homo sapiens mRNA; cDNA DKFZp566 24.5

128727 M64174 Hs.50651 Janus kinase 1 (a protein tyrosine kinase) 7.3

128764 N49308 Hs.104938 ESTs; Weakly similarto alpha 1 (XVIII) c 9.2

128781 X85372 Hs.105465 small nuclear ribonucleoprotein polypepti 5.4

128793 W93562 Hs.105749 KIAA0553 protein 4.6

128835 W15528 Hs.106390 Homo sapiens mRNA; cDNA DKFZp586 4

128845 AA455658 Hs.10649 basement membrane-induced gene 6.9

128871 AA400271 Hs.106778 Homo sapiens mRNA for putative Ca2+-t 4.5

128922 AA252023 Hs.9589 ESTs; Weakly similar to HRIHFB2157 [H 6.4

128925 D61676 Hs.21851 Homo sapiens mRNA; cDNA DKFZp586 6.4

128938 AA410325 Hs.107260 ESTs 7

128946 N29353 Hs.107318 kynurenine 3-monooxygenase (kynurenin 5.2

128948 AA485655 Hs.223025 proteasome (prosome; macropain) subunit 13.1

128955 F10290 Hs.185807 Homo sapiens clone 24758 mRNA sequen 5.8

129005 AA460049 Hs.13323 ESTs; Weakly similar to SODIUM- AND 12.6

129009 AA131421 Hs.75607 ESTs 9.8

129017 H13108 Hs.107968 ESTs 13.9

129057 X62466 Hs.276770 CDW52 antigen (CAMPATH-1 antigen) 10.7

129075 AA129465 Hs.83765 ESTs 4.7

129095 L12350 Hs.108623 thrombospondin 2 4.4

129124 AA234530 Hs.108802 N-ethylmaleimide-sensitive factor 20.7

129160 AA131252 Hs.109007 ESTs 5.9

129164 AA282183 Hs.109045 ESTs 5.8

129180 R40556 Hs.318401 ESTs; Highly similarto HSPC039 protein 7.6

129224 X89109 Hs.109606 coronin; actin-binding protein; 1A 12

129229 AA211941 Hs.109643 polyadenylate binding protein-interacting 7.9

129240 W24360 Hs.237868 interleukin 7 receptor 5.3

129241 AA435665 Hs.109706 ESTs; Moderately similarto HN1 [M.mus 8.4

129243 H88033 Hs.109727 KIAA0733 protein 7.8

129247 AA151574 Hs.109733 pilin-like transcription factor 6.4

129259 AA090695 Hs.181385 ESTs 6.2

129270 Z35227 Hs.109918 ras homolog gene family; member H 5.4

129281 AA026318 Hs.289101 glucose regulated protein; 58kD 4.4

129300 C20976 Hs.110165 ESTs; Highly similar to ribosomal protein 5.7

129318 N93155 Hs.285976 calmoduUn 1 (phosphorylase kinase; delta 7.7

129319 AA037467 Hs.30340 ESTs 6

129351 AA167268 Hs.62349 Human ras inhibitor mRNA; 3' end 9.3

129366 H18027 Hs.184697 plexin C1 18.2

129383 W92984 Hs.288224 ESTs 5.9

129388 AA151621 Hs.110964 ESTs 4.1

129391 T80814 Hs.11101 discs; large (Drosophila) homolog 3 (neur 10.9

129404 AA172056 Hs.317584 ESTs 5.3

129406 N23707 Hs.111138 KIAA0712gene produd 4

129426 AA412087 Hs.111323 EST; Highly similar to protein inhibitor o 8

129453 AA421213 Hs.111632 Lsm3 protein 5.5

129513 C00225 Hs.306163 ESTs; Weakly similarto fos39554_1 [H.s 5.5

129519 AA298786 Hs.112242 ESTs 6.8

129606 R21443 Hs.166254 heat shock 90kD protein 1; alpha 5

129622 AA278243 Hs.323949 ESTs 6.8

129626 AA447410 Hs.111334 ESTs; Weakly similarto 111! ALU SUBFA 5.1

129627 AA258308 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564 5.3

129628 U26727 Hs.1174 cyclin-dependent kinase inhibitor 2A (mel 8.2

129642 R50008 Hs.11806 7-dehydrocholesterol reductase 4.3

129663 AA442768 Hs.11866 translocase of inner mitochondrial membr 4.4

129665 M88458 Hs.118778 KDEL (Lys-Asp-Glu-Leu) endoplasmic re 4

129691 X06700 Hs.119571 collagen; type III; alpha 1 (Ehlers-Danlos 6

129783 AA454618 Hs.12479 associated molecule with the SH3 domain 6.4

129800 AA252436 Hs.12540 lysophospholipase I 7.7

129836 AA452161 Hs.206521 YME1 (S.cerevisiae)-like 1 5

129850 N20593 Hs.288932 GDP dissociation inhibitor 2 6.9

129869 AA102520 Hs.13015 ESTs; Weakly similar to heat shock prate 5

129896 AA043021 Hs.13225 UDP-Gal:betaGlcNAc beta 1 ;4- galactosy 6.6

129982 M87789 immunoglobulin gamma 3 (Gm marker) 4

129985 AA450045 Hs.140452 cargo selection protein (mannose 6 phosp 5.8 130029 AA236412 Hs.236510 ESTs; Moderately similar to PFT27 [M.m 5.6

130033 M90696 Hs.181301 cathepsin S 5.4

130036 AA195260 Hs.125849 ESTs; Moderately similarto 111! ALU SU 7.4

130069 AA055896 Hs.146428 collagen; type V; alpha 1 7.6

130077 T24055 Hs.91379 ribosomal protein L26 4

130080 X14850 Hs.147097 H2A histone family; member X 12.1

130096 AA223874 Hs.197955 KIAA0704 protein 5

130114 AA234717 Hs.14992 ESTs 7.8

130125 M36803 Hs.1504 hemopexin 7.2

130135 M61764 Hs.21635 tubulin; gamma 1 5.6

130170 AA610070 Hs.151469 calcium/calmodulin-dependent serine pro 7.5

130189 D43947 Hs.151761 KIAA0100 gene product 6.4

130208 AA620556 Hs.15250 peroxisomal D3;D2-enoyl-CoA isomerase 6.4

130211 D50840 Hs.23703 UDP-glucose ceramide glucosyltransferas 4.5

130235 X14046 Hs.153053 CD37 antigen 9.1

130276 S75295 Hs.169149 karyopherin alpha 1 (importin alpha 5) 8.6

130280 L13738 Hs.153937 activated p21cdc42Hs kinase 5

130313 AA620323 Hs.154320 ubiquitin-activating enzyme E1C (homolo 6.1

130314 D86967 Hs.154332 KIAA0212 gene product 10

130328 AA135673 Hs.154668 KIAA0391 gene product 6.1

130356 X84373 Hs.155017 nuclear receptor interacting protein 1 10.6

130367 Z38501 Hs.8768 ESTs; Weakly similarto 111! ALU SUBFA 8.3

130378 T47333 Hs.155188 TATA box binding protein (TBP)-associa 7.1

130384 X66364 Hs.166071 cyclin-dependent kinase 5 5.6

130393 D13630 Hs.155291 KIAA0005 gene product 4.1

130399 AA449417 Hs.155356 Homo sapiens mRNA for putative glucosy 4.6

130407 N29888 Hs.155410 ESTs 7

130414 M21121 Hs.241392 small inducible cytokine A5 (RANTES) 4.1

130417 U58522 Hs.155485 huntingtin-interacting protein 2 7.9

130421 D21260 Hs.178710 clathrin; heavy polypeptide-like 2 4

130441 U35835 Hs.155637 protein kinase; DNA-a ivated; catalytic p 6.8

130455 X17059 Hs.155956 N-acetyltransferase 1 (arylamine N-acetyl 26.4

130498 L38951 Hs.180446 karyopherin (importin) beta 1 4.8

130499 AA416723 Hs.158286 Homo sapiens mRNA for KIAA0446 prat 6.1

130511 L32137 Hs.1584 cartilage oligomeric matrix protein (pseud 8.3

130553 AA430032 Hs.252587 pituitary tumor-transforming 1 7.5

130558 H96654 Hs.15984 ESTs; Weakly similar to gene pp21 protei 5.6

130568 AA232535 Hs.16085 ESTs; Highly similar to CGI-13 protein [H 4

130583 W24957 Hs.293907 ESTs; Moderately similar to similar to Ce 13.3

130585 H66211 Hs.16331 ESTs 10.1

130604 X03635 Hs.1657 estrogen receptor 1 39.9

130614 AA132007 Hs.16697 ESTs 5.1

130619 AA477739 Hs.12532 ESTs 5.9

130622 AA235247 Hs.16846 ESTs; Weakly similar to cytochrome P45 4.1

130625 F03969 Hs.260720 matrix metalloproteinase 2 (gelatinase A; 8.3

130627 L23808 Hs.1695 matrix metalloproteinase 12 (macrophage 10.3

130629 M60346 Hs.1697 ATPase; H+transporting; lysosomal (vacu 7

130635 M87503 Hs.1706 interferon-stimulated transcription factor 5.5

130639 D59711 Hs.17132 ESTs 7.2

130677 H17861 Hs.17767 ESTs 13.5

130681 D82808 Hs.17820 Rho-associated; coiled-coil containing pro

130693 AA487202 Hs.17962 ESTs 6.1

130703 N63295 Hs.18103 ESTs 4.3

130706 AA488843 Hs.201673 cornichon-like 4

130712 AA292066 Hs.279762 adenylate cyclase 7 5.1

130714 X92896 Hs.18212 DNA segment on chromosome X (unique) 8.4

130715 T98227 Hs.171952 occludin 5.7

130744 AA203527 Hs.18747 POP7 (processing of precursor; S. cerevis 6.2

130747 AA471293 Hs.6879 ESTs 8.2

130751 AA435633 Hs.18879 Homo sapiens clone 23965 mRNA sequen 8.3

130796 R39390 Hs.19525 ESTs 4.5

130800 AA223386 Hs.19574 ESTs; Weakly similarto katanin p80 subu 7.7

130855 AA425439 Hs.143323 putative DNA/chromatin binding motif 4.3

130859 AA287327 Hs.20478 ceroid-lipofuscinosis; neuronal 2; late infa 9.8

130866 M58028 Hs.2055 ubiquitin-activating enzyme E1 (A1S9T a 4.3

130880 D14678 Hs.20830 kinesin-like 2 4.5

130891 D31891 Hs.20991 SET domain; bifurcated; 1 4 130905 AA056489 Hs.129998 ESTs 8.7

130913 W03592 Hs.21198 translocase of outer mitochondrial membr 20.9

130919 AA291710 Hs.21276 collagen; type IV; alpha 3 (Goodpasture a 9

130921 AA074596 Hs.194688 bromodomain adjacent to zinc finger dom 5.3

130944 M97935 Hs.21486 signal transducer and activator of transcrip 18.8

130974 X57985 Hs.2178 H2B histone family; member Q 13.4

130987 R45698 Hs.21893 ESTs; Weakly similarto cAMP inducible 8.5

130999 N48963 Hs.21992 KIAA0689 protein 7.2

131010 AA435748 Hs.169341 ESTs; Weakly similar to phosphatidic acid 5.2

131046 X02530 Hs.2248 small inducible cytokine subfamily B (Cy 10.1

131091 T35341 Hs.22880 ESTs; Highly similarto dipeptidyl peptid 6.3

131153 H11760 Hs.23606 ESTs 7.3

131185 M25753 Hs.23960 cyclin B1 6.2

131200 AA609427 Hs.293732 ESTs; Moderately similarto !!!! ALU SU 4.3

131206 AA044078 Hs.24210 ESTs 5.5

131210 AA430047 Hs.95549 ESTs 7.1

131227 AA429472 Hs.236522 DKFZP434P106 protein 5.6

131244 D38076 Hs.24763 RAN binding protein 1 5.5

131245 AA620599 Hs.24766 DKFZP564E1962 protein 6.7

131257 AA256042 Hs.24908 ' ESTs 5.8

131319 U25997 Hs.25590 stanniocalcin 8.9

131339 AA463450 Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 6.5

131388 R34531 Hs.92200 KIAA0480 gene product 9.2

131410 H84658 Hs.279836 ESTs 12.1

131472 AA608962 Hs.27258 calcyclin binding protein 18.1

131475 Z39053 Hs.27263 ESTs 7.5

131501 AA121127 Hs.8207 H3 histone; family 3A 5.5

131514 X02152 Hs.2795 lactate dehydrogenase A 5.1

131524 N39152 Hs.301804 ESTs 4.3

131528 D60856 Hs.28309 UDP-glucose dehydrogenase 8.4

131544 N33236 Hs.28555 ESTs; Weakly similarto B0511.8 [C.eleg 5.6

131557 D30946 Hs.28707 signal sequence receptor; gamma (transloc 8.7

131562 U90551 Hs.28777 H2A histone family; member L 18.8

131564 AA491465 Hs.28792 ESTs 11.8

131586 AA235385 Hs.26966 ESTs; Moderately similar to alternatively 4.7

131587 M15182 Hs.183868 glucuronldase; beta 5.2

131589 U52100 Hs.29191 epithelial membrane protein 2 4.4

131615 D14533 Hs.192803 xeroderma pigmentosum; complementatio 4.6

131664 AA136126 Hs.30327 mitogen-activated protein kinase-activated 4.3

131679 AA136660 Hs.30579 ESTs 9.4

131684 U26174 Hs.3066 granzyme K (serine protease; granzyme 3 9.7

131687 L11066 Hs.3069 heat shock 70kD protein 9B (mortalin-2) 6.2

131689 AA599653 Hs.30696 transcription factor-like 5 (basic helix-loo 8.3

131693 W60913 Hs.110796 ESTs; Weakly similar to cDNA EST yk45 9

131710 AA233225 Hs.30985 MRS1 protein 5.2

131716 D49738 Hs.31053 cytoskeleton-associated protein 1 6.6

131742 D31352 Hs.31433 ESTs 11

131762 H46831 Hs.107767 ESTs; Moderately similar to CaM-KII inh 4.9

131781 AA460450 Hs.31989 DKFZP586G1722 protein 9.2

131795 N32724 Hs.32317 Sox-like transcriptional fador 4.5

131809 L76517 Hs.3260 presenilin 1 (Alzheimer disease 3) 5.4

131814 AA437226 Hs.157 interleukin 10 receptor; alpha 4

131838 AA091932 Hs.180628 dynamin-like protein 6.7

131877 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 5

131885 AA044095 Hs.3402 ESTs 11.1

131891 AA158258 Hs.30376 heterogeneous nuclear protein similarto r 5.6

131925 AA248470 Hs.183180 ESTs; Weakly similar to RING finger pro 4.5

131930 AA205460 Hs.69476 ESTs 14.3

131941 D62657 Hs.35086 ubiquitin-specific protease 1 6.2

131965 W90146 Hs.35962 ESTs 6.3

131970 D86960 Hs.3610 KIAA0205 gene product 4.2

131971 R70167 Hs.154938 ESTs 4.3

131974 AA410424 Hs.268122 Homo sapiens mRNA; cDNA DKFZp586 4.6

131977 F09788 Hs.3622 procollagen-proline; 2-oxoglutarate 4-diox 6.4

131994 AA479515 Hs.279882 Human DNA sequence from clone 703H1 12

131997 D82399 Hs.136644 Homo sapiens clone 23714 mRNA sequen 10

132017 W67251 Hs.267659 Homo sapiens vav 3 oncogene (VAV3) m 4.7 132021 T68246 Hs.306079 chaperonin containing TCP1; subunit 5 (e 5.2

132065 D82226 Hs.211594 proteasome (prosome; macropain) 26S sub 8.5

132085 D44466 Hs.3887 proteasome (prosome; macropain) 26S sub 13.5

132089 AA131971 Hs.39122 ESTs 4.8

132109 AA599801 Hs.40098 ESTs 6.2

132143 AA257056 Hs.7972 KIAA0871 protein 14.6

132149 T10822 Hs.324743 ESTs 5.3

132153 N90141 Hs.41066 ESTs; Moderately similar to ELONGATI 9.2

132160 AA281770 Hs.295923 seven in absentia (Drosophila) homolog 1 5.5

132164 U84573 Hs.41270 procollagen-lysine; 2-oxoglutarate 5-dioxy 8.1

132180 AA405569 Hs.418 fibroblast activation protein; alpha; sepras 15.4

132183 L19183 Hs.199695 hypothetical protein 12.2

132225 AA128980 ESTs 5.6

132227 AA412620 Hs.4248 ESTs 6.7

132235 F09058 Hs.42656 ESTs 6.2

132256 AA608856 Hs.431 murine leukemia viral (bmi-1) oncogene h 6

132298 N41849 Hs.7120 Homo sapiens cytokine receptor related p 5.6

132314 AA285290 Hs.44499 small EDRK-rich factor 2 6.8

132325 N37065 Hs.44856 ESTs 4.7

132384 AA479933 Hs.46967 Human DNA sequence from clone 167A1 4.2

132387 R70914 Hs.281434 heat shock 70kD protein 1 9.1

132393 W85888 Hs.47334 ESTs; Moderately similarto !!!! ALU SU 4

132406 F09979 Hs.4774 ESTs 15

132407 AA431459 Hs.47783 ESTs 8

132413 AA132969 Hs.260116 KIAA1104 protein 4

132446 AA426218 Hs.48764 ESTs 5.3

132465 AA047896 Hs.49169 ESTs 15.4

132482 AA429478 Hs.238126 ESTs; Highly similar to CGI-49 protein [H 9

132492 T03749 Hs.4990 KIAA1089 protein 8.5

132528 AA283006 Hs.50758 chromosome-associated polypeptide C 4.3

132540 AA488987 Hs.5097 synaptogyrin 2 9.8

132543 AA417152 Hs.5101 protein regulator of cytokinesis 1 10.1

132580 L37042 Hs.283738 casein kinase 1; alpha 1 5.9

132586 AA412452 Hs.52515 DKFZP434N024 protein 4.2

132608 AA199588 Hs.5321 ARP3 (actin-related protein 3; yeast) horn 4.2

132616 AA386264 Hs.283558 isocitrate dehydrogenase 2 (NADP+); mit 5.2

132617 AA171913 Hs.5338 carbonic anhydrase XII 10.1

132618 AA253330 Hs.279916 adaptor-related protein complex 1; gamma 4.8

132640 U33821 Hs.5437 Taxi (human T-cell leukemia virus type I 5.7

132668 AA453614 Hs.5460 KIAA0776 protein 4.4

132694 M60830 Hs.5509 ecotropic viral integration site 2B 15.6

132700 N47109 Hs.5521 ESTs 7

132724 AA417962 Hs.55498 geranylgeranyl diphosphate synthase 1 5.6

132738 W42674 Hs.264636 ESTs; Moderately similarto neuronal thre 4.9

132742 AA490862 Hs.292812 ESTs; Weakly similar to C43H8.1 [C.eleg 7.9

132744 X54326 Hs.55921 glutamyl-prolyl-tRNA synthetase 4.1

132795 H99152 Hs.57079 ESTs 8

132807 AA331777 Hs.57301 mutL (E. coli) homolog 1 (colon cancer; n 8

132811 U25435 Hs.57419 transcriptional repressor 4

132817 AB004884 Hs.57553 tousled-like kinase 2 6.5

132840 N23817 Hs.5807 Homo sapiens clone 23675 mRNA sequen 5.6

132845 D62588 Hs.5813 ESTs 12.4

132847 T48195 Hs.58189 eukaryotic translation initiation factor 3; s 7

132856 W79865 Hs.58367 glypican 4 6.2

132869 N26855 Hs.203961 ESTs 6.5

132874 AA425776 Hs.58609 ESTs 5.6

132880 AA444369 Hs.177537 ESTs 7.2

132894 D82422 Hs.5944 ESTs 7.5

132900 N56451 Hs.5978 LIM domain only 7 4.4

132903 AA235404 Hs.5985 Homo sapiens clone 25186 mRNA sequen 9.1

132904 X83618 Hs.59889 3-hydroxy-3-methylglutaryl-CoenzymeA 10.7

132906 AA142857 Hs.234896 ESTs; Highly similar to gemiπiπ [H.sapie 10.2

132914 AA496037 Hs.60293 ESTs 4.7

132918 AA252605 Hs.6051 KIAA0616 protein 7.1

132936 AB002305 Hs.6111 KIAA0307 gene product 8.3

132951 U04209 Hs.61418 microfibrillar-associated protein 1 4.3

132957 AA234791 Hs.61469 Human gene from PAC 753P9; chromoso 13.2 132959 AA028103 Hs.61472 ESTs; Weakly similarto unknown [S.cere 18.9

132968 N77151 Hs.61638 myosin X 5.8

132984 H80409 Hs.62112 zinc finger protein 207 4.3

132990 AA458761 Hs.18387 transcription factor AP-2 alpha (activating 4.2

132994 AA505133 Hs.279905 solute carrier family 2 (facilitated glucose 26.4

132998 Y00062 Hs.170121 protein tyrosine phosphatase; receptor typ 4.4

133002 AF006082 Hs.42915 ARP2 (actin-related protein 2; yeast) horn 4.7

133005 C21400 Hs.278605 KIAA0970 protein 6.6

133015 AA047036 Hs.246315 ESTs 7.9

133016 W81298 Hs.6289 growth factor receptor-bound protein 2 5.2

133039 X62055 Hs.63489 protein tyrosine phosphatase; non-recepto 4

133050 S67325 Hs.63788 propionyl Coenzyme A carboxylase; beta 5.2

133056 AA071387 Hs.6396 jumping translocation breakpoint 5

133062 R33663 Hs.64056 ESTs 5.4

133083 N70633 Hs.6456 chaperonin containing TCP1; subunit 2 (b 6

133091 AA122147 Hs.64691 KIAA0483 protein 5

133093 AA598749 Hs.285996 ESTs 5.6

133124 AA156049 Hs.267923 ESTs 4.1

133126 D16469 Hs.6551 ATPase; H+ transporting; lysosomal (vacu 6.2

133196 R37367 Hs.6727 Ras-GTPase activating protein SH3 doma 5.1

133214 Y10659 Hs.285115 interleukin 13 receptor; alpha 1 6.2

133225 241415 Hs.6823 ESTs; Weakly similar to intrinsic factor-B 8.3

133228 N90029 Hs.6831 Homo sapiens clone 1400 unknown prate 4.7

133239 AA059405 Hs.179882 Homo sapiens clone 24655 mRNA sequen 5.5

133240 D31161 Hs.242894 ESTs 9

133257 AF006086 Hs.6895 actin related protein 2/3 complex; subunit 7.7

133264 W72187 Hs.69192 ESTs; Weakly similar to cDNA EST yk37 6.7

133274 AA488886 Hs.6949 ESTs 4.2

133281 AA421079 Hs.69594 ESTs; Weakly similarto Sox-like transcri 4.9

133283 AA410507 Hs.6968 ESTs 4.3

133287 L15702 Hs.69771 B-factor; properdin 9.3

133294 R79723 Hs.69997 zinc finger protein 238 30.4

133297 AA600057 Hs.70266 KIAA0905 protein 10.4

133318 AA256168 Hs.152316 ESTs 8.5

133362 H06195 Hs.7194 ESTs; Highly similarto CGI-59 protein [H 14

133370 AA156897 Hs.72157 DKFZP564I1922 protein 5

133391 X57579 Hs.727 inhibin; beta A (activin A; activin AB alp 13.9

133395 AA491296 Hs.72805 ESTs 4.3

133422 N79516 Hs.73287 ESTs; Weakly similarto eyelid [D.melano 4.5

133431 AA255438 Hs.7358 Homo sapiens mRNA; cDNA DKFZp566 8

133435 T23983 Hs.323966 ESTs 5

133449 AA094989 Hs.7381 voltage-dependent anion channel 3 8.7

133468 X03068 Hs.73931 major hlstocompatibility complex; class II 5

133484 X78710 Hs.211581 metal-regulatory transcription factor 1 5.3

133506 AA316868 Hs.74346 ESTs; Weakly similar to 140G11.h [D.me 6.8

133517 X52947 Hs.74471 gap junction protein; alpha 1; 43kD (conn 5.7

133551 D63480 Hs.278634 KIAA0146 protein 4.8

133569 AA313977 Hs.172772 transcription elongation factor B (Sill); po 9.5

133572 W94333 Hs.279915 translocase of inner mitochondrial membr 5

133577 F03717 Hs.75063 human immunodeficiency virus type I enh 7.4

133589 L37368 Hs.75104 RNA-binding protein S1; serine-rich do 5

133608 D13315 Hs.75207 glyoxalase I 4.2

133617 AA148318 Hs.75249 KIAA0069 protein 4.5

133627 U09587 Hs.75280 glycyl-tRNA synthetase 10

133633 D21262 Hs.75337 nucleolar phosphoprotein p130 4.5

133634 U24166 Hs.234279 microtubule-associated protein; RP/EB fa 15.2

133640 D83004 Hs.75355 ubiquitin-conjugating enzyme E2N (homo 9.1

133644 D89077 Hs.75367 Src-like-adapter 6.4

133649 AA479139 Hs.75393 acid phosphatase 1; soluble 4.8

133652 AA287383 Hs.7540 ESTs 4.2

133674 AA458946 Hs.75497 ESTs 4.3

133700 K01396 Hs.297681 protease inhibitor 1 (anti-elastase); alpha- 8.3

133705 N21648 Hs.75659 MpV17 transgene; murine homolog; glom 4.6

133716 Y00282 Hs.75722 ribophorin II 7.5

133720 L27841 Hs.75737 pericentriolar material 1 9.4

133752 U49278 Hs.75875 ubiquitin-conjugating enzyme E2 variant 4.5

133765 D21255 Hs.75929 cadherin 11 (OB-cadherin; osteoblast) 6.4 133772 W73693 Hs.76038 isopentenyl-diphosphate delta isomerase 7.9

133774 Z23090 Hs.76067 heat shock 27kD protein 1 4.1

133776 J03473 Hs.177766 ADP-ribosyltransferase (NAD+; poly (AD 13

133784 AA214305 Hs.301064 ESTs 5.2

133814 M33882 Hs.76391 myxovirus (influenza) resistance 1; homol 11.7

133829 AA453783 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564 9.4

133834 AA147510 Hs.288660 serine protease; umbilical endothelium 4.8

133839 M59815 Hs.170250 complement component 4A 6.7

133842 U73477 Hs.2850 3 putative human HLA class II associated p 7.1

133845 T68510 Hs.76704 ESTs 6.3

133859 U86782 Hs.178761 26S proteasome-associated padl homolog 13.7

133867 D43948 Hs.76989 KIAA0097 gene product 4.1

133868 U58090 Hs.183874 cullin 4A 4

133871 AA454597 Hs.182793 ESTs 4.7

133893 X01060 Hs.77356 transferrin receptor (p90; CD71) 8.3

133914 N32811 Hs.77542 ESTs 5

133918 W72783 Hs.58382 ESTs; Weakly similarto C13F10.5 [C.ele 4.5

133944 AA045870 Hs.7780 Homo sapiens mRNA; cDNA DKFZp564 6.3

133946 AA156565 Hs.173878 4-nitrophenylphosphatase domain and non 6.4

133963 L34587 Hs.184693 transcription elongation factor B (Sill); po 6.3

133980 D00760 Hs.250811 proteasome (prosome; macropain) subunit 11.9

133990 C02374 Hs.7822 Homo sapiens mRNA; cDNA DKFZp564 8.2

133999 M28213 Hs.78305 RAB2; member RAS oncogene family 5.2

134030 J03077 Hs.78575 prosaposin (variant Gaucher disease and v 4.6

134032 Z81326 Hs.78589 protease inhibitor 12 (neuroserpin) 6.5

134045 S82470 Hs.78768 BB1 11.9

134046 D28473 Hs.172801 isoleucine-tRNA synthetase 5.2

134064 D87685 Hs.78893 KIAA0244 protein 7.3

134070 H98621 Hs.78946 cullin 3 4.7

134087 U51166 Hs.173824 fhymine-DNA glycosylase 7

134090 M22382 Hs.79037 heat shock 60kD protein 1 (chaperonin) 4.5

134098 X06323 Hs.79086 ribosomal protein; mitochondrial; L3 9.4

134110 U41060 Hs.79136 LIV-1 protein; estrogen regulated 4.4

134132 U32519 Hs.220689 Ras-GTPase-activating protein SH3-doma 6.6

134168 AA398908 Hs.181634 Human Chromosome 16 BAC clone CIT9 8.6

134170 M63138 Hs.79572 cathepsin D (lysosomal aspartyl protease) 9.3

134208 U88871 Hs.79993 peroxisomal biogenesis factor 7 6.3

134258 L28010 Hs.808 heterogeneous nuclear ribonucleoprotein F 4.3

134288 AA430008 Hs.8117 ESTs 6.9

134310 AA313414 Hs.8148 Homo sapiens clone 24856 mRNA sequen 7.4

134326 U16306 Hs.81800 chondroitin sulfate proteoglycan 2 (versic 6.1

134329 D38551 Hs.81848 RAD21 (S. pombe) homolog 8.6

134331 AA452020 Hs.111222 ESTs; Weakly similarto CGI-128 protein 6.1

134351 R82074 Hs.82109 syndecan 1 4.4

134357 L43575 Hs.82171 Human clone 191B7 placenta expressed m 6.6

134363 M37033 Hs.82212 CD53 antigen 5.3

134367 X54199 Hs.82285 phosphoribosylglycinamide formyltransfe 4.8

134374 D62633 Hs.8236 ESTs 15.2

134375 AA412720 Hs.82389 ESTs; Highly similar to CGI-118 protein 7.2

134376 X02874 Hs.82396 2';5'-oligoadenylate synthetase 1 6.4

134381 U56637 Hs.184270 capping protein (actin filament) muscle Z- 4

134388 M15841 Hs.82575 small nuclear ribonucleoprotein polypepti 5.7

134395 L09717 Hs.8262 lysosomal-associated membrane protein 2 6.9

134399 H99801 Hs.82689 tumor rejection antigen (gp96) 1 4.5

134401 AA243746 Hs.211577 kinectin 1 (kinesin receptor) 11.2

134405 J04177 Hs.82772 collagen; type XI; alpha 1 15.3

134415 AA329274 Hs.82911 protein tyrosine phosphatase type IVA; 4.1

134417 D87969 Hs.82921 solute carrier family 35 (CMP-sialic acid t 4.2

134419 L08044 Hs.82961 trefoil factor 3 (intestinal) 5.9

134421 AA122386 Hs.82985 collagen; type V; alpha 2 5.8

134423 W96151 Hs.83006 ESTs; Highly similarto CGI-139 protein 4.4

134438 AA449984 Hs.246857 ESTs; Highly similar to proteine kinase JN 7

134446 T25732 Hs.83419 KIAA0252 protein 4.6

134453 X70683 Hs.83484 SRY (sex determining region Y)-box 4 5.1

134470 X54942 Hs.83758 CDC28 protein kinase 2 20.3

134487 R38185 Hs.83954 Homo sapiens unknown mRNA 5

134495 D63477 Hs.84087 K1AA0143 protein 16.1 134498 M63180 Hs.84131 threonyl-tRNA synthetase 6.1

134506 U45328 Hs.84285 ubiquitin-conjugating enzyme E2I (homol 4.6

134529 H24460 Hs.848 FK506-biπding protein 4 (59kD) 6.2

134570 U66615 Hs.172280 SWI/SNF related; matrix associated; actin 4.8

134582 AA234966 Hs.86041 CGG triplet repeat binding protein 1 4.7

134600 R68884 Hs.86347 ESTs; Weakly similar to predicted using G 5.8

134623 X74496 Hs.86978 prolyl endopepfidase 4.5

134654 W23625 Hs.8739 ESTs; Weakly similar to ORF YGR200c [ 13.7

134655 AA454070 Hs.123090 ESTs 5.8

134675 AA250745 Hs.87773 protein kinase; cAMP-dependent; catalyti 8.9

134711 X04011 Hs.88974 cytochrome b-245; beta polypeptide (chro 6.8

134714 U89922 Hs.890 lymphotoxin beta (TNF superfamily; mem 35.7

134722 W47183 Hs.284226 ESTs; Weakly similarto neural F box pro 8.1

134776 J05582 Hs.89603 mucln l; transmembrane 6.2

134806 Z49099 Hs.89718 spermine synthase 4.2

134810 M27394 Hs.89751 membrane-spanning 4-domains; subfamily 7

134840 U51477 Hs.89981 diacylglycerol kinase; zeta (104kD) 4.1

134843 H60595 Hs.90061 progesterone binding protein 4.7

134853 D82348 Hs.90280 5-aminoimidazole-4-carboxamide ribonuc 10.2

134866 U84011 Hs.904 amylo-1 ;6-g lucosidase; 4-alpha-g lucanotr 12.1

134868 Z39762 Hs.90419 KIAA0882 protein 6

134885 N27670 Hs.9071 progesterone membrane binding protein 5

134982 N46086 Hs.92308 ESTs 4.1

134989 AA236324 Hs.92381 Homo sapiens mRNA; chromosome 1 spe 16.8

134992 H05625 Hs.5831 ESTs 4

134993 AA282343 Hs.301005 purine-rich element binding protein B 4.4

135010 D59675 Hs.92927 ESTs 7

135015 U54999 Hs.278338 LGN protein 4.8

135029 AA224180 ESTs; Moderately similarto 17-beta-hydr 13.6

135032 AA243497 Hs.173685 Human DNA sequence from clone 30M3 4

135037 U77948 Hs.278589 general transcription factor II; i 8

135059 AA598449 Hs.93832 Homo sapiens clone 24483 unknown mRN 5.4

135071 L08069 Hs.94 heat shock protein; DNAJ-like 2 9.3

135083 AA495950 Hs.94262 ESTs 6.7

135117 W52493 Hs.94694 Homo sapiens clone 24837 mRNA sequen 10.2

135144 AA044842 Hs.95260 Homo sapiens mRNA; cDNA DKFZp586 6.6

135154 AA126433 Hs.267812 sorting nexin 4 7.4

135218 D31157 Hs.324277 ESTs; Weakly similar to growth factor-res 6.2

135237 AA454930 Hs.9691 ESTs 19.5

135243 AA215333 Hs.97101 putative G protein-coupled receptor 8.8

135335 H20989 Hs.198281 pyruvate kinase; muscle 12.4

135349 D83174 Hs.9930 collagen-binding protein 2 (colligen 2) 5.5

135367 AA480109 Hs.9963 TYRO protein tyrosine kinase binding pro 5.4

135389 U05237 Hs.99872 fetal Alzheimer antigen 7.8

135400 M23263 Hs.99915 androgen receptor (dihydrotestosterone re 9.1

135411 L10333 Hs.99947 reticulon 1 5.3

300019 M97935 AFFX control: STAT1 8.3

300021 M97935 AFFX control: STAT1 7

300022 M97935 AFFX control: STAT1 14

300089 AI199738 Hs.208275 ESTs; Weakly similar to HI! ALU CLASS 9.1

300107 AI694585 Hs.270464 ESTs; Weakly similarto lϋ! ALU CLASS 7.4

300254 AW079607 Hs.188417 ESTs; Weakly similar to ZnT-3 [H.sapien 30.1

300328 AW015860 Hs.224623 ESTs 11.9

300549 AA699328 Hs.298119 ESTs 5.5

300711 AI492179 Hs.166244 ESTs; Weakly similarto cDNA EST yk40 11

300921 AW293224 Hs.232165 ESTs 11

301124 T79326 Hs.298262 ESTs; Weakly similar to dJ88J8.1 [H.sapi 8.8

301165 N85789 Hs.150186 ESTs; Weakly similarto PTERIN-4-ALP 6

301576 AI682905 Hs.270431 ESTs; Weakly similarto HI! ALU SUBFA 4.7

301604 AA373124 Hs.24809 ESTs; Weakly similar to C1 G10.1 [C.ele 8

301704 AA526313 Hs.293691 ESTs 4.2

301782 N99399 Hs.143046 EST cluster (not in UniGene) with exon h 18

301884 AA312082 Hs.105445 GDNF family receptor alpha 1 20.7

301936 NM_004694Hs.114924 EST cluster (not in UniGene) with exon h 11.6

302002 AF013956 Hs.5637 chramobox homolog 4 (Drosophila Pc da 9.2

302032 NM 001992Hs.128087 EST cluster (not in UniGene) with exon h 4.3

302067 H05698 Hs.222399 ESTs; Weakly similarto protein-tyrosine 7.8 302145 NM 003613HS.151407 EST cluster (not in UniGene) with exon h 15.1

302236 AH28606 Hs.6557 zinc finger protein 161 25.8

302276 NM_004448Hs.323910 EST cluster (not in UniGene) with exon h 21.6

302290 AL117607 Hs.175563 Homo sapiens mRNA; cDNA DKFZp564 41.4

302326 NM_004271Hs.184018 EST cluster (not in UniGene) with exon h 8.9

302342 AB023141 Hs.190386 KIAA0924 protein 5.4

302372 AL117406 Hs.200102 Homo sapiens mRNA; cDNA DKFZp434 8.9

302422 AB021227 Hs.3743 matrix metalloproteinase 24 (membrane-in 5.2

302431 AF129530 Hs.226434 EST cluster (not in UniGene) with exon h 5.3

302501 AF022726 Hs.251446 EST cluster (not in UniGene) with exon h 9.9

302505 AL049650 Hs.247874 multiple UniGene matches 4.3

302533 L36149 Hs.248116 chemokine (C motif) XC receptor 1 4.9

302638 AA463798 Hs.102696 ESTs; Weakly similar to C11D2.4 [C.eleg 5.3

302656 AW293005 Hs.70704 ESTs 8.4

302792 AA343696 Hs.46821 ESTs; Weakly similarto putative [H.sapie 4.5

302820 X04588 Hs.85844 EST cluster (not in UniGene) with exon h 6.8

302838 U66049 Hs.82171 EST cluster (not in UniGene) with exon h 8.4

302892 N58545 Hs.42346 histone deacetylase 3 22.8

302977 AW263124 Hs.315111 EST cluster (not in UniGene) with exon h 6.8

302989 N46406 Hs.84700 EST cluster (not in UniGene) with exon h 8.9

303007 AA478876 Hs.317714 pallid (mouse) homolog; pallidin 10.1

303052 AF140242 Hs.279926 EST cluster (not in UniGene) with exon h 24.4

303131 AW081061 Hs.103180 actin-like 6 6.3

303132 AI929819 Hs.4055 ESTs 17.7

303153 U09759 Hs.246857 mitogen-activated protein kinase 9 11.4

303387 AA908797 Hs.180799 ESTs 15.8

303499 AI815990 Hs.293515 ESTs 7.2

303502 AA488528 EST cluster (not in UniGene) with exon h 5.3

303576 T07216 Hs.301226 EST cluster (not in UniGene) with exon h 16.2

303620 AA397546 Hs.119151 ESTs 8.9

303634 AI953377 Hs.28444 ESTs; Weakly similarto predicted using G 12

303642 AW299459 Hs.111977 EST cluster (not in UniGene) with exon h 4.2

303654 AA436942 Hs.288529 ESTs 8.4

303733 AW502498 Hs.15220 ESTs; Weakly similar to zinc finger prote 5.2

303780 AI424014 Hs.18995 ESTs; Moderately similarto KIAA0456 p 28.4

303792 C75094 Hs.199839 ESTs; Highly similarto NG22 [H.sapiens 4.4

303842 AI337304 Hs.126268 ESTs; Weakly similar to similar to PDZ d 8.1

303951 AW475081 Hs.172928 collagen; type I; alpha 1 7.5

304465 AA421948 EST singleton (not in UniGene) with exon 6.5

304507 AA456426 EST 5.4

304591 AA505702 EST singleton (not in UniGene) with exon 9.8

304601 AA507875 EST singleton (not in UniGene) with exon 7.5

304659 AA533185 EST singleton (not in UniGene) with exon 7

305040 AA630582 Hs.169476 glyceraldehyde-3-phosphate dehydrogena 12.4

305134 AA653159 Hs.179661 EST singleton (not in UniGene) with exon 8.7

305415 AA725116 Hs.78465 EST singleton (not in UniGene) with exon 5.3

305453 AA738110 EST singleton (not in UniGene) with exon 4.1

305898 AA872838 keratin 8 7.7

305913 AA876109 EST singleton (not in UniGene) with exon 6.3

305950 AA884479 EST singleton (not in UniGene) with exon 5.6

306004 AA889992 Hs.2186 EST singleton (not in UniGene) with exon 13.2

306009 AA894560 Hs.283370 EST singleton (not in UniGene) with exon 4.4

306060 AA906161 Hs.76277 EST singleton (not in UniGene) with exon 4.6

306398 AA970548 Hs.297681 EST singleton (not in UniGene) with exon 7.6

306505 AA987722 Hs.172928 EST singleton (not in UniGene) with exon 19.7

306576 AA995761 Hs.276092 EST singleton (not in UniGene) with exon 5.5

307117 AI184111 Hs.76067 heat shock 27kD protein 1 7.7

307138 AI185516 Hs.172928 collagen; type I; alpha 1 8.8

307187 AI190870 Hs.276417 EST singleton (not in UniGene) with exon 4.1

307542 AI280859 Hs.62954 EST singleton (not in UniGene) with exon 6

307554 AI281603 Hs.172928 EST singleton (not in UniGene) with exon 10.8

307806 A1351739 Hs.276726 EST singleton (not in UniGene) with exon 4.7

308079 AI472733 Hs.270208 ESTs 4.2

308307 AI581398 Hs.172928 collagen; type I; alpha 1 5.4

308511 AI687580 Hs.169476 EST singleton (not in UniGene) with exon 10.1

308615 AI738593 Hs.101774 EST singleton (not in UniGene) with exon 15.1

308677 AI761173 EST singleton (not in UniGene) with exon 4.6 308852 AI829848 Hs.182937 peptidylprolyl isomerase A (cyclophilin A 5.9

308974 AI872290 Hs.300697 immunoglobulin gamma 3 (Gm marker) 4.5

308981 AI873242 EST singleton (not in UniGene) with exon 7.6

308995 AI880172 EST singleton (not in UniGene) with exon 6.6

309177 A1951118 EST singleton (not in UniGene) with exon 24.3

309186 AI952723 Hs.90207 EST singleton (not in UniGene) with exon 6.1

309198 AI955915 major histocompatibility complex; class I; 5.6

309226 AI969897 EST singleton (not in UniGene) with exon 6.2

309279 AI990102 EST singleton (not In UniGene) with exon 7.9

309583 AW170035 EST 64.5

309624 AW191929 Hs.252989 EST 5.3

309629 AW192764 Hs.172928 collagen; type I; alpha 1 6.9

309641 AW194230 Hs.253100 EST 11.4

309698 AW238461 Hs.73742 ribosomal protein; large; P0 4.3

309700 AW241170 Hs.179661 Homo sapiens clone 24703 beta-tubulin m 11.9

310073 AI335004 Hs.148558 ESTs 4.2

310094 AW450967 Hs.235240 ESTs 5.7

310373 AW080778 Hs.145582 ESTs 4.8

310438 AW022192 Hs.200197 ESTs 39.1

310470 AI281848 Hs.194691 ESTs 4.9

310583 AW205632 Hs.211198 ESTs 7

310877 T47784 Hs.188955 ESTs 4.1

311067 AI587332 Hs.209115 ESTs 11.2

311166 AI821294 Hs.118599 ESTs 24.1

311199 T57896 Hs.191095 EST cluster (not in UniGene) 5.7

311465 A1758660 Hs.206132 ESTs 15.7

311587 AI828254 Hs.271019 ESTs 6.4

311774 AA700870 Hs.14304 ESTs 6.2

311785 AI056769 Hs.133512 ESTs 5

311923 T60843 Hs.189679 ESTs 5.9

311935 AA216387 EST cluster (not in UniGene) 5.5

311972 N51511 Hs.188449 ESTs 5.2

312014 AI435650 Hs.128778 ESTs 4.3

312047 AA588275 Hs.180669 ESTs 14.7

312147 T89855 Hs.195648 EST cluster (not in UniGene) 9.8

312153 AA759250 Hs.153028 cytochrome b-561 27.1

312168 T92251 Hs.198882 ESTs 4.2

312172 AI222168 Hs.191168 ESTs 6.1

312226 A1796815 Hs.199993 ESTs; Weakly similar to ubiquitous TPR 5.5

312292 AW451893 Hs.151124 ESTs 18.4

312312 AI080505 Hs.134529 ESTs 11.9

312369 AA582039 Hs.173884 Homo sapiens mRNA; chromosome 1 spe 4

312407 R46180 Hs.153485 ESTs 13.6

312430 AW139117 Hs.117494 ESTs 4.1

312470 AW451347 Hs.175862 ESTs 4.6

312483 AI417526 Hs.7753 ESTs 15.3

312521 AA033609 Hs.319093 ESTs 12.5

312544 AI498371 Hs.183526 ESTs 14.6

312638 AW439195 Hs.256880 ESTs 5.3

312754 R99834 Hs.250383 ESTs 8.4

312772 H63791 EST cluster (not in UniGene) 4.3

312821 AA699325 Hs.269880 ESTs 8.3

312837 AW292286 Hs.255058 ESTs 7.1

312849 AA846353 Hs.194054 ESTs 5.9

312854 AA828713 Hs.321058 EST cluster (not in UniGene) 4.1

312992 AA088446 Hs.170298 ESTs 7.3

313096 AI422367 Hs.163533 ESTs 6.1

313112 AA732534 Hs.269099 ESTs 4.2

313126 AA720887 Hs.283313 EST cluster (not in UniGene) 18.1

313136 N59284 Hs.288010 ESTs 17

313197 AI738851 Hs.222487 ESTs 12.9

313219 N74924 Hs.182099 ESTs 7.1

313258 AW068358 Hs.183918 ESTs 13.7

313328 AW449211 Hs.105445 ESTs 27.9

313352 AW292127 Hs.144758 ESTs

313417 AA741151 Hs.137323 ESTs 8.2

313455 AW081702 Hs.98571 ESTs 6.9 313590 AA804410 Hs.291677 EST cluster (not in UniGene) 5.3

313663 AI953261 Hs.169813 ESTs 7.6

313667 U69201 Hs.13684 ESTs; Weakly similar to choline kinase is 12.5

313749 AW450376 Hs.119004 ESTs 5.5

313832 AW271022 Hs.133294 ESTs 4.3

313881 AA535580 Hs.16331 ESTs 7.7

313915 AI969390 Hs.163443 ESTs 27.1

313955 AI858884 Hs.270647 ESTs 5.7

313974 AI310151 Hs.173524 ESTs 4.3

314097 AA648744 Hs.269493 ESTs 14.5

314129 AA228366 Hs.115122 ESTs 9.5

314359 AA205569 Hs.194193 ESTs 5.4

314384 AA535840 Hs.162203 ESTs; Weakly similarto alternatively spli 5.3

314394 AI380563 Hs.130816 ESTs 13.2

314462 AA347951 Hs.326413 ESTs 6.2

314465 AA602917 Hs.156974 ESTs 18.1

314470 AI934422 Hs.30661 ESTs ' 4.2

314488 AA358265 Hs.182890 ESTs 6.1

314506 AA833655 Hs.206868 ESTs 27.8

314510 AI204418 Hs.190080 ESTs 9.5

314558 AI873274 Hs.190721 ESTs 22.5

314661 AA436432 Hs.324239 EST cluster (not in UniGene) 13.3

314691 AW207206 Hs.136319 ESTs 21.4

314754 AW026761 Hs.134374 ESTs 4.4

314775 AI149880 Hs.188809 ESTs 4.4

314943 AI476797 Hs.184572 cell division cycle 2; G1 to S and G2 to M 18.4

314961 AW008061 Hs.231994 ESTs 10.2

314963 AI689617 Hs.200934 ESTs 5.3

315006 AI538613 Hs.298241 ESTs 20.7

315010 AA531082 Hs.240049 ESTs 5

315019 AA532807 Hs.105822 ESTs 6.1

315033 A1493046 Hs.146133 ESTs 12

315036 AA534953 Hs.163297 ESTs 8.3

315037 AW205863 Hs.133988 ESTs; Weakly similar to gene MAC25 pr 6.1

315051 AW292425 Hs.163484 EST 12.7

315054 AI968598 Hs.78768 ESTs 7.6

315073 AW452948 Hs.257631 ESTs 13.9

315080 AA744550 Hs.136345 ESTs 4.4

315083 AI221325 Hs.205442 ESTs 5.1

315088 AA557351 Hs.152448 ESTs; Moderately similarto MULTIFUN 4.7

315175 AI025842 Hs.152530 ESTs 11.9

315196 AA972756 Hs.44898 ESTs 28.8

315296 AA876905 Hs.125286 ESTs 16.1

315303 AW194364 Hs.128022 ESTs; Weakly similarto FIG-1 PROTEIN 25.7

315352 AA604799 Hs.136528 ESTs; Moderately similarto III! ALU SU 12.3

315364 AA643602 Hs.155485 ESTs; Highly similarto serine protease [H 4.6

315368 AW291563 Hs.104696 ESTs 4.8

315390 AI801565 Hs.200113 ESTs; Weakly similar to alternatively spli 4.4

315408 AW273261 Hs.216292 ESTs 5

315458 AA872000 Hs.116104 ESTs 7.6

315472 AA828850 Hs.165469 ESTs 4.9

315478 AA665612 Hs.120874 ESTs 5.2

315498 AA628539 Hs.116252 ESTs; Moderately similarto llll ALU SU 4.8

315527 AI791138 Hs.116768 ESTs 4.4

315530 AI200852 Hs.127780 ESTs 22.4

315562 AA737415 Hs.152826 ESTs 5.9

315634 AA837085 Hs.220585 ESTs

315647 AA648983 Hs.212911 ESTs 15

315652 A1521489 Hs.3053 ESTs 6.3

315676 AW002565 Hs.124660 ESTs 9.2

315680 AA814309 Hs.123583 ESTs 8.1

315735 AI831760 Hs.155111 ESTs 13.4

315741 AA812168 Hs.122559 ESTs 5.4

315769 AA744875 Hs.189413 ESTs 4.4

315978 AA830893 Hs.119769 ESTs 10.4

315984 AI015862 Hs.131793 ESTs 5

316042 AW297979 Hs.170698 ESTs 14.7 316136 AA830808 Hs.124366 ESTs 4

316177 AI908272 Hs.293102 EST cluster (not in UniGene) 32.6

316313 AA741300 Hs.202599 ESTs 4.8

316405 AA757900 Hs.270823 ESTs 4.8

316480 AI749921 Hs.205377 ESTs 12.9

316564 AI743571 Hs.168799 ESTs; Weakly similar to !!!! ALU SUBFA 8.1

316714 AA809792 Hs.123307 ESTs 5

316715 AI440266 Hs.170673 ESTs 4.2

316828 AA828116 Hs.173076 ESTs 5.2

316869 AI954880 Hs.134604 ESTs 13.3

316905 AW138241 Hs.210846 ESTs 6.2

316943 AW014875 Hs.137007 ESTs 5.3

316949 AA856749 Hs.124620 ESTs 7.2

317008 AW051597 Hs.143707 ESTs 4.1

317028 AA962623 Hs.189144 ESTs; Weakly similarto RENAL SODIU 4.2

317067 AI805392 Hs.325335 ESTs 4.5

317069 AI732892 Hs.190489 ESTs 6.4

317210 AA490718 EST cluster (not in UniGene) 4.4

317298 AI922374 Hs.158549 ESTs 5.9

317658 AW139077 Hs.202217 ESTs 4.6

317674 AW294909 Hs.132208 ESTs 5.2

317685 AI798630 Hs.149997 ESTs 4.3

317836 AA983913 Hs.128929 ESTs 12.4

317881 AI827248 Hs.224398 ESTs 12.1

317902 AI828602 Hs.211265 ESTs 8.8

317916 AI565071 Hs.159983 ESTs 12.6

318042 AW294522 Hs.149991 ESTs 5.6

318053 AI074465 Hs.133469 ESTs 4

318064 AW296888 Hs.170939 ESTs 5.2

318070 AI024594 Hs.248942 ESTs 4.7

318073 AW167087 Hs.131562 ESTs 15.7

318146 AI040125 Hs.150521 ESTs 5.9

318186 AW016773 Hs.3709 ESTs 5.3

318481 AI291584 Hs.145921 ESTs; Weakly similarto HYPOTHETICA 7.6

318566 AI335361 Hs.226376 ESTs 5.8

318617 AW247252 Hs.75514 nucleoside phosphorylase 11.1

318662 AI285898 Hs.294014 ESTs 16.3

318691 AW192139 Hs.181307 H3 histone; family 3A 4

318740 NM 002543Hs.77729 EST cluster (not in UniGene) 21.3

318744 AI793124 Hs.144479 ESTs 35

318948 AA317274 Hs.13996 ESTs 11.7

319163 F15257 Hs.27 glycine dehydrogenase (decarboxylating; 7

319478 R06841 Hs.270307 EST cluster (not in UniGene) 8.9

319545 R83716 Hs.14355 ESTs 8.2

319668 NM 002731 Hs.87773 EST cluster (not in UniGene) 25.4

319763 AA460775 Hs.6295 ESTs 7

319913 AA179304 Hs.271586 ESTs; Moderately similar to !!!! ALU SU 8.7

319936 W22152 Hs.282929 EST cluster (not in UniGene) 5.6

319951 AA307665 Hs.14559 ESTs 4.9

319962 H06350 Hs.135056 ESTs 9.2

319977 AA632632 EST cluster (not in UniGene) 4.6

320074 AA321166 Hs.278233 EST cluster (not in UniGene) 16.7

320092 AF022799 Hs.113292 calpain 9 (nCL-4) 5.4

320107 AA836461 Hs.291712 EST cluster (not in UniGene) 5.3

320133 D63271 EST cluster (not in UniGene) 5.5

320167 AA984373 Hs.90790 EST cluster (not in UniGene) 15

320187 T99949 Hs.303428 EST cluster (not in UniGene) 6.7

320211 AL039402 Hs.125783 DEME-6 protein 24.3

320401 U90449 Hs.152717 nucleoside diphosphate kinase type 6 (inh 10

320458 AI884396 Hs.24131 ESTs 5.4

320488 R31386 Hs.191791 EST cluster (not in UniGene) 4.9

320521 N31464 Hs.24743 ESTs 9.5

320661 AA864846 Hs.115175 EST cluster (not in UniGene) 6.6

320691 R61576 Hs.313951 hypothetical protein 5.9

320699 R63161 Hs.118249 EST cluster (not in UniGene) 4

320727 U96044 Hs.181125 EST cluster (not in UniGene) 15.3

320993 AL050145 Hs.225986 Homo sapiens mRNA; cDNA DKFZp586 7.2 321012 AA737314 Hs.194324 EST cluster (not in UniGene) 6.1

321050 AW393497 EST cluster (not in UniGene) 5

321051 AF134149 Hs.240395 EST cluster (not in UniGene) 11.4

321171 AI769410 Hs.221461 ESTs 7.7

321192 AA295304 Hs.297939 ESTs; Weakly similarto neogenin [H.sap 5.5

321354 AA078493 EST cluster (not in UniGene) 16.9

321387 H68014 Hs.141278 ESTs; Weakly similar to !!!! ALU SUBFA 4.2

321412 AW366305 Hs.22891 EST cluster (not in UniGene) 6.3

321489 AW392474 Hs.172759 ESTs; Moderately similarto 111! ALU SU 9

321539 N98619 Hs.42915 ARP2 (actin-related protein 2; yeast) horn 11.3

321593 H84762 Hs.253197 ESTs 10.4

321666 D28390 Hs.272897 EST cluster (not in UniGene) 19.9

321891 AW157424 Hs.165954 ESTs 5.6

321910 H67065 Hs.271530 ESTs; Weakly similar to III! ALU SUBFA 5.4

321953 AW068268 Hs.292833 ESTs; Weakly similar to !!!! ALU CLASS 6.5

321978 N77342 Hs.21851 EST cluster (not in UniGene) 10.2

322017 AA310039 Hs.9192 ESTs 9.8

322026 AA233527 Hs.283675 low density lipoprotein receptor (familial 27.8

322035 AL137517 Hs.306201 EST cluster (not in UniGene) 40.2

322171 AF085968 Hs.48474 EST cluster (not in UniGene) 5.7

322175 AF085975 EST cluster (not in UniGene) 7.7

322236 AL134970 Hs.104222 follistatin-like 1 14.4

322303 W07459 Hs.157601 EST cluster (not in UniGene) 13.4

322735 AA086123 Hs.297856 EST cluster (not in UniGene) 7.6

322777 AA679082 Hs.269947 ESTs 4.4

322818 AW043782 Hs.293616 ESTs 21

322882 AW248508 Hs.279727 DiGeorge syndrome critical region gene 2 15.3

322975 C16391 EST cluster (not in UniGene) 21.3

322991 C18965 Hs.159473 ESTs 11.7

323011 AA580288 EST cluster (not in UniGene) 8.9

323091 AW014094 Hs.210761 ESTs 10.8

323107 AI301107 Hs.150790 ESTs 6.5

323136 AL120351 Hs.30177 EST cluster (not in UniGene) 5.5

323168 AL120862 Hs.124165 ESTs 17.9

323195 AI064982 Hs.117950 multifunctional polypeptide similar to SA 5.8

323201 AL049370 Hs.13350 Homo sapiens mRNA; cDNA DKFZp586 11.6

323203 AA203135 Hs.130186 ESTs 6.4

323243 W44372 Hs.110771 EST cluster (not in UniGene) 7.3

323244 T70731 Hs.193620 EST cluster (not in UniGene) 15.8

323328 AA228078 Hs.255096 EST cluster (not in UniGene) 4.8

323332 AI829520 Hs.227513 ESTs 20.2

323333 AA228883 Hs.208558 EST cluster (not in UniGene) 8.8

323570 AL038623 Hs.208752 ESTs; Weakly similarto llll ALU SUBFA 5

323604 AI751438 Hs.41271 ESTs; Weakly similarto !!!! ALU SUBFA 6.5

323685 AA344205 Hs.289088 EST cluster (not in UniGene) 7.1

323753 AA327102 Hs.70266 EST cluster (not in UniGene) 6.1

323817 AA410943 EST cluster (not in UniGene) 16.8

323845 AI684674 Hs.41127 ESTs; Weakly similarto waclaw [D.melan 10.1

323930 AA570698 Hs.8173 ESTs 6.4

323997 AA844907 Hs.274454 EST cluster (not in UniGene) 8

324047 AA378201 Hs.271340 EST cluster (not in UniGene) 6.3

324261 AL044891 Hs.269350 EST cluster (not in UniGene) 50.1

324302 AA543008 Hs.292471 ESTs; Weakly similarto !!!! ALU SUBFA 5.7

324338 AL138357 Hs.145078 ESTs 9.5

324344 AW502000 Hs.46677 EST cluster (not in UniGene) 4.4

324432 AA464510 Hs.152812 EST cluster (not in UniGene) 16.7

324495 AW501411 Hs.122489 ESTs; Weakly similar to 111! ALU CUSS 5.5

324497 AW152624 Hs.136340 ESTs 5.4

324598 AA502659 Hs.163986 ESTs

324603 AW016378 Hs.292934 ESTs 23.1

324620 AA448021 Hs.94109 EST cluster (not in UniGene) 21.2

324727 AI610425 Hs.19597 ESTs 5

324774 AI031771 Hs.132586 ESTs 5

324783 AA640770 Hs.200994 EST cluster (not in UniGene) 4.1

324824 AI826999 Hs.224624 ESTs 6.3

324826 AA704806 Hs.143842 ESTs 11.7

324902 D31323 Hs.271492 ESTs 4.8 324961 AA613792 EST cluster (not in UniGene) 13.3

324987 T06882 Hs.172634 ESTs 19.6

324988 T06997 Hs.121028 EST cluster (not in UniGene) 24.5

325146 AI064690 Hs.171176 ESTs 4.6

325622 CH.14 hs gi|5867000 5.2

326213 CH.17 hs gi|5867224 8.1

326474 CH.19 hsgi|5867405 12.7

326816 CH.20 hs gi[6552458 9.4

326817 CH.20 hs gi|6552458 11.7

327110 CH.21 hs gi|6117842 14.7

327196 CH.01 hs gi|5867446 5.1

327283 CH.01 hs gi|5867478 4.3

327313 CH.01 hs gi|5867501 4.8

327450 CH.02 hs gi|5867766 4.1

328059 CH.06 hs gi|6117819 6.2

328304 CH.07 hsgi[6004478 5.4

328492 CH.07 hs gi|5868455 7

328857 CH.07 hs gi|6381927 5.2

329367 CH.X hs gi|5868842 7.6

329373 CH.X_hs gi|6682537 12

329655 CH.14 p2 gi|6448516 4

329899 CH.15 p2 gi|6563505 4

329960 CH.16 p2 gi|5091594 7.6

330084 CH.19_p2 gi|6015302 4

330384 M23263 androgen receptor (dihydrotestosterone re 5.8

330385 AA449749 ESTs; Highly similarto secreted apoptosi 10.2

330387 H14624 ESTs; Highly similar to secreted apoptosi 4.4

330388 X03363 HER2 receptor tyrosine kinase (c-erbB-2; 17.7

330409 D50692 Hs.78221 c-myc binding protein 10.1

330460 TIGR:HT544 Hs.73946 Endothelial Cell Growth Factor 1 5.5

330486 M13755 Hs.833 interferon-stimulated protein; 15 kDa 67

330494 M29696 Hs.237868 interleukin 7 receptor 6

330500 M34423 Hs.79222 galactosidase; beta 1 13.1

330510 M75099 Hs.227729 FK506-binding protein 2 (13kD) 29

330513 M81057 Hs.180884 carboxypeptidase B1 (tissue) 38.5

330541 U22970 Hs.265827 multiple UniGene matches 7.4

330542 U23942 Hs.226213 cytochrome P450; 51 (lanosteral 14-alpha 15

330547 U32989 Hs.183671 tryptophan 2;3-dioxygenase 11

330551 U39840 Hs.299867 hepatocyte nuclear factor 3; alpha 6.5

330562 U49082 Hs.76460 transporter protein 7.7

330573 U62800 Hs.83393 cystatin E/M 4

330673 D57823 Hs.321403 Sec23 (S. cerevisiae) homolog A 10.5

330711 AA164687 Hs.177576 mannosyi (alpha-1 ;3-)-glycoprotein beta-1 24.3

330814 AA015730 Hs.265398 ESTs; Weakly similar to traπsformation-r 44.1

330850 AA075298 Hs.322710 ESTs 4.4

330874 AA127474 Hs.191157 ESTs; Weakly similarto HI! ALU SUBFA 8.1

330884 AA133457 Hs.102548 ESTs 5.2

330912 AA195936 Hs.82719 general transcription factor IIA; 1 (37kD a 5

330924 AA232136 Hs.159737 Homo sapiens mRNA; cDNA DKFZp434 9.1

330997 H55762 Hs.9302 ESTs 7.6

331014 H98597 Hs.30340 ESTs 13.5

331024 N32919 Hs.27931 ESTs 9.1

331046 N66563 Hs.191358 ESTs 10.5

331135 R61398 Hs.4197 ESTs 7.4

331145 R72427 Hs.129873 ESTs; Weakly similarto CYTOCHROME 41.9

331148 R73816 Hs.17385 ESTs 4.7

331222 T98531 Hs.173904 ESTs 4.1

331230 W69807 Hs.16537 hypothetical protein; similarto (U06944) 4.9

331306 AA252079 Hs.63931 dachshund (Drosophila) homolog 15.1

331327 AA281076 Hs.109221 ESTs 4.8

331337 AA287662 Hs.50495 ESTs 7.6

331341 AA303125 Hs.23240 ESTs; Weakly similar to 111! ALU SUBFA 13

331344 AA357927 Hs.126550 ESTs 12.4

331362 AA417956 Hs.40782 ESTs 6.5

331363 AA421562 Hs.91011 anterior gradient 2 (Xenepus laevis) homo 28.2

331376 AA443802 Hs.41007 ESTs; Weakly similar to cDNA EST yk47 15.1

331384 AA456001 Hs.93847 ESTs 7.9 331478 N26608 Hs.40639 ESTs 7

331526 N49967 Hs.46624 ESTs 19.8

331533 N51517 Hs.47282 ESTs 6.5

331681 W85712 Hs.119571 collagen; type III; alpha 1 (Ehlers-Danlos 13.8

331686 W88502 Hs.182258 ESTs 9.9

331750 AA284372 Hs.111471 ESTs 5.6

331751 AA284840 Hs.143818 ESTs 5.8

331760 AA292721 Hs.154434 ESTs; Weakly similar to unknown [H.sap 7.4

331763 AA312861 Hs.96704 ESTs 7.8

331825 AA411144 Hs.292882 ESTs 15.2

331890 AA432166 Hs.3577 succinate dehydrogenase complex; subuni 24.3

331952 AA454756 Hs.97837 ESTs 5

332015 AA487910 Hs.208800 ESTs; Weakly similar to III! ALU CLASS 10.5

332043 AA490831 Hs.125056 ESTs 11.4

332060 AA504779 Hs.191402 ESTs 13.6

332071 AA598594 Hs.205293 ESTs 9.1

332093 AA608794 Hs.112592 ESTs 8.8

332139 AA620669 Hs.112879 EST 9

332219 N22508 Hs.139315 ESTs 7.1

332225 N33213 Hs.100425 ESTs 12.2

332246 N57927 Hs.120777 ESTs; Weakly similarto RNA POLYME 15.6

332247 N58172 Hs.109370 ESTs 16.9

332260 N70088 Hs.138467 ESTs 4

332269 N91279 Hs.109654 ESTs; Moderately similar to outer membr 8.2

332336 T96130 Hs.137551 ESTs 7.7

332340 W15495 Hs.129781 chromosome 21 open reading frame 5 14.1

332347 W60326 Hs.288684 ESTs 4.4

332362 W93640 Hs.4779 ESTs; Moderately similar to similar to AD 16.9

332467 AA489630 Hs.119004 KIAA0665 gene product 4.8

332499 M12036 Hs.323910 Human tyrosine kinase-type receptor (HE 10.4

332513 AA018182 Hs.154424 deiodiπase; Iodothyranine; type II 5.8

332526 AA281753 Hs.77515 inositol 1;4;5-triphosphate receptor; type 19

332532 N63192 Hs.1892 EST; Highly similarto PHENYLETHAN 15.3

332565 AA234896 Hs.25272 E1A binding protein p300 12.3

332607 R41791 Hs.36566 LIM domain kinase 1 11.1

332640 AA417152 Hs.5101 protein regulator of cytokinesis 1 18.2

332694 AA262768 Hs.243901 KIAA1067 protein 15.2

332702 H93968 Hs.75725 transgelin 2 4.7

332705 T59161 Hs.76293 thy osin; beta 10 5.5

332749 AA479968 Hs.88251 arylsulfatase A 9.8

332927 CH22 FGENES.38 1 17.7

332929 CH22 FGENES.38_3 4.7

332930 CH22_FGENES.38_4 7.4

332955 CH22_FGENES.48_12 5.4

332958 CH22 FGENES.48J5 17.8

332961 CH22 FGENES.48 18 10.6

332983 CH22 FGENES.54 5 4.3

333009 CH22 FGENES.61J 5.2

333010 CH22 FGENES.6U 8.1

333013 CH22 FGENES.61_5 8.5

333108 CH22 FGENES.79J4 5.6

333139 CH22_FGENES.83_16 6.3

333254 CH22 FGENES.118_2 6.8

333305 CH22 FGENES.137_2 11.4

333343 CH22_FGENES.139_12 5.1

333388 CH22 FGENES.144_3 12.7

333456 CH22 FGENES.157_5 4.2

333459 CH22 FGENES.157J 7.6

333517 CH22 FGENES.173 2 8.2

333585 CH22 FGENES.203_4 5

333679 CH22 FGENES.247_6 4.3

333743 CH22 FGENES.264 1 13.4

333758 CH22 FGENES.268 1 4

333767 CH22 FGENES.271 6 5.6

333768 CH22 FGENES.271 7 12.2

333769 CH22 FGENES.271J 48.3

333795 CH22_FGENES.275_1 6.1 333796 CH22_FGENES.275_3 6.8 333892 CH22_FGENES.292_14 4.4 333904 CH22_FGENES.294_2 6.5 333905 CH22_FGENES.294_3 9.3 333921 CH22_FGENES.296_12 9.6 333968 CH22_FGENES.307_4 15.9 334102 CH22_FGENES.327_60 7.1 334222 CH22_FGENES.360_3 6.7 334223 CH22_FGENES.360_4 33.5 334264 CH22_FGENES.367_15 18.5 334343 CH22_FGENES.375_25 6.1 334360 CH22_FGENES.378_5 6.1 334784 CH22_FGENES.432_9 4.8 334789 CH22_FGENES.432_14 5.1 334794 CH22_FGENES.434_2 7 334889 CH22_FGENES.452_3 12.4 335004 CH22_FGENES.472_8 7.9 335115 CH22_FGENES.496_2 18.8 335287 CH22_FGENES.526_11 4.5 335342 CH22_FGENES.536_1 5.3 335491 CH22_FGENES.570_23 24 335495 CH22_FGENES.570_28 7 335498 CH22_FGENES.571_7 12.2 335544 CH22_FGENES.576_5 8.4 335610 CH22_FGENES.583_4 12.9 335653 CH22_FGENES.590_4 6.7 335682 CH22_FGENES.595_2 12.1 335687 CH22_FGENES.596_2 13.9 335755 CH22_FGENES.604_4 11.5 335782 CH22_FGENES.609_4 17.9 335791 CH22_FGENES.611_7 27.3 335809 CH22_FGENES.617_6 19.2 335822 CH22_FGENES.619_7 19.1 335823 CH22_FGENES.619_8 4.5 335824 CH22_FGENES.619_11 40.2 335825 CH22_FGENES.619_12 34.3 335895 CH22_FGENES.635_3 10.2 335917 CH22_FGENES.636_13 6 335920 CH22_FGENES.636_16 8.8 336035 CH22_FGENES.678_6 5.9 336042 CH22_FGENES.679_4 5.8 336093 CH22_FGENES.691_2 11.6 336096 CH22_FGENES.691_5 7.6 336150 CH22_FGENES.706_6 6.3 336152 CH22_FGENES.706_9 10.5 336416 CH22_FGENES.823_38 5 336444 CH22_FGENES.827_10 4.8 336449 CH22_FGENES.829_6 13.6 336471 CH22_FGENES.829_30 6.9 336512 CH22_FGENES.834_7 21.4 336558 CH22_FGENES.842_3 8.2 336560 CH22_FGENES.842_5 9 336676 CH22_FGENES.43-4 9.4 336959 CH22_FGENES.367-13 19 337968 CH22_EM:AC005500.GENSCAN.103-2 13.4 338008 CH22_EM:AC005500.GENSCAN.127-9 15.2 338057 CH22_EM:AC005500.GENSCAN.160-1 13.9 338410 CH22_EM:AC005500.GENSCAN.341-6 338451 CH22_EM:AC005500.GENSCAN.359-3 11.6 338588 CH22_EM:AC005500.GENSCAN.432-1 10.3 338665 CH22_EM:AC005500.GENSCAN.464-2 4.8 338689 CH22_EM:AC005500.GENSCAN.475-3 6.7 338832 CH22_DJ246D7.GENSCAN.6-9 4.8 338980 CH22_DA59H18.GENSCAN.2-4 5.1 339352 CH22_BA354H2.GENSCAN.29-7 6.9 339373 CH22_BA232E17.GENSCAN.1-29 4.3 TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigenelD's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

123619 371681 AA602964 AA609200 103207 30635_-4 X72790 103349 11052_-2 X89059

110856 19346J4 AA992380 N33063 N21418 H79958 R21911 H79957 113248 328626J T63857 AW971220 AA493469 T63699

123169 44573_2 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517

AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 A1858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273

AA969759 N75628 N22388 H84729 H60052 T92487 A1022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 123533 genbank_AA608751 AA608751

116480 genbank_C14088 C14088 132225 genbank_AA128980 AA128980

125154 genbank_W38419 W38419

118475 genbank_N66845 N66845

102919 25180_2 M21191 AL035748 AA021266 AA323126 AA180515 AI613029 D28356 NM_000034 M11560 AW401425 AW248248 AA012956 AA323294 W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367

AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385 AA054395 H30840 AW498825 AA086141 AI557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257 AW176086 AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 C04921 AA345696 R89640 AA085425 AA481708 AA313637 AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854

AA192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 AI366131 H14328 AA197161 AA379497 AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921 AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789 AW362775 AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553

R87925 AA292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW372969 AA337549 AA327342 H93855 AI074079 F29118 AA852940 F35696 AA345963 AA079578 AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 AI909845 AW374374 AW374382 AW374401 AW374373 AW374370 AI909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 AI525039

H13744 R31007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149 AA806213 AA481936 C04941 AW375299 M21190 AA410818 AA250940 AI354547 AA317422 AA250903 AI865497 AA890603 AA366197 AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393 AW376830 AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811

H44129 N84794 F01135 AA477852 AA293062 AW361595 H27194 AI831650 H43253 H24797 AI564680 AA380090 W20057 AI921586 AI192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00946 C03986 AI318091 AI860172 AA582179 AI633388 AA557193 R68075 F24105 AW518239 W56622 AI625219 AI925243 AW468046 AI921828 AA339164 AI144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 AI680458 AA159956 AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 AI630871 AI633128 AW514329 AA010455 AA563928 AI571596 AI128394 W73707 AI423575 AA583809 AA657988 AI950837 AA169782 AA600009 AI885540 AA771884 AI978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 AI905695 AA480115 AA574051

AI889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 AI038538 AA411329 AA781570 AI833176 AA935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 AI460085 AA193244 AI538037 AA515572 AA758587 AI149311 AA508610 AA206409 AA534004 AA994600 AA827543 AI916349 AW245129 AW517804 D25663 AA781985 AA284536 AI819422 H16040 H27531 AA456564 AA845555 AI423596 AA012908 AA889439 AA716311 AA968868 AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 AI342442 AI003519 AI002503 AI347597

AI040946 AA197162 AA987883 AA292865 AW001944 AI640711 AW244044 AA456784 F30588 AA290829 H24754 AI978683 AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204 AW513025 AA628543 AA583705 F25702 AI368748 AI124097 A1880086 AA477513 AI758834 AI690753 AA477746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 AI569314 AA961665 AI922050 AI759000 AA555236 AA514432 AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 AI361315 AA284988 F36340 AI361322

F26969 AA991922 AA021267 F26973 AI361314 F35891 AI918509 AA250964 AA190992 AA577139 AA865535 AA134324 AW192842 AI224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007 AI830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921 T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259 AA179789 AA088908 H43704 AA194320 F35950 AI880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390

AI302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301 A1025737 AA101239 AA088887 AI214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715 F37529 AI811549AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245 AA331222 F25634 F21996 W28215 F21911 R65793 AI192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411

H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455 F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 F24835 F34672 F26474 AI926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297 AI937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863 F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566

F34230 F33258 F20860 F17998 AI695701 118600 genbank_N69222 N69222

118952 genbank_N92966 N92966

120873 genbank_AA358015 AA358015 113702 genbank_T97307 T97307

129982 221_267 Z14221 AW381862 M97920AW401444Z66542 M29470AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165

AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991

AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 AI268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080

D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z9289B U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF1 4067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520

AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664

AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 115763 genbank_AA421560 AA421560

124357 genbank_N22401 N22401

108733 504187J AA121022 AA126422 101544 entrez_M31169 M31169

124447 genbank_N48000 N48000 124677 genbank_R01073 R01073

124777 genbank_R41933 R41933

119302 genbank_T25725 T25725 103680 entrez_Z93784Z93784

135029 H58818_at H58818

112253 genbank_R51818 R51818

Pkey CAT number Accession

322175 46877J AF085975 H53458 H53459

323011 139750J AA580288 AA315655 AA133031 AA377748

322975 1510563 J C16391 C16413

317210 211994J AW881145 AA490718 M85637 AA304575 T06067 AA331991

323817 233566 AA410943 AW948953 AA334202 AA332882

309583 1046029_-2 AW170035

324961 376239J AA613792 AW182329 T05304 AW858385

303502 325188J BE174240AA488528AL042253

320133 447553.1 BE151746 BE336853 D63271 T94955 AA774994

311935 174129J AA216387 T63548 AA228676

321050 502195J C05928AW393497

319977 345248J AA534222 AA632632 T81234

312772 4380_7 AW962299 AA310349 AW962294 H63791 H63751

321354 116028_-2 AA078493

336512 CH22_3941FG_834_7_LINK_DJ

336558 CH22_3992FG_842_3_LINK_DJ

336560 CH22_3994FG_842_5_LINK_DJ

329367 c_x_hs

329373 c x hs

336676 CH22_4154FG_43_4_

338008 CH22_6490FG__LINK_EM:ACOO

338057 CH22_6558FG_LINKJΞM:AC00

329655 c14_p2

336959 CH22_4764FG_367_13_

329899 c15_p2

329960 c16_p2

338410 CH22_7O67FG_LINK_EM:AC00

338451 CH22_7124FG_LINK_EM:AC00

338588 CH22_7331FG_LINK_EM:AC00

338665 CH22_7438FG_LINK_EM:AC00

338689 CH22_7464FG__LINK_EM:AC00

308677 AI761173

338832 CH22_7678FG_LINK_DJ246D7

338980 CH22_7859FG__LINK_DA59H18

333009 CH22_233FG_61_1_LINK_EM:A

333010 CH22_234FG_61_2_LINK_EM:A

333013 CH22_237FG_61_5_LINK_EM:A

308981 AI873242

308995 AI880172

333108 CH22_336FG_79_14_LINK_EM:

333139 CH22_368FG_83_16_LINK_EM:

333254 CH22_495FG_118_2_LINK_EM;

333305 CH22_550FG_137_2_UNK_EM:

333343 CH22_589FG_139_12_LIN _EM

333388 CH22_634FG_144_3_LINK_EM:

326213 c17_hs

333456 CH22_706FG_157_5_LINK_EM:

333459 CH22_709FG_157_8_LINK_EM:

333517 CH22_773FG_173_2_LINK_EM:

333585 CH22_846FG_203_4_LINK_EM:

333679 CH22_941 FG_247_6_LINK_EM:

326474 c19 hs

333743 CH22J 009FG_264_1_LINK_EM

333758 CH22J 024FG_268_1_LINK_EM

333767 CH22_1034FG_271_6_LINK_EM

333768 CH22_1035FG_271_7 LINK_EM

333769 CH22_1036FG_271_8_LINK_EM

333795 CH22_1063FG_275_1_LINK_EM

333796 CH22_1065FG_275_3_L1NK_EM

335004 CH22_2326FG_472_8_UN _EM

333892 CH22_1163FG_292_14_LINK_E

335115 CH22_2447FG_496_2_LINK_EM

333904 CH22_1176FG_294_2_LINK_EM 333905 CH22_1177FG_294_3_LINK_EM

333921 CH22_1194FG_296_12_LINK_E

333968 CH22_1245FG_307_4_LINK_EM

328059 c_6_hs 335287 CH22_2629FG_526_11_LINK_E

326816 c20_hs

326817 c20 hs

335342 CH22_2689FG_536_1_LINK_EM

335491 CH22_2843FG_570_23_LINK_E 335495 CH22_2847FG_570_28_LINK_E

335498 CH22_2850FG_571_7_LINK_EM

328304 c_7_hs

305453 AA738110

335544 CH22_2899FG_576_5_LINK_EM 335610 CH22_2969FG_583_4_LINK_EM

335653 CH22_3013FG_590_4_LINK_EM

335682 CH22_3043FG_595_2_UNK_EM

335687 CH22_3048FG_596_2_LINK_EM

328492 c_7_hs 335755 CH22_3122FG_604_4_LINK_EM

335782 CH22_3151FG_609_4_LINK_EM

335791 CH22_3160FG_611_7_LINK_EM

335809 CH22_3181FG_617_6_LINK_EM

335822 CH22_3195FG_619_7_LINK_EM 335823 CH22_3196FG_619_8_LINK_EM

335824 CH22_3197FG_619_11_LINK_E

335825 CH22_3198FG_619_12_LINK_E 335895 CH22_3272FG_635_3_LINK_EM 335917 CH22_3294FG_636_13_LINK_E 335920 CH22_3297FG_636_16_LINK_E

305898 AA872838

305913 AA876109

305950 AA884479

328857 c_7_hs 330084 c19_p2

337968 CH22_6419FG_LINK_EM:AC00

309177 AI951118

309198 AI955915

309226 AI969897 339352 CH22_8317FG_UNK_BA354I1

309279 AI990102

339373 CH22_8348FG_UNK_BA232E1

325622 c14_hs

334102 CH22 1380FG_327_60_LINK_E 332927 CH22_148FG_38_1_LINK_C20H

332929 CH22_150FG_38_3_LINK_C20H

332930 CH22_151FG_38_4_LINK_C20H 332955 CH22_179FG_48_12_LINK_EM: 332958 CH22_182FG_48_15_LINK_EM: 332961 CH22_185FG_48_18_LINK_EM:

332983 CH22_207FG_54_5_LINK_EM:A

334222 CH22_1506FG_360_3_LINK_EM

334223 CH22_1507FG_360_4_LINK_EM 334264 CH22_1551FG_367_15_LINK_E 327110 c21_hs

334343 CH22_1636FG_375_25_LINK_E

334360 CH22_1654FG_378_5_LINK_EM

327196 cjjis

327283 c_1_hs 327313 c_1_hs

304465 AA421948

304507 AA456426

327450 c_2_hs

304591 AA505702 304601 AA507875

304659 AA533185

334784 CH22_2096FG_432_9_UNK_EM 334789 CH22_2101FG 432_14_LINK_E 334794 CH22_2106FG 434_2_LINK_EM 336035 CH22_3420FG 678_6_LINK_DJ 336042 CH22_3427FG 679_4_LINK_DJ 336093 CH22_3481FG 691_2_LINK_DJ 336096 CH22_3484FG 691_5_LINK_DJ 334889 CH22_2206FG 452_3_LINK_EM 336150 CH22_3540FG 706_6_LINK_DA 336152 CH22_3543FG 706_9_UNK_DA 336416 CH22_3833FG 823_38_LINK_B 336444 CH22_3864FG 827_10_LINK_D 336449 CH22_3870FG 829_6_LINK_DJ 336471 CH22_3894FG 829_30_LINK_D

TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand: Indicates DNA strand from which exons were predicted. N position: Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition

332955 Dunham ,,, I. etal. Plus 2508896-2508992 332958 Dunham, , I. etal. Plus 2516164-2516310 332961 Dunham ,, I. etal. Plus 2521424-2521555 333139 Dunham; , I. etal. Plus 3369495-3369571 333254 Dunham i,, I. etal. Plus 2521424-2521555 333305 Dunham; , I. etal. Plus 4630388-4630645 333388 Dunham i,, I. etal. Plus 49137494913805 333517 Dunham , I. etal. Plus 5570729-5570925 333585 Dunham i,, I. etal. Plus 6234778-6234894 333679 Dunham; , I. etal. Plus 7068795-7068896 333767 Dunham ,, I. etal. Plus 7694407-7694623 333768 Dunham ',, I. etal. Plus 7695440-7695697 333769 Dunham , I. etal. Plus 7696625-7696707 333795 Dunham, , I. etal. Plus 7807688-7807795 333796 Dunham, , I. etal. Plus 7808253-7808319 333892 Dunham i,, I. etal. Plus 8156825-8157001 333921 Dunham i,, I. etal. Plus 8380325-8380441 333968 Dunham i,, I. etal. Plus 8681004-8681241 334102 Dunham i,, I. etal. Plus 9995140-9996373 334264 Dunham i,, 1. etal. Plus 13234447-13234544 334343 Dunham i,, I. etal. Plus 13655828-13656307 334794 Dunham ι,, l. etal. Plus 16374312-16374458 334889 Dunham, , I. etal. Plus 19286024-19286515 335287 Dunham ,,, I. etal. Plus 22299047-22299299 335491 Dunham, , I. etal. Plus 24128651-24128827 335495 Dunham, , I. etal. Plus 24140688-24140872 335498 Dunham , I. etal. Plus 24172082-24172161 335653 Dunham, , I. etal. Plus 25329710-25329802 335687 Dunham i:, I. etal. Plus 25445952-25446064 335809 Dunham, , I. etal. Plus 26310772-26310909 335822 Dunham i,, I. etal. Plus 26364087-26364196 335823 Dunham i,, I. etal. Plus 26365925-26366004 335824 Dunham, , I. etal. Plus 26376860-26376942 335825 Dunham i,, I. etal. Plus 26378175-26378268 336035 Dunham , I. etal. Plus 29016748-29017410 336093 Dunham i,, I. et.al. Plus 29556922-29557002 336096 Dunham , I. etal. Plus 29578878-29579047 336444 Dunham i,, I. et.al. Plus 34190585-34190718 336959 Dunham i,, I. etal. Plus 13233040-13233126 338008 Dunham i,, I. et.al. Plus 7697068-7697236 338057 Dunham i,, I. etal. Plus 8526397-8526522 338410 Dunham i,, I. etal. Plus 19292807-19292916 338588 Dunham i,, I. etal. Plus 22896767-22896920 338665 Dunham i,, I. etal. Plus 24472654-24472853 338832 Dunham ;,, I. etal. Plus 27775128-27775290 338980 Dunham i,, I. etal. Plus 29896789-29896874 339352 Dunham i,, I. etal. Plus 33544784-33545121 332929 Dunham, . et.al. Minus 2020758-2020664

332930 Dunham, . etal. Minus 2022565-2022497

332983 Dunham, . etal. Minus 2631933-2631797

333009 Dunham, . etal. Minus 2766043-2765856

333010 Dunham, . etal. Minus 2766207-2766119

333013 Dunham, . etal. Minus 2772278-2772039

333108 Dunham, . etal. Minus 3240494-3240389

333343 Dunham, . etal. Minus 4692886-4692753

333456 Dunham, .etal. Minus 2631933-2631797

333459 Dunham, . etal. Minus 5144548-5144344

333743 Dunham, . etal. Minus 7573218-7573060

333758 Dunham, . etal. Minus 7666413-7666091

333904 Dunham, . etal. Minus 8217374-8217261

333905 Dunham, . etal. Minus 8217796-8217670

334222 Dunham, . etal. Minus 12732417-12732289

334223 Dunham, . et.al. Minus 12734365-12734269

334360 Dunham, . etal. Minus 13728850-13728751

334784 Dunham, . etal. Minus 16294548-16294360

334789 Dunham, . etal. Minus 16306095-16305996

335004 Dunham, . etal. Minus 20581911-20581794

335115 Dunham, . etal. Minus 21388250-21388146

335342 Dunham, . etal. Minus 22597448-22597284

335544 Dunham, . etal. Minus 24650505-24650403

335610 Dunham, . etal. Minus 25068943-25068841

335682 Dunham, . etal. Minus 25421215-25421093

335755 Dunham, . etal. Minus 25763806-25763747

335782 Dunham, . etal. Minus 25908578-25908440

335791 Dunham, . et.al. Minus 25948563-25948411

335895 Dunham, .etal. Minus 26975307-26975239

335917 Dunham, . et.al. Minus 27028481-27028377

335920 Dunham, . et.al. Minus 27034927-27034811

336042 Dunham, . et.al. Minus 29041694-29041500

336150 Dunham, . etal. Minus 30150423-30150256

336152 Dunham, . et.al. Minus 30156053-30155870

336416 Dunham, . etal. Minus 34047408-34047311

336449 Dunham, . et.al. Minus 34204707-34204577

336471 Dunham, . etal. Minus 34215091-34214978

336512 Dunham, . etal. Minus 34278373-34278275

336558 Dunham, . etal. Minus 34375825-34375698

336560 Dunham, . etal. Minus 34376814-34376596

336676 Dunham, . etal. Minus 2022565-2022497

337968 Dunham, . etal. Minus 7095797-7095680

338451 Dunham, . etal. Minus 20174286-20174193

338689 Dunham, . etal. Minus 24893073-24892972

339373 Dunham, . etal. Minus 33860127-33860047

325622 5867000 Plus 69994-70075

329655 6448516 Minus 35565-35843

329899 6563505 Minus 111058-111783

329960 5091594 Minus 1031-1162

326213 5867224 Minus 60751-60927

326474 5867405 Plus 16995-18101

330084 6015302 Minus 57019-59337

326816 6552458 Plus 198354-198436

326817 6552458 Plus 199909-200001

327110 6117842 Plus 94608-94785

327196 5867446 Plus 180921-181333

327283 5867478 Minus 567-962

327313 5867501 Minus 89734-89838

327450 5867766 Minus 47928-48076

328059 6117819 Plus 37052-37204

328492 5868455 Minus 4609446241

328304 6004478 Minus 3884-3952

328857 6381927 Minus 80557-81051

329367 5868842 Minus 87201-87587

329373 6682537 Minus 38950-39301 TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast cancer cells.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal breast tissue

Pkey ExAccn UniGene ID Unigene Title R1

100038 M97935 AFFX control: STAT1 16.7

100114 D00596 Hs.82962 thymidylate synthetase 15.9

100975 J02923 Hs.76506 lymphocyte cytosolic protein 1 (L-plastin) 30.1

101031 J05070 Hs.151738 matrix metalloproteinase 9 (gelatinase B; 9 37.2

101104 L07615 Hs.169266 Human neuropeptideY receptor Y1 (NPYY 18.3

101143 L12723 Hs.90093 heat shock 70kD protein 4 17.4

101332 L47276 Hs.156346 Homo sapiens (cell line HL-6) alpha topois 18.9

101378 M13755 Hs.833 interferon-stimulated protein; 15 kDa 18.1

101809 M86849 Hs.323733 Homo sapiens connexin 26 (GJB2) mRNA 22.5

102618 U65932 Hs.81071 extracellular matrix protein 1 23.2

102721 U79241 Hs.118666 Human clone 23759 mRNA; partial eds 15

102817 U90904 Hs.83724 Human clone 23773 mRNA sequence 15.2

102907 X06985 Hs.202833 heme oxygenase (decycling) 1 22.7

102985 X17644 Hs.2707 G1 to S phase transition 1 20.6

103060 X57766 Hs.155324 matrix metalloproteinase 11 (stromelysin 3 17.8

103180 X69433 Hs.5337 isocitrate dehydrogenase 2 (NADP+); mite 18.9

103206 X72755 Hs.77367 monokine induced by gamma interferon 15.1

103821 AA157623 Hs.198793 KIAA0750 gene product 23.3

104115 AA428090 Hs.26102 ESTs 28.7

104667 AA007234 Hs.30098 ESTs 16.6

105186 AA191512 Hs.28005 Homo sapiens mRNA; cDNA DKFZp564G 19.3

106103 AA421104 Hs.12094 ESTs 15.4

107151 AA621169 Hs.8687 ESTs 19

109415 AA227219 Hs.110826 trinucleotide repeat containing 9 20.1

110189 H20543 Hs.6278 DKFZP586B1621 protein 16.6

110561 H59617 Hs.5199 ESTs; Weakly similar to UBIQUITIN-CON 19.5

110734 H98714 Hs.24131 ESTs 30.2

110915 N46252 Hs.29724 ESTs 23.2

111179 N67239 Hs.10760 ESTs 37

111357 N91023 Hs.87128 ESTs 15

112134 R46025 Hs.7413 ESTs 17.4

113970 W86748 Hs.8109 ESTs 15

114124 Z38595 Hs.125019 ESTs; Highly similar to KIAA0886 protein 22

114292 Z40715 Hs.184641 delta-6 fatty acid desaturase 19.4

114901 AA236276 Hs.196437 ESTs; Weakly similarto R26660J; partial 16.9

114965 AA250737 Hs.72472 ESTs 35.1

115652 AA405098 Hs.38178 ESTs 16.1

115875 AA433943 Hs.43946 ESTs; Weakly similar to Weak similarity t 33.5

116790 H29532 Hs.101174 microtubule-associated protein tau 22.2

116921 H72948 Hs.821 biglycan 20.7

117412 N26722 Hs.42645 ESTs 18.1

120241 Z41815 Hs.65946 ESTs 15.6

120325 AA195651 Hs.104106 ESTs 15.2

121596 AA416740 Hs.174104 ESTs 22.6

123619 AA609200 ESTs 23.1

124006 D60302 Hs.270016 ESTs 20.6

125852 H09290 Hs.76550 Homo sapiens mRNA; cDNA DKFZp564B 25.9

126160 N90960 Hs.265398 ESTs; Weakly similar to transformation-rel 16.4 127677 AA916752 Hs.264190 ESTs; Highly similarto MEM3 [M.muscul 17.3

128595 U31875 Hs.152677 short-chain alcohol dehydrogenase family m 27.1

128717 T30617 Hs.104222 Homo sapiens mRNA; cDNA DKFZp566L 24.5

129124 AA234530 Hs.108802 N-ethylmaleimide-sensitive factor 20.7

129366 H18027 Hs.184697 plexin C1 18.2

130455 X17059 Hs.155956 N-acetyltransferase 1 (arylamine N-acetylt 26.4

130604 X03635 Hs.1657 estrogen receptor 1 39.9

130913 W03592 Hs.21198 translocase of outer mitochondrial membra 20.9

130944 M97935 Hs.2 486 signal transducer and activator of transcript 18.8

131472 AA608962 Hs.27258 calcyclin binding protein 18.1

131562 U90551 Hs.28777 H2A histone family; member L 18.8

132180 AA405569 Hs.418 fibroblast activation protein; alpha; seprase 15.4

132406 F09979 Hs.4774 ESTs 15

132465 AA047896 Hs.49169 ESTs 15.4

132994 AA505133 Hs.279905 solute carrier family 2 (facilitated glucose t 26.4

133294 R79723 Hs.69997 zinc finger protein 238 30.4

133634 U24166 Hs.234279 microtubule-associated protein; RP/EB fam 15.2

134374 D62633 Hs.8236 ESTs 15.2

134405 J04177 Hs.82772 collagen; type XI; alpha 1 15.3

134470 X54942 Hs.83758 CDC28 protein kinase 2 20.3

134495 D63477 Hs.84087 K1AA0143 protein 16.1

134714 U89922 Hs.890 lymphotoxin beta (TNF superfamily; memb 35.7

135237 AA454930 Hs.9691 ESTs 19.5

301884 AA312082 Hs.105445 GDNF family receptor alpha 1 20.7

302276 NM 004448HS.323910 EST cluster (not in UniGene) with exon hit 21.6

302290 AL117607 Hs.175563 Homo sapiens mRNA; cDNA DKFZp564N 41.4

309177 AI951118 EST singleton (not in UniGene) with exon 24.3

309583 AW170035 EST 64.5

310438 AW022192 Hs.200197 ESTs 39.1

311166 AI821294 Hs.118599 ESTs 24.1

312153 AA759250 Hs.153028 cytochrome b-561 27.1

313915 AI969390 Hs.163443 ESTs 27.1

314506 AA833655 Hs.206868 ESTs 27.8

314558 AI873274 Hs.190721 ESTs 22.5

314691 AW207206 Hs.136319 ESTs 21.4

314943 AI476797 Hs.184572 cell division cycle 2; G1 to S and G2 to M 18.4

315196 AA972756 Hs.44898 ESTs 28.8

316177 AI908272 Hs.293102 EST cluster (not in UniGene) 32.6

318073 AW167087 Hs.131562 ESTs 15.7

318662 AI285898 Hs.294014 ESTs 16.3

318740 NM 002543HS.77729 EST cluster (not in UniGene) 21.3

318744 AI793124 Hs.144479 ESTs 35

319668 NM 002731 Hs.87773 EST cluster (not in UniGene) 25.4

320074 AA321166 Hs.278233 EST cluster (not in UniGene) 16.7

320211 AL039402 Hs.125783 DEME-6 protein 24.3

320727 U96044 Hs.181125 EST cluster (not in UniGene) 15.3

322818 AW043782 Hs.293616 ESTs 21

322882 AW248508 Hs.279727 DiGeorge syndrome critical region gene 2 15.3

324261 AL044891 Hs.269350 EST cluster (not in UniGene) 50.1

324432 AA464510 Hs.152812 EST cluster (not in UniGene) 16.7

324603 AW016378 Hs.292934 ESTs 23.1

324620 AA448021 Hs.94109 EST cluster (not in UniGene) 21.2

324988 T06997 Hs.121028 EST cluster (not in UniGene) 24.5

330388 X03363 HER2 receptor tyrosine kinase (c-erbB-2; E 17.7

330486 M13755 Hs.833 interferon-stimulated protein; 15 kDa 67

330814 AA015730 Hs.265398 ESTs; Weakly similarto transformation-rel 44.1

331145 R72427 Hs.129873 ESTs; Weakly similarto CYTOCHROME 41.9

331306 AA252079 Hs.63931 dachshund (Drosophila) homolog 15.1

331890 AA432166 Hs.3577 succinate dehydrogenase complex; subunit 24.3

332526 AA281753 Hs.77515 inositol 1;4;5-triphosphate receptor; type 3 19

332532 N63192 Hs.1892 EST; Highly similar to PHENYLETHANO 15.3

332694 AA262768 Hs.243901 KIAA1067 protein 15.2

332958 CH22 FGENES.48 15 17.8

333769 CH22_FGENES.271_8 48.3

333968 CH22 FGENES.307 4 15.9

334223 CH22_FGENES.360 4 33.5

334264 CH22_FGENES.367_15 18.5 335791 CH22_FGENES.611 7 27.3 336512 CH22_FGENES.834_7 21.4 338008 CH22_EM:AC005500.GENSCAN.127-9 15.2

TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigenelD's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

309583 1046029_-2 AW170035 336512 CH22_3941FG_834_7_LINK_DJ

338008 CH22_6490FG__LINK_EM:AC0O

333769 CH22_1036FG_271_8_LINK_EM

333968 CH22_1245FG_307_4_L1NK_EM

335791 CH22_3160FG_611_7_LINK_EM 309177 AI951118

332958 CH22_182FG_48_15_LINK_EM:

334223 CH22_1507FG_360_4_LINK_EM

334264 CH22_1551FG_367_15_LINK_E

123619 371681 1 AA602964 AA609200

TABLE 14B Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed. Pkey: Unique number corresponding to an Eos probeset

Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489495. Strand: Indicates DNA strand from which exons were predicted.

NLposition: Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition

332958 Dunham, 1. etal. Plus 2516164-2516310 333769 Dunham, I. etal. Plus 7696625-7696707

333968 Dunham, I. etal, Plus 8681004-8681241

334264 Dunham, I. etal. Plus 13234447-13234544

338008 Dunham, I. etal, Plus 7697068-7697236

334223 Dunham, I. etal. Minus 12734365-12734269 335791 Dunham, I. etal. Minus 25948563-25948411

336512 Dunham, I. etal. Minus 34278373-34278275

TABLE 15: Table 3 from BRCA 001-5 US

Table 15 shows genes downregulated in breast cancer cells.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of normal breast tissue to tumor

Pkey ExAccn UniGene IDUnigene Title R1

100115 D00632 Hs.172153 glutathione peroxidase 3 (plasma) 1.7

100499 TIGR-.HT1428 Hs.283108 Globin, Beta 1.5

100502 TIGR:HT1496 Hs.169228 Adrenal-Specific Protein Pg2 2.3

100815 TIGR:HT4268 Hs.9739 L-Glycerol-3-Phosphate:Nad+Oxidoreduct 1.7

101125 L10373 Hs.82749 transmembrane 4 superfamily member 2 1.5

101367 M12963 Hs.4 alcohol dehydrogenase 1 (class I); alpha po 2.9

101397 M15856 Hs.180878 lipoprotein lipase 1.6

101883 M98399 Hs.75613 CD36 antigen (collagen type I receptor; thr 1.6

102227 U25138 Hs.93841 potassium large conductance calcium-activ 1.6

102857 X00129 Hs.76461 retinol-binding protein 4; interstitial 3

103211 X73079 Hs.288579 polymeric immunoglobulin receptor 1.8

103496 Y09267 Hs.132821 flavin containing monooxygenase 2 1.5

103562 Z21966 Hs.2815 POU domain; class 6; transcription factor 1 1.8

104672 AA007629 glycerol-3-phosphate dehydrogenase 1 (sol 2.4

105083 AA146619 Hs.18791 ESTs; Weakly similar to CALCIUM-BIND 1.7

105138 AA164519 Hs.15248 ESTs 1.5

106075 AA417915 Hs.25930 ESTs 1.5

106870 AA487576 Hs.26530 serum deprivation response (phosphatidyls 1.6

107099 AA609645 Hs.211568 eukaryotic translation initiation factor4 gam 2.7

107616 AA004901 Hs.261164 ESTs 1.6

107997 AA037388 Hs.82223 Human DNA sequence from clone 141 H5 o 1.7

108604 AA099820 Hs.49696 ESTs 2.4

111130 N64265 Hs.19515 yz44h12.s1 Morton Fetal Cochlea Homo sa 1.7

111837 R36447 Hs.24453 ESTs 1.6

112538 R70255 ESTs 1.9

112808 R97970 Hs.281022 EST 1.5

113086 T40652 Hs.209100 DKFZP434C171 protein 1.9

115740 AA418033 Hs.283559 ESTs 1.6

115949 AA443800 Hs.43125 ESTs 2

115965 AA446661 Hs.173233 ESTs 2.2

117224 N20300 Hs.218707 ESTs 1.7

117513 N32174 Hs.44317 SRY (sex-determining region Y)-box 10 1.7

119059 R15436 Hs.77889 Friedreich ataxia region gene X123 1.7

119175 R71792 Hs.301002 ESTs; Weakly similar to cell death activate) 2.8

119359 T71021 . Hs.285681 ESTs; Highly similar to WS basic-helix-loo 1.9

119798 W73386 Hs.249129 ESTs 3

120889 AA365784 Hs.97044 ESTs 1.6

121381 AA405747 Hs.97984 ESTs; Weakly similar to WASP-family pro 1.8

121750 AA421184 Hs.97549 ESTs 1.5

122127 AA434447 Hs.106771 ESTs 2.5

122348 AA443695 Hs.293410 ESTs 2.1

122485 AA448300 Hs.160318 phospholemman 1.5

123443 AA598841 Hs.167382 natriuretic peptide receptor A guanylate cy 1.8

123505 AA600135 ESTs; Moderately similarto III! ALU SUB 1.5

125284 W94688 Hs.103253 perilipin 1.7

126300 D81972 HUM427D08B Human fetal brain (TFujiw 1.8

126747 R72515 Hs.160318 phospholemman 1.6

127218 AA309765 Hs.116017 ESTs; Weakly similar to KIAA0795 protei 1.5

127357 AA452788 Hs.75432 zx39g11.r1 Soares_total_fetus_Nb2HF8_9 1.7 127638 AA634405 Hs.122608 ESTs 1.5

128213 AA972780 Hs.129194 ESTs; Weakly similar to llll ALU SUBFA 1.5

128351 AI092391 Hs.134886 ESTs 1.5

128842 N44757 Hs.20340 ESTs 1.6

128870 R71403 Hs.75309 eukaryotic translation elongation factor 2 1.7

129146 AA459944 Hs.108924 DKFZP586P1422 protein 1.5

129285 T62068 Hs.11006 ESTs 2.1

129331 N93465 Hs.279772 ESTs; Highly similar to CGI-38 protein [H 1.5

130085 M62402 Hs.274313 insulin-like growth factor binding protein 6 1.7

130400 M25079 Hs.283108 hemoglobin; beta 1.7

131267 AA211776 Hs.2504 myomesin 1 (skelemin) (185kD) 3.8

131277 AA131466 Hs.23767 ESTs 1.9

131282 M12272 Hs.4 alcohol dehydrogenase 3 (class I); gamma p 2.2

131304 AA295848 Hs.25475 aquaporin 7 1.7

131810 D49487 Hs.194236 leptin (murine obesity homolog) 2.5

132788 AA045503 Hs.56874 ESTs; Weakly similar to Homo sapiens p2 1.6

132931 Z41452 Hs.6090 deleted in bladder cancer chromosome regi 1.5

133120 X64559 Hs.65424 tetranectin (plasminogen-binding protein) 2

133314 U95367 Hs.70725 gamma-aminobutyric acid (GABA) A recep 1.5

133507 X74295 Hs.74369 integrin; alpha 7 1.7

133601 S95936 Hs.284176 transferrin 2.3

133702 N56898 Hs.75652 glutathione S-transferase M5 1.9

134111 N79674 Hs.8022 TU3A protein 4.6

134699 U56814 Hs.88646 deoxyribonuclease l-like 3 1.5

134749 L10955 Hs.89485 carbonic anhydrase IV 1.6

135173 M72885 Hs.95910 Human G0S2 protein gene; complete eds 1.9

300132 AW027556 Hs.156286 ESTs 1.7

300732 AI369956 Hs.257891 ESTs 1.5

300750 AA514805 Hs.293055 ESTs 1.8

301140 AI807692 Hs.129129 ESTs 1.6

301396 AA923549 Hs.224121 ESTs 2.1

302910 N77976 Hs.251577 hemoglobin; alpha 1 1.8

303798 V00505 Hs.36977 hemoglobin; delta 1.6

303831 T04868 Hs.46780 EST cluster (not in UniGene) with exon hit 1.7

303844 U94362 Hs.58589 glycogenin 2 1.5

304182 H91086 EST singleton (not in UniGene) with exon 1.5

304622 AA516384 EST singleton (not in UniGene) with exon 1.5

304682 AA550994 EST singleton (not in UniGene) with exon 1.7

305612 AA782347 Hs.272572 EST singleton (not in UniGene) with exon 1.5

306193 AA923457 EST singleton (not in UniGene) with exon 1.5

307206 AI192534 EST singleton (not in UniGene) with exon 1.6

307377 AI222691 EST singleton (not in UniGene) with exon 1.5

308023 AI452732 Hs.251577 EST singleton (not in UniGene) with exon 1.9

308359 AI612774 Hs.79372 retinoid X receptor; beta 1.5

309838 AW296073 Hs.255504 EST 1.5

310403 AI720978 Hs.148006 ESTs; Moderately similar to alternatively s 1.8

311671 AW241947 Hs.232478 ESTs 1.6

311794 AW238092 Hs.254759 ESTs 2.1

312082 T79860 Hs.118180 ESTs 1.9

312575 H25237 Hs.306814 ESTs 2.3

313076 N49684 Hs.143040 ESTs 1.8

313283 W32480 Hs.157099 ESTs 2.2

313374 AW328672 Hs.132760 ESTs 1.9

314701 AI754634 Hs.131987 ESTs 1.7

315391 AA759098 Hs.192007 ESTs 1.8

315688 AA680055 Hs.264885 ESTs 1.5

316249 AA948612 Hs.130414 ESTs 1.6

316586 AI205077 Hs.294085 ESTs 1.7

316890 AA837079 Hs.24647 ESTs 1.5

316983 AI480204 Hs.177131 ESTs 1.5

317604 AI650625 Hs.300756 ESTs 1.6

317951 AW206520 Hs.129621 ESTs 1.5

319400 W26902 Hs.154085 ESTs 1.7

320757 H22654 Hs.6382 EST cluster (not in UniGene) 1.5

321594 AA021402 Hs.11067 ESTs 1.7

322102 H45589 EST cluster (not in UniGene) 1.5

322814 AI824495 Hs.211038 ESTs 2.2 322929 A1365585 Hs.146246 ESTs 2.3

323831 AA335715 Hs.200299 ESTs 1.7

324044 AL045752 Hs.22350 ESTs 1.8

324675 AW014734 Hs.157969 ESTs 2.2

325272 CH.11_hsgi|5866902 1.5

325558 CH.12 hs gi|6056302 1.6

325656 CH.14 hsgi|6056305 1.6

326120 CH.17_hs gi|5867194 1.5

326139 CH.17_hs gi|5867203 1.5

326855 CH.20 hs gi|6552460 1.5

327438 CH.02 hs gi|6004454 1.6

329733 CH.14 p2 gi|6065783 1.6

330931 F01443 Hs.284256 ESTs 4.6

331591 N71677 Hs.42146 ESTs 1.9

332159 AA621393 Hs.112984 EST 1.5

332364 W94688 Hs.103253 I perilipin 2.1

332502 H21819 Hs.14896 Homo sapiens clone 24590 mRNA sequenc 1.5

334175 CH22_FGENES.349_10 1.5

334347 CH22_FGENES.375_31 1.8

334737 CH22 FGENES.424 12 1.8

335352 CH22 FGENES.539 5 1.5

335639 CH22_FGENES.584_19 1.6

336244 CH22_FGENES.746_2 1.5

336336 CH22_FGENES.814_8 1.7

336865 CH22 FGENES.305-1 1.6

337494 CH22 FGENES.799-12 1.6

337764 CH22 EM:AC000097.GENSCAN.119-1 1.8

337983 CH22 EM:AC005500.GENSCAN.110-1 2

338192 CH22 EM:AC005500.GENSCAN.228-1 1.5

339366 CH22 BA354I12.GENSCAN.34-2 1.5

TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigenelD's for Table 15. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

126300 250375_2 D81972 BE003132 112538 504579J AA908813 R70255

123505 genbank_AA600135 AA600135 *

104672 6735_7 AA349096 AI368018 F21390 F17759 R48772 AI421485 AI300352 H43971 AI378525 F33652 R47898 AI264177 F22289 N28263

AI276281 R48205 AI245302 AI190036 AI281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375 H45809 F33447 AA774528 AA007629 H42537 C01077 F32386 322102 46708J H45589 H19807 AF075038 H19808 H42437

336865 CH22_4590FG_305_1_

338192 CH22_6755FG__LINK_EM:AC00

329733 c14_p2

326120 c17_hs 326139 c17_hs

326855 c20_hs

335352 CH22_2699FG_539_5_LINK_EM

335639 CH22_2999FG_584_19_L1NK_E

307206 AI192534 307377 A1222691

337494 CH22_5727FG_799_12_

337764 CH22_6115FG__LINK_EM:AC00

337983 CH22_6438FG_LINK_EM:AC00

339366 CH22_8336FG__LINK_BA354I1 325272 c11_hs

325558 c12_hs

325656 c14_hs

334175 CH22_1455FG_349_10_LINK_E

304182 H91086 334347 CH22_1640FG_375_31_LINK_E

327438 c_2_hs

304622 AA516384

334737 CH22_2049FG_424J2_UNK_E

304682 AA550994 336244 CH22_3642FG_746_2_LINK_DA

306193 AA923457

336336 CH22_3746FG_814_8_LINK_BA TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Unique number corresponding to an Eos probeset

Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (Gl) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Strand: Indicates DNA strand from which exons were predicted.

NLposition: Indicates nucleotide positions of predicted exons.

Pkey Ref Strand NLposition

334347 Dunham, . etal. Plus 13663814-13663926

334737 Dunham, . et.al. Plus 15998517-15998685

335639 Dunham, . etal. Plus 25173591-25173696

337494 Dunham, . et.al. Plus 33339024-33339148

334175 Dunham, . etal. Minus 11668659-11668597

335352 Dunham, . etal. Minus 22681512-22681384

336244 Dunham, . etal. Minus 31402729-31402583

336336 Dunham, . etal. Minus 33797209-33797076

336865 Dunham, . etal. Minus 8622405-8622289

337764 Dunham, . etal. Minus 4035640-4035446

337983 Dunham, . etal. Minus 7275495-7275271

338192 Dunham, . etal. Minus 13248453-13248277

339366 Dunham, . etal. Minus 33647431-33647293

325272 5866902 Minus 13247-13312

325558 6056302 Plus 70930-71030

325656 6056305 Minus 78190-78707

329733 6065783 Plus 163237-163450

326120 5867194 Plus 36116-36276

326139 5867203 Minus 218901-218960

326855 6552460 Minus 111390-111463

327438 6004454 Minus 199569-199692

TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in breast cancer cells.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemp lar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of normal breast tissue to tumor

Pkey ExAccn UniGene ID Unigene Title R1

100502 TIGR:HT1496 Hs.169228 Adrenal-Specific Protein Pg2 2.3

101367 M12963 Hs.4 alcohol dehydrogenase 1 (class I); alpha 2.9

102857 X00129 Hs.76461 retinol-binding protein 4; interstitial 3

104672 AA007629 glycerol-3-phosphate dehydrogenase 1 2.4

107099 AA609645 Hs.211568 eukaryotic translation initiation factor 4 gam 2.7

108604 AA099820 Hs.49696 ESTs 2.4

115949 AA443800 Hs.43125 ESTs 2

115965 AA446661 Hs.173233 ESTs 2.2

119175 R71792 Hs.301002 ESTs; Weakly similar to cell death activator 2.8

119798 W73386 Hs.249129 ESTs 3

122127 AA434447 Hs.106771 ESTs 2.5

122348 AA443695 Hs.293410 ESTs 2.1

129285 T62068 Hs.11006 ESTs 2.1

131267 AA211776 Hs.2504 myomesin 1 (skelemin) (185kD) 3.8

131282 M12272 Hs.4 alcohol dehydrogenase 3 (class I); gamma 2.2

131810 D49487 Hs.194236 leptin (murine obesity homolog) 2.5

133120 X64559 Hs.65424 tetranectin (plasminogen-binding protein) 2

133601 S95936 Hs.284176 transferrin 2.3

134111 N79674 Hs.8022 TU3A protein 4.6

301396 AA923549 Hs.224121 ESTs 2.1

311794 AW238092 Hs.254759 ESTs 2.1

312575 H25237 Hs.306814 ESTs 2.3

313283 W32480 Hs.157099 ESTs 2.2

322814 AI824495 Hs.211038 ESTs 2.2

322929 AI365585 Hs.146246 ESTs 2.3

324675 AW014734 Hs.157969 ESTs 2.2

330931 F01443 Hs.284256 ESTs 4.6

332364 W94688 Hs.103253 perilipin 2.1

337983 CH22_EM:AC005500.GENSCAN.110-1 2

TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigenelD's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

104672 6735_7 AA349096 AI368018 F21390 F17759 R48772 AI421485 AI300352 H43971 AI378525 F33652 R47898 AI264177 F22289 N28263

AI276281 R48205 AI245302 AI190036 AI281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375 H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

R1 : Ratio of tumor to normal breast tissue

Pkey ExAccn UnigenelD Unigene Title R1

100227 AV654694 Hs.82316 interferon-induced, hepatitis C-associat 3

100405 AW291587 Hs.82733 nidogen 2 3.2

100406 AI962060 Hs.118397 AE-binding protein 1 3.6

100420 D86983 Hs.118893 Melanoma associated gene 3.2

100911 X83300 Hs.289103 SMA4 5.2

100960 J00124 Hs.117729 keratin 14 (epidermolysis bullosa simple 4.3

101011 BE387036 Hs.1211 acid phosphatase 5, tartrate resistant 3

101183 AA442324 Hs.795 H2A histone family, member O 3.2

101194 L20971 Hs.188 phosphodiesterase 4B, cAMP-specific (dun 3

101329 U66042 Hs.82171 Homo sapiens clone 191B7 placenta expres 4.1

101378 BE563085 Hs.833 interferon-stimulated protein, 15 kDa 5.3

101474 R07566 Hs.73817 small inducible cytokine A3 (homologous 3.9

101491 M25809 Hs.64173 ATPase, H+ transporting, lysosomal (vacu 4.5

101530 M29874 Hs.1360 cytochrome P450, subfamily IIB (phenobar 9

101602 AA353776 Hs.901 CD48 antigen (B-cell membrane protein) 3.4

101663 NM 003528 Hs.2178 H2B histone family, member Q 5.6

101758 BE019494 Hs.79217 pyrroline-5-carboxylate reductase 1 3.6

101767 M81057 Hs.180884 carboxypeptidase B1 (tissue) 12

101817 M89907 Hs.152292 SWI/SNF related, matrix associated, acti 3.2

101851 BE260964 Hs.82045 midkine (neurite growth-promoting factor 4.1

101878 M97815 Hs.183650 cellular retinoic acid-binding protein 2 6.5

102209 NM 002038 Hs.265827 interferon, alpha-inducible protein (clo 3

102214 U23752 Hs.32964 SRY (sex determining region Y)-box 11 3

102297 NM_001504 Hs.198252 G protein-coupled receptor 9 3.7

102299 NM 005824 Hs.155545 37 kDa leucine-rich repeat (LRR) protein 3.7

102301 NM_005651 Hs.183671 tryptophan 2,3-dioxygenase 5.2

102305 AL043202 Hs.90073 chromosome segregation 1 (yeast homolog) 3.5

102369 U39840 Hs.299867 hepatocyte nuclear factor 3, alpha 3.9

102591 U62325 Hs.324125 amyloid beta (A4) precursor protein-bind 4

102721 H16646 Hs.118666 hypothetical protein PP591 3.5

102739 AA363025 Hs.155572 Human clone 23801 mRNA sequence 3.2

102791 AF080229 gb:Human endogenous retrovirus K clone 1 3

102804 NM 002318 Hs.83354 lysyl oxidase-like 2 3.2

102903 M73779 Hs.250505 retinoic acid receptor, alpha 3.3

103010 X52509 Hs.161640 tyrosine aminotransferase 12.4

103042 T81656 Hs.252259 ribosomal protein S3 4.5

103117 X63578 Hs.295449 pan/albumin 3

103207 X72790 gb:Humaπ endogenous retrovirus mRNA for 5.9

103282 BE390551 Hs.77628 steroidogenic acute regulatory protein r 3.9

103284 AI751601 Hs.8375 TNF receptor-associated factor 4 3.3

103329 X85134 Hs.72984 retinoblastoma-binding protein 5 3.1

103364 X90872 Hs.279929 gp25L2 protein 3

103385 NM_007069 Hs.37189 similar to rat HREV107 3.4

103456 AA496425 Hs.9629 papillary renal cell carcinoma (transloc 3.2 103498 Y09306 Hs.30148 homeodomain-interacting protein kinase 3 3.4

103558 BE616547 Hs.2785 keratin 17 3.7

103563 L02911 Hs.150402 Activin A receptor, type I (ACVR1) (ALK 3.2

103612 BE336654 Hs.70937 H3 histone family, member A 4.5

103825 AI571835 Hs.55468 ESTs 4

104073 AW779318 Hs.88417 ESTs 3.8

104103 AW021102 Hs.21509 ESTs 4.3

104115 AF183810 Hs.26102 opposite strand to trichorhinophalangeal 7.6

104168 AA461618 Hs.31704 ESTs, Weakly similar to KIAA0227 [H.sapi 3.6

104173 AA084273 Hs.76561 ESTs, Weakly similar to S47072 finger pr 4

104181 AF173296 Hs.283740 DC6 protein 3

104189 AB040927 Hs.301804 KIAA1494 protein 3.2

104269 AI559444 Hs.293960 ESTs 4.3

104307 AI929700 Hs.111680 endosulfine alpha 3.1

104518 H20816 Hs.112423 Homo sapiens mRNA; cDNA DKFZp586H420 (f 3.2

104556 AV650851 Hs.96900 hypothetical protein; KIAA1830 protein 4.4

104658 AA360954 Hs.27268 Homo sapiens cDNA: FLJ21933 fis, clone H 3.2

104748 AA015879 Hs.33536 ESTs 3.2

104755 T49951 Hs.9029 DKFZP434G032 protein 4.5

104825 AA035613 Hs.141883 ESTs 6.9

104830 AW294092 Hs.21594 hypothetical protein MGC15754 11.1

104865 T79340 Hs.22575 B-cell CLL/lymphoma 6, member B (zinc fi 3.5

104906 BE298684 Hs.26802 protein kinase domains containing protei 6.5

104961 H78517 Hs.33905 ESTs 3.6

105038 AW503733 Hs.9414 KIAA1488 protein 4.5

105088 H58589 Hs.35156 Homo sapiens cDNA FLJ11027 fis, clone PL 3.8

105092 AA148982 Hs.29068 ESTs 3

105093 AL137566 Hs.32405 Homo sapiens mRNA; cDNA DKFZp586G0321 (f 4.8

105304 AW134924 Hs.190325 ESTs 8.2

105397 AA814807 Hs.7395 hypothetical protein FLJ23182 3.1

105409 AW505076 Hs.301855 DiGeorge syndrome critical region gene 8 4.2

105431 AA252033 Hs.242413 hypothetical protein DKFZp434K1421 4.4

105552 AA256750 Hs.28802 centaurin-alpha 2 protein 3.2

105598 AA279439 Hs.279763 hypothetical protein FLJ10504 3.5

105650 W16741 Hs.25635 HSPC003 protein 3.7

105688 AI299139 Hs.17517 ESTs 5.5

105808 AI133161 Hs.286131 CGI-101 protein 3.5

105809 AW973653 Hs.20104 hypothetical protein FLJ00052 3.3

105909 AA195191 Hs.5111 hypothetical protein FLJ20729 3.2

105965 AA131657 Hs.23830 ESTs 3.3

106135 AL117474 Hs.41181 Homo sapiens mRNA; cDNA DKFZp727C191 (fr 3.2

106184 W28948 Hs.10762 ESTs 3.3

106293 N39842 Hs.301444 KIAA1673 4.1

106400 BE397649 Hs.94109 Homo sapiens cDNA FLJ13634 fis, clone PL 3.1

106474 BE383668 Hs.42484 hypothetical protein FLJ10618 3.2

106484 AA351978 Hs.4943 hepatocellular carcinoma associated prot 7.8

106533 AL134708 Hs.145998 ESTs 3

106614 AA648459 Hs.335951 hypothetical protein AF301222 3.8

106636 AW958037 Hs.286 ribosomal protein L4 3.3

106661 AW499914 Hs.7579 hypothetical protein FLJ10402 3

106743 BE613328 Hs.21938 hypothetical protein FLJ12492 4.2

106844 AA485055 Hs.158213 sperm associated antigen 6 3.4

106864 AI311928 gb:qo89h04.x1 NCI_CGAP_Kid5 Homo sapiens 4.4

106865 AW192535 Hs.19479 ESTs 3.6

106871 AW472981 Hs.321130 hypothetical protein MGC2771 4.1

106942 AA995351 Hs.31314 retinoblastoma-binding protein 7 3.6

106968 AF216751 Hs.26813 CDA14 5.3

107105 AW963419 Hs.155223 stanniocalcin 2 3.4

107158 N32849 Hs.31844 hypothetical protein FLJ12586 3.1

107248 AW263124 Hs.315111 nuclear receptor co-repressor/HDAC3 comp 5.9

107265 BE379594 Hs.49136 ESTs, Moderately similar to ALU7_HUMAN A 3.9

107630 AW961576 Hs.60178 ESTs 4.6

107710 AI955040 Hs.265398 ESTs, Weakly similar to transformation-r 3

107890 AA025386 Hs.61311 ESTs, Weakly similar to S10590 cysteine 3.1

107985 T40064 Hs.71968 Homo sapiens mRNA; cDNA DKFZp564F053 (fr 4.8

108000 AI263307 Hs.239884 H2B histone family, member L 3.3

108217 AA058686 Hs.62588 ESTs 3.8 108435 T82427 Hs.194101 Homo sapiens cDNA: FLJ20869 fis, clone A 3

108591 AB033073 Hs.43857 similar to glucosamine-6-sulfatases 3.3

108733 AA121022 gb:zn84f10. Stratagene lung carcinoma 3.9

108771 AF068290 Hs.79741 hypothetical protein FLJ10116 6.1

108819 AA011449 Hs.271627 ESTs 3.6

108912 AA136674 Hs.118681 EST 3.9

109086 AF186114 Hs.270737 tumor necrosis factor (ligand) superfaml 3.7

109124 AK000684 Hs.183887 hypothetical protein FLJ22104 3.1

109132 AI970536 Hs.16603 hypothetical protein FLJ13163 3.7

109163 N23235 Hs.30567 ESTs, Weakly similar to B34087 hypotheti 4.5

109277 AA196443 Hs.86043 Homo sapiens cDNA FLJ13558 fis, clone PL 3.7

109410 AW504732 Hs.21275 hypothetical protein FLJ11011 4.6

109454 AA232255 Hs.295232 ESTs, Moderately similar to A46010 X-lin 6.4

109514 AA234087 Hs.262346 ESTs, Weakly similar to S72482 hypotheti 4.8

109581 R45584 Hs.23025 ESTs, Weakly similar to ALU5 HUMAN ALU S 3.3

109632 AA325138 Hs.235873 hypothetical protein FLJ22672 3

109644 AW973964 Hs.291531 ESTs, Highly similarto 1203217A dehydro 3

109700 F09609 gb:HSC33H092 normalized infant brain cDN 3.2

109768 F06838 Hs.14763 ESTs 3.2

109807 R43646 Hs.12422 ESTs 3.8

109842 AW818436 Hs.23590 solute carrier family 16 (monocarboxylic 3.3

109895 AK001680 Hs.30488 DKFZP434F091 protein 3.6

110024 AW973152 Hs.31050 ESTs 4.2

110561 AA379597 Hs.5199 HSPC150 protein similar to ubiquitin-con 5.1

110675 H89355 Hs.249159 adrenergic, alpha-2A-, receptor 5.3

110707 AI239832 Hs.15617 ESTs, Weakly similar to ALU4_HUMAN ALU S 3.7

110915 BE092285 Hs.29724 hypothetical protein FLJ13187 3.7

111139 N64683 Hs.290943 ESTs 4

111155 N66563 Hs.191358 ESTs 3.1

111199 AI767435 Hs.29822 ESTs 4.5

111336 AI457338 Hs.29894 ESTs 5.4

111510 R07856 Hs.16355 ESTs 3.2

111532 R08440 gb:yf19f09.s1 Soares fetal liver spleen 3.1

111689 AA602004 Hs.23260 ESTs 3.2

111823 R35252 Hs.24944 ESTs, Weakly similar to 2109260A B cell 3.3

111876 R38239 Hs.293246 ESTs, Weakly similarto putative p150 [H 3.1

111892 AA421081 Hs.12388 ESTs 3.4

111893 AF070526 Hs.13429 Homo sapiens clone 24787 mRNA sequence 3.3

112125 AW379029 Hs.118338 ESTs, Weakly similar to unnamed protein 4.4

112170 BE246743 Hs.288529 hypothetical protein FLJ22635 7.3

112287 AB033064 Hs.334806 KIAA1238 protein 3.2

112300 H24334 Hs.26125 ESTs 4.4

112303 R54797 gb:yg87b07.s1 Soares infant brain 1NIB H 3.4

112478 R66067 Hs.28664 ESTs 8.2

112561 AI791493 Hs.129873 ESTs, Weakly similar to A36036 cytochrom 5.5

112631 R82040 gb:yj06b06.s1 Soares placenta Nb2HP Homo 3.9

112637 R82331 Hs.164599 ESTs 5.4

112657 AW844878 Hs.19769 hypothetical protein MGC4174 3.2

112678 AI418466 Hs.33665 ESTs 4.7

112917 AA082465 Hs.125031 choline/ethanolaminephosphotransferase 3.7

113070 AB032977 Hs.6298 KIAA1151 protein 3.1

113095 AA828380 Hs.126733 ESTs 3.4

113117 AW813731 Hs.159153 ESTs, Moderately similar to S65657 alpha 3.4

113187 BE613410 Hs.31575 SEC63, endoplasmic reticulum translocon 3.2

113200 T57773 Hs.10263 ESTs 3.5

113206 BE262470 Hs.241471 RNB6 6.2

113374 T79925 Hs.269165 ESTs, Weakly similar to ALU1 HUMAN ALU S 3.7

113440 U54727 Hs.191445 ESTs 3

113494 T91451 Hs.86538 ESTs 3.4

113518 AW367788 Hs.323954 postmeiotic segregation increased 2-like 3.1

113571 AI702609 Hs.15713 hypothetical protein MGC2776 3.1

113822 NMJ04585 Hs.17466 retinoic acid receptor responder (tazaro 3.9

113835 AI912410 Hs.27475 Homo sapiens cDNA FLJ12749 fis, clone NT 3

113938 W81598 gb:zd88g02.s1 Soares_fetal_hear_NbHH19W 4.6

113947 W84768 gb:zh53d03.s1 Soares fetal liver spleen 3.1

113970 W27249 Hs.8109 hypothetical protein FLJ21080 6.9

114086 AA378776 Hs.288649 hypothetical protein MGC3077 4.3 114148 AW470411 Hs.288433 neurotrimin 4.1

114424 AW780192 Hs.267596 ESTs 3.4

114518 AW163267 Hs.106469 suppressor of varl (S.cerevlsiae) 3-like 3.1

114563 AI979168 Hs.82226 glycoprotein (transmembrane) nmb 4.8

114965 AI733881 Hs.72472 BMP-R1B 10.1

114995 AA769266 Hs.193657 ESTs 3.6

115121 AI634549 Hs.88155 ESTs 3.2

115134 AW968073 Hs.194331 ESTs, Highly similar to A55713 inositol 4.2

115167 AA749209 Hs.43728 hypothetical protein 3

115253 BE149845 Hs.289038 hypothetical protein MGC4126 3.6

115277 AA814100 Hs.86693 ESTs 3.9

115327 N46436 Hs.109221 ESTs 3.4

115354 AA281636 Hs.334827 ESTs 4.8

115657 AA405620 Hs.55158 ESTs, Weakly similar to T29520 hypotheti 3.5

115676 AA953006 Hs.88143 ESTs 9.3

115709 AW293849 Hs.58279 ESTs, Weakly similar to ALU7 HUMAN ALU S 3.4

115729 AA417812 Hs.38775 ESTs 4

115787 AI126772 Hs.40479 ESTs 3.1

115830 AW970529 Hs.86434 hypothetical protein FLJ21816 3.6

115835 AA521410 Hs.41371 ESTs 3.1

115850 NM 14937 Hs.52463 K1AA0966 protein 3

115900 AK001500 Hs.165186 hypothetical protein FLJ13852 3.2

115935 AA354549 Hs.41181 Homo sapiens mRNA; cDNA DKFZp727C191 (fr 3

115948 AL042465 Hs.43445 poly(A)-specific ribonuclease (deadenyla 3.1

116092 AB041035 Hs.93847 NM_016931 :Homo sapiens NADPH oxidase 4 ( 6.7

116115 AL042355 Hs.70202 WD repeat domain 10 3.6

116184 AW450737 Hs.128791 CGI-09 protein 3.1

116192 AA464976 Hs.62528 ESTs, Moderately similar to A46010 X-lin 3.3

116208 AI219083 Hs.42532 ESTs, Moderately similar to ALU8_HUMAN A 3.2

116246 AF265555 Hs.250646 baculoviral IAP repeat-containing 6 3.6

116443 AW962196 Hs.321264 LBP protein 32 4.1

116470 AI272141 Hs.83484 SRY (sex determining region Y)-box 4 4.1

116726 AK001114 Hs.53913 hypothetical protein FLJ10252 8.6

116845 AA649530 gb:ns44f05.s1 NCI CGAP_Alv1 Homo sapiens 3.2

117026 H88256 Hs.50456 ESTs, Moderately similar to ZN75 HUMAN Z 3.5

117216 AI569804 Hs.42792 ESTs, Weakly similar to I78885 serine/th 3.1

117296 AL133427 Hs.42506 Homo sapiens mRNA full length insert cDN 3.2

117403 H84455 Hs.40639 ESTs 4.7

117691 AB040959 Hs.93836 DKFZP434N014 protein 3

118229 AW968941 Hs.166254 hypothetical protein DKFZp566l133 3.3

118363 AI183838 Hs.48938 hypothetical protein FLJ21802 4.3

118416 N66028 Hs.49105 FKBP-associated protein 3.1

118470 AW970584 Hs.291033 ESTs 3.4

118502 AL157488 Hs.50150 Homo sapiens mRNA; cDNA DKFZp564B182 (fr 5.2

118695 AK000465 Hs.50081 KIAA1199 protein 3.4

118925 N92293 Hs.206832 ESTs, Moderately similar to ALU8 HUMAN A 3.3

119025 BE003760 Hs.55209 Homo sapiens mRNA; cDNA DKFZp434K0514 (f 19.7

119036 R95872 Hs.117572 chemokine binding protein 2 3.7

119063 R16833 Hs.53106 ESTs, Moderately similar to ALU1_HUMAN A 4.1

119075 M10905 Hs.287820 fibronectin 1 3.2

119620 W47620 Hs.56009 2'-5'-oligoadenylate synthetase 3 (100 k 3.3

119741 AF041853 Hs.43670 kinesin family member 3A 3.1

119747 AI970797 Hs.64859 ESTs 5

119754 AL037824 Hs.194695 ras homolog gene family, member I 3.8

119905 AW449064 Hs.119571 collagen, type III, alpha 1 (Ehlers-Danl 3.1

120084 W94472 Hs.59529 ESTs, Moderately similar to ALU1_HUMAN A 8.4

120241 AA825686 Hs.321176 ESTs, Weakly similar to S65824 reverse t 3.6

120326 AA196300 Hs.21145 hypothetical protein RG083M05.2 3.2

120742 AA225084 gb:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens 3.6

120870 AA357172 Hs.292581 ESTs, Moderately similar to ALU1 HUMAN A 5.8

120885 AA365515 Hs.301872 hypothetical protein MGC4840 3

120970 AA398118 Hs.97579 ESTs, Weakly similar to A46010 X-linked 3.7

121054 AW976570 Hs.97387 ESTs 5.3

121095 AA320134 Hs.196029 Homo sapiens mRNA for KIAA1657 protein, 4

121103 AA398936 Hs.97697 EST 3.5

121121 AA399371 Hs.189095 similar to SALL1 (sal (Drosophila)-like 6.3

121337 AW885727 Hs.301570 ESTs 4.7 121351 AW206227 Hs.287727 hypothetical protein FLJ23132 5

121611 M31669 Hs.1735 inhibin, beta B (activin AB beta polypep 3.6

121643 AA640987 Hs.193767 ESTs 5.6

121770 NM 015902 Hs.278428 progestin induced protein 3.4

122125 AK000492 Hs.98806 hypothetical protein 4.1

122338 AA443311 Hs.98998 ESTs 3

122417 AA446965 Hs.112092 ESTs 4,7

122513 AI767879 Hs.99214 ESTs 3.8

122544 AW973253 Hs.292689 ESTs 3

122655 AA323296 Hs.97837 Homo sapiens mRNA; cDNA DKFZp547J047 (fr 5.6

122805 AA526911 Hs.82772 collagen, type XI, alpha 1 3.2

122851 AW205931 Hs.99598 hypothetical protein MGC5338 8.6

123105 AA487809 Hs.166011 catenin (cadherin-associated protein), d 3

123111 AA228776 Hs.191721 ESTs 6.9

123249 AA371307 Hs.125056 ESTs 3.6

123273 AA491253 Hs.173611 Empirically selected from AFFX single pr 7

123385 BE149685 Hs.17767 KIAA1554 protein 3.1

123419 T66087 Hs.112482 Homo sapiens unknown mRNA sequence 3.4

123485 A1308876 Hs.103849 hypothetical protein DKFZp761D112 3.1

123645 AI675944 Hs.188691 Homo sapiens cDNA FLJ12033 fis, clone HE 3.8

123819 AA580082 Hs.112264 ESTs 4.7

124012 AA352723 Hs.241471 RNB6 3.8

124243 H69125 Hs.133525 ESTs 4.1

124357 N22401 gb:yw37g07.s1 Morton Fetal Cochlea Homo 4.1

124359 N22508 Hs.139315 Homo sapiens cDNA: FLJ21479 fis, clone C 3.6

124567 AW451645 Hs.151504 Homo sapiens cDNA FLJ11973 fis, clone HE 3.1

124911 N34151 Hs.174195 interferon induced transmembrane protein 3.5

124972 R41396 Hs.101774 hypothetical protein FLJ23045 4.3

125006 BE065136 Hs.145696 splicing factor (CC1.3) 6

125042 T78906 Hs.269432 ESTs, Moderately similar to ALU1_HUMAN A 8.1

125184 W60326 Hs.288684 Homo sapiens cDNA FLJ11750 fis, clone HE 4.7

125243 AW970536 Hs.105413 ESTs 3.1

125286 AF086534 Hs.187561 ESTs, Moderately similar to ALU1_HUMAN A 3.3

125304 AL359573 Hs.124940 GTP-binding protein 3

125330 AW880562 Hs.114574 ESTs 3

125331 AI422996 Hs.161378 ESTs 3.2

125685 AI924630 Hs.4943 hepatocellular carcinoma associated prot 3.2

126257 N99638 gb:za39g11 ,r1 Soares fetal liver spleen 4

126474 AW975814 Hs.326714 Homo sapiens clone IMAGE:713177, mRNA se 4

126666 AA648886 Hs.151999 ESTs 3.8

126872 AW450979 gb:UI-H-BI3-ala-a-12-0-Ul.s1 CI_CGAP_Su 3

127431 AW771958 Hs.175437 ESTs, Moderately similar to PC4259 ferri 3.6

127980 AA961459 Hs.125644 ESTs 4.1

127997 AW068311 Hs.311054 Homo sapiens mRNA full length insert cDN 3.3

128420 AA650274 Hs.41296 fibronectin leucine rich transmembrane p 4.6

128609 NM 003616 Hs.102456 survival of motor neuron protein interac 3.9

128946 Y13153 Hs.107318 kynurenine 3-monooxygenase (kynurenine 3 3.1

128955 AA775076 Hs.185807 Homo sapiens, Similarto PRO0478 protein 3.9

129092 D56365 Hs.63525 poly(rC)-binding protein 2 3.3

129270 AA357185 Hs.109918 ras homolog gene family, member H 3.1

129301 AF182277 Hs.330780 cytochrome P450, subfamily IIB (phenobar 3.9

129385 AA172106 Hs.110950 Rag C protein 6.2

129619 AA209534 Hs.284243 tetraspan NET-6 protein 3.4

129629 AK000398 Hs.11747 hypothetical protein FLJ20391 3

129725 X56411 Hs.1219 alcohol dehydrogenase 4 (class II), pi p 3.2

130069 AI754813 Hs.146428 collagen, type V, alpha 1 5.4

130092 X03363 Hs.323910 v-erb-b2 avian erythroblastic leukemia v 4.4

130298 AI347487 Hs.132781 class I cytokine receptor 4.6

130382 NM 003450 Hs.155204 zinc finger protein 174 5.6

130622 AI582291 Hs.16846 ESTs, Weakly similar to 04HUD1 debrisoqu 3

130703 R77776 Hs.18103 ESTs 3.8

130881 AA809875 Hs.25933 ESTs 4.2

130954 AB014544 Hs.21572 KIAA0644 gene product 4.7

131095 AI399653 Hs.22917 ESTs 4.3

131153 H09048 Hs.23606 ESTs 3.8

131253 R71802 Hs.24853 ESTs 3.5

131372 AW293399 Hs.144904 nuclear receptor co-repressor 1 3.6 131507 AI826268 Hs.27769 ESTs, Weakly similar to MCAT_HUMAN MITOC 3.2

131587 AI695549 Hs.183868 glucuronidase, beta 3.1

131739 AF017986 Hs.31386 secreted frizzled-related protein 2 3.2

131795 BE501849 Hs.32317 high-mobility group 20B 3.2

131970 D86960 Hs.3610 KIAA0205 gene product 3.6

131986 NM 002314 Hs.36566 LIM domain kinase 1 3.2

132093 AA400091 Hs.39421 ESTs 3.2

132122 AA426202 Hs.40403 Cbp/p300-interacting transactivator, wit 3

132159 D76435 Hs.41154 Zic family member 1 (odd-paired Drosophi 3.2

132333 AA192669 Hs.45032 ESTs 3.5

132406 AL133731 Hs.4774 Homo sapiens mRNA; cDNA DKFZp761C1712 (f 9.2

132482 AV660345 Hs.238126 CGI-49 protein 8.2

132543 BE568452 Hs.5101 protein regulator of cytokinesis 1 3.4

132624 AA326108 Hs.33829 bHLH protein DEC2 3.2

132700 AA319233 ■ . Hs.5521 ESTs 4.8

132725 NM 006276 Hs.184167 splicing factor, arginine/serine-rich 7 3.6

132799 W73311 Hs.169407 SAC2 (suppressor of actin mutations 2, y 3.2

132847 T48195 Hs.58189 eukaryotic translation initiation factor 3.5

132857 Y00272 Hs.184572 cell division cycle 2, G1 to S and G2 to 4.4

132936 AL120659 Hs.6111 aryl-hydrocarbon receptor nuclear transl 4.8

133130 AI128606 Hs.6557 zinc finger protein 161 3.3

133142 AW952412 Hs.65874 ESTs, Weakly similar to A40348 Elav/Sex- 3.5

133167 AW162840 Hs.6641 kinesin family member 5C 4.5

133225 AW600291 Hs.6823 hypothetical protein FLJ10430 3.3

133274 AA085191 Hs.6949 hypothetical protein MGC11275 3

133275 Z93241 Hs.239934 CGI-96 protein 4.5

133287 AW797437 Hs.69771 B-factor, properdin 4.1

133376 BE618768 Hs.7232 acetyl-Coenzyme A carboxylase alpha 5.1

133462 AW675064 Hs.73875 fumarylacetoacetate hydrolase (fumaiylac 3

133740 AW162919 Hs.170160 RAB2, member RAS oncogene family-like 3.4

133831 BE274552 Hs.76578 protein inhibitor of activated STAT3 3.9

133976 AI908165 Hs.169946 GATA-binding protein 3 (T-cell receptor 6.2

134666 BE391929 Hs.8752 transmembrane protein 4 3.1

134710 AI433797 Hs.8889 serine hydroxymethyltransferase 1 (solub 3

134731 D89377 Hs.89404 msh (Drosophila) homeo box homolog 2 5.8

134776 J05582 Hs.89603 mucin l, transmembrane 4

135230 AF064804 Hs.96757 suppressor of Ty (S.cerevisiae) 3 homolo 3.2

135303 R61253 Hs.98265 KIAA1877 protein 3.3

135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 4.8

135411 L10333 Hs.99947 reticulon 1 3.8

300089 AI199738 Hs.208275 ESTs, Weakly similar to ALUA HUMAN 111! 3.8

300233 AW614220 Hs.189402 ESTs 4.2

300254 AW183618 Hs.55610 solute carrier family 30 (zinc transport 9.9

300256 AW591433 Hs.298241 Transmembrane protease, serine 3 4.9

300378 Z45270 Hs.235873 hypothetical protein FLJ22672 3.4

300973 AA572949 Hs.207566 ESTs 3.5

301111 R10799 Hs.191990 ESTs 3.8

301341 AA887801 Hs.208229 G protein-coupled receptor 13.9

301548 AI091631 Hs.203845 two pore potassium channel KT3.3 4.4

301884 AA312082 Hs.105445 GDNF family receptor alpha 1 5.7

301936 U79745 Hs.114924 solute carrier family 16 (monocarboxylic 8.6

301976 T97905 gb:ye54c10. Soares fetal liver spleen 3.9

302001 AB020711 Hs.278346 KIAA0904 protein 7.7

302067 BE542706 Hs.222399 CEGP1 protein 7.3

302094 AW749321 Hs.6786 ESTs 3.3

302099 AL049670 Hs.137576 ribosomal protein L34 pseudogene 1 4.2

302145 NM_003613 Hs.151407 cartilage intermediate layer protein, nu 7.9

302235 AL049987 Hs.166361 Homo sapiens mRNA; cDNA DKFZp564F112 (fr 5.6

302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c-erb-b2, 5.4

302290 AA179949 Hs.175563 Homo sapiens mRNA; cDNA DKFZp564N0763 (f 34.1

302372 AL117406 Hs.200102 ATP-binding cassette transporter MRP8 6.7

302378 AL109712 Hs.296506 Homo sapiens mRNA full length insert cDN 4

302384 AI678059 Hs.202676 synaptonemal complex protein 2 4.3

302385 AJ224172 Hs.204096 lipophilin B (uteroglobin family member) 13.8

302680 AW192334 Hs.38218 . ESTs 9.6

302830 AI038997 Hs.132921 ESTs 5

302857 AF282265 Hs.44836 inner centromere protein antigens (135kD 3.4 302892 AW176909 Hs.42346 calcineurin-binding protein calsarcin-1 3.4

302970 W05608 Hs.312679 ESTs, Weakly similar to A49019 dynein he 5.1

303271 AA652687 Hs.96151 Human DNA sequence from clone RP5-1103G7 3.7

303289 AL121460 Hs.272673 hypothetical protein FLJ20508 4.1

303357 AW006352 Hs.159643 ESTs, Weakly similar to T32554 hypotheti 4.2

303540 AA355607 Hs.309490 ESTs, Weakly similarto putative WHSC1 p 4.3

303563 AA367699 Hs.10082 potassium intemiediatesmall conductance 3.3

303642 AW299459 gb:xs50d08.x1 NCI CGAP Kid11 Homo sapien 4.2

303780 AI424014 Hs.18995 KIAA1304 protein 3.6

303797 AW629759 gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens 4.9

303852 R53434 Hs.90207 hypothetical protein MGC11138 3.7

304328 AA149951 Hs.62112 zinc finger protein 207 3

304782 AA582081 gb:nn32h08.s1 NC l_CGAP_Gas1 Homo sapiens 4.1

305913 AA876109 gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens 3

305917 AA876469 gb:oe48b04.s1 NCI CGAP Pr25 Homo sapiens 3.1

307010 AI140014 gb:qa68f09.x1 Soares fetaLheart NbHH19W 3.5

307041 AI144243 gb;qb85b12.x1 Soares feta_heart_NbHH19W 3.9

308106 AI476803 gb:tj77e12.x1 Soares_NSF_F8_9W_OT_PA_P_S 4.3

308307 AI581398 Hs.172928 collagen, type I, alpha 1 4.6

308615 AK000142 Hs.101774 hypothetical protein FLJ23045 4.4

309177 AI951118 Hs.326736 Homo sapiens breast cancer antigen NY-BR 17.3

309328 AW024348 Hs.233191 EST, Weakly similar to A27217 glucose tr 3.2

309574 AW168083 gb:xg59g04.x1 NC l_CGAP_Ut4 Homo sapiens 3.1

309583 AW170035 Hs.326736 Homo sapiens breast cancer antigen NY-BR 57.6

310064 AI199712 Hs.148486 ESTs, Weakly similar to 1917210A Pro/Arg 4.6

310098 AI685841 Hs.161354 ESTs 3.6

310438 AW022192 Hs.200197 ESTs 4.6

310683 AI939456 Hs.160870 ESTs 3.2

310727 AK000703 Hs.323822 Homo sapiens mRNA for KIAA1551 protein, 3.6

310781 AI380797 Hs.158992 ESTs 10.2

310895 AI955121 Hs.165724 N-acetylgalactosamine-4-θ-sulfotransfera 3.4

310955 AI476732 Hs.263912 ESTs 10.9

311117 AI671439 Hs.196029 Homo sapiens mRNA for KIAA1657 protein, 3.1

311166 AI821005 Hs.118599 ESTs 10.8

311237 AA641098 Hs.208809 ESTs, Moderately similar to ALU1.HUMAN A 4.3

311465 AI758660 Hs.206132 ESTs 4.4

311587 AI828254 Hs.271019 ESTs, Weakly similarto A47582 B-cell gr 5.1

311598 AW023595 Hs.232048 ESTs 5.8

311774 AA700870 Hs.14304 ESTs 3.3

311785 AI056769 Hs.133512 ESTs 3.9

311872 R12375 Hs.194600 ESTs 3.3

311889 AA767342 Hs.122483 ESTs, Weakly similar to PSF_HUMAN PTB-AS 3

311913 AI358522 Hs.270188 ESTs 3

311923 T60843 Hs.189679 ESTs 5.6

311935 AA216387 gb:nc16b02.s1 NCI CGAP_Pr1 Homo sapiens 5.2

312019 AA373630 Hs.188750 ESTs 3

312021 AA759263 Hs.14041 ESTs 3.4

312067 T78968 Hs.14411 ESTs 3.5

312090 T80177 Hs.118064 similarto rat nuclear ubiquitous casein 3.8

312147 AI633744 Hs.195648 ESTs, Weakly similarto I38022 hypotheti 4.4

312153 BE261944 Hs.118625 hexokinase l 5.2

312168 T92251 Hs.198882 ESTs 3.3

312182 T94344 Hs.326263 ESTs 3.3

312187 AA700439 Hs.188490 ESTs 3.4

312199 AW438602 Hs.191179 ESTs 3.9

312219 H73505 Hs.117874 ESTs 4

312226 AA315703 Hs.199993 ESTs, Weakly similarto ALUB_HUMAN III! 4.9

312299 AA972712 Hs.269737 ESTs 5.7

312544 AA516420 Hs.183526 ESTs, Weakly similar to I38022 hypotheti 6.3

312638 AW439195 Hs.256880 ESTs, Weakly similar to S65657 alpha-1 C- 4.9

312826 AW291545 Hs.185018 ESTs 4.9

312837 AW292286 Hs.255058 ESTs 4.4

312980 AA497043 Hs.115685 ESTs 3.1

313070 AI422023 Hs.161338 ESTs 4.3

313079 N76497 Hs.1787 proteolipid protein 1 (Pelizaeus-Merzbac 3.3

313089 AF026944 Hs.293797 ESTs 5.8

313096 AW073310 Hs.163533 Homo sapiens cDNA FLJ14142 fis, clone MA 4.5 313126 AA746503 Hs.283313 ESTs 10

313166 AI801098 Hs.151500 ESTs 3.5

313197 AW979008 Hs.222487 ESTs 3.3

313280 AW960454 Hs.222830 ESTs 4.7

313325 AI420611 Hs.127832 ESTs 3.4

313328 AW449211 Hs.105445 GDNF family receptor alpha 1 12.4

313352 AW150945 Hs.144758 ESTs 4.1

313385 AI032087 Hs.269819 ESTs 3

313393 AI674685 Hs.200141 ESTs 5.2

313417 AA741151 Hs.137323 ESTs 3.5

313434 W92070 gb:zh48g05.r1 Soares_feta_liver_spleen_ 3.7

313569 AI273419 Hs.135146 hypothetical protein FLJ13984 3

313591 AA046309 gb:zf12f01.s1 Soares fetal heart_NbHH19W 5.6

313615 AI540978 Hs.301997 hypothetical protein FLJ13033 3.2

313915 C18863 Hs.163443 Homo sapiens cDNA FLJ11576 fis, clone HE 26.3

313975 AW175896 Hs.65114 keratin 18 3

313979 AI535895 Hs.221024 ESTs 4.9

313997 AV657317 Hs.288649 hypothetical protein MGC3077 3.9

314043 AA827082 Hs.291872 ESTs 3.1

314078 AW129357 Hs.329700 ESTs 8.3

314097 AA648744 Hs.269493 ESTs 6.6

314121 AI732083 Hs.187619 ESTs 6.2

314129 AA228366 Hs.115122 ESTs 4

314138 AA740616 gb:ny97f11.s1 NCLCGAP GCB1 Homo sapiens 5.9

314236 AA743396 Hs.189023 ESTs 3.1

314244 AL036450 Hs.103238 ESTs 4

314305 AI280112 Hs.125232 Homo sapiens cDNA FLJ13266 fis, clone OV 8

314306 AI697901 Hs.192425 ESTs 3.7

314322 AA907153 Hs.190060 ESTs 3.3

314394 AW961597 Hs.130816 ESTs, Moderately similar to I38022 hypot 4.2

314401 AI660412 Hs.234557 ESTs 3.3

314465 AA602917 Hs.156974 ESTs 4.7

314506 AA833655 Hs.206868 Homo sapiens cDNA FLJ14056 fis, clone HE 8.5

314510 AI204418 Hs.190080 ESTs 4

314546 AW007211 Hs.16131 hypothetical protein FLJ12876 3.4

314547 AA399272 Hs.144341 ESTs 6.7

314558 AI873274 Hs.190721 ESTs 27.4

314627 AA425310 Hs.155766 ESTs, Weakly similarto A47582 B-cell gr 4.4

314648 AW979268 gb:EST391378 MAGE resequences, MAGP Homo 4.6

314691 AW207206 Hs.136319 ESTs 20.7

314729 AA457367 Hs.191638 ESTs 3.6

314754 AW026761 Hs.134374 ESTs 3.6

314814 BE350122 Hs.157367 ESTs, Weakly similar to I78885 serine/th 4.9

314864 AW971198 Hs.294068 ESTs 4.3

314881 AI095087 Hs.152299 ESTs, Moderately similar to S65657 alpha 3.7

314882 AA828032 Hs.189076 ESTs 3.1

314981 AW972359 Hs.293334 ESTs 3

315006 AI538613 Hs.298241 Transmembrane protease, serine 3 10.9

315021 AA533447 Hs.312989 ESTs 5.3

315051 AW292425 Hs.163484 ESTs 12.9

315060 AA551104 Hs.189048 ESTs, Moderately similarto ALUC.HUMAN I 5.8

315073 AW452948 Hs.257631 ESTs 4.2

315080 AA744550 Hs.136345 ESTs 3.7

315175 A1025842 Hs.152530 ESTs 6

315183 AW136134 Hs.220277 ESTs 3.9

315193 AI241331 Hs.131765 ESTs, Moderately similarto I38937 DNA/R 4.4

315196 AI367347 Hs.44898 Homo sapiens clone TCCCTA00151 mRNA sequ 8.2

315198 AI741506 Hs.165900 ESTs, Weakly similar to ALU1JHUMAN ALU S 3.6

315240 R38772 Hs.172619 myelin transcription factor 1-like 3.4

315263 AW510994 Hs.220740 ESTs 3.4

315282 A1222165 Hs.144923 ESTs 4.9

315296 AA876905 Hs.125286 ESTs 4

315368 AB037745 Hs.104696 KIAA1324 protein 4.7

315397 AA218940 Hs.137516 fidgetin-like 1 3.1

315489 AI378817 Hs.191847 ESTs 3.1

315498 AA628539 Hs.116252 ESTs, Moderately similar to ALU1_HUMAN A 3.2

315526 AI193043 Hs.128685 ESTs, Weakly similarto T17226 hypotheti 4.1 315530 AW015415 Hs.127780 ESTs 8.9

315562 AA737415 Hs.152826 ESTs 5.5

315634 AA837085 Hs.220585 ESTs 6.3

315647 AA648983 Hs.212911 ESTs 3.6

315707 AI418055 Hs.161160 ESTs 5.1

315772 AW515373 Hs.271249 Homo sapiens cDNA FLJ13580 fis, clone PL 3.1

315850 AW270550 Hs.116957 ESTs 3.8

315858 AA737345 Hs.294041 ESTs 5

315878 AA683336 Hs.189046 ESTs 3.1

315977 AW865916 Hs.151206 ESTs 4.7

315978 AA830893 Hs.119769 ESTs 4.1

315995 AI217477 Hs.194591 ESTs 4.1

316012 AA764950 Hs.119898 ESTs 7

316042 AI469960 Hs.170698 ESTs 4.9

316052 AI962796 Hs.136754 ESTs 4.1

316072 AW517524 Hs.135201 N0D2 protein 3.2

316074 AW975114 Hs.293273 ESTs 3.8

316100 AW203986 Hs.213003 ESTs 3.2

316133 AI187742 Hs.125562 ESTs 3.7

316177 AI904982 Hs.293102 ESTs, Moderately similar to ALU1_HUMAN A 30.7

316186 AI433540 gb:ti69g05.x1 NCI CGAP Kid11 Homo sapien 3.1

316244 AI640761 Hs.224988 ESTs 3.5

316303 AA740994 Hs.209609 ESTs 3.8

316313 AA741300 Hs.202599 ESTs, Weakly similar to 138022 hypotheti 4.4

316364 AA747807 Hs.149500 ESTs 3.2

316580 AA938198 Hs.146123 poly(A) polymerase gamma 9.4

316697 AW293174 Hs.252627 ESTs 4.4

316715 A1440266 Hs.170673 ESTs, Weakly similar to T24832 hypotheti 3

316868 AI660898 Hs.195602 ESTs 3.2

316869 AI954880 Hs.134604 ESTs 3.2

316886 AA836331 Hs.134981 ESTs 4.4

316897 AA838114 Hs.221612 ESTs 3.7

316943 AW014875 Hs.137007 ESTs 4.6

317069 AI732892 Hs.190489 ESTs 5.9

317194 AW445167 Hs.126036 ESTs 4.1

317360 AI125252 Hs.126419 ESTs 3.5

317404 AI806867 Hs.126594 ESTs 5.1

317452 AA972965 Hs.135568 ESTs 6.9

317501 AI822034 Hs.137097 ESTs 4.6

317674 AW294909 Hs.132208 ESTs 4.3

317803 AW664964 Hs.128899 ESTs 6.1

317834 X56348 Hs.287270 ret proto-oncogene (multiple endocrine n 3.1

317850 AI681545 Hs.152982 hypothetical protein FLJ13117 3.4